WO1990000399A1 - Retroviral protease binding peptides - Google Patents

Retroviral protease binding peptides Download PDF

Info

Publication number
WO1990000399A1
WO1990000399A1 PCT/US1989/002972 US8902972W WO9000399A1 WO 1990000399 A1 WO1990000399 A1 WO 1990000399A1 US 8902972 W US8902972 W US 8902972W WO 9000399 A1 WO9000399 A1 WO 9000399A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
hydroxy
alk
oxo
methyl ester
Prior art date
Application number
PCT/US1989/002972
Other languages
French (fr)
Inventor
Geoffrey Bainbridge Dreyer
William Francis Huffman
Thomas Downing Meek
Brian Walter Metcalf
Michael Lee Moore
Original Assignee
Smithkline Beckman Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corporation filed Critical Smithkline Beckman Corporation
Publication of WO1990000399A1 publication Critical patent/WO1990000399A1/en
Priority to FI910084A priority Critical patent/FI910084A0/en
Priority to DK002691A priority patent/DK2691A/en
Priority to NO91910053A priority patent/NO910053L/en
Priority to NO920319A priority patent/NO920319D0/en
Priority to NO920318A priority patent/NO920318D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/09—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3223—Esters of cycloaliphatic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Definitions

  • Retroviruses that is, viruses within the family of Retroviridae, are a class of viruses which transport their genetic material as ribonucleic acid rather than
  • RNA-tumor viruses also known as RNA-tumor viruses, their presence has been associated with a wide range of diseases in humans and animals. They are beIleved to be the causative agents in pathological states associated with infection by Rous sarcoma virus (RSV), murine leukemia virus (MLV), mouse mammary tumor virus (MMTV), feline leukemia virus (FeLV), bovine leukemia virus (BLV), Mason-Pfizer monkey virus (MPMV), simian sarcoma virus (SSV), simian acquired immunodeficiency syndrome (SAIDS), human T-lymphotropic virus (HTLV-I, -II) and human immunodeficiency virus (HIV-1, HIV-2), which is the etiologic agent of AIDS (acquired immunodeficiency syndrome) and AIDS related complexes, and many others.
  • RSV Rous sarcoma virus
  • MMV murine leukemia virus
  • MMTV mouse mammary tumor virus
  • the pathogens have, in many of these cases, been isolated, no effective method for treating this type of infection has been developed.
  • the HTLV and HIV have been especially well characterized.
  • all retroviruses are rather similar in overall structure.
  • the extracellular virus particle is composed of an outer membrane studded with viral glycoproteins, a core of structural proteins, and a genome of single stranded ribonucleic acid.
  • the retroviral genome has a distinctive regional organization, referred to as the 5'-gag-pol-env-3' structure, wherein the gag region encodes the core structural proteins, the pol region encodes certain critical viral enzymes such as reverse transcriptase,
  • Viral replication occurs only within host cells and is dependent upon host cellular functions. Critical to this replication is the production of functional viral proteins. Protein synthesis is accomplished by
  • Retroviral proteases have not been well characterized. Both the proteases and their polyprotein substrates are recovered from virion particles in very low yield. To assess their activity, it is necessary to provide a substrate to express the proteolytic activity. Use of the
  • Proteases are enzymes which cleave peptide bonds in proteins and polypeptides. They are present in most
  • regulatory function is their ability to act selectively upon polypeptides. This selectivity is comprised of two factors, 1.) their ability to act upon specific substrates and 2.) their ability to hydrolyze only specific peptide bonds. On a structural level this substrate specificity is the result of the primary amino acid sequence, the resultant local
  • conformation of a large polypeptide may be significantly different than that of a small peptide, it is difficult to predict which amino acid sequence will bind optimally in a small peptide.
  • retroviruses and suggest a sequence preference for cleavage at X-Pro for the retroviral proteases, wherein X is usually either an aromatic (Phe, Tyr) or a large and hydrophobic (Met, Leu) amino acid. It is further suggested that this sequence is usually flanked on either side by a small and hydrophobic amino acid.
  • retroviral proteases may be acid proteases. This is based upon the observation that pepstatin, a known acid protease inhibitor, has been shown to be a weak inhibitor of the retroviral proteases associated with bovine leukemia virus, Moloney murine leukemia virus and human T-cell leukemia virus.
  • Kettner, et al. U.S. Patent No. 4,636,492 and Kettner, et al., U.S. Patent No. 4,644,055. Accordingly, tri- and tetra-peptides which substantially correspond to the amino acid sequence of the cleavage site of the substrate of the protease are modified to possess a C-terminal halomethyl ketone moiety. The halomethyl ketone, being a reactive moiety, is presumed to react with the protease once binding of the peptide has been effected.
  • Pepstatin a pentapeptide inhibitor isolated from a Streptomyces culture, has been shown to inhibit a wide range of acid proteases, and has attracted attention due to its ability to inhibit renin and pepsin. (See Umezawa, H. et al., J. Antibiot., Tokyo, 23, 259-263(1970).) Pepstatin contains the unusual amino acid, (3S, 4S)-4-amino-3-hydroxy-6-methylheptanoic acid (AHMHA), called statine, in two
  • This unusual amino acid is not an ⁇ -amino acid, but is beIleved to function as a
  • statine to probe the relationship between structure and inhibitory activity.
  • (3S, 4S)-4-amino-3- hydroxy-5-phenylpentanoic acid (AHPPA) showed activity similar to statine when incorporated into peptides in place of statine.
  • This invention comprises peptides, hereinafter
  • proteases are useful as substrates for assaying protease activity. In another respect, these peptides are inhibitors of viral protease and are useful for treating disease related to infection by these agents.
  • This invention is also a pharmaceutical composition, which comprises a compound of formula (I) and a
  • This invention further constitutes a method for treating viral disease, which comprises administering to a mammal in need thereof an effective amount of a compound of formula
  • This invention also provides a method for assaying viral protease activity.
  • this invention is a compound, as shown hereinafter as formula (lIb), which can be used as an intermediate in the preparation of the peptides of formula (I), which renders the peptide resistant to degradation by a viral protease.
  • A is BocNH, CbzNH, H, R' R"N, R"CONR' or DnsNH, or if a,b and c are 0 and Y is a covalent bond, then A is H, Boc, Cbz, R" or R"CO;
  • B is one or more D or L amino acids, ⁇ -Ala or is a covalent bond
  • C and D are the same or different and are Glx, Asx, Ala, ⁇ -Ala, Arg, Gly, Ile, Leu, Lys, Ser, Thr, Val, Met or His;
  • Q is a D or L amino acid and is Ser, Thr, Asp, His, Cys, Arg or Ala;
  • W is Pro or ⁇ 3-dehydro-Pro ;
  • X is Ala, Gly, Ile, Leu, Val, Met, Lys, Glx or Asx; Y is one or more D or L amino acids, or is a covalent bond;
  • Z is CO 2 R"", CONR' R"", COR', CH 2 OH, CH 2 NR'R”" or H, or if d and e are 0 and Y is a covalent bond, Z is OR"" or NR'R""; a, b, c, d and e are each independently 0 or 1, provided that c and e are not simultaneouly 0;
  • M is Cha, Phe(4'R a ) or -NHCHR 1 R 2 -; wherein:
  • R 1 is independently C 1-5 Alk, (CH 2 ) n SC 1-5 Alk,
  • R a is halogen, OR 1 , NO 2 , NH 2 or H;
  • R 2 is (CH 2 ) n -, CHR 3 (CH 2 ) m CO-, CO (CH 2 ) m CO-,
  • R 3 and R3' are each independently OH, H or NH 2 ;
  • m is independently 0, 1, 2 or 3;
  • n is independently 1 or 2;
  • p is 0, 1 or 2;
  • R' is H or C 1-5 Alk
  • R" is H or C 1-18 Alk
  • R" is H, C 1-5 Alk, C 3-6 Cycloalkyl, (CH 2 ) n C 6 H 5,
  • Prodrugs are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) in vivo.
  • A comprises the terminal amino group of the peptide
  • Z comprises the terminal carboxyl group of the peptide.
  • the terminal residues of the peptide are "des-amino" and “descarboxy” amino acids respectively.
  • A comprises the terminal amino group of the residue corresponding to B; or, when B is a covalent bond, to Q; or, when a is 0 and B is a covalent bond, to C; or when B is a covalent bond and a and b are 0, to D.
  • B is a covalent bond and a, b, and c are 0, the amino group of M is substituted by an acyl or alkyl group, as specially provided by A in formula (I).
  • Z comprises the terminal carboxyl group of the amino acid residue corresponding to Y; or when Y is a covalent bond, to X; or When Y is a covalent bond and d and e are 0, the terminal carboxyl group of M is substituted by Z as specially provided in formula (I).
  • ⁇ -Ala refers to 3-amino propanoic acid.
  • Cha refers to cyclohexylalanine.
  • Boc refers to the t- butyloxycarbonyl radical
  • Dns refers to the dansyl radical, which is 1-dimethylamino napthylene-5-sulfonyl
  • Cbz refers to the carbobenzyloxy radical
  • BrZ refers to the o-bromobenzyloxycarbonyl radical
  • Clz is the p-chlorocarbobenzyloxy radical
  • CI 2 Z refers to the 2,4-dichlorocarbobenzyloxy radical
  • Bzl refers to the benyzl radical
  • MeBzl refers to the 4-methyl benzyl radical
  • Ac refers to acetyl
  • Alk or C 1-5 Alk refers to C 1-5 alkyl
  • Ph refers to phenyl
  • DCC refers to the residue constitutes ty
  • DMSO dimethylsulfoxide
  • DMF dimethyl formamide
  • THF tetrahydrofuran
  • HF hydrofluoric acid
  • TFA trifluoroacetic acid
  • C 1-5 alkyl as appIled herein is meant to include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiary butyl, pentyl and isopentyl.
  • Asp and Glu which have
  • carboxylic acid side chains encompass free carboxylic acids, C 1-5 alkyl and benzyl ester side chains.
  • C 1-18 Alk is intended to include any straight or branched chain alkyl group of 1 to 18 carbons.
  • the peptides of this invention bind to viral proteases in a manner which mimics the binding of the natural
  • the peptides are generally dodecapeptides or smaller. However, longer peptides which encompass the residues defined herein as -Q-C-D-M-W-X-, as given in formula (I), are also beIleved to be active and are considered within the scope of this invention.
  • X is preferably a neutral or acidic amino acid.
  • X is Ala, Gly, Ile, Leu, Val, Met, Lys, Glx or Asx. Valine is especially suitable.
  • D is preferably a neutral and hydrophobic amino acid, although certain hydrophilic residues such as Asp and Ser are
  • the residue corresponding to C may be a neutral, acidic or basic amino acid. Glu, Gln, Arg, Lys, Ser, Ala, ⁇ -Ala, Asn and Gly are suitable. Gln, Asn and Ala are especially preferred for C.
  • the residue Q is preferably a hydrophilic residue, such as D- or L-, Ser, Thr, Asp or His. Especially preferred are Thr and Ser.
  • B corresponds to one or more amino acids, which may be hydrophilic or hydrophobic, or it may be a covalent bond in the shorter peptides.
  • the identity of B is not critical and a residue may be chosen for the favorable physico-chemical and biochemical properties it confers on the overall peptide, such as water solubility and resistance to exopeptidases.
  • the choice of a D-amino acid often confers resistance to exopeptidases when the D-amino acid is at the terminus of the peptide.
  • Q may be advantageous for Q to be a D-amino acid.
  • B is preferably one or two D- or L-amino acids chosen from Ala, ⁇ -Ala, Gly, Ile, Val, Leu, Met, His, Lys, Arg, Glx, Asx, Cys,
  • B is preferably a covalent bond.
  • Y may correspond to one or more amino acids, or a covalent bond. If it is one or more amino acids, they may be hydrophilic or hydrophobic. One to three residues are preferred, but a longer chain is acceptable. In much the same manner as B, the residues of Y may be used to confer favorable biochemical or physio-chemical properties to the peptide. Thereby, the use of hydrophilic residues may be used to confer desirable solubility properties or D-amino acids at the carboxy terminus may be used to confer
  • Y is one to three amino acids chosen from Ala, Gly, Ile, Leu, Met, Val, Arg, Lys, Thr, Ser, Cys, Glx or Asx.
  • Y may be a covalent bond but a single amino acid is especially suitable.
  • Ala, Gly, Ile, Met, Arg, Asx and Val are preferred.
  • Valine is especially preferred.
  • Peptides wherein M is Cha or Phe(4'Ra) and d is 1 may act as substrates, and are hydrolyzed to smaller peptides.
  • the substrates may generally be of any length, 6-9 residues is preferred. These are conveniently used to assay for protease activity.
  • they may compete with the natural viral substrates and thereby serve to inhibit viral replication and, hence, disease progression in vivo; although, due to their metabolic instability, their duration of action may be short.
  • these peptides may be used in an assay for protease activity by subjecting the peptide to the protease in a suitably buffered medium.
  • Analysis of the activity is carried out in such a manner as to detect the hydrolytic cleavage of the peptide.
  • One such method constitutes the separation of at least one of the product peptides, or a derivative thereof, and its
  • chromatographic means can be used to effect the separation of the peptide products using conventional solid supports such as silica gel, octadecyl silane, Sephadex®, ion exchange resins or adsorption resins. Detection/quantitation of the products is effected by ultraviolet absorption or other spectroscopic analysis.
  • incorporation or substitution of a radioactive isotope in the peptide, such as tritium or 13 C label in one or more of the amino acids, provides for
  • incorporation of a fluorescent moiety, such as a dansyl group on the amino terminus of the peptide provides for fluorescent detection/quantitation.
  • Fluorogenic methods which would incorporate a quenching agent into the peptide, such as a 3-(4-N-methyl-pyridyl)-propyl oxy ester of the carboxy terminus, in addition to the fluorescent marker, would also be useful to assay protease activity. Such methods are disclosed, for example, by Dunn, et al., Anal. Biochem.. 129, 502(1983), and provide for continuous
  • protease binding activity of the peptides of this invention is demonstrated by their ability to act as substrates.
  • the following table illustrates the substrate kinetics of these peptides.
  • proteases and thereby inhibit the proteolytic activity.
  • Modifications of such peptides which bind to viral proteases so as to retard the hydrolysis of the peptide provide a means for effecting longer lived inhibition of protease activity.
  • another subgeneric group of compounds of this invention comprises the peptides wherein the residue M is -NHCHR 1 R 2 -.
  • These peptides contain an unnatural amino acid, which is not an ⁇ -amino acid.
  • These peptides do not possess a peptide bond in the same manner as a substrate and therefore, although they bind to the protease in a manner which mimics the binding of the natural substrate, are resistant to hydrolysis.
  • Peptides of 2-9 residues are suitable.
  • Peptides of 3-6 residues are preferred.
  • R 1 is CH 2 C 6 H 4 -R a , CH 2 C 6 H 11 or C 1-5 Alk.
  • R 2 is preferably CHR 3 CHR 3' (CH 2 ) m CO-, CHR 3 CHR 3' CHR 1 CO-,
  • R', R 3 , R 3' , m and n have the meanings defined in formula (I).
  • R 1 is CH 2 C 6 H 4 -Ra and R 2 is CH(OH) CH 2 CH 2 CO-.
  • the peptides of formula (I) have the partial structure -Ala-NHCH (CH 2 Ph) CH (OH) CH 2 CH 2 CO-Val-Val-.
  • retroviruses an inhibitor or substrate is likely to be broadly active over the range of retroviruses.
  • DNA viruses which are dependant upon virally encoded proteases, such as the hepatitis virus, may also be susceptible to such
  • the peptides of the invention are prepared by coupling the appropriate amino acid residues, optionally removing any protective groups and optionally modifying the amino or carboxy terminus of the peptide. They are prepared
  • amino acid or peptide is suitably protected as known in the peptide art.
  • carbobenzyloxy-group is preferred for protection of the amino group, especially at the ⁇ position.
  • a benzyl group or suitably substituted benzyl group is used to protect the mercapto group of cysteine, or other thiol containing amino acids; or the hydroxyl of serine or threonine.
  • the tosyl or nitro group may be used for protection of the guanidine of Arg or the imidazole of His, and a suitably substituted carbobenzyloxy group or benzyl group may be used for the hydroxyl group of Tyr, Ser or Thr, or the ⁇ -amino group of lysine.
  • Suitable substitution of the carbobenzyloxy or benzyl protecting groups is ortho and/or para substitution with chloro, bromo, nitro or methyl, and is used to modify the reactivity of the protective group.
  • Cysteine and other sulfur-containing amino acids may also be protected by formation of a disulfide with a thioalkyl or thioaryl group.
  • the protective groups are, most conveniently, those which are not removed by mild acid treatment. These protective groups are removed by such methods as catalytic hydrogenation, sodium in liquid ammonia or HF treatment as known in the art.
  • the peptide is built up sequentially starting from the carboxy terminus and working toward the amino terminus of the peptide.
  • Solid phase synthesis is begun by covalently attaching the C terminus of a protected amino acid to a suitable resin, such as a
  • MBHA chloromethyl resin
  • CMR chloromethyl resin
  • a BHA or MBHA support resin is used if the carboxy terminus of the product peptide is to be a carboxamide.
  • a CMR support is generally used if the carboxy terminus of the product peptide is to be a carboxyl group, although this may also be used to produce a
  • the amino group is hydrolyzed by mild acid treatment, and the free carboxyl of the second protected AA is coupled to this amino group. This process is carried out sequentially, without isolation of the
  • the completed peptide may then be deblocked and/or split from the carrying resin in any order.
  • HBr/acetic acid splits the peptide from the resin and produces the carboxy terminal amino acid as a carboxylic acid.
  • Treatment of a CMR supported peptide with ammonia or alkyl amines in an alcoholic solvent provides a carboxamide or alkyl carboxamide at the carboxy terminus.
  • the CMR resin may be treated with an appropriate alcohol, such as methyl, ethyl, propyl, butyl or benzyl alcohol, in the presence of triethylamine to cleave the peptide from the resin and produce the ester directly.
  • an appropriate alcohol such as methyl, ethyl, propyl, butyl or benzyl alcohol
  • Esters of the peptides of this invention may also be prepared by conventional methods from the carboxylic acid precursor.
  • the carboxylic acid is treated with an alcohol in the presence of an acid catalyst.
  • the carboxylic acid may be converted to an activated acyl intermediate, such as an acid halide or activated anhydride or ester, and treated with an alcohol, preferably in the presence of a base.
  • the preferred method for cleaving a peptide from the support resin is to treat the resin supported peptide with anhydrous HF in the presence of a suitable cation scavenger, such as anisole or dimethoxy benzene.
  • a suitable cation scavenger such as anisole or dimethoxy benzene.
  • Peptides hydrolyzed in this way from the CMR are carboxylic acids, those split from the BHA resin are obtained as carboxamides.
  • Modification of the terminal amino group of the peptide is accomplished by alkylation or acetylation as is generally known in the art. These modifications may be carried out upon the amino acid prior to incorporation into the peptide, or upon the peptide after it has been synthesized and the terminal amino group liberated, but before the protecting groups have been removed.
  • acetylation is carried out upon the free amino group using the acyl halide, anhydride or activated ester, of the corresponding alkyl acid, in the presence of a tertiary amine.
  • Mono-alkylation is carried out most
  • Dialkylation may be carried by treating the amino group with an excess of an alkyl halide in the presence of a base.
  • the longer chain alkyl and acyl groups of this invention are beIleved to have advantageous properties due to their affinity for lipid membranes.
  • Myristylation or stearylation is useful.
  • Solution synthesis of peptides is accomplished using conventional methods used to form amide bonds.
  • a protected Boc-amino acid which has a free carboxyl group is coupled to a protected amino acid which has a free amino group using a suitable carbodiimide coupling agent, such as N, N' dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole (HOBT) and dimethylamino pyridine (DMAP).
  • a suitable carbodiimide coupling agent such as N, N' dicyclohexyl carbodiimide (DCC)
  • catalysts such as 1-hydroxybenzotriazole (HOBT) and dimethylamino pyridine (DMAP).
  • HOBT 1-hydroxybenzotriazole
  • DMAP dimethylamino pyridine
  • a protected Boc-amino acid or peptide is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran (THF), in the presence of a base, such as N-methyl morpholine, DMAP or a trialkyl amine, with isobutyl chloroformate to form the "activated anhydride", which is subsequently reacted with the free amine of a second protected amino acid or peptide.
  • anhydrous solvent such as methylene chloride or tetrahydrofuran (THF)
  • a base such as N-methyl morpholine, DMAP or a trialkyl amine
  • the protecting groups may be removed as hereinbefore described, such as by
  • hydrofluoric acid or alkali hydrofluoric acid or alkali.
  • Esters are often used to protect the terminal carboxyl group of peptides in solution synthesis. They may be converted to carboxylic acids by treatment with an alkali metal hydroxide or carbonate, such as potassium hydroxide or sodium carbonate, in an aqueous alcoholic solution. The acids may be converted to other esters via an activated acyl intermediate as previously described.
  • the amides and substituted amides of this invention are prepared from carboxylic acids of the peptides in much the same manner.
  • ammonia or a substituted amine may be reacted with an activated acyl intermediate to produce the amide.
  • Use of coupling reagents, such as DCC, is convenient for forming substituted amides from the carboxylic acid itself and a suitable amine.
  • methyl esters of this invention may be converted to the amides, or substituted-amides, directly by treatment with ammonia, or a substituted amine, in methanol solution.
  • a methanol solution of the methyl ester of the peptide is saturated with ammonia and stirred in a
  • Carboxamides are preferred embodiments of this invention due their enhanced stability relative to esters.
  • the amino acid which constitutes the M residue of the peptide comprises either phenylalanine, a derivative thereof, or an unnatural amino acid denoted as -NHCHR 1 R 2 -.
  • the derivatives of phenylalanine include tyrosine; (O-C 1- 5 alkyl)tyrosine, 4'-halophenylalanine, 4'-nitrophenylalanine and 4'-aminophenylalanine as are generally well known in the peptide art.
  • R 1 is independently C 1-5 Alk, (CH 2 ) n SC 1-5 Alk,
  • R a is halogen, OR', NO 2 , NH 2 or H;
  • R 2 is (CH 2 ) n -, CHR 3 (CH 2 ) m CO-, CO(CH 2 ) m CO-, CHR 3 CHR 3' (CH 2 ) m CO-, CHR 3 CHR 3' CHR 1 (CH 2 ) m CO-,
  • R 3 and R3' are each independently OH, H or NH 2 ;
  • m is independently 0, 1, 2 or 3;
  • n is independently 1 or 2;
  • p is 0, 1 or 2;
  • R 5 is H
  • R 6 is CH 3 CO, C 1-5 Alk, Dns, Cbz or Boc, or taken together R 5 and R 6 are phthalimido;
  • X is H, halogen, OR", OC 1-5 Alk, NHR'R" or OCOC 1-5 Alk; R' H or C 1-5 Alk; and
  • R" is H or C 1-18 Alk.
  • peptide substrate which binds to a protease may be converted to an inhibitor by replacement of one or both of the amino acids at the scissile site by a suitable compound of formula (Ila).
  • the unnatural amino acids are generally not ⁇ -amino acids, but are derived from ⁇ -amino acids.
  • identity of R 1 is established by the choice of an amino acid of formula (III), wherein R 1 is chosen as previously set forth.
  • aldehyde of formula (V) thereby provides a versatile
  • the N-methoxy-methyl amides of these ⁇ -amino acids are also useful intermediates for this use.
  • the ⁇ -amino acids may be obtained from natural sources, commercial sources or may be synthesized by a number of methods well known in the peptide art.
  • Alcohols of formula (IV) may be obtained from the diborane reduction of the corresponding protected amino acid.
  • Aldehydes of formula (V) may be obtained from the reduction of the methyl ester of the corresponding amino acid, for example with diisobutyl aluminum hydride (DIBAL).
  • DIBAL diisobutyl aluminum hydride
  • the alcohol of formula (IV) may be oxidized to the aldehyde using a mild oxidizing agent, such as the Dess Martin periodinane or using the Swern method (DMSO, oxalyl chloride, triethylamine).
  • a mild oxidizing agent such as the Dess Martin periodinane or using the Swern method (DMSO, oxalyl chloride, triethylamine).
  • amino acids alanine, valine, leucine and isoleucine are especially useful for producing chiral aldehydes.
  • ⁇ -Amino butyric acid, ⁇ -amino isobutyric acid and ⁇ -amino pentanoic acid are especially useful for producing chiral aldehydes.
  • any alkyl- ⁇ -amino acid can be synthesized by alkylation of a nitro-acetic acid ester with an appropriate alkyl halide in the presence of a base, such as triethylamine, DBU or other tertiary amine.
  • a base such as triethylamine, DBU or other tertiary amine.
  • Alkoxides such as sodium methoxide or ethoxide are also suitable bases.
  • Subsequent reduction of the ⁇ -nitro alkyl acid or ester with hydrogen and a palladium or platinum catalyst yields the amino acid.
  • it is common to produce ⁇ -amino acids by alkylation of an N-benzylidine glycine ester, such as a methyl or ethyl ester.
  • R 1 is aryl or aralkyl
  • amino acids in which R 1 is aryl or aralkyl are available commercially, or are well known in the art such as phenylalanine, 4'-halo and 4'-nitrophenylalanine, tyrosine, (O-alkyl) tyrosine, phenylglycine and (4'-hydroxy)phenylglycine.
  • Homologs of these compounds may be prepared by conventional techniques of amino acid synthesis. Thus, alkylation of a nitro acetic acid ester or a N-benzylidene glycine with 1-phenyl-2-bromoethane or 1-phenyl- 3-bromopropane, as described above, produces the homologous amino acids.
  • ⁇ -amino acids in which R 1 contains an oxygen or sulfur are obtained from serine, homo-serine, threonine, cysteine or methionine or alkylation or these amino acids, excepting methionine.
  • Alkylation is carried out by treating the corresponding hydroxyl or thiol compound with a base, such as triethylamine, DBU or sodium hydride, and an
  • alkyl halide such as methyl, ethyl, isopropyl or isobutylbromide.
  • di-homoanalogues are prepared by conventional techniques for producing amino acids as
  • an ester of nitro acetic acid is treated with a base, as previously described and acrolein in a Michael reaction.
  • the aldehyde produced is subsequently reduced by a mild reducing agent, such as sodium borohydride, to yield the desired hydroxy group.
  • a mild reducing agent such as sodium borohydride
  • Subsequent catalytic reduction of the nitro group yields the ⁇ -amino 5-hydroxy pentanoic acid.
  • the corresponding mercapto analogue may be synthesized from the hydroxy intermediate.
  • the hydroxyl group is converted to a halide, such as by treatment with phosphorous tribromide or oxalyl bromide or chloride in the presence of triethylamine or another tertiary amine, or by treatment with triphenyl phosphine and carbon tetrabromide.
  • a halide such as by treatment with phosphorous tribromide or oxalyl bromide or chloride in the presence of triethylamine or another tertiary amine, or by treatment with triphenyl phosphine and carbon tetrabromide.
  • Treatment of the halide with sodium sulfide or potassium thioacetate followed by saponification with sodium hydroxide yields the 5-mercapto-2-amino pentanoic acid.
  • This intermediate may be further alkylated in the same manner as cysteine or serine described herein above.
  • a hydrocarbon substituent at R 2 is suitably accomplished by reaction of the aldehyde of formula (V) with an organometallic hydrocarbon, such as a Grignard reagent or organo-lithium species.
  • organometallic hydrocarbon such as a Grignard reagent or organo-lithium species.
  • the incipient carboxylic acid functionality of R 2 is in protected form as in an ortho ester or disguised, as in an oxidizable olefin.
  • the organometallic species is a magnesium or lithium alkylide generated from lithium or magnesium and an alkylene halide, such as allyl bromide, 1-bromo-3-butene, 1-bromo-4-pentene, or 1-bromo-5-hexene, or an alkyl substituted derivative thereof .
  • Oxidation of the hydroxy- or keto-alkane is accomplished by conventional methods, such as with potassium permanganate or by ozonolysis followed by standard dimethyl sulfide workup and subsequent oxidation with potassium permanganate or Jones reagent. As would be obvious to one skilled in the art, this method is inapplicable when R 1 contains a sulfur substituent.
  • the hydroxyl may be further converted to chloride or bromide using a halogenating agent, such as phosphorous trichloride or phosphorous tribromide, and subsequently reduced to a methylene group with hydrogen and Raney® nickel.
  • a halogenating agent such as phosphorous trichloride or phosphorous tribromide
  • the keto group may be reductively aminated with sodium cyanoborohydride and an ammonium halide, such as ammonium chloride or bromide.
  • the carboxylic acid may be converted to an ester, amide, aldehyde, anhydride or acyl halide by common methods well known in the chemical art.
  • the introduction of unsaturation at R 2 may be derived from the amino acid products corresponding to formulas (VII). Reduction of the carbonyl group to a hydroxyl group, as previously indicated, and subsequent elimination of the hydroxyl group, provides the unsaturated compounds of this invention.
  • the hydroxyl group may be eliminated by
  • R1, R5, R6, X and n are as definded in formula (Ila), are prepared by a process which comprises reacting a compound of formula (V), under reducing conditions, with an ester or acid of proline, ⁇ 3-dehydro-proline or 2-carboxypiperidine, and thereafter, in any order, converting the ester to a carboxylic acid, ester, aldehyde or amide; or converting the acid to an ester, amide, anhydride or acyl halide.
  • a hydroxy-amino acid of formula (IV) is converted to the corresponding halide using a conventional reagent, such as phosphorous tribromide, phosphorous oxychloride or thionyl chloride in the presence of a base, such as triethylamine or pyridine, and treated with the thioalkanoic acid or ester again in the presence of a base.
  • a conventional reagent such as phosphorous tribromide, phosphorous oxychloride or thionyl chloride in the presence of a base, such as triethylamine or pyridine, and treated with the thioalkanoic acid or ester again in the presence of a base.
  • the sulfide produced in this way may be further oxidized to a sulfoxide by treatment with a mild oxidizing agent, such as sodium metaperiodate, or a sulfone, by treatment with potassium permanganate.
  • dimethyl oxaloacetate is treated with diethylamino sulfur trifluoride (DAST) to produce ⁇ -difluoro dimethyl succinate.
  • DAST diethylamino sulfur trifluoride
  • oxidized to the corresponding aldehyde using a mild oxidizing method such as Collins reagent, the Dess-Martin periodinane or the Swern method (DMSO, oxalyl chloride, triethylamine).
  • Collins reagent the Dess-Martin periodinane or the Swern method (DMSO, oxalyl chloride, triethylamine).
  • derivatives of these homologues may be prepared by alkylation of the initial ⁇ -keto diester with a base and alkyl halide prior to conducting the sequence.
  • alkylation of dimethyl oxalacetate with 2 equivalents of methyl iodide in the presence of DBU yields 2-keto-3, 3-dimethyl succinnate.
  • Further conversion by the above sequence to 2,2 dimethyl-3,3-difluoro-4-oxo-methyl butanoate, condensation with 2-phenyl nitroethane and reduction with hydrogen and 5% Pd/C yields 2,2 dimethyl-3,3-difluoro-4-hydroxy-5-amino-6-phenyl methyl hexanoate.
  • pyridine/chromium trioxide are suitable oxidants.
  • phosphinyl substituent at R is carried out by a condensation of benzyl carbamate with triphenyl phosphite and an aldehyde of the general formula R 1 CHO, such as phenylacetaldehyde, isobutyraldehyde or 2-methyl butyraldehyde, in acetic acid to yield a phosphonate of formula (IX).
  • organo metallic reagent such as the lithium or Grignard reagent derived from alkyl bromide, bromo-3-butene, 2-(2-methylpropenyl) chlorocyclopentane or 2- (2-methyl propenyl)-cyclohexane, yields the alkenyl methyl phosphinates of this invention as given by formula (Xa) and (Xb):
  • R 1 , R 5 , R 6 , R', R", m and n are as defined for formula (Ila) and R" ' is C 1-5 alkyl.
  • Subsequent oxidation, such as with potassium permanganate or by ozonolysis as herein described affords the corresponding alkyl phosphinate carboxylic acids of this invention. Accordingly, the compounds of formulas (XI):
  • R 1 , R 5 , R 6 , R', X and n are as defined as in formula (Ila), may be prepared by oxidizing a compound of formula
  • phosphinate to the phosphinic acid may be accomplished by treatment with a strong acid, such as hydrogen bromide.
  • a strong acid such as hydrogen bromide.
  • R 1 contains a sulfur substituent.
  • a further aspect of this invention relates to the preparation of completely novel amino acids which, when properly incorporated into peptides, provide a nonhydrolyzable imitation of a peptide bond.
  • These compounds are prepared as hereinbefore described and are further illustrated in the Examples which follow. They are
  • R 1 is independently C 1-5 Alk, -(CH 2 ) n SC 1-5 Alk,
  • R a is halogen, NO 2 , OH, OC 1-5 Alk, NH 2 , or H;
  • R 2 is (CH 2 ) n -X, (CH 2 ) n CO-X, CHR 3 CHR 1 CHR' (CH 2 ) m CO-, COCR 1 CHR' (CH 2 ) m CO-X, CHR 3 CF 2 (CH 2 ) m CO-X, COCF 2 CR'R" (CH 2 ) m CO-X, CHR 3 (CH 2 ) m CO-X, CO (CH 2 ) m CO-X,
  • R 3 is H, NH 2 or OH
  • R 5 is H
  • R 6 is CH 3 CO, C 1-5 Alk, Dns, Cbz or Boc, or taken together R 5 and R 6 are phthalimido;
  • X is H, halogen, OH, OC 1-5 Alk, NHR'R" or OCOC 1-5 Alk; R' and R" are H or C 1-5 Alk; m is independently 0, 1, 2 or 3; and n is independently 1 or 2; provided that R 2 is not CHR 3 CH 2 CO-X, COCH 2 CO-X, COCF 2 CO-X or CHR 3 CF 2 CO-X when R 1 is phenylmethylene, isobutyl or cyclohexylmethylene, and R 2 is not CH (OH) CH 2 CH 2 CO-X or
  • diastereomeric These diasteromers are usually separable by chromatography over silica gel or an octadecyl silane chromatographic support with a suitable mobile phase. If silica gel is used, a mixture of ethyl acetate and hexane or methanol and chloroform or methylene chloride are used to elute the diasteromers. If an octadecyl silane support is used, a mixture of water and methanol or acetonitrile may be used to purify the diastereomers.
  • the mobile phase may be buffered by the addition of .02 to .5 % of acetic acid, trifluoracetic acid or phosphate buffer. If the residue, designated as M, possesses only a single chiral center, or the diasteromers are difficult to separate, it may be preferable to
  • the unnatural amino acids of the M residue are N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • an acid addition salt may be
  • Acid addition salts of the peptides are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, maleic, succinic or methanesulfonic.
  • an acid such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, maleic, succinic or methanesulfonic.
  • the acetate salt form is especially useful. If the final peptide contains an acidic group, cationic salts may be prepared.
  • the parent compound such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, maleic, succinic or methanesulfonic.
  • an alkaline reagent such as a hydroxide, carbonate or alkoxide, containing the appropriate cation.
  • Cations such as Na + , K + , Ca ++ and NH 4 + are examples of cations present in pharmaceutically
  • Certain of the compounds form inner salts or zwitterions which may also be acceptable.
  • the compounds of formula (I), wherein M is -HNCHR 1 R 2 -, are used to induce anti-viral activity in patients which are infected with susceptible viruses and require such treatment.
  • the method of treatment comprises the administration orally, parenterally, buccally, trans-dermally, rectally or by insufflation, of an effective quantity of the chosen
  • Dosage units of the active ingredient are selected from the range of .05 to 15 mg/kg. These dosage units may be
  • protease inhibiting properties of the peptides of this invention are demonstrated by their ability to inhibit the hydrolysis of a peptide
  • rHIV protease in the range of about 10 nM to about 250 ⁇ M.
  • the following table is representative of the inhibition constants of these peptides.
  • compositions of the peptides of this invention, or derivatives thereof, may be formulated as solutions or lyophilized powders for parenteral
  • Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
  • the liquid formulation is generally a buffered, isotonic, aqueous solution.
  • suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvmylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • a preferred composition for parenteral administration may additionally be comprised of a quantity of the compound encapsulated in a liposomal carrier.
  • the liposome may be formed by dispersion of the peptides in an aqueous phase with phospholipids, with or without cholesterol, using a variety of techniques, including conventional handshaking, high pressure extrusion, reverse phase evaporation and
  • compositions is more fully disclosed in copending Application Serial No. 06/763,484 and is incorporated herein by
  • Such a carrier may be optionally directed toward its site of action by an immunoglobulin or protein reactive with the viral particle or infected cells.
  • the choice of such proteins would" of course be dependent upon the antigenic determinants of the infecting virus.
  • An example of such a protein is the CD-4 T-cell glycoprotein, or a derivative thereof, such as sCD-4 (soluble CD-4), which is reactive with the glycoprotein coat of the human immunodeficiency virus (HIV).
  • sCD-4 soluble CD-4
  • these peptides may be encapsulated
  • compositions may be added to enhance or stabilize the
  • Liquid carriers include syrup, peanut oil, olive oil,
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl
  • the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
  • a pulverized powder of the peptides of this invention may be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
  • excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols
  • the pulverized powders may also be compounded with an oily preparation, gel, cream or emulsion, buffered or unbuffered, and administered through a transdermal patch.
  • Beneficial effects may be realized by co-administering, individually or in combination, other anti-viral agents with the protease inhibiting compounds of this invention.
  • anti-viral agents include nucleoside analogues,
  • Nucleoside analogues which include 2',3'-dideoxycytidine(ddC), 2',3'-dideoxyadenine (ddA) and
  • compositions comprise an anti-viral agent, a protease inhibiting peptide of this invention and a pharmaceutically acceptable carrier.
  • the enzyme used to assay the peptide of this invention was produced in this manner and purified from the cell pellet as follows.
  • the E. coli cell pellet was resuspended in a buffer consisting of 50 mM TrisHC1, pH 7.5; 1.0 mM each DTT, EDTA and PMSF
  • the protease was N85-95% pure.
  • immunoblot analysis >90% of the immunoreactive material was precipitated at the ammonium sulfate step.
  • activity assay the highest peak of activity was found in the fractions collected at 45 and 46 minutes.
  • the activity itself cannot be used to obtain reliable recovery data as it is influenced by high salt, i.e., with increasing salt, increasing levels of activity were obtained. Thus, with each step in the purification, more total activity was
  • reaction rates were linear over the time course of the
  • MENDT buffer 50 mM Mes (pH 6.0; 2-(N-morpholino) ethanesulfonic acid), 1
  • reaction mixtures 37°C were quenched after 10-20 minutes with an equal volume of cold 0.6 N trichloroacetic acid, and, following centrifugation to remove precipitated material, peptidolysis products were analyzed by reverse phase HPLC (Beckman
  • Peptide amides are synthesized by solid phase peptide synthesis using benzhydrylamine resin as the support.
  • Protected amino acids are added sequentially starting from the carboxyl terminus until the desired sequence has been obtained.
  • the t-butyloxycarbonyl (Boc) group is used for protection of the alpha-amino group.
  • Side chain functional groups are protected as follows: arginine and histidine, tosyl (Tos); cysteine, p-methylbenzyl (MeBzl); serine and threonine, benzyl ether (Bzl); lysine, p-chlorocarbobenzoxy (Clz); glutamic acid and aspartic acid, benzyl ester (OBzl); tyrosine,
  • p-bromocarbobenzoxy (BrZ). Removal of the Boc group is accomplished by treatment with 50% trifluoroacetic acid (TFA) in methylene chloride. Neutralization of the amine-TFA salt is accomplished by treatment with 7% diisopropylethylamine (DIEA) in methylene chloride. Amino acids are coupled to the growing peptide using 3 equiv. Boc-amino acid and 3 equiv. 1-hydroxybenzotriazole (HOBt) in DMF and 3 equiv. of
  • DCC dicyclohexylcarbodiimide
  • Boc-Arg (Tos) -Ala-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared in the usual way. After removal of the N-terminal Boc group with 50% TFA in
  • the peptide was cleaved from the resin with removal of the side chain protecting groups by treatment with anhydrous liquid HF (10 ml) in the presence of anisole (1 ml) at 0°C for 50 minutes. After removal of the HF under vacuum, the resin was washed with ethyl ether and air-dried. The resin was then extracted with 2 x 30 ml 1% HOAC/H 2 O followed by 2 x 30 ml 10% HOAC/H 2 O. The combined extracts were lyophilized to yield 476 mg crude peptide.
  • Boc-Phe-OMe (12.9 g, 46.4 mmol), prepared as above, was dissolved in dry toluene (50 mL) and cooled to -78°C.
  • Diisobutylaluminum hydride (25% in toluene, 77.3 mL, 116 mmol, 150% excess) was added over 2 min.
  • methanol (15 mL) was added slowly to control effervescence.
  • the mixture was poured into Rochelle salt (94 g potassium sodium tartrate in 1 L water, 150 mL) and shaken with ether (100 mL) until extractable.
  • the aqueous phase was Washed with ether (3 X 100 mL).
  • the organic phases were combined, dried (MgSO 4 ), and evaporated.
  • Example 3(f) By the same procedure used to prepare the compound of Example 3(f), except substituting isomer A (186 mg, 0.50 mmol) from Example 3 (e), the titled compound was obtained (135 mg, 0.37 mmol) as a white solid in 75% yield.
  • the 2-hydroxy configuration of isomer B was determined in the same manner as isomer A.
  • N-Boc-L-serine-O-benzyl ester (5.90 g, 20.0 mmol) and N-methylmorpholine (2.74 ml, 25.0 mmol) in THF (100 ml) at 40°C under argon. After 45 min. N-methylmorpholine (2.75 ml, 25.0 mmol) and solid L-alanine methyl ester hydrochloride (3.22 g, 23.0 mmoir were added. The mixture was allowed to stir with gradual warming to 20°C. After 18 hr. the mixture was diluted with ethyl acetate and washed successively with 5% HCl, 5% NaHCO 3 and brine. Filtration and removal of solvent under vacuum provided the titled compound (7.54 g, 19.8 mmol) as an oil in 99% yield.
  • Example 2(d) The compound of Example 2(d) (0.35 g, 1.0 mmol) was coupled to Val-Val-BHA (1.0 mmol) using DCC (0.21 g, 1.0 mmol) and HOBT (0.15 g, 1 mmol) in 50% CH 2 Cl 2 /DMF overnight.
  • Quantitative ninhydrin test indicated 83% coupling.
  • the peptide resin was acetylated with Ac 2 O (1 mL in 30 mL CH 2 C1 2 ) until the ninhydrin test was negative. The peptide was then completed and acetylated, according to the procedure of Example 1, using half of the resin.
  • TLC R f 0.34 (B:A:W 4 : 1 :1), 0.68 (B:E:A:W 1:1:1:1).
  • HPLC (Hamilton PRP-1 250 X 4.1 mm analytical HPLC column, water-acetonitrile- 0.1% TFA, 95:5 to 60:40 over 15 min.) k' 2.73.
  • Amino acid analysis Ser 0.57, Gln 1.00, Asn 1.00, Val 2.00.
  • Example 2(d) The compound of Example 2(d) (0.87 g, 2.5 mmol) was coupled to Val-Val-BHA (1.2 mmol) with DCC (0.52 g, 2.5 mmol) and HOBt (0.38 g, 2.5 mmol) in 30 mL of 50% CH 2 Cl 2 /DMF overnight. Ninhydrin test showed complete coupling.
  • the peptide was completed using 0.6 g (0.4 mmol) of the resin.
  • the peptide was cleaved from the resin using 15 mL HF with 1.5 mL anisole at 0°C for 1 h.
  • the peptide resin mixture was washed with ether (3X) followed by HOAc (4X). Lyophilization of the HOAc gave 192.5 mg crude peptide (62%).
  • the resin supported intermediate Ac-Ser (Bzl) -Gln-Asn- [3(RS)-AHPPA]-Pro-Val-Val-BHA was prepared on a 1 mm scale in the usual manner according to Example 1.
  • Boc-AHPPA used was racemic at the 3 position.
  • the peptide was cleaved from the resin and the benzyl group was removed from the serine hydroxyl by treatment at 0° with 10 ml of anhydrous HF and 1 ml of anisole for 60 min.
  • the HF was removed in vacuo at 0°.
  • the residue was triturated with diethyl ether, the peptide was extracted with acetic acid (3 x 20 ml) and lyophilized to yield 302 mg.
  • the resin supported intermediate Ac-Ser (Bz)-Gln-Asn- [3(RS)-AHPPA]-Val-Val-NH 2 was prepared in the usual manner on a .5 mm scale.
  • the Boc-AHPPA used was racemic in the 3 position.
  • the peptide was cleaved from the resin with removal of the benzyl protecting group by treatment with anhydrous HF (10 ml) in the presence of anisole (1 ml) at 0° for 60 min. After removal of the HF at 0° under vacuum, the resin was triturated with diethyl ether and air-dried. The peptide was extracted from the resin with acetic acid (4 x 20 ml) and lyophilized to yield 110 mg. The peptide was purified using counter current distribution (B:A:W, 4:1:5; 200 transfers). The major fractions were pooled,
  • the resin supported intermediate Boc-Ser (Bzl)-Gln-Asn- [3(R)-AHPPA]-Val-Val-BHA was prepared in the usual manner on a 1 mm scale. Omitting the acetylation step, the peptide was cleaved from the resin with removal of the benzyl protecting group by treatment with HF (10 ml) and anisole (1 ml) at 0° for 60 min. The HF was removed under vacuum at 0°. The residue was triturated with diethyl ether and the peptide was extracted from the residue with acetic acid (4 x 10 ml). The acetic acid extract was lyophilized to yield 85 mg. 40 mg of the crude peptide was purified by preparative HPLC
  • the resin supported peptide intermediate Boc-Ser (Bz)-Gln-Asn-[3(S)-AHPPA]-Val-Val-NH 2 was prepared in the usual manner on a 1 mm scale.
  • the peptide was cleaved from the resin, deblocked and purified in the same manner as in
  • Example 21(d) The compound of Example 21(d) (5 mg, 6.2 mmol) was dissolved in trifluoroacetic acid (.25 ml). After 90 min., the solution was concentrated under vacuum, the residue was dissolved in methanol (.5 ml) and concentrated HCl (about .025 ml) was added. The solution was concentrated, the resulting gum was triturated with ether and dried under vacuum to afford the titled compound (4.5 mg.) as a white solid.
  • Example 23(f) The product of Example 23(f) (1.3 mg, 1.6 mmol), was dissolved in trifluoroacetic acid. After 90 min. the solution was concentrated to dryness under vacuum. The residue was triturated with ether and the ether was removed under vacuum to yield the titled hexapeptide as a white solid.
  • Example 23(f) Using the procedure of Example 23(f), the hexapeptide of Example 23(e) (23 mg, 26 mmol) was debenzylated to provide the titled compound as a white solid (18.9 mg, 23.5 mmol; 90% yield).
  • Example 27 The compound of Example 25 (1.2 mg, 1.5 mmol) was dissolved in trifluoroacetic acid. After 90 min. the solution was concentrated to dryness under vacuum. The residue was triturated with ether to yield a white solid.
  • Example 27
  • Example 27(d) The product of Example 27(d) (12 mg, 15 mmol) was dissolved in trifluoroacetic acid (0.5 ml). After 90 min the solution was concentrated under vacuum; the residue was dissolved in methanol (1 ml) and cone. HCl (ca .05 ml) was added. The solution was concentrated, the resulting gum was triturated with ether and dried under vacuum to afford the titled compound (11 mg) as a white powder.
  • Example 27 Using the procedure of Example 27 (d), the above compound of Example 32(c) (23 mg, 24 mmol) was hydrogenolyzed to provide the titled compound (19.1 mg, 22
  • Trimethylsilyl bromide (4.0 ml, 30 mmol) was added to a solution of the compound of Example 32(d) (9.6 mg, 11.3 mmol) in dry CH 2 Cl 2 (1 ml). After 4.5 hr 1:1 water:acetic acid
  • N-methyl morpholine (0.27 ml, 2.5 mmol)
  • isobutyl chloroformate 0.246 ml, 1.9 mmol
  • Example 35(b) The tripeptide of Example 35(b) (115 mg, .179 mmol) is treated with trifluoroacetic acid and HCl according to the procedure of Example 34 (c).
  • the resulting hydrochloride salt was coupled to Boc-Ser (Bzl)-Ala-Ala (83 mg, .19 mmol) using N-methyl morpholine (50 mg, .51 mmol), and
  • hexapeptide was obtained as white crystals (40 mg; 25% yield) .
  • Example 35(c) 39 mg, 40.6 mmol was deprotected by the hydrogenolysis procedure of Example 34 (d).
  • the titled compound was obtained as white crystals (2.3 mg;

Abstract

Peptide mimics of the retrovirus protease polyprotein substrate bind to viral proteases and are useful in assaying for protease activity or inhibiting protease activity and in treating viral disease.

Description

TITLE
RETROVIRAI, PROTEASE BINDING PEPTIDES
BACKGROUND
Retroviruses, that is, viruses within the family of Retroviridae, are a class of viruses which transport their genetic material as ribonucleic acid rather than
deoxyribonucleic acid. Also known as RNA-tumor viruses, their presence has been associated with a wide range of diseases in humans and animals. They are beIleved to be the causative agents in pathological states associated with infection by Rous sarcoma virus (RSV), murine leukemia virus (MLV), mouse mammary tumor virus (MMTV), feline leukemia virus (FeLV), bovine leukemia virus (BLV), Mason-Pfizer monkey virus (MPMV), simian sarcoma virus (SSV), simian acquired immunodeficiency syndrome (SAIDS), human T-lymphotropic virus (HTLV-I, -II) and human immunodeficiency virus (HIV-1, HIV-2), which is the etiologic agent of AIDS (acquired immunodeficiency syndrome) and AIDS related complexes, and many others. Although the pathogens have, in many of these cases, been isolated, no effective method for treating this type of infection has been developed. Among these viruses, the HTLV and HIV have been especially well characterized. Although diverse in detail, all retroviruses are rather similar in overall structure. The extracellular virus particle is composed of an outer membrane studded with viral glycoproteins, a core of structural proteins, and a genome of single stranded ribonucleic acid. The retroviral genome has a distinctive regional organization, referred to as the 5'-gag-pol-env-3' structure, wherein the gag region encodes the core structural proteins, the pol region encodes certain critical viral enzymes such as reverse transcriptase,
integrase and protease, and the env region encodes the envelope glycoproteins. Viral replication occurs only within host cells and is dependent upon host cellular functions. Critical to this replication is the production of functional viral proteins. Protein synthesis is accomplished by
translation of the open reading frames into polyprotein constructs, corresponding to the gag, pol and env reading frames, which are processed, at least in part, by a viral protease into the functional proteins. The proteolytic activity provided by the viral protease in processing the polyproteins cannot be provided by the host and is essential to the life cycle of the retrovirus. In fact, it has been demonstrated that retroviruses which lack the protease or contain a mutated form of it, lack infectivity. See Katoh et al., Virology. 145, 280-92(1985), Crawford, et al., J.
Virol., 53, 899-907(1985) and Debouk, et al., Proc. Natl. Acad. Sci. USA. 84, 8903-6(1987). Inhibiton of retroviral protease, therefore, presents a method of therapy for retroviral disease.
Retroviral proteases have not been well characterized. Both the proteases and their polyprotein substrates are recovered from virion particles in very low yield. To assess their activity, it is necessary to provide a substrate to express the proteolytic activity. Use of the
natural substrate to assay proteolytic activity presents experimental difficulty in production, purification and quantitation of the substrate and its hydrolysis products. Many of these disadvantages can be overcome by the use of a small peptide which can be produced synthetically, and in pure form, to assay proteolytic activity. It is therefore highly desirable and advantageous to produce small peptides which may be used as substrates for these enzymes.
Proteases are enzymes which cleave peptide bonds in proteins and polypeptides. They are present in most
biological systems, where they serve both metabolic and regulatory functions. Their role in metabolism is to hydrolyze polypeptides to smaller peptides and ultimately to their constituent amino acids. Their role in biological regulation is pervasive and is the subject of several reviews. See as an example Biological Functions of
Proteinases, edited by H. Holzer and H. Tschesche, SpringerVerlag, Berlin-Heidelberg-New York (1979).
One of their regulatory roles is that of posttranslational processing of polypeptides to form functional proteins, enzymes and mediators. Essential to their
regulatory function is their ability to act selectively upon polypeptides. This selectivity is comprised of two factors, 1.) their ability to act upon specific substrates and 2.) their ability to hydrolyze only specific peptide bonds. On a structural level this substrate specificity is the result of the primary amino acid sequence, the resultant local
conformation of the substrate polypeptide and the amino acids which form the peptide bond at the cleavage site.
Sequence information regarding the putative cleavage site in polyprotein natural substrates is available for several retroviral proteases. However, peptide substrates for retroviral proteases are heretofore unknown. Further, since the binding interactions of the natural substrate are unknown, it is often difficult to predict what length peptide will be acceptable. In a similar manner, since the
conformation of a large polypeptide may be significantly different than that of a small peptide, it is difficult to predict which amino acid sequence will bind optimally in a small peptide.
Examination of viral proteins by amino acid sequencing has suggested certain common amino acid residues within the cleavage region for retroviral proteases. For instance, Casey, et al., J. Virol., 55, 417-23(1985) disclose the amino terminal sequence of the mature p24 gag protein from HIV-1 as Pro-Ile-Val-Gln-Asn, indicating that a proline residue is involved in the cleavage site. diMarzo Veronese, et al.,
Science, 231, 1289-90(1986) have proposed a cleavage site (indicated by *) for the reverse transcriptase (RT) of ThrLeu-Asn-Phe*-Pro which gives RT a proline amino terminus.
Debouck, et al., Proc. Natl. Acad. Sci. USA, 84, 890306(1987), have suggested that the protease of HIV-1 is autocatalytic and disclose that the amino terminus of the protease contains the sequence Pro-Gln-Ile-Thr-Leu. Pearl, et al., Nature, 328, 482(1987) have compared certain core precursor polypeptide substrates for a large group of
retroviruses and suggest a sequence preference for cleavage at X-Pro for the retroviral proteases, wherein X is usually either an aromatic (Phe, Tyr) or a large and hydrophobic (Met, Leu) amino acid. It is further suggested that this sequence is usually flanked on either side by a small and hydrophobic amino acid.
The structure of many retroviral proteases has been examined, based primarily upon their predicted amino acid sequence deduced from their nucleotide structure. They are generally encoded at the 5' end of the pol region, the 3' end of gag region or between (but out of frame with)
the two regions. Yasunaga et al., FEBS Lett., 199, 2 , 14549(1986) disclose good sequence homology between famiIles of retrovirus and demonstrate several highly conserved sequences among members of the lentivirus family and the HTLV/BLV subfamily of retroviruses.
Methods to express retroviral proteases in E. coli have been disclosed by Debouck, et al., Proc. Natl. Acad. Sci. USA, 8903-06(1987) and Graves, et al., Proc. Natl. Acad. Sci. USA, 85, 2449-53(1988) for the HIV-1 virus.
Little biochemical characterization of retroviral proteases has been undertaken to date. However, it has been suggested by Katoh, et al., Nature. 329, 654-6(1987), that certain retroviral proteases may be acid proteases. This is based upon the observation that pepstatin, a known acid protease inhibitor, has been shown to be a weak inhibitor of the retroviral proteases associated with bovine leukemia virus, Moloney murine leukemia virus and human T-cell leukemia virus.
Methods for producing protease inhibitors of retroviral proteases have been disclosed by Kettner, et al., U.S. Patent No. 4,636,492 and Kettner, et al., U.S. Patent No. 4,644,055. Accordingly, tri- and tetra-peptides which substantially correspond to the amino acid sequence of the cleavage site of the substrate of the protease are modified to possess a C-terminal halomethyl ketone moiety. The halomethyl ketone, being a reactive moiety, is presumed to react with the protease once binding of the peptide has been effected.
Although unrelated to retroviral proteases, Umezawa et al. have isolated inhibitors of a diverse group of proteases by screening microbial culture filtrates. See Proteinase Inhibitors: Medical and Biological Aspects, eds. Katunuma et al., pp. 3-15(1983), Japan Sci. Soc. Press, Tokyo/SpringerVerlag, Berlin. Certain of these peptide inhibitors, such as bestatin, amastatin and pepstatin, contain unusual amino acids which are not α-amino acids. These inhibitors are beIleved to function by presenting a non-hydrolyzable carboncarbon bond to the proteolytic enzyme at the scissile site.
Pepstatin, a pentapeptide inhibitor isolated from a Streptomyces culture, has been shown to inhibit a wide range of acid proteases, and has attracted attention due to its ability to inhibit renin and pepsin. (See Umezawa, H. et al., J. Antibiot., Tokyo, 23, 259-263(1970).) Pepstatin contains the unusual amino acid, (3S, 4S)-4-amino-3-hydroxy-6-methylheptanoic acid (AHMHA), called statine, in two
positions of the pentapeptide. This unusual amino acid is not an α-amino acid, but is beIleved to function as a
dipeptide mimic and present a carbon-carbon bond to the enzyme instead of a scissile peptide bond. Peptide
derivatives containing statine, have been used to inhibit the human proteases renin and pepsin. (See Cazaubon et al., U.S. Patent No. 4,481,192.) Modifications of pepstatin to optimize its activity toward the inhibition of renin, have been made by several groups. Rich et al., J. Med. Chem., 23, 27-33(1980), have shown that the chirality of the statine incorporated into pepstatin is important for binding and have made
modifications of statine to probe the relationship between structure and inhibitory activity. Thus, (3S, 4S)-4-amino-3- hydroxy-5-phenylpentanoic acid (AHPPA) showed activity similar to statine when incorporated into peptides in place of statine.
Other "dipeptide analogues" which contain a carboncarbon bond in place of a peptide bond have been synthesized and studied by several groups. Many of these attempts have involved structures closely related to statine by
modification of the carbon bearing the hydroxyl group and the adjacent carbon. Thus, oxo derivatives, diamino derivatives, dihydroxy derivatives (Thaisrivongs et al., J. Med . Chem., 30, 976-82(1987)), deshydroxy derivatives (Rich et al., J. Med. Chem.. 23, 27-33(1980)), phosphorous-containing
derivatives (Grannousis, et al., J. Med. Chem., 1603¬
09(1987)) and fluoro derivatives (Fearon et al., ________________
Chem., 30, 1617-22(1987) and Thaisivongs et al., J. Med.
Chem., 20, 2080-87(1986)) of statine have all been
synthesized and reported for their ability to inhibit renin or pepsin. Variations, in which a substituted methylene group is inserted α to the carboxyl group of statine have also been reported for inhibition of renin (Luly et al., European Patent Application EP 229667, Fung et al., PCT Patent Application PCT/WO 88/05050; Evans, U.S. Patent
4,665,055; Hester et al., European Patent Application EP 173 481). These "dipeptide analogues" have shown variable abilities to inhibit renin and pepsin, their specific acitvity being also dependent upon adjacent moieties which mediate binding to these enzymes. The synthetic methods employed within these disclosures are incorporated herein by reference.
There exists a need for peptides which bind retroviral proteases in order to assay protease activity and to provide inhibitors of retroviral protease activity for pharmaceutical use. Such pharmaceutical use provides therapy for diseases which have been heretofore untreatable.
SUMMARY OF THE INVENTION
This invention comprises peptides, hereinafter
represented as formula (I), which bind to retroviral
proteases. In one respect, these peptides are useful as substrates for assaying protease activity. In another respect, these peptides are inhibitors of viral protease and are useful for treating disease related to infection by these agents.
This invention is also a pharmaceutical composition, which comprises a compound of formula (I) and a
pharmaceutically acceptable carrier.
This invention further constitutes a method for treating viral disease, which comprises administering to a mammal in need thereof an effective amount of a compound of formula
(I).
This invention also provides a method for assaying viral protease activity.
In yet another aspect, this invention is a compound, as shown hereinafter as formula (lIb), which can be used as an intermediate in the preparation of the peptides of formula (I), which renders the peptide resistant to degradation by a viral protease.
DETAILED DESCRIPTION OF THE INVENTION
The peptides of this invention are illustrated by formula (I):
A-B-(Q)a-(C)b-(D)c-M-(W)d-(X)e-Y-Z
(I)
wherein: A is BocNH, CbzNH, H, R' R"N, R"CONR' or DnsNH, or if a,b and c are 0 and Y is a covalent bond, then A is H, Boc, Cbz, R" or R"CO;
B is one or more D or L amino acids, β-Ala or is a covalent bond;
C and D are the same or different and are Glx, Asx, Ala, β-Ala, Arg, Gly, Ile, Leu, Lys, Ser, Thr, Val, Met or His;
Q is a D or L amino acid and is Ser, Thr, Asp, His, Cys, Arg or Ala;
W is Pro or Δ3-dehydro-Pro ;
X is Ala, Gly, Ile, Leu, Val, Met, Lys, Glx or Asx; Y is one or more D or L amino acids, or is a covalent bond;
Z is CO2R"", CONR' R"", COR', CH2OH, CH2NR'R"" or H, or if d and e are 0 and Y is a covalent bond, Z is OR"" or NR'R""; a, b, c, d and e are each independently 0 or 1, provided that c and e are not simultaneouly 0;
M is Cha, Phe(4'Ra) or -NHCHR1R2-; wherein:
R1 is independently C1-5Alk, (CH2) nSC1-5Alk,
(CH2)nOC1-5Alk, (CH2)nC3-7cycloalkyl or (CH2) mC6H4-Ra; Ra is halogen, OR1, NO2, NH2 or H;
R2 is (CH2)n-, CHR3(CH2)mCO-, CO (CH2)mCO-,
CHR3CHR3,(CH2) mCO-, CHR3CHR3, CHR1(CH2) mCO-, CHR3CHR1CHR' (CH2)mCO-, CHR3CHR' CHR1 (CH2) mCO-,
COCHR1CHR' (CH2)mCO-, COCF2CR'R" (CH2) mCO-, COCF2 (CH2) mCO, CH=CR' CHR" (CH2 ) mCO-, COCH=CR' (CH2)mCO-,
CH2S(O)pCHR' (CH2)mCO-, CH2NR'CHR" (CH2)mCO-,
P=O(OR') (CH2)mCO-, K v
Figure imgf000011_0001
R3 and R3' are each independently OH, H or NH2; R4 is OH, H, NH2 or =0; m is independently 0, 1, 2 or 3; n is independently 1 or 2; p is 0, 1 or 2; and
R' is H or C1-5Alk;
R" is H or C1-18Alk;
R"" is H, C1-5Alk, C3-6Cycloalkyl, (CH2)nC6H5,
(CH2)nC5H4N, (CH2)nOH, (CH2)nNH2, or (CH2)nNHC (NH)NH2; and pharmaceutically acceptable salts thereof.
Also included in this invention are pharmaceutically acceptable addition salts, complexes or prodrugs of the compounds of this invention. Prodrugs are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) in vivo. Inasmuch as it may differ from conventional notation, it should be noted in formula (I) that A comprises the terminal amino group of the peptide and Z comprises the terminal carboxyl group of the peptide. Thus, when A and Z are H, the terminal residues of the peptide are "des-amino" and "descarboxy" amino acids respectively.
Employing this representation, A comprises the terminal amino group of the residue corresponding to B; or, when B is a covalent bond, to Q; or, when a is 0 and B is a covalent bond, to C; or when B is a covalent bond and a and b are 0, to D. When B is a covalent bond and a, b, and c are 0, the amino group of M is substituted by an acyl or alkyl group, as specially provided by A in formula (I). In similar fashion, Z comprises the terminal carboxyl group of the amino acid residue corresponding to Y; or when Y is a covalent bond, to X; or When Y is a covalent bond and d and e are 0, the terminal carboxyl group of M is substituted by Z as specially provided in formula (I).
The operation of the subscripts a-c in formula (I) is to denote that residues may be removed from the amino terminus of the peptide with retention of utility in the compounds. Such operation is intended to proceed in a sequential fashion; such that a is not 0 unless, Y is a covalent bond, b is not 0 unless a is 0, and c is not 0 where b is 0. At the carboxy terminus, e is not 0 unless Y is a covalent bond. As more fully described hereinafter, d operates independently and is 1 when M is Cha or Phe(Ra), and either 1 or 0, preferably 0, when M is -NHCHR1R2.
Other abbreviations and symbols commonly used in the art are used herein to describe the peptides.
3 1 3 1
Amino Acid letter letter Amino Acid letter letter
code code code code
Alanine Ala A Leucine Leu L
Arginine Arg R Lysine Lys K
Asparagine Asn N Methionine Met M
Aspartic AcidAsp D Phenylalanine Phe F
Cysteine Cys C Proline Pro P 3 1 3 1
Amino Acid letter letter Amino Acid letter letter
code code code code
Glutamine Gln Q Serine Ser S
Glutamic Acid Glu E Threonine Thr T
Glycine Gly G Tryptophan Trp W
Histidine His H Tyrosine Tyr Y
Isoleucine Ile I Valine Val V
Asparagine or Aspartic Acid Asx B
Glutamine or Glutamic Acid Glx Z
In accordance with conventional representation, the amino terminus is on the left and the carboxy terminus is on the right. Unless specified otherwise, all chiral amino acids (AA) are assumed to be of the L absolute configuration. (4'Ra)Phe refers to phenylalanine substituted in the 4 position of the phenyl ring by Ra. It should be appreciated that when Ra is hydrogen, the residue constitutes
phenylalanine and when Ra is OH, the residue constitutes tyrosine. β-Ala refers to 3-amino propanoic acid. Cha refers to cyclohexylalanine. Boc refers to the t- butyloxycarbonyl radical, Dns refers to the dansyl radical, which is 1-dimethylamino napthylene-5-sulfonyl, Cbz refers to the carbobenzyloxy radical, BrZ refers to the o-bromobenzyloxycarbonyl radical, Clz is the p-chlorocarbobenzyloxy radical, CI2Z refers to the 2,4-dichlorocarbobenzyloxy radical, Bzl refers to the benyzl radical, MeBzl refers to the 4-methyl benzyl radical, Ac refers to acetyl, Alk or C1-5Alk refers to C1-5 alkyl, Ph refers to phenyl, DCC refers to dicyclohexylcarbodiimide, DMAP refers to dimethylaminopyridine, HOBT refers to 1-hydroxybenzotriazole, NMM is N-methylmorpholine, DTT is dithiothreitol, EDTA is ethylenediamine tetraacetic acid, DIEA is diisopropyl ethylamine, DBU is 1,8
diazobicyclo [5.4.0]undec-7-ene, DMSO is dimethylsulfoxide, DMF is dimethyl formamide and THF is tetrahydrofuran. HF refers to hydrofluoric acid and TFA refers to trifluoroacetic acid. C1-5alkyl as appIled herein is meant to include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tertiary butyl, pentyl and isopentyl. As used herein in the compounds of this invention, Asp and Glu, which have
carboxylic acid side chains, encompass free carboxylic acids, C1-5alkyl and benzyl ester side chains. C1-18Alk is intended to include any straight or branched chain alkyl group of 1 to 18 carbons.
The peptides of this invention bind to viral proteases in a manner which mimics the binding of the natural
substrate. The peptides are generally dodecapeptides or smaller. However, longer peptides which encompass the residues defined herein as -Q-C-D-M-W-X-, as given in formula (I), are also beIleved to be active and are considered within the scope of this invention. The residues closest to the putative cleavage site of the peptide, designated as M-W, are most important for binding. X is preferably a neutral or acidic amino acid. Suitably, X is Ala, Gly, Ile, Leu, Val, Met, Lys, Glx or Asx. Valine is especially suitable. D is preferably a neutral and hydrophobic amino acid, although certain hydrophilic residues such as Asp and Ser are
acceptable. Gln, Asn, Ala, β-Ala, Ile, Leu, Val and Met are preferred. Gln, Asn and Ala are especially preferred. The residue corresponding to C may be a neutral, acidic or basic amino acid. Glu, Gln, Arg, Lys, Ser, Ala, β-Ala, Asn and Gly are suitable. Gln, Asn and Ala are especially preferred for C. The residue Q is preferably a hydrophilic residue, such as D- or L-, Ser, Thr, Asp or His. Especially preferred are Thr and Ser.
B corresponds to one or more amino acids, which may be hydrophilic or hydrophobic, or it may be a covalent bond in the shorter peptides. The identity of B is not critical and a residue may be chosen for the favorable physico-chemical and biochemical properties it confers on the overall peptide, such as water solubility and resistance to exopeptidases. The choice of a D-amino acid often confers resistance to exopeptidases when the D-amino acid is at the terminus of the peptide. When B is a covalent bond, it may be advantageous for Q to be a D-amino acid. When B is not a covalent bond, B is preferably one or two D- or L-amino acids chosen from Ala, β-Ala, Gly, Ile, Val, Leu, Met, His, Lys, Arg, Glx, Asx, Cys,
Ser or Thr. For producing the smallest peptides of this invention which bind to retroviral protease, B is preferably a covalent bond.
Y may correspond to one or more amino acids, or a covalent bond. If it is one or more amino acids, they may be hydrophilic or hydrophobic. One to three residues are preferred, but a longer chain is acceptable. In much the same manner as B, the residues of Y may be used to confer favorable biochemical or physio-chemical properties to the peptide. Thereby, the use of hydrophilic residues may be used to confer desirable solubility properties or D-amino acids at the carboxy terminus may be used to confer
resistance to exopeptidases. Preferably Y is one to three amino acids chosen from Ala, Gly, Ile, Leu, Met, Val, Arg, Lys, Thr, Ser, Cys, Glx or Asx. For the shorter peptides of this invention, Y may be a covalent bond but a single amino acid is especially suitable. Ala, Gly, Ile, Met, Arg, Asx and Val are preferred. Valine is especially preferred.
Peptides wherein M is Cha or Phe(4'Ra) and d is 1 may act as substrates, and are hydrolyzed to smaller peptides. Although the substrates may generally be of any length, 6-9 residues is preferred. These are conveniently used to assay for protease activity. In addition, they may compete with the natural viral substrates and thereby serve to inhibit viral replication and, hence, disease progression in vivo; although, due to their metabolic instability, their duration of action may be short. Typically, these peptides may be used in an assay for protease activity by subjecting the peptide to the protease in a suitably buffered medium.
Analysis of the activity is carried out in such a manner as to detect the hydrolytic cleavage of the peptide. One such method constitutes the separation of at least one of the product peptides, or a derivative thereof, and its
quantitation.
In such assay, chromatographic means can be used to effect the separation of the peptide products using conventional solid supports such as silica gel, octadecyl silane, Sephadex®, ion exchange resins or adsorption resins. Detection/quantitation of the products is effected by ultraviolet absorption or other spectroscopic analysis.
Alternatively, incorporation or substitution of a radioactive isotope in the peptide, such as tritium or 13C label in one or more of the amino acids, provides for
detection/quantitation based upon radioactivity. In another alternative, incorporation of a fluorescent moiety, such as a dansyl group on the amino terminus of the peptide, provides for fluorescent detection/quantitation. Fluorogenic methods, which would incorporate a quenching agent into the peptide, such as a 3-(4-N-methyl-pyridyl)-propyl oxy ester of the carboxy terminus, in addition to the fluorescent marker, would also be useful to assay protease activity. Such methods are disclosed, for example, by Dunn, et al., Anal. Biochem.. 129, 502(1983), and provide for continuous
monitoring of the activity. These fluorogenic methods have advantages in that the hydrolysis is observed directly without a need for separation of the hydrolysis products.
The protease binding activity of the peptides of this invention, wherein M is Cha or (4'Ra)Phe, is demonstrated by their ability to act as substrates. The following table illustrates the substrate kinetics of these peptides.
Table I
Substrate Kinetics of
Peptides Binding to rHIV Protease
Compound of Rel. KM Kcat
Example No. Vo (mM) (min-1)
1 1.0 6.7 42
39 1.0 6.9 41
40 .35 8.6 16
41 neg.* - -
42 1.34 1.9 21
43 .48 20 30
44 .48 2.2 5 Table I (Continued)
Substrate Kinetics of
Peptides Binding to rHIV Protease
Compound of Rel. KM Kcat
Example No. Vo (mM) (min-1)
45 .46 11 21
46 1.23 2.3 12
47 .36 8 15
48 1.0 6.8 35
49 .65 6.0 18.4
50 .32 5.0 1.8
51 neg.* - -
52 neg.* - -
53 .71 1.6 12
54 .39 .71 2.03
55 .86 6.5 23.0
56 1.45 1.2 31
57 neg.* - -
59 .56 3.3 8.0
60 .54 8.0 18
61 .51 2.3 6.4
62 .05 - -
63 .045 4.9 1.8
64 1.24 - -
65 .11 19 14
66 1.25 11.7 183
67 .07 - -
68 .98 - -
69 .70 - -
70 .56 - -
95 neg.* 12.8 5.3
96 .34 17.7 90.4
98 .16 25 65
99 .09 6.2 1.4
100 .045 1.8 .38
101 .06 6.2 7.8 Table I (Continued)
Substrate Kinetics of
Peptides Binding to rHIV Protease
Compound of Rel. KM Kcat
Example No, Vo (mM) (min-1)
102 1.27 7.7 96
105 1.09 - -
107 .24 - -
108 neg.* - -
109 1.24 - -
110 1.29 9.8 103
111 1.33 34 374
112 neg.* - -
113 neg.* - -
115 .48 7.1 16
118 neg.* - -
119 neg.* 30 -
121 .80 .96 16.6
*negligible
-not done
In another respect, these substrate peptides in which M is Cha or Phe(4'Ra) are also useful indicators for
discovering amino acid sequences which bind to viral
proteases and thereby inhibit the proteolytic activity.
Modifications of such peptides which bind to viral proteases so as to retard the hydrolysis of the peptide provide a means for effecting longer lived inhibition of protease activity.
Accordingly, another subgeneric group of compounds of this invention comprises the peptides wherein the residue M is -NHCHR1R2-. These peptides contain an unnatural amino acid, which is not an α-amino acid. These peptides do not possess a peptide bond in the same manner as a substrate and therefore, although they bind to the protease in a manner which mimics the binding of the natural substrate, are resistant to hydrolysis. Peptides of 2-9 residues are suitable. Peptides of 3-6 residues are preferred. Preferably when M is -NHCHR1R2-, d=0 and W is absent, since the unnatural amino acid may act as a dipeptide mimic. In one preferred embodiment R1 is CH2C6H4-Ra, CH2C6H11 or C1-5Alk. R2 is preferably CHR3CHR3' (CH2) mCO-, CHR3CHR3'CHR1CO-,
CHR3CHR1CHR,CO-, CHR3 (CH2)mCO-, CO(CH2)mCO-,
COCHR1CHR' (CH2)mCO-, CHR3CF2 (CH2) mCO-, -COCF2 (CH2) mCO-,
-P=O(OR') (CH2)mCO-
Figure imgf000019_0001
wherein, R', R3, R3', m and n have the meanings defined in formula (I). In preferred embodiments, R1 is CH2C6H4-Ra and R2 is CH(OH) CH2CH2CO-. Suitably the peptides of formula (I) have the partial structure -Ala-NHCH (CH2Ph) CH (OH) CH2CH2CO-Val-Val-.
When administered to an animal infected or potentially infected with a virus, which is dependent upon a virally encoded protease for processing of viral polyproteins, viral replication is inhibited, hence, disease progression is retarded. Inasmuch as there appear to exist consensus
sequences for the polyprotein substrates of various
retroviruses, an inhibitor or substrate is likely to be broadly active over the range of retroviruses. DNA viruses, which are dependant upon virally encoded proteases, such as the hepatitis virus, may also be susceptible to such
treatment.
The following compounds are included in, but in no way limit, the scope of this invention:
2-(acetyl-serylglutaminylasparaginyl)amino-3-phenylpropyl-prolylvalyl valinamide;
2-(serylglutaminylasparaginyl)amino-3-phenylpropyl-prolylvalyl valinamide;
2-(acetyl-serylglutaminylasparaginyl)amino-3-hydroxy-1-oxo-5-phenylpentylprolylvalyl valinamide; 2-(acetyl-serylglutaminylasparaginyl)amino-3-hydroxy-1-oxo-5-phenylpentylvalyl valinamide;
2-(seryl glutaminylasparaginyl)amino-3(S)-hydroxy-1-oxo-5-phenyl pentylvalyl valinamide;
2-((2-(tert-butoxycarbonyl-serylalanylalanyl)amino-1-oxo-3-phenylpropyl)cyclopentylcarbonylvalyl valine methyl ester;
2-(2-(serylalanylalanyl)amino-1-oxo-3-phenylpropyl)cyclopentyl-carbonylvalylvaline methyl ester, trifluoracetic acetic acid salt;
2-(2-(tert-butdxycarbonyl-serylalanylalanyl)amino-1-hydroxy-3-phenylpropyl)cyclopentylcarbonylvalyl valine methyl ester;
2-(-1-hydroxy-3-phenyl-2-(serylalanylalanyl)amino-propyl)cyclopentylcarbonylvalylvaline methyl ester,
trifluoracetic acid salt;
2-((1-methoxy-1-(2-phenyl-1-(tert-butyloxycarbonyl-seryl-alanylalanyl)amino)ethyl)phosphinyl) cyclopentylcarbonylvalylvaline methyl ester;
2-((1-hydroxy-1-(2-phenyl-1-(serylalanylalanyl)amino) ethyl)phosphinyl)cyclopentylcarbonyl-valyl valine methyl ester;
5-(tert-butoxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester;
5-(tert-butoxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxy-phenyl)hexyl-valyl valine methyl ester;
4-(tert-butoxycarbonyl-serylalanylalanyl)amino-2,2-difluoro-3-hydroxy-1-oxo-5-phenylpentyl-valyl valine methyl ester, hydrochloride;
4-(serylalanylalanyl)amino-2,2-difluoro-3-hydroxy-1-oxo- 5-phenylpentyl-valyl valine methyl ester, hydrochloride;
4-(serylalanylalanyl)amino-2,2-difluoro-1,3-dioxo-5-phenylpentyl-valyl valine methyl ester, hydrochloride;
5-(t-butyloxycarbonylserylalanylalanyl)amino-4-hydroxy- 6-(4-hydroxy)phenyl-1-oxo-hexyl-valyl amide
5-((carbobenzyloxy-D-seryl)alanylalanyl)amino-4-hydroxy- 1-oxo-6-phenylhexyl-valyl valine methyl ester;
5-((D-seryl)alanylalanyl)amino-4-hydroxy-1-oxo-6- phenylhexyl-valyl valine methyl ester; 5-(t-butyloxycarbonylserylalanylalanyl)amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine;
5-(serylalanylalanyl)amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine, hydrochloride;
2-((1-hydroxy-2-(serylalanylalanyl)amino-3-cyclohexyl)-propyl)cyclopentanecarbonyl-valyl valine methyl ester, hydrochloride;
2-((2-(tert-butoxycarbonyl-serylalanylalanyl)amino-1-oxo-3-phenylpropyl)cyclopentylcarbonylvalyl valinamide;
2-(2-(serylalanylalanyl)amino-1-oxo-3-phenylpropyl)cyclo-pentylcarbonylvalylvalinamide, trifluoracetic acetic acid salt;
2-(2-(tert-butoxycarbonyl-serylalanylalanyl)amino-1-hydroxy-3-phenylpropyl)cyclopentylcarbonylvalyl valinamide;
2-(-1-hydroxy-3-phenyl-2-(serylalanylalanyl)amino-propyl)-cyclopentylcarbonylvalylvalinamide, trifluoracetic acetic acid salt;
2-((1-methoxy-1-(2-phenyl-1-(tert-butyloxycarbonyl-seryl-alanylalanyl)amino)ethyl)phosphinyl) cyclopentylcarbonyl-valylvalinamide;
2-((1-hydroxy-1-(2-phenyl-1- (serylalanylalanyl)amino)ethyl)-phosphinyl)cyclopentylcarbonyl-valyl valinamide;
5-(tert-butoxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valinamide;
5-(tert-butoxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxy-phenyl)hexyl-valyl valinamide;
4-(tert-butoxycarbonyl-serylalanylalanyl)amino-2,2-difluoro-3-hydroxy-1-oxo-5-phenylpentyl-valyl valinamide, hydrochloride;
4-(serylalanylalanyl)amino-2,2-difluoro-3-hydroxy-1-oxo-5-phenylpentyl-valyl valinamide, hydrochloride;
4-(serylalanylalanyl)amino-2,2-difluoro-1,3-dioxo-5-phenylpentyl-valyl valinamide, hydrochloride;
5-((carbobenzyloxy-D-seryl)alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valinamide;
5-((D-seryl)alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valinamide; 5-(t-butyloxycarbonylserylalanylalanyl)amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valinamide;
5-(serylalanylalanyl)amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valinamide, hydrochloride;
2-((1-hydroxy-2-(serylalanylalanyl)amino-3-cyclohexyl)-propyl)cyclopentanecarbonyl-valyl valinamide, hydrochloride;
(4S,5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester, acetic acid salt;
(4S,5S)-5-((carbobenzyloxy-β-alanyl)alanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester;
(4S,5S)-5-((β-alanyl)alanyl)amino-4-hydroxy-1-oxo-6-(4- hydroxyphenyl)hexyl-valyl valine methyl ester, hydrochloride;
(4S, 5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-cyclohexyl-hexyl-valyl valine methyl ester;
(4S,5S)-5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester;
(4S,5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester;
(4S,5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valinamide, acetic acid salt;
(4S,5S)-5-((carbobenzyloxy-β-alanyl)alanyl)amino-4- hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valinamide;
(4S,5S)-5-((β-alanyl)alanyl)amino-4-hydroxy-1-oxo-6-(4- hydroxyphenyl)hexyl-valyl valinamide, hydrochloride;
(4S, 5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6- cyclohexyl-hexyl-valyl valinamide;
(4S,5S)-5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-1- oxo-6-phenylhexyl-valyl valinamide;
(4S,5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6- phenylhexyl-valyl valinamide; (4S,5S)-5-(carbobenzyloxyalanyl)amino-4-hydroxy-1-oxo-6- phenylhexyl-valyl valine methyl ester; (4S,5S)-5-(alanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine, acetic acid salt;
(4S,5S)-5-(tert-butyloxycarbonylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester;
(4S,5S)-5-alanylamino-4-hydroxy-1-oxo-6-(4- hydroxyphenyl)-hexyl-valyl valine methyl ester, acetic acid salt;
(4S,5S)-5-(carbobenzyloxyalanyl)amino-4-hydroxy-1-oxo-6- phenylhexyl-valyl valinamide;
(4S,5S)-5-(alanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valinamide;
(4S,5S)-5-(tert-butyloxycarbonylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valinamide;
(4S,5S)-5-(alanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)-hexyl-valyl valinamide, acetic acid salt;
(4RS,5S)-5-amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine benzyl ester, hydrochloride;
(1R,2R)-2-(((1S,2S)-1-hydroxy-2-amino-3-cyclohexyl)propyl)-cyclopentanecarbonyl-valyl valine methyl ester, hydrochloride;
(4S,5S)-5-amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester, hydrochloride;
(4S,5S)-5-(tert-butyloxycarbonyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester;
(4RS,5S)-5-amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valinamide, hydrochloride;
(1R,2R)-2-(((1S,2S)-1-hydroxy-2-amino-3- cyclohexyl)propyl)-cyclopentanecarbonyl-valyl valinamide, hydrochloride;
(4S,5S)-5-amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valinamide, hydrochloride;
(4S,5S)-5-(tert-butyloxycarbonyl)amino-4-hydroxy-1-oxo- 6-phenylhexyl-valyl valinamide;
(5S)-5(carbobenzyloxyalanyl)amino-4-hydroxy-1-oxo-6-phenyl-hexyl-valine, isobutyl amide; (5S)-5-(myristyl)amino-4-hydroxy-1-oxo-6-phenyl-hexyl valine, isobutyl amide;
(5S)-5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-1-oxo-6-phenyl-hexyl valine, isobutylamide;
(5S)-5-(stearyl)amino-4-hydroxy-1-oxo-6-phenyl-hexyl valine, isobutyl amide;
5-(carbobenzyloxyalanyl)amino-4-hydroxy-2-methyl-1-oxo-6-phenyl-hexylvalyl valine, methyl ester;
7-methyl-5-(carbobenzyloxyalanyl)amino-3,4-dihydroxy-2-phenyl-1-oxo-octyl valine, isobutylamide;
5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl valine, isobutyl amide;
5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy- (1-oxo)hexyl-valyl valinol;
carbobenzyloxy-alanyl-(3-hydroxy-5-amino-6-phenyl)hexanoyl-valyl-(4-aminomethyl)pyridine;
5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-6-phenyl- (1-oxo)hexyl-valine isobutylamide;
(4S,5S)-5-(methoxycarbonyl-alanylalanyl)amino-6-phenyl-4-hydroxy-1-oxo-hexyl-valyl valine;
(4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-1-oxo-hexyl-valyl valine;
(4S,5S)-5-(alanylalanyl)amino-6-phenyl-4-hydroxy-1-oxo-hexyl-valyl valine;
(4RS,5S)-5-((tert-butyloxycarbonyl)isoleucyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl-(O-benzyl)aspartic acid methyl ester; and
(4RS,5S)-5-((tert-butyloxycarbonyl)isoleucyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl-aspartic acid methyl ester.
Certain individual preferred compounds are:
(4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4- hydroxy-1-oxo-hexyl-valyl valine methyl ester;
(4S,5S)-5-(alanylalanyl)amino-6-phenyl-4-hydroxy-1-oxo- hexyl-valyl valine methyl ester;
(4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4- hydroxy-1-oxo-hexyl-valyl valine methyl ester; (4S,5S)-5-(alanyl)amino-6-phenyl-4-hydroxy-1-oxo-hexyl-valyl valine methyl ester; and
(4RS,5S)-5-((tert-butyloxycarbonyl)isoleucyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl-(O-benzyl) aspartic acid methyl ester; and the carboxylic acids and carboxamides thereof.
The peptides of the invention are prepared by coupling the appropriate amino acid residues, optionally removing any protective groups and optionally modifying the amino or carboxy terminus of the peptide. They are prepared
preferably by the solid phase technique of Merrifield (J. Am. Chem. Soc.. 85, 2149 (1964)), although solution methods known to the art may be successfully employed. Solution methods or a combination of solid phase and solution methods may be used in a convergent synthesis in which di-, tri-, tetra-, or penta-peptide fragments are prepared by solid phase or solution synthesis and either coupled to other di-, tri- or tetra-peptides, or further modified by solution synthesis. The methods of peptide synthesis generally set forth in J. M. Stewart and J. D. Young, "Solid Phase Peptide Synthesis",
Pierce Chemical Company, Rockford, II (1984) or M. Bodonsky, Y. A. Klauser and M. A. Ondetti, "Peptide Synthesis", John Wiley & Sons, Inc., New York, N,Y. (1976) may be used to produce the peptides of this invention and are incorporated herein by reference.
Each amino acid or peptide is suitably protected as known in the peptide art. For example, the Boc- or
carbobenzyloxy-group is preferred for protection of the amino group, especially at the α position. A benzyl group or suitably substituted benzyl group is used to protect the mercapto group of cysteine, or other thiol containing amino acids; or the hydroxyl of serine or threonine. The tosyl or nitro group may be used for protection of the guanidine of Arg or the imidazole of His, and a suitably substituted carbobenzyloxy group or benzyl group may be used for the hydroxyl group of Tyr, Ser or Thr, or the ε-amino group of lysine. Suitable substitution of the carbobenzyloxy or benzyl protecting groups is ortho and/or para substitution with chloro, bromo, nitro or methyl, and is used to modify the reactivity of the protective group. Cysteine and other sulfur-containing amino acids may also be protected by formation of a disulfide with a thioalkyl or thioaryl group. Except for the Boc group, the protective groups are, most conveniently, those which are not removed by mild acid treatment. These protective groups are removed by such methods as catalytic hydrogenation, sodium in liquid ammonia or HF treatment as known in the art.
If solid phase methods are used, the peptide is built up sequentially starting from the carboxy terminus and working toward the amino terminus of the peptide. Solid phase synthesis is begun by covalently attaching the C terminus of a protected amino acid to a suitable resin, such as a
benzhydrylamine resin (BHA), methylbenzhydrylamine resin
(MBHA) or chloromethyl resin (CMR), as is generally set forth in U.S. Patent No. 4,244,946. A BHA or MBHA support resin is used if the carboxy terminus of the product peptide is to be a carboxamide. A CMR support is generally used if the carboxy terminus of the product peptide is to be a carboxyl group, although this may also be used to produce a
carboxamide or ester.
Once the first protected amino acid (AA) has been coupled to the desired resin, the amino group is hydrolyzed by mild acid treatment, and the free carboxyl of the second protected AA is coupled to this amino group. This process is carried out sequentially, without isolation of the
intermediate, until the desired peptide has been formed. The completed peptide may then be deblocked and/or split from the carrying resin in any order.
Treatment of a CMR supported peptide with HF or
HBr/acetic acid splits the peptide from the resin and produces the carboxy terminal amino acid as a carboxylic acid. Treatment of a CMR supported peptide with ammonia or alkyl amines in an alcoholic solvent provides a carboxamide or alkyl carboxamide at the carboxy terminus.
If an ester is desired, the CMR resin may be treated with an appropriate alcohol, such as methyl, ethyl, propyl, butyl or benzyl alcohol, in the presence of triethylamine to cleave the peptide from the resin and produce the ester directly.
Esters of the peptides of this invention may also be prepared by conventional methods from the carboxylic acid precursor. Typically, the carboxylic acid is treated with an alcohol in the presence of an acid catalyst. Alternatively, the carboxylic acid may be converted to an activated acyl intermediate, such as an acid halide or activated anhydride or ester, and treated with an alcohol, preferably in the presence of a base.
The preferred method for cleaving a peptide from the support resin is to treat the resin supported peptide with anhydrous HF in the presence of a suitable cation scavenger, such as anisole or dimethoxy benzene. This method
simultaneously removes all protecting groups, except a thioalkyl group protecting sulfur, and splits the peptide from the resin. Peptides hydrolyzed in this way from the CMR are carboxylic acids, those split from the BHA resin are obtained as carboxamides.
Modification of the terminal amino group of the peptide is accomplished by alkylation or acetylation as is generally known in the art. These modifications may be carried out upon the amino acid prior to incorporation into the peptide, or upon the peptide after it has been synthesized and the terminal amino group liberated, but before the protecting groups have been removed.
Typically, acetylation is carried out upon the free amino group using the acyl halide, anhydride or activated ester, of the corresponding alkyl acid, in the presence of a tertiary amine. Mono-alkylation is carried out most
conviently by reductive alkylation of the amino group with an appropriate aliphatic aldehyde or ketone in the presence of a mild reducing agent, such as lithium or sodium
cyanoborohydride. Dialkylation may be carried by treating the amino group with an excess of an alkyl halide in the presence of a base. The longer chain alkyl and acyl groups of this invention are beIleved to have advantageous properties due to their affinity for lipid membranes.
Myristylation or stearylation, for example, is useful.
Solution synthesis of peptides is accomplished using conventional methods used to form amide bonds. Typically, a protected Boc-amino acid which has a free carboxyl group is coupled to a protected amino acid which has a free amino group using a suitable carbodiimide coupling agent, such as N, N' dicyclohexyl carbodiimide (DCC), optionally in the presence of catalysts such as 1-hydroxybenzotriazole (HOBT) and dimethylamino pyridine (DMAP). Other methods, such as the formation of activated esters, anhydrides or acid halides, of the free carboxyl of a protected Boc-amino acid, and subsequent reaction with the free amine of a protected amino acid, optionally in the presence of a base, are also suitable. For example, a protected Boc-amino acid or peptide is treated in an anhydrous solvent, such as methylene chloride or tetrahydrofuran (THF), in the presence of a base, such as N-methyl morpholine, DMAP or a trialkyl amine, with isobutyl chloroformate to form the "activated anhydride", which is subsequently reacted with the free amine of a second protected amino acid or peptide. The peptide formed by these methods may be deprotected selectively, using conventional techniques, at the amino or carboxy terminus and coupled to other peptides or amino acids using similar techniques.
After the peptide has been completed, the protecting groups may be removed as hereinbefore described, such as by
hydrogenation in the presence of a palladium or platinum catalyst, treatment with sodium in liquid ammonia,
hydrofluoric acid or alkali.
Esters are often used to protect the terminal carboxyl group of peptides in solution synthesis. They may be converted to carboxylic acids by treatment with an alkali metal hydroxide or carbonate, such as potassium hydroxide or sodium carbonate, in an aqueous alcoholic solution. The acids may be converted to other esters via an activated acyl intermediate as previously described.
The amides and substituted amides of this invention are prepared from carboxylic acids of the peptides in much the same manner. Thus, ammonia or a substituted amine may be reacted with an activated acyl intermediate to produce the amide. Use of coupling reagents, such as DCC, is convenient for forming substituted amides from the carboxylic acid itself and a suitable amine.
In addition, the methyl esters of this invention may be converted to the amides, or substituted-amides, directly by treatment with ammonia, or a substituted amine, in methanol solution. A methanol solution of the methyl ester of the peptide is saturated with ammonia and stirred in a
pressurized reactor to yield the simple carboxamide of the peptides. Carboxamides are preferred embodiments of this invention due their enhanced stability relative to esters.
The amino acid which constitutes the M residue of the peptide comprises either phenylalanine, a derivative thereof, or an unnatural amino acid denoted as -NHCHR1R2-. The derivatives of phenylalanine include tyrosine; (O-C1- 5alkyl)tyrosine, 4'-halophenylalanine, 4'-nitrophenylalanine and 4'-aminophenylalanine as are generally well known in the peptide art.
An intermediate useful in the synthesis of the peptides of the invention wherein M is -NHCHR1R2 is represented by the formula (Ila):
wherein:
Figure imgf000029_0001
R1 is independently C1-5Alk, (CH2)nSC1-5Alk,
(CH2)nOC1-5Alk,
(CH2)nC3-7Cycloalkyl or (CH2)mC6H4-Ra;
Ra is halogen, OR', NO2, NH2 or H;
R2 is (CH2)n-, CHR3(CH2)mCO-, CO(CH2)mCO-, CHR3CHR3' (CH2)mCO-, CHR3CHR3'CHR1(CH2)mCO-,
CHR3CHR1CHR' (CH2)mCO-, CHR3CHR' CHR1 (CH2)mCO-,
COCHR1CHR' (CH2)mCO- COCF2CR'R" (CH2)mCO-, COCF2 (CH2)mCO-, CH=CR*CHR" (CH2)mCO-, COCH=CR' (CH2)mCO-,
CH2S(O)pCHR' (CH2)mCO-, CR2NR'CHR" (CH2)mCO-,
P=O(OR') (CH2)mCO-,
Figure imgf000030_0001
R3 and R3' are each independently OH, H or NH2; R4 is OH, H, NH2 or =0; m is independently 0, 1, 2 or 3; n is independently 1 or 2; p is 0, 1 or 2;
R5 is H;
R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OR", OC1-5Alk, NHR'R" or OCOC1-5Alk; R' H or C1-5Alk; and
R" is H or C1-18Alk.
These unnatural amino acids have utility in themselves as intermediates which may be used to prepare protease inhibitors. Accordingly, a peptide substrate which binds to a protease may be converted to an inhibitor by replacement of one or both of the amino acids at the scissile site by a suitable compound of formula (Ila).
The unnatural amino acids are generally not α-amino acids, but are derived from α-amino acids. Thus, the identity of R1 is established by the choice of an amino acid of formula (III), wherein R1 is chosen as previously set forth.
Figure imgf000031_0001
Protection of the amino group of the α-amino acid, such as by the Boc, acetyl or phthaloyl group, and conversion of the acid or ester to an alcohol of formula (IV) or an
aldehyde of formula (V) thereby provides a versatile
intermediate for the introduction of the R2 substituent, and the preparation compounds of this invention which are
designated by formula (Ila). The N-methoxy-methyl amides of these α-amino acids are also useful intermediates for this use. The α-amino acids may be obtained from natural sources, commercial sources or may be synthesized by a number of methods well known in the peptide art.
Alcohols of formula (IV) may be obtained from the diborane reduction of the corresponding protected amino acid. Aldehydes of formula (V) may be obtained from the reduction of the methyl ester of the corresponding amino acid, for example with diisobutyl aluminum hydride (DIBAL).
Alternatively the alcohol of formula (IV) may be oxidized to the aldehyde using a mild oxidizing agent, such as the Dess Martin periodinane or using the Swern method (DMSO, oxalyl chloride, triethylamine).
For instances in which R1 is Alk, the amino acids alanine, valine, leucine and isoleucine are especially useful for producing chiral aldehydes. α-Amino butyric acid, α-amino isobutyric acid and α-amino pentanoic acid are
commercially available as racemates. In general, any alkyl-α-amino acid can be synthesized by alkylation of a nitro-acetic acid ester with an appropriate alkyl halide in the presence of a base, such as triethylamine, DBU or other tertiary amine. Alkoxides, such as sodium methoxide or ethoxide are also suitable bases. Subsequent reduction of the α-nitro alkyl acid or ester with hydrogen and a palladium or platinum catalyst yields the amino acid. Alternately, it is common to produce α-amino acids by alkylation of an N-benzylidine glycine ester, such as a methyl or ethyl ester. Thus treatment of the benzylidine with a strong base, such as sodium or potassium hydride or lithium diisopropylamide, followed by alkylation with an appropriate alkyl chloride and subsequent acid hydrolysis of the benzylidene group yields the desired amino acid. These methods are also adaptable to the formation of cycloalkyl amino acids, for instance, by use of the cycloalkyl methyl bromide or the 2-cycloalkyl ethyl bromide. Other methods for synthesis of chiral amino acids have been disclosed by Evans, et al., Tet. Let., 1123(1987).
Most amino acids in which R1 is aryl or aralkyl are available commercially, or are well known in the art such as phenylalanine, 4'-halo and 4'-nitrophenylalanine, tyrosine, (O-alkyl) tyrosine, phenylglycine and (4'-hydroxy)phenylglycine. Homologs of these compounds may be prepared by conventional techniques of amino acid synthesis. Thus, alkylation of a nitro acetic acid ester or a N-benzylidene glycine with 1-phenyl-2-bromoethane or 1-phenyl- 3-bromopropane, as described above, produces the homologous amino acids.
The α-amino acids in which R1 contains an oxygen or sulfur are obtained from serine, homo-serine, threonine, cysteine or methionine or alkylation or these amino acids, excepting methionine. Alkylation is carried out by treating the corresponding hydroxyl or thiol compound with a base, such as triethylamine, DBU or sodium hydride, and an
appropriate alkyl halide, such as methyl, ethyl, isopropyl or isobutylbromide. The di-homoanalogues are prepared by conventional techniques for producing amino acids as
described above. Accordingly, an ester of nitro acetic acid is treated with a base, as previously described and acrolein in a Michael reaction. The aldehyde produced is subsequently reduced by a mild reducing agent, such as sodium borohydride, to yield the desired hydroxy group. Subsequent catalytic reduction of the nitro group yields the α-amino 5-hydroxy pentanoic acid. The corresponding mercapto analogue may be synthesized from the hydroxy intermediate. Thus, after protection of the amino and carboxyl groups as known in the art, the hydroxyl group is converted to a halide, such as by treatment with phosphorous tribromide or oxalyl bromide or chloride in the presence of triethylamine or another tertiary amine, or by treatment with triphenyl phosphine and carbon tetrabromide. Treatment of the halide with sodium sulfide or potassium thioacetate followed by saponification with sodium hydroxide, yields the 5-mercapto-2-amino pentanoic acid.
This intermediate may be further alkylated in the same manner as cysteine or serine described herein above.
As previously indicated the α-amino acids hereinbefore described may be converted to aldehydes and alcohols of formula (IV) and (V). Subsequent elaboration of these intermediates to introduce the substituent R2, and thereby form the compounds of this invention designated in formula (Ila), is dependent upon the nature of R2.
Introduction of a hydrocarbon substituent at R2 is suitably accomplished by reaction of the aldehyde of formula (V) with an organometallic hydrocarbon, such as a Grignard reagent or organo-lithium species. The incipient carboxylic acid functionality of R2 is in protected form as in an ortho ester or disguised, as in an oxidizable olefin. In one embodiment, the organometallic species is a magnesium or lithium alkylide generated from lithium or magnesium and an alkylene halide, such as allyl bromide, 1-bromo-3-butene, 1-bromo-4-pentene, or 1-bromo-5-hexene, or an alkyl substituted derivative thereof .
Addition of the organometallic reagent to an aldehyde of formula (IV) yields a hydroxy-alkene of formula (VIa) or (Vlb), wherein Ro is OH, R1' is H, C1-5Alk, (CH2)nOC1-5Alk,
(CH2)nC3-7cycloalkyl or (CH2)mC6H4-Ra and R1, R5, R6, R', R", m and n are as defined for formula (Ila).
Figure imgf000034_0001
Alternatively, addition of an organometallic alkylidene, such as a Grignard reagent, to the N-methoxy methyl amide of an amino acid of formula (III) yields the keto-alkenes of formula (VIa) and (Vlb), wherein Ro is =0. Using the same procedures, except substituting a 1-metallo-2-propenyl cyclopentane or 1-metallo-2-propenyl cyclohexane, the
corresponding cycloalkyl alkenes of formula (VIc), wherein R1, R5, R6, R', R" m and n are as defined in formula (Ila), are prepared. Accordingly, a process for preparing a
compound of formula (VIla), (Vllb) or (VIIc), wherein R1' is
H, C1-5Alk, (CH2)nOC1-5Alk, (CH2)nC3-7cycloalkyl or
(CH2)mC6H4-Ra and R1, R4, R5, R6, R', R", X, m and n are as defined in formula (Ila), comprises oxidizing a compound of formula (VIa), (Vlb) or (VIe) to a keto-carboxylic acid
(VIla), (Vllb) or (VIIc), wherein R4 is =0 and X is OH, and thereafter in any order optionally reducing or reductively aminating the keto group, and optionally converting the carboxylic acid to an ester, amide, aldehyde, anhydride or acyl halide. Suitably R' is H and m is 0, and in a preferred embodiment of compound (VIla), R1' is H.
Oxidation of the hydroxy- or keto-alkane is accomplished by conventional methods, such as with potassium permanganate or by ozonolysis followed by standard dimethyl sulfide workup and subsequent oxidation with potassium permanganate or Jones reagent. As would be obvious to one skilled in the art, this method is inapplicable when R1 contains a sulfur substituent.
Other methods adaptable to prepare certain compounds of this type are disclosed by Holladay et al., J. Med. Chem., 30, 374-83(1987) and Kempf, D., J. Org. Chem , 51, 21, 392126(1986).
Reduction of the keto-compounds of formula (Vila), (Vllb) and (VIIc) (Ro is =0) using a conventional reducing agent, such as sodium borohydride, yields the corresponding alcohol. If the alcohol is desired, it is often useful to protect it, such as by formation of a benzyl or silyl ether, or an acetate to prevent unwanted side reactions, such as lactonization, and to improve the efficiency of later
incorporation into the peptides of this invention. Such protection of the alcohol is conveniently carried out prior or subsequent to the oxidation steps leading to the
carboxylic acid. The hydroxyl may be further converted to chloride or bromide using a halogenating agent, such as phosphorous trichloride or phosphorous tribromide, and subsequently reduced to a methylene group with hydrogen and Raney® nickel. If an amino group is desired, the keto group may be reductively aminated with sodium cyanoborohydride and an ammonium halide, such as ammonium chloride or bromide.
The carboxylic acid may be converted to an ester, amide, aldehyde, anhydride or acyl halide by common methods well known in the chemical art.
The introduction of unsaturation at R2 may be derived from the amino acid products corresponding to formulas (VII). Reduction of the carbonyl group to a hydroxyl group, as previously indicated, and subsequent elimination of the hydroxyl group, provides the unsaturated compounds of this invention. The hydroxyl group may be eliminated by
conversion to a mesylate or halide, as previously provided, and treatment with a base such as DBU or lithium
diisopropylamide. Other methods of elimination of the hydroxyl group, such as treatment with warm mineral acid (HCl, H2SO4) may also be suitable. Another procedure for introduction of unsaturation at R2 involves Wittig olefination of an aldehyde of formula (V). Reduction of these unsaturated compounds with hydrogen and a palladium catalyst provides an alternative overall method for effecting removal of the ketone group in the compounds of formulas (VII) (Ro is =0).
Introduction of a nitrogen substituent at R2 is
accomplished by reaction of an amino aldehyde of formula (V), under reducing conditions with an ester of a C1-4amino alkanoic acid, or alkyl amino C1-4alkanoic acid or a
structure where the' amino moeity is encompassed in a
saturated or unsaturated 5 or 6 membered ring. Examples of such amines are the benzyl or methyl esters of glycine, alanine, 3-amino propionic acid, 4-amino-pentanoic acid butanoic acid, proline, Δ3-dehydro proline, and 2-carboxy piperidine. Suitable reducing conditions would include the use of hydrogen and a palladium or platinum catalyst, or sodium cyanoborohydride. Accordingly, compounds of formula (VIII):
Figure imgf000036_0001
wherein R1, R5, R6, X and n are as definded in formula (Ila), are prepared by a process which comprises reacting a compound of formula (V), under reducing conditions, with an ester or acid of proline, Δ3-dehydro-proline or 2-carboxypiperidine, and thereafter, in any order, converting the ester to a carboxylic acid, ester, aldehyde or amide; or converting the acid to an ester, amide, anhydride or acyl halide.
Introduction of a sulfur substituent at R2 is
accomplished by reaction of a thioalkanoic acid or ester with an α-amino acid derivative. Accordingly, a hydroxy-amino acid of formula (IV) is converted to the corresponding halide using a conventional reagent, such as phosphorous tribromide, phosphorous oxychloride or thionyl chloride in the presence of a base, such as triethylamine or pyridine, and treated with the thioalkanoic acid or ester again in the presence of a base. The sulfide produced in this way may be further oxidized to a sulfoxide by treatment with a mild oxidizing agent, such as sodium metaperiodate, or a sulfone, by treatment with potassium permanganate.
Introduction of a fluorocarbon substituent at R2, wherein the fluorine is y to the amino group, is accomplished by treatment of an aldehyde of formula (V) with ethyl difluorobromoacetate and activated zinc dust. Thaisrivongs, et al., J. Med. Chem.. 29, 2080-87 (1986) disclose such chemistry for diflubrostatine-type compounds. Homologues of these compounds may be prepared from α-keto diesters, such as dimethyl oxaloacetate.
Illustrative of the method, dimethyl oxaloacetate is treated with diethylamino sulfur trifluoride (DAST) to produce α-difluoro dimethyl succinate. Preferential
reduction of the α-difluoro ester functionality with sodium borohydride yields the difluoro alcohol, which may be
oxidized to the corresponding aldehyde using a mild oxidizing method such as Collins reagent, the Dess-Martin periodinane or the Swern method (DMSO, oxalyl chloride, triethylamine).
Condensation of the α-difluoro aldehyde with a nitro compound of the formula R1CH2NO2, such as 2-nitrophenyl ethane or a 1-nitro C1-5alkane, in the presence of a base, such as DBU or K2CO3, and subsequent reduction of the nitro group with hydrogen and either a 5% Pd/C or platinum black catalyst yields the desired difluoro homologues. Alkylated
derivatives of these homologues may be prepared by alkylation of the initial α-keto diester with a base and alkyl halide prior to conducting the sequence. For example, alkylation of dimethyl oxalacetate with 2 equivalents of methyl iodide in the presence of DBU yields 2-keto-3, 3-dimethyl succinnate. Further conversion by the above sequence to 2,2 dimethyl-3,3-difluoro-4-oxo-methyl butanoate, condensation with 2-phenyl nitroethane and reduction with hydrogen and 5% Pd/C yields 2,2 dimethyl-3,3-difluoro-4-hydroxy-5-amino-6-phenyl methyl hexanoate. Further oxidation of these compounds to provide the fluoroketone may be carried out at this stage, but it is often more suitably carried out after the residue has been incorporated into the peptide. Mσffatt oxidation (DMSO, acetic anhydride), Dess-Martin periodinane or
pyridine/chromium trioxide are suitable oxidants.
Introduction of a phosphinyl substituent at R is carried out by a condensation of benzyl carbamate with triphenyl phosphite and an aldehyde of the general formula R1CHO, such as phenylacetaldehyde, isobutyraldehyde or 2-methyl butyraldehyde, in acetic acid to yield a phosphonate of formula (IX).
Figure imgf000038_0001
Further treatment of the phosphonate with an alkoxide provides the corresponding phosphonic acid monoalkyl ester. Thus, treatment with sodium methoxide yields the phosphonic acid monomethyl ester. Conversion of this phosphonic acid to a phosphonyl halide with a suitable halogenating reagent, such as thionyl chloride or bromide, provides a suitable reactive intermediate for further elaboration of the side chain. Treatment with an organo metallic reagent, such as the lithium or Grignard reagent derived from alkyl bromide, bromo-3-butene, 2-(2-methylpropenyl) chlorocyclopentane or 2- (2-methyl propenyl)-cyclohexane, yields the alkenyl methyl phosphinates of this invention as given by formula (Xa) and (Xb):
Figure imgf000038_0002
Figure imgf000038_0003
wherein R1, R5, R6, R', R", m and n are as defined for formula (Ila) and R" ' is C1-5 alkyl. Subsequent oxidation, such as with potassium permanganate or by ozonolysis as herein described affords the corresponding alkyl phosphinate carboxylic acids of this invention. Accordingly, the compounds of formulas (XI):
Figure imgf000039_0002
Figure imgf000039_0003
wherein R1, R5, R6, R', X and n are as defined as in formula (Ila), may be prepared by oxidizing a compound of formula
(Xa) or (Xb) to a carboxylic acid, optionally hydrolyzing the alkyl phosphinate to the phosphinic acid, and optionally converting the carboxylic acid to an ester, amide, aldehyde, anhydride or acyl halide. Hydrolysis of the alkyl
phosphinate to the phosphinic acid may be accomplished by treatment with a strong acid, such as hydrogen bromide. As would be obvious to one skilled in the art, this method is inapplicable when R1 contains a sulfur substituent. Methods adaptable for synthesis of certain of these compounds are reported for instance by Giannousis et al., J. Med . Chem., 30, 1603-09(1987).
A further aspect of this invention relates to the preparation of completely novel amino acids which, when properly incorporated into peptides, provide a nonhydrolyzable imitation of a peptide bond. These compounds are prepared as hereinbefore described and are further illustrated in the Examples which follow. They are
incorporated into the peptides of this invention by methods known to the art and are given by formula (lIb) as:
wherein:
Figure imgf000039_0001
R1 is independently C1-5Alk, -(CH2)nSC1-5Alk,
-(CH2)nOC1-5Alk, -(CH2)nC3-7cycloalkyl or -(CH2)mC6H4-Ra;
Ra is halogen, NO2, OH, OC1-5Alk, NH2, or H; R2 is (CH2)n-X, (CH2)nCO-X, CHR3CHR1CHR' (CH2)mCO-, COCR1CHR' (CH2)mCO-X, CHR3CF2 (CH2)mCO-X, COCF2CR'R" (CH2)mCO-X, CHR3 (CH2)mCO-X, CO (CH2)mCO-X,
Figure imgf000040_0001
R3 is H, NH2 or OH;
R4 is H, NH2, OH, or =O;
R5 is H;
R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; R' and R" are H or C1-5Alk; m is independently 0, 1, 2 or 3; and n is independently 1 or 2; provided that R2 is not CHR3CH2CO-X, COCH2CO-X, COCF2CO-X or CHR3CF2CO-X when R1 is phenylmethylene, isobutyl or cyclohexylmethylene, and R2 is not CH (OH) CH2CH2CO-X or
COCH2CH2CO-X, when R1 is isobutyl.
Incorporating a compound of formula (lIb) into a peptid in the place of one or two amino acid residues which undergo cleavage by a protease, especially a retroviral protease, provides a method for producing protease inhibiting activity.
It will be appreciated that the above synthetic methods introduce chiral centers in a non-selective, or racemic, manner. As is often the case in biological systems, a single configuration of chiral centers is usually optimal. In many of the compounds, there are more than one chiral center, which renders compounds with varying chiral centers
diastereomeric. These diasteromers are usually separable by chromatography over silica gel or an octadecyl silane chromatographic support with a suitable mobile phase. If silica gel is used, a mixture of ethyl acetate and hexane or methanol and chloroform or methylene chloride are used to elute the diasteromers. If an octadecyl silane support is used, a mixture of water and methanol or acetonitrile may be used to purify the diastereomers. In the case of acidic or basic compounds, the mobile phase may be buffered by the addition of .02 to .5 % of acetic acid, trifluoracetic acid or phosphate buffer. If the residue, designated as M, possesses only a single chiral center, or the diasteromers are difficult to separate, it may be preferable to
incorporate the residue into the peptide, wherein the chiral centers of the other constituent amino acids confer further asymetry, and render the resulting diasteromers separable at a later stage. However, while it may sometimes be preferable to separate diasteromers, it is by no means necessary to separate the chiral centers to practice this invention.
The unnatural amino acids of the M residue are
incorporated into the peptides of this invention as
hereinbefore described by methods common in the peptide art.
If the final peptide, after it has been deprotected, contains a basic group, an acid addition salt may be
prepared. Acid addition salts of the peptides are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, maleic, succinic or methanesulfonic. The acetate salt form is especially useful. If the final peptide contains an acidic group, cationic salts may be prepared. Typically the parent
compound is treated with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation. Cations such as Na+, K+, Ca++ and NH4 + are examples of cations present in pharmaceutically
acceptable salts. Certain of the compounds form inner salts or zwitterions which may also be acceptable.
The compounds of formula (I), wherein M is -HNCHR1R2-, are used to induce anti-viral activity in patients which are infected with susceptible viruses and require such treatment. The method of treatment comprises the administration orally, parenterally, buccally, trans-dermally, rectally or by insufflation, of an effective quantity of the chosen
compound, preferably dispersed in a pharmaceutical carrier. Dosage units of the active ingredient are selected from the range of .05 to 15 mg/kg. These dosage units may be
administered one to ten times daily for acute or chronic infection.
The protease inhibiting properties of the peptides of this invention, wherein M is -HNCHR1R2-, are demonstrated by their ability to inhibit the hydrolysis of a peptide
substrate by rHIV protease in the range of about 10 nM to about 250 μM. The following table is representative of the inhibition constants of these peptides.
Table II
Inhibition of rHIV Protease
Compound of Ki
Example No. (μM)
15 14
16 1
17 68
18 6.7
19 7
20 32
21 160
22 47
23 27
24 6
25 40
26 60 Table II (Continued)
Inhibition of rHIV Protease
Compound of Ki
Example No. (μM)
27 .26
28 .026
29 ≥28
30 14
31 1.2
32 220
33 3.6
34 .140
35 .110
36 10
37 3.5
38 .15
Pharmaceutical compositions of the peptides of this invention, or derivatives thereof, may be formulated as solutions or lyophilized powders for parenteral
administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use. The liquid formulation is generally a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution. Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvmylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
A preferred composition for parenteral administration may additionally be comprised of a quantity of the compound encapsulated in a liposomal carrier. The liposome may be formed by dispersion of the peptides in an aqueous phase with phospholipids, with or without cholesterol, using a variety of techniques, including conventional handshaking, high pressure extrusion, reverse phase evaporation and
microfluidization. A suitable method of making such
compositions is more fully disclosed in copending Application Serial No. 06/763,484 and is incorporated herein by
reference. Such a carrier may be optionally directed toward its site of action by an immunoglobulin or protein reactive with the viral particle or infected cells. The choice of such proteins would" of course be dependent upon the antigenic determinants of the infecting virus. An example of such a protein is the CD-4 T-cell glycoprotein, or a derivative thereof, such as sCD-4 (soluble CD-4), which is reactive with the glycoprotein coat of the human immunodeficiency virus (HIV). Such proteins are disclosed in copending Application Serial No. 07/160,463, which is incorporated herein by reference. Similar targeting proteins could be devised, by methods known to the art, for other viruses and are
considered within the scope of this invention.
Alternately, these peptides may be encapsulated,
tableted or prepared in a emulsion or syrup for oral
administration. Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the
composition, or to facilitate preparation of the composition. Liquid carriers include syrup, peanut oil, olive oil,
glycerin, saline and water. Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin. The carrier may also include a sustained release material such as glyceryl monostearate or glyceryl
distearate, alone or with a wax. The amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit. The pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms. When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension. Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
For rectal administration, a pulverized powder of the peptides of this invention may be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository. The pulverized powders may also be compounded with an oily preparation, gel, cream or emulsion, buffered or unbuffered, and administered through a transdermal patch.
Beneficial effects may be realized by co-administering, individually or in combination, other anti-viral agents with the protease inhibiting compounds of this invention. Examples of anti-viral agents include nucleoside analogues,
phosphonoformate, rifabutin, ribaviran, phosphonothioate oligodeoxynucleotides, castanospermine, dextran sulfate, alpha interferon and ampligen. Nucleoside analogues, which include 2',3'-dideoxycytidine(ddC), 2',3'-dideoxyadenine (ddA) and
3'-azido-2', 3'-dideoxythymide (AZT), are especially useful. AZT is one preferred agent. Suitably pharmaceutical compositions comprise an anti-viral agent, a protease inhibiting peptide of this invention and a pharmaceutically acceptable carrier.
The Examples which follow serve to illustrate this invention. The Examples are intended to in no way limit the scope of this invention, but are provided to show how to make and use the compounds of this invention.
In the Examples, all temperatures are in degrees
Centigrade. Amino acid analyses were performed upon a Dionex Autoion 100. Analysis for peptide content is based upon Amino Acid Analysis. FAB mass spectra were performed upon a VG Zab mass spectrometer using fast atom bombardment. The
abbreviations used to represent the eluent composition for thin layer chromatography and counter current distribution are B: n-butanol, A: acetic acid, W: water, E: ethyl acetate and IP: isopropanol. NMR were recorded at 250 MHz using a Bruker AM 250 spectrometer. Multiplicities indicated are: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet and br indicates a broad signal. 4 (S)-Amino-3 (R)-hydroxy-5-phenyl hexanoic acid [AHPPA] and its 3 (R) epimer [3-R-AHPPA] were prepared by the method of Rich, et al., J. Med. Chem., 23, 27-33 (1980). The racemate [3-R, S-AHPPA] was obtained by omitting the final chromatography in this method. Purification of Recombinant HIV Protease
Methods for expressing recombinant HIV protease in E.
coli have been described by Debouck, et al., Proc. Natl. Acad. Sci. USA, 84, 8903-6(1987). The enzyme used to assay the peptide of this invention was produced in this manner and purified from the cell pellet as follows. The E. coli cell pellet was resuspended in a buffer consisting of 50 mM TrisHC1, pH 7.5; 1.0 mM each DTT, EDTA and PMSF
(phenylmethylsulfonyl fluoride). The cells were lysed by sonication and insoluble material was removed by centrifugation at 15,000 x g av, for 15 min. The clarified supernatant was then brought to 40% of saturation with ammonium sulfate. This suspension was stirred at room temperature for 30 min. and then centrifuged as above. The resulting precipitate was
redissolved/resuspended in a minimal volume of 20 mM Tris-HCl, pH 7.5; 200 mM NaCl; 0.1 mM each DTT and EDTA. The sample was centrifuged again before application (in 5 ml aliquots) to a Beckman TSK G2000SW preparative HPLC gel filtration column (2.1 cm x 60 cm.). The column was equilibrated in the same buffer at a flow rate of 4 ml/min. The effluent of the column was monitored at 280 nm and 1 min. fractions collected. Typically, the rHIVPRT (recombinant HIV protease) eluted 45-46 min. into the run. At this stage, the protease was N85-95% pure. By immunoblot analysis >90% of the immunoreactive material was precipitated at the ammonium sulfate step. By activity assay, the highest peak of activity was found in the fractions collected at 45 and 46 minutes. Analysis of the TSK column fractions by RP-HPLC and SDS-PAGE indicated that the majority of the 11,000 Mr protein is also found in fractions 45 and 46. The activity itself cannot be used to obtain reliable recovery data as it is influenced by high salt, i.e., with increasing salt, increasing levels of activity were obtained. Thus, with each step in the purification, more total activity was
recovered than was started with. The overall yield of rHIVPRT was N1 mg from a 50 gm E. coli cell pellet. Substrate Kinetics for HIV Protease Activity
Initial rate data for oligopeptides were determined at pH 6.0, 37°C. Reaction mixtures (0.01-0.1 mL) contained 50 mM Mes (2-N-morpholino) ethanesulfonic acid), 1 mM EDTA, 1 mM DTT, 0.2 M NaCl, 0.1% (v/v) Triton X-100 (pH 6.0), 10% DMSO, and variable concentrations of the peptides. After incubation at 37°C for several minutes, reaction was initiated by the addition of purified HIV protease (0.01-2 mg), and reactions were quenched after 10-30 min. with an equal volume of either ice-cold 0.6 N tricholoroacetic acid or 0.2% trifluoroacetic acid. Samples were centrifuged at 17,000 rpm for 5 min., and the peptide substrates and products were separated and
quantified (by peak integration) by reverse phase HPLC.
Initial rates were determined as (mM peptide product
formed)/min based on the percentage of conversion of substrate to product for a given concentration of substrate. Typically, reaction rates were linear over the time course of the
reaction, and less than 15-20% of the substrate had been converted to product at reaction endpoint. Kinetic constants (Michaelis constants, maximal velocities) were determined by fitting initial rate data to the Michaelis-Menten equation (v = Vmax(S)/(Km + (S))) using the Fortran program of Cleland (W. W. Cleland, Adv. Enzymol. 29, 1, (1967)). The turnover number (kcat) was obtained as kcat = Vmax/Et, where it is assumed that one active site is present per 22-kD dimer of HIV protease.
An estimate of substrate viability was obtained by
determination of a relative initial velocity (rel Vo). This assay was run in the same manner, except the percent hydrolysis of substrate after 10-20 min. was compared to the percent hydrolysis of Ac-Arg-Ala-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
(control) after a similar incubation. This established a comparison of initial reaction velocity at one time point relative to the control peptide. Inhibition of HIV protease activity
A typical assay contained 10 mL MENDT buffer (50 mM Mes (pH 6.0; 2-(N-morpholino) ethanesulfonic acid), 1 mM EDTA, 1 mM dithiothreitol, 200 mM NaCl, 0.1% Triton X-100); 2, 3, or 6 mM N-acetyl-L-arginyl-L-alanyl-L-seryl-L-glutaminyl-L-asparaginyl- L-tyrosyl-L-prolyl-L-valyl-L-valinamide (Ac-Arg-Ala-Ser-GlnAsn-Tyr-Pro-Val-Val-NH2; Km=7 mM) ; and micromolar and submicromolar concentrations of synthetic compounds. Following incubation at 37°C for several minutes, the reaction was initiated with purified 0.01-1 mg HIV protease. Reaction mixtures (37°C) were quenched after 10-20 minutes with an equal volume of cold 0.6 N trichloroacetic acid, and, following centrifugation to remove precipitated material, peptidolysis products were analyzed by reverse phase HPLC (Beckman
Ultrasphere ODS, 4.5 mm x 25 mm; mobile phase: 5-20%
acetonitrile/H2O - .1% TFA (15 min), 20% acetonitrile/H2O - .1%
TFA (5 min) at 1.5 mL/min, detection at 220 nm. The elution positions of Ac-Arg-Ala-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2 (17-18 min) and Ac-Arg-Ala-Ser-Gln-Asn-Tyr (10-11 min) were confirmed with authentic material. Initial rates of Ac-Arg-Ala-Ser-Gln-Asn-Tyr formation were determined from integration of these peaks, and typically, the inhibitory properties of the
synthetic compounds were determined from slope/intercept analysis of a plot of 1/v vs. [inhibitor] (Dixon analysis). Ki values resulting from this type of primary analysis are
accurate for competitive inhibitors only, and under conditions in which the Michaelis constant of the substrate used is welldetermined. Example 1
General procedure for solid phase peptide synthesis
Peptide amides are synthesized by solid phase peptide synthesis using benzhydrylamine resin as the support.
Protected amino acids are added sequentially starting from the carboxyl terminus until the desired sequence has been obtained. The t-butyloxycarbonyl (Boc) group is used for protection of the alpha-amino group. Side chain functional groups are protected as follows: arginine and histidine, tosyl (Tos); cysteine, p-methylbenzyl (MeBzl); serine and threonine, benzyl ether (Bzl); lysine, p-chlorocarbobenzoxy (Clz); glutamic acid and aspartic acid, benzyl ester (OBzl); tyrosine,
p-bromocarbobenzoxy (BrZ). Removal of the Boc group is accomplished by treatment with 50% trifluoroacetic acid (TFA) in methylene chloride. Neutralization of the amine-TFA salt is accomplished by treatment with 7% diisopropylethylamine (DIEA) in methylene chloride. Amino acids are coupled to the growing peptide using 3 equiv. Boc-amino acid and 3 equiv. 1-hydroxybenzotriazole (HOBt) in DMF and 3 equiv. of
dicyclohexylcarbodiimide (DCC) in methylene chloride.
Completeness of coupling is checked by ninhydrin test and couplings repeated as necessary. The general protocol is given below.
1. Wash with CH2Cl2 1 x 1 min.
2. Wash with 50% TFA 1 X 1 min.
3. Deblock with 50% TFA 1 X 20 min.
4. Wash with CH2CI2 6 X 1 min.
5. Neutralize with 7% DIEA 3 X 2 min.
6. Wash with CH2CI2 4 X 1 min.
7. Wash with DMF 2 X 1 min.
8. Boc-AA + HOBt in DMF do not drain
9. DCC in CH2C12 2 hr.
10. Wash with DMF 2 X 1 min.
11. Wash with CH2C12 3 X 1 min.
For attachment of the first (C-terminal) residue to the BHA resin, the synthesis is begun at step 5. For all
subsequent amino acids, the synthesis is begun at step 1. Preparation of Ac-Arg-Ala-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
The protected nonapeptide resin Boc-Arg (Tos) -Ala-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared in the usual way. After removal of the N-terminal Boc group with 50% TFA in
CH2C12 and neutralizing the resulting TFA salt with 7% DIEA in CH2CI2, the resin-bound peptide was acetylated with acetic anhydride (2 ml) in CH2C12 (30 ml) for 30 minutes.
The peptide was cleaved from the resin with removal of the side chain protecting groups by treatment with anhydrous liquid HF (10 ml) in the presence of anisole (1 ml) at 0°C for 50 minutes. After removal of the HF under vacuum, the resin was washed with ethyl ether and air-dried. The resin was then extracted with 2 x 30 ml 1% HOAC/H2O followed by 2 x 30 ml 10% HOAC/H2O. The combined extracts were lyophilized to yield 476 mg crude peptide.
The crude peptide was purified by countercurrent
distribution using the system n-BuOH/HOAc/H2O 4:1:5. The appropriate fractions were pooled, evaporated to dryness and the residue lyophilized from 1% HOAC/H2O to yield 294 mg partially purified peptide. An aliquot of 100 mg partially purified peptide was further purified by gel filtration on a 2.6 x 70 cm G-15 Sephadex® column using 1% HOAc as eluant. The appropriate fractions were pooled and lyophilized to yield 89 mg of the purified title compound.
TLC (n-BuOH/HOAc/H2O 4:1:1) Rf=0.49.
HPLC: (Hamilton PRP-1, CH3CN/H2O/0.1% TFA, 5% to 40% CH3CN, 15 minutes, linear gradient, 1.5 ml/min.) k'=2.6; FAB-MS: m/z 1074 (M+H+).
Example 2
Preparation of (2S)-N-(2-N-tert-butyloxycarbonyl)amino-3-phenyl) propyl-proline
N-tert-butyloxycarbonyl-L-phenylalanine methyl ester
a) L-phenylalanine methyl ester hydrochloride (10.0 g, 46.4 mmol) was dissolved in a mixture of triethylamine (12.9 mL, 92.8 mmol) and DMF (60 mL). N-t-butyl dicarbonate ( 16.0 mL, 69.6 mmol, 50% excess) was added over 5 min. at room temperature. After stirring for 16 h, the mixture was filtered and concentrated under reduced pressure. Flash chromatography over silica gel using 20% EtOAc in hexane gave 13.0 g of the titled compound.
TLC: (20% EtOAc in hexane) Rf=0.31.
NMR (CDCI3): δ7.23 (m,5H), 5.16 (d, 1H, J=8 Hz), 4.57 (q, 1H, J=7 Hz), 3.66 (s,3H), 3.07 (d, 2H, J=6 Hz), 1.40 (s, 9H). N-tert-butyloxycarbonyl-L-phenylalaninal
b) Boc-Phe-OMe (12.9 g, 46.4 mmol), prepared as above, was dissolved in dry toluene (50 mL) and cooled to -78°C. Diisobutylaluminum hydride (25% in toluene, 77.3 mL, 116 mmol, 150% excess) was added over 2 min. After stirring for 15 min. at -78°C, methanol (15 mL) was added slowly to control effervescence. The mixture was poured into Rochelle salt (94 g potassium sodium tartrate in 1 L water, 150 mL) and shaken with ether (100 mL) until extractable. The aqueous phase was Washed with ether (3 X 100 mL). The organic phases were combined, dried (MgSO4), and evaporated.
The resulting product was used directly in the next step. TLC: (20% EtOAc in hexane) Rf=0.21.
NMR (CDCI3): δ9.69 (s,1H), 7.28 (m, 5H), 5.05 (s,1H), 4.43 (q,1H,J=7 Hz), 3.10 (d,2H,J=7 Hz), 1.43 (s,9H).
(2S)-N-(2-(N-tert-butyloxycarbonyl)amino-3-phenyl)propyl-L-proline benzyl ester
c) The crude aldehyde, prepared as above, 2 (b), was dissolved in 1% acetic acid in methanol (250 mL) with L-proline benzyl ester hydrochloride ( 18.1 g, 75 mmol).
Sodium cyanoborohydride (3.06 g, 48.7 mmol, 5% excess) was added, and the mixture was allowed to stir at room
temperature for 16 h. The solution was then evaporated, and the residue was partitioned between EtOAc and 1N HCl. The organic layer was washed with 1N HCl (2X), 1N NaHCO3 (3X), and water (IX). Evaporation of the organic phase gave 13.5 g of the titled benzyl ester. Flash chromatography of a portion of the crude material (silica gel, 20% EtOAc in hexane) gave pure product which was crystallized from CHCI3 and hexane. These crystals gave a satisfactory x-ray crystal structure (S,S).
mp: 79-79.5°C.
TLC: (20% EtOAc in hexane); Rf=0.31.
NMR (CDCI3): δ7.33 (s,5H), 7.20 (s,5H), 5.14 (s,2H), 4.95
(d, 1H,J=9 Hz), 4.05 (d, 1H,J=7 Hz), 3.17 (m, 2H), 2.63 (m, 5H), 1.87 (m,4H), 1.35 (s, 9H). MS : m/z 439 (M+H) +, 383 , 365 , 347 , 339 , 303 , 231, 218 , 91,
79 .
Anal. Calc'd for C26H34N2O4: C, 71.21; H, 7.81; N, 6.39;
Found C, 71.00; H, 7.83; N, 6.25.
(2S)-N-(2-(N-tert-butyloxycarbonyl)amino-3-phenyl)propyl-L-proline
d) The protected reduced dipeptide (0.44 g, 1.0 mmol), prepared as above, 2(c), was dissolved in methanol (100 mL) with 10% Pd/C (0.5& g) and hydrogenated under 45 psi H2 for 1 h. The mixture was filtered and concentrated to give 0.35 g (100%) of the titled compound.
TLC: (B:A:W 4:1:1); Rf=0.66.
NMR (DMSO-d6): δ7.26 (s,5H), 6.80 (d, 1H,J=9 Hz), 6.00 (s,2H), 3.78 (s,1H), 2.9 (m, 6H), 1.85 (m, 4H), 1.30 (s,9H).
Performing the same sequence, except substituting benzyl piperidine-2—carboxylate for proline benzyl ester, yields (2S)-N-(2-(N-t-butyloxycarbonyl)amino-3-phenyl)propyl-piperdine-2-carboxylic acid.
Performing the sequence 2(a)-2(c), except substituting Δ3-dehydro-proline methyl ester for proline benzyl ester, yields methyl (2S)-N-(2-(N-t-butyloxycarbonyl)amino-3-phenyl) propyl-L-proline. Saponification of the methyl ester with 5 equivalents of K2CO3 in 4:1 methanol:water yields
2(S)-N-(2-(N-t-butyloxycarbonyl)amino-3-phenyl)propyl-L- proline. Example 3
Preparation of (1R,2R)-2-(((2S)-2-tert-butyloxycarbonylamino- 3-phenyl-1-oxo)propyl)cyclopentanecarboxvlic acid 6-carbomethoxybicyclo T3.1.01hexane
a) Neat ethyl diazoacetate (53 ml, 0.50 mol) was added via a syringe drive over a 4 hour period to a
stirred mixture of rhodium acetate dimer (1.0 g, 0.0023 mol) and cyclopentene (250 ml, 2.5 mol) immersed in a 20-25°C water bath. After an additional 30 minutes, excess
cyclopentene was removed by rotary evaporation. The residue was diluted with CH2C12, filtered through Celite® and concentrated by rotary evaporation. The residue was
distilled at 44-46°C/0.5 mmHg to provide the titled compound (46.5 g, 0.302 mol) as a mixture of carboethoxy epimers in 60% yield.
TLC: (80:20 Hexanes: ethyl acetate) Rf=0.67.
NMR (CDCI3): δ 4.1 -(2H, overlapping quartets),
2.0-1.5 (7H, m), 1.45-1.1 (5H, m).
6- (1-hydrpxy-1-methylethyl) bi cyclo [3 , 1 , 0] hexane
b) A 1.4 M solution of methyl lithium in ether (350 ml, 0.50 mol) was stirred rapidly under Ar at -78°C while the product of Example 3(a) (27.67 g, 0.180 mol) was added neat via syringe over a 15 minute period. The mixture was stirred 1 hour at -78°, then was allowed to warm to room temperature over a 2 hour period. Water (400 ml) was added cautiously, followed by 3N HCl (ca. 200 ml) until the solution was neutral. The ether layer was separated and the aqueous layer was extracted twice with ether. The combined ether extracts were dried over MgSO4 and concentrated by rotary evaporation.
The residue was distilled (80°-90°/15 mmHg) to provide the titled product (19.79 g, 0.141 mol) as a mixture of epimers in 79% yield.
TLC: (80:20 Hexanes: ethyl acetate) Rf=0.36, 0.17.
NMR (CDCl3): δ2.0 - 1.6 (5H, m), 1.5 - 1.0 (9H, m), 0.55 (1H, m).
(±)-trans-2-(2-methylpropenyl)chlorocyclopentane
c) A solution of the product of example 3(b), above, (19.6 g, 0.140 mol) in THF (125 ml) was added at once to a rapidly stirring mixture of 37% aqueous HCl (250 ml) and THF (125 ml) chilled in an ice bath. After 3.5 - 4.0 minutes the mixture was poured into ice water (1 1.) and was quickly extracted with pentane (3 x 250 ml). The pentane extracts were washed with 5% NaHCO3 (200 ml), dried over MgSO4 and concentrated by rotary evaporation (25°C/15mm). The residue was distilled at 78°-80°C/15 mmHg through an 8 inch Vigreux column to provide the titled compound (18.65 g, 0.118 mol) in 84% yield.
TLC: (hexanes) Rf=0.71
NMR (CDCI3) : δ4.95 (1H, dm), 3.84 (1H, apparent quartet), 2.87 (1H, apparent quintet), 2.2 (1H, m), 2.07 - 1.75 (4H, m), 1.72 (3H, d; J=1.2 Hz), 1.68 (3H, d; J=1.2 Hz), 1.33 (1H, m).
GC-MS (isobutane) : -m/z 158 (M)+, 123 (M+H-HC1)+.
IR (film) : 2980, 1455, 1382, 838 cm-1
2-(2-methylpropenyl)lithiocyclopentane
d) A dry 50 ml flask fitted with a reflux condenser was purged with Ar. Powdered lithium (0.34 g, 49 mmol; 1% Na content; 25 wt % dispersion in mineral oil) was introduced and was rinsed with 2 x 10 ml dry pentane to remove mineral oil. A solution of the product of Example 3(c) (1.58 g, 10.0 mmol) in dry freeze-thaw degassed pentane (20 ml) was added. The mixture was stirred under reflux in a 55°C oil bath for 19 hr., then was allowed to settle. The supernatant was withdrawn via syringe and filtered under Ar through a dry fritted glass filter. The resulting clear yellow solution (17.6 ml) was 0.45 M in the titled compound by titration against menthol with 1, 10-phenanthroline as indicator. The titled product was produced in 79% yield.
(1R,2R)-2-((2S)-2-tert-butyloxycarbonylamino-3-phenyl-1- oxo)propyl-2-methylpropenylcyclopentane
e) To a stirred solution of Boc-L-phenylalanine (1.59 g, 6.00 mmol) in ether (40 ml) at -78° under Ar was added n- butyllithium (4.00 ml, 1.50 M in hexanes; 6.00 mmol). After 10 minutes, the product of Example 3(d) (37 ml, 0.32 M in pentane; 11.8 mmol) was added dropwise over a 10 minute period. After 10 minutes, the solution was warmed to 0° and stirred 1 hour 45 minutes, then water (200 ml) was added with vigorous stirring. The mixture was extracted with ethyl acetate and the crude product was purified three times by flash chromatography (95:5 hexanes : ethyl acetate) to provide isomer B (0.356 g, 9.60 mmol; 16% yield based on Boc-L-Phe), which elutes second, and isomer A (0.314 g, 8.46 mmol; 14% yield) which elutes first.
(isomer B)
(1R,2R)-2-((2S)-2-tert-butyloxycarbonylamino-3-phenyl-1-oxo)propyl-2-methylpropenylcyclopentane
TLC: (95:5 hexanes: ethyl acetate) Rf=0.19.
NMR (CDC13) : δ7.28-7.08 (5H), 5.06 (1H, d; J=7.8Hz; NH), 4.95(1H, d; J=9.6Hz; vinyl), 4.61 (1H, apparent quartet), 3.11 (1H, m), 3.10 (1H, dd; benzylic), 2.83 (1H, dd;
benzylic), 2.77 (1H, m), 2.05 - 1.25 (6H), 1.68 (3H; methyl), 1.62 (3H; methyl), 1.39 (9H, s; Boc).
MS (DCI/NH3) : m/z 372 (M+H)+, 316, 272.
(isomer A)
(1S,2S)-2-((2S)-2-tert-butyloxycarbonylamino-3-phenyl-1-oxo)propyl-2-methylpropenylcyclopentane
mp. 42-44°C.
TLC: (95:5 hexanes: ethyl acetate) Rf=0.26.
NMR (CDCI3) : δ 7.27-7.08 (5H), 5.18 (1H, d; J=7.7Hz; NH), 5.00
(1H, d; J=9.3 Hz; vinyl), 4.57 (1H, apparent quartet), 3.05
(1H, dd; J=13.9, 6.7 Hz; benzylic), 2.95 (1H, dd; J=13.9, 5.8 Hz; benzylic), 2.79 - 2.58 (2H, m), 1.95-1.20 (6H, m), 1.70
(3H; methyl), 1.52 (3H; methyl), 1.41 (9H; Boc).
MS (DCI/NH3) : m/z (M+H)+, 372, 316, 272.
(1R,2R)-2-(((2S)-2-tert-butyloxycarbonylamino-3-phenyl-1-oxo)propyl)cyclopentanecarboxylic acid
f) A solution of the product of Example 3(e) isomer B (186 mg, 0.50 mmol) in 4 : 1 CH2Cl2/CH3OH (5 ml) was stirred at
-78°, and ozone was introduced in a stream until a blue color persisted (ca. 2 min.). The solution was purged with argon, (CH3)2S (0.5 ml) was added and the solution was allowed to warm to 20°C. After 2 hr. the volatile components were removed under vacuum. The resulting crude aldehyde was dissolved in 5 ml acetone and treated with Jones Reagent (0.25 ml, 2. OM) at 0° with stirring for 3 min. Isopropanol (0.2 ml) was added. The mixture was diluted with water and extracted with CH2Cl2, and the extracts were concentrated.
Flash chromatography (80:20 hexanes : ethyl acetate followed by 80:20:4 hexanes : ethyl acetate:acetic acid) provided the titled compound (148 mg, 0.410 mmol) as a glass in 82% yield. m.p. 94.5-96°C
TLC: (80:20:4 hexanes :ethyl acetate:acetic acid) Rf=0.27.
NMR (CDC13) : δ7.26-7.13(5H, m), 5.12 (1H, d; J=8.0 Hz),
4.70(1H, apparent quartet), 3.46-3.27 (2H, m), 3.16(1H, dd; J=14 Hz, 6.2 Hz), 2.93 (1H, dd; J=14.0 Hz, 6.5 Hz), 2.141.67 (6H, m), 1.39(12H, s).
MS (DCI/NH3) : m/z 362 (M+H)+. Performing the same sequence, except substituting cyclohexene for cyclopentene in 3(a), yields 2-(((2S)-2-tert-butyloxycarbonylamino-3-phenyl-1-oxo)propyl)cyclohexanecarboxylic acid Example 4
Preparation of (1S,2S)-2-(((2S)-2-tert-butyloxycarbonylamino- 1-oxo-3-phenyl)propyl)cyclopentanecarboxylic acid
By the same procedure used to prepare the compound of Example 3(f), except substituting isomer A (186 mg, 0.50 mmol) from Example 3 (e), the titled compound was obtained (135 mg, 0.37 mmol) as a white solid in 75% yield.
TLC: (80:20:5 hexanes :ethyl acetate :acetic acid) Rf=0.41.
NMR (CDCL3) : δ7.32-7.12(5H, m), 5.13 (1H,d; J=8.1 Hz),
4.71(1H, apparent quartet), 3.42 (1H, apparent quartet), 3.22¬
3.08 (2H, m), 2.91(1H, dd; J=13.8, 6.9 Hz; benzylic), 2.20¬
1.62 (6H, m), 1.38 (12H, s).
MS (DCI/NH3) : m/z 362 (M+H)+, 323 (M+NH3+H-tBu)+, 262, 120. Example 5
Preparation of (1R,2R)-2-(((1RS,2S)-1-hydroxy-2- tertbutyloxycarbonylamino-3- phenyl)propyl)cyclopentanecarboxylic acid
To a solution of the compound of Example 7 (f) (216 mg, 0.598 mmol) in methanol (5 ml) at 0° was added NaBH4 (25 mg,
0.66 mmol) with stirring. After 20 min. dilute HCl
was added and the mixture was extracted with CH2CI2 to provide the titled compound as a mixture of epimers (216 mg,
0.595 mmol) in 100% yield and approximately 2:1 ratio.
NMR (CDCI3) : δ7.35-7.15 (5H), 5.05 (1H; NH), 3.87-3.56 (2H),
2.95-2.60 (3H), 2.38 (1H), 2.19-1.55 (6H), 1.38 (9H).
MS (DCI/NH3) : m/z 364 (M+H)+, 325, 308 (M-C (CH3) 3+H)+, 264 (M-OCOC(CH3)3+H)+, 183, 160, 120
Performing the same reduction upon 2-(((2S)-2-tert-butyloxycarbonylamino-3-phenyl-1-oxo)propyl)cyclohexanecarboxylic acid yields the
corresponding 2-(((2S)-2-tert-butyloxycarbonylamino-3-phenyl-1-hydroxoy)propyl)cyclohexanecarboxylic acid
Example 6
Preparation of (1R,2R)-2-(((1S,2S)-1_-hydroxy-2-tert-butyloxy-carbonylamino-3-phenyl)propyl)cyclopentanecarboxylic acid
(1R,2R)-methyl-2-(((1S,2S)-2-tert-butyloxycarbonγlamino-1-hydroxy-3-phenyl)propyl)cyclopentanecarboxylate
a) A solution of the epimers of Example 5 (140 mg, 0.386 mmol) in ether (5 ml) at 0° was treated with excess ethereal diazomethane for about 5 min. (until a yellow color persisted). Acetic acid (0.1 ml) was added and the solution was concentrated by rotary evaporation. Separation by HPLC (80:20 ethyl acetate: hexanes) on silica provided isomer A (47.0 mg, 0.125 mmol), which eluted first, followed by isomer B (50.6 mg, 0.134 mmol). isomer A
(1R,2R)-methyl-2-(((1S,2S)-2-tert-butyloxycarbonylamino-1-hydroxy-3-phenyl)propyl)cyclopentanecarboxylate
TLC: (2:1 hexanes : ethyl acetate) Rf=0.54. NMR (CDCI3) : δ 7.32-7.18 (5H, m), 4.85 (1H, d; J=8.7 Hz; NH), 3.72 (1H, m), 3.66 (3H, s), 3.52 (1H, dd), 2.90 (2H, apparent d; benzylic), 2.58 (1H, apparent quartet), 2.40 (1H, m), 1.92-1.50 (6H, m), 1.39 (9H, s).
MS (DCI/NH3) : m/z 378 (M+H)+, 339, 322 (M-C (CH3) 3+H)+, 321, 304(M-OC(CH3)3+H)+, 278 (M-OCOC (CH3) 3+H)+, 120.
The 2-hydroxy configuration was assigned as follows. Isomer A was converted to its oxazolidinone derivative by treatment with TFA to remove the BOC protecting group, followed by treatment with phosgene and triethylamine. The oxazolidinone ring hydrogens had an NMR coupling constant consistent with a trans relationship (J=5.3 Hz), which was confirmed by a lack of observed NOE, thus establishing the 2-hydroxy configuration to be (S). isomer B
(1R,2R)-methyl-2-(((1R,2S)-2-tert-butyloxycarbonylamino-1-hydroxy-3-phenyl)propyl)cyclopentanecarboxylate
TLC: (2:1 hexanes: ethyl acetate) Rf=0.42.
NMR (CDCI3) : δ 7.31-7.16 (5H, m), 4.92 (1H, d; J=8.7 Hz), 3.89 (1H, m), 3.72 (3H, s), 3.64 (1H, apparent d), 3.41 (1H, dd; J=14.2, 4.2 Hz; benzylic), 2.72 (2H, m), 2.36 (1H, apparent quintet), 2.06-1.40 (6H, m), 1.32 (9H, s).
MS (DCI/NH3) : m/z 378 (M+H)+, 322, 278, 120.
The 2-hydroxy configuration of isomer B was determined in the same manner as isomer A.
In an alternate procedure, the two epimers were cleanly separated by preparative HPLC (Rainin Dynamax® 1 in. x 25 cm silica column, 20 ml/min, 75:25:1 hexanes :ethyl
acetate : formic acid) to provide Isomer A (49% yield) and Isomer B (35% yield) . (1R,2R)-2-(((1S,2S)-1-hydroxy-2-tert-butyloxycarbonylamino-3- phenyl)propyl)cyclopentanecarboxylic acid
b) To a solution of isomer A of Example 6(a) (23.7 mg, 63.2 m mol) in 2:1:1 THF :water:methanol (2 ml) was added 10% NaOH (ca. 0.2 mmol). After 2.5 hr. the mixture was diluted with ethyl acetate and washed with 5% HCl. Drying over MgSO4 and evaporation provided the titled compound (21.4 mg, 59.0 m mol) in 94% yield,
m.p.: 120-122°C
TLC: (80:20:4 hexanes :ethyl acetate: acetic acid) Rf=0.34. NMR (CD3OD) : δ7.23 (5H), 3.73 (1H, m), 3.53 (1H, m), 2.85 (1H, dd; benzylic), 2.73 (1H, dd; benzylic), 2.55 (1H, m), 2.37 (1H, m), 1.90-1.57 (6H), 1.35 (9H, s).
Example 7
Preparation of (1R,2R_)-2-( ((1R,2S)-1-hydroxy-2-tert-butyloxycarbonylamino-3-phenyl)propyl)cyclopentanecarboxylic acid
By the procedure of Example 6 (b), isomer B of Example 6(a) (20.1 mg, 53.6 m mol) provided the titled compound (19.3 mg, 53.2 mmol; 99% yield),
m.p.: 133-135°C
TLC: (80:20:4 hexanes : ethyl acetate : acetic acid)
Rf=0.27.
NMR (CD3OD) : δ7.21 (5H), 3.75 (1H, m), 3.49 (1H, dd), 2.96
(1H, dd; benzylic), 2.77-2.42 (3H), 1.95-1.83 (3H), 1.78-1.60
(2H), 1.50 (1H, m), 1.30 (9H, s).
Example 8
Preparation of (1S, 2S)-2-(((1RS,2S)-2-tert-butyloxycarbonylamino-1-hydroxy-3-phenyl)propyl)cyclopentanecarboxylic acid
Using the procedure of Example 5 except substituting the compound of Example 4 (38 mg, 0.105 mmol), the titled
compound was obtained (35.5 mg, 0.0978 mmol) in a 1:1 ratio and 93% yield as a white solid.
TLC: (80:20:5 hexanes : ethyl acetate: acetic acid) Rf=0.26. NMR (CDCI3) : δ 7.32-7.14 (5H, m), 3.93-3.60 (2H, m), 3.383.21(1H, two multiplets), 3.05-2.70 (2H, m), 2.55-2.38 (1H, m), 2.35-1.54 (7H, m), 1.31-1.14 (9H, two singlets). Example 9
Preparation of valyl valine methyl ester hydrochloride phenylmethoxycarbonyl-valyl valine methyl ester
a) Isobutyl chloroformate (1.30 ml, 10.0 mmol) was added dropwise over 10 min. to a stirring solution of N-Cbz-L-valine (2.51g, 10.0 mmol) and N-methylmorpholine (1.21 ml, 11.0 mmol) in THF (30 ml) at -40°C under argon. After 1 hr., solid L-valine methyl ester hydrochloride (1.68 g, 10.0 mmol) was added, followed by more N-methylmorpholine (1.21 ml, 11.0 mmol). The mixture was stirred with warming to 20°C over 24 hr., then was filtered and concentrated to a solid by rotary evaporation. Flash chromatography (gradient, 0 to 5% CH3OH in CHCI3) provided the titled compound (3.44 g, 9.50 mmol) as a white solid in 95% yield.
NMR (CDCI3) : δ7.34(5H, m), 6.80 (1H,d), 5.62 (1H, d), 5.13 (2H, s), 4.56 (1H, dd), 4.17(1H, dd), 3.74(3H, s), 2.15(2H, m), 1.00-0.88 (12H, overlapping doublets). valylvaline methyl ester hydrochloride
b) A solution of the compound of Example 9(a) (535 mg, 1.47 mmol) in acetic acid (4 ml) was stirred with 10% Pd on carbon (50 mg) under an H2 atmosphere for 5 hr. The mixture was filtered, diluted with CH3OH, acidified with 37% HCl (0.2 ml), and concentrated under vacuum to a gum. The residue was triturated with ether and dried under vacuum to yield the titled compound (395 mg, 1.47 mmol) as a white powder.
NMR (CD3OD) : δ4.36(1H, d; J=5.8 Hz), 3.8K1H, d; J = 5.7 Hz),
3.73(3H, s), 2.21 (2H, septet), 1.09(3H, d; J = 7.0 Hz), 1.06 (3H,d; J=6.9 Hz), 0.998 (6H, overlapping doublets).
MS (FAB + VE) : m/z 231 (M + H)+, 188, 171, 132, 72, 55. Example 10
Preparation of tert-butyloxycarbonyl-(O-phenylmethyl)- serylalanyl alanine tert-butyloxycarbonyl-(O-Phenylmethyl) seryl alanine methyl ester
a) Isobutyl chloroformate (2.59 ml, 20.0 mmol) was added dropwise over 15 min. to a stirred solution of
N-Boc-L-serine-O-benzyl ester (5.90 g, 20.0 mmol) and N-methylmorpholine (2.74 ml, 25.0 mmol) in THF (100 ml) at 40°C under argon. After 45 min. N-methylmorpholine (2.75 ml, 25.0 mmol) and solid L-alanine methyl ester hydrochloride (3.22 g, 23.0 mmoir were added. The mixture was allowed to stir with gradual warming to 20°C. After 18 hr. the mixture was diluted with ethyl acetate and washed successively with 5% HCl, 5% NaHCO3 and brine. Filtration and removal of solvent under vacuum provided the titled compound (7.54 g, 19.8 mmol) as an oil in 99% yield.
TLC: (1:1 ethyl acetate : hexanes) Rf=0.5.
NMR (CDC13) : δ7.32 (5H, m), 7.11 (1H, br m), 5.41 (1H, br m), 4.65-4.53(3H,m), 4.30(1H, br m), 3.92(1H, dd; J=9.2 Hz, 3.9 Hz), 3.73(3H, s), 3.58(1H,dd; J=9.2 Hz, 616 Hz), 1.45(9H, s), 1.39(3H, d; J=7.1 Hz). tert-butyloxycarbonyl-(O-phenylmethyl)seryl alanine
b) Sodium hydroxide (0.8 g, 20 mmol) in water (50 ml) was added in portions over 2 hr . to a solution of the
compound of Example 10(a) (7.5 g, 19.7 mmol) in 2:1
methanol : water (225 ml). Stirring was continued 1 hr. longer until the solution was approximately neutral and TLC
indicated complete reaction. The solution was concentrated by rotary evaporation, diluted with water, and extracted with ethyl acetate. The aqueous layer was acidified with 10% HCl and extracted twice with ethyl acetate. Drying over MgSO4 and concentration under vacuum provided the titled compound (6.89 g, 18.8 mmol) as a glass in 96% yield.
NMR (CDCI3) : δ7.32 (5H, m), 5.62 (1H, broad), 4.60 (1H, m), 4.55 (2H, s), 4.36 (1H, broad), 3.87 (1H, dd), 3.61 (1H, dd), 1.46-1.40 (12H, m). tert-butyloxycarbonyl-(O-phenylmethyl) serylalanyl alanine methyl ester
c) Isobutyl chloroformate (2.42 ml, 18.8 mmol) was added dropwise over 18 min. to a stirring solution of the compound of Example 10(b) (6.89 g, 18.8 mmol) and N-methyl morpholine (2.74 ml, 25.0 mmol) in THF (100 ml) at -40°C under argon. After 20 min. N-methyl morpholine (2.74 ml, 25.0 mmol) and solid L-alanine methyl ester hydrochloride (3.07 g, 22.0 mmol) were added. The mixture was allowed to stir with gradual warming to 20°C for 20 hr., then was diluted with ethyl acetate and washed successively with 5% HCl, 5% NaHCO3 and brine. Filtration and removal of solvent under vacuum yielded the crude product (7169 g) as a solid.
Recrystallization (2:1 hexanes : ethyl acetate) provided the titled compound (7.55 g, 16.7 mmol) in 89% yield as white crystals .
TLC: (1:1 ethyl acetate:hexanes) Rf=0.15.
NMR (CDCI3) : δ 7.32 (5H, m), 7.00 (1H,d), 6.90(1H,d), 5.44 (1H, d), 4.58(2H, s), 4.54(2H, m), 4.30(1H, broad), 3.90(1H, dd), 3.74(3H, s), 3.64 (1H, dd), 1.44(9H, s), 1.38(6H, overlapping doublets). tert-butyloxycarbonyl-(O-phenylmethyl)serylalanyl alanine
d) Sodium hydroxide (0.25 g, 6.2 mmol) was added in portions over 4 hr . to a solution of the compound of Example
10(c) (2.79 g, 6.19 mmol) in 2 : 1 methanol :water (75 ml), at such a rate that the pH remained between 7 and 9. Stirring was continued for an additional 10 hr., then the solution was concentrated by rotary evaporation. Water was added and the solution was extracted twice with ethyl acetate. The aqueous layer was acidified with 10% HCl and extracted three times with ethyl acetate. Drying (MgSO4) of the organic extract and removal of solvent umder vacuum provided the titled compound (2.58 g, 5.90 mmol) in 95% yield as a white powder. NMR (CDCI3) : δ7.30 (7H, m; aromatic + NH), 5.57 (1H, broad),
4.64-4.46(4H, m), 4.38(1H, broad), 3.86 (1H,dd), 3.65(1H, dd), 1.44(9H,s), 1.39(6H, overlapping doublets).
MS (FAB + VE) : m/z 438 (M+H)+, 382, 338, 293, 249, 221, 203. MS (FAB-VE) : m/z 436 (M-H)-, 336, 254.
Example 11 Preparation of trans-2-((1-methoxy-1-(2-phenvl-1-phenylmethoxycar-bonylamino)ethyl)phosphinyl)cyclopentanecarboxylic acid
(±)-2-phenyl-1-phenylmethoxycarbonylaminoethyl
phosphonic acid, monomethyl ester
(a) (±)-diphenyl-(2-phenyl-1-phenylmethoxycarbonylamino) ethyl phosphonate was prepared as described in Synthesis. 985(1979). Briefly, a mixture of triphenyl phosphite (0.1 mol), phenylacetaldehyde (.15 mol, freshly distilled), benzyl carbamate(.1 mol), and glacial acetic acid (15 ml) was stirred for 1 hr. until the exothermic reaction subsites. The mixture was then heated at 80-85°C for 1 hr. and volatile products were removed on a rotary exaporator under reduced pressure with heating on a boiling water bath. The oily residue was dissolved in methanol (180 ml) and left for crystallization at -10°C. After 1-3 hr. the crystalline ester was collected by filtration and
recrystallized by dissolving it in a minimum amount of hot chloroform (30-40 ml) and adding a 4-fold volume of methanol.
A portion of the resulting diphenyl phosphonate (2.44 g, 5.00 mmol) was stirred for 2 days in methanol (75 ml) with sodium methoxide (1.6 g, 30 mmol). The solution was diluted with 5% HCl (250 ml) and extracted with ether. The ether layer was extracted with 5% Na2CO3 and brine, then was concentrated. The crude dimethyl phosphonate was stirred for 1 day as a solution in 50 ml methanol and 50 ml 10% NaOH. The solution was acidified with 10% HCl (300 ml) and
extracted with CH2CI2. Removal of solvent provided a solid which was dissolved in hot CHCI3 (100 ml). Hexane (50 ml) was added and the solution was stored overnight at -20°C. The resulting crystals were collected by filtration to provide the title compound (1.53 g, 4.38 mmol) in 88% yield. 2-(2-methylpropenyl) cyclopentylmagnesium bromide
b) To a stirring suspension of magnesium turnings (432 mg, 18 mmol) in dry ether (15 ml) and dry benzene (5 ml) under Ar in a flask equipped with a reflux condenser was added neat 1,2-dibromoethane (1.55 ml, 18 mmol) cautiously in dropwise fashion over 30 min. A 10.0 ml aliquot (9.0 mmol) of the resulting clear MgBr2 solution was added to a -78° solution of 2-(2-methyl propenyl) lithiocyclopentane (the compound of Example 3(d)) (8.6 mmol) in pentane (20 ml) and THF (20 ml). The resulting heterogenous mixture was warmed to 0° to give a clear orange solution of the corresponding Grignard reagent (8.6 mmol) which was recooled to -78° for use in step (b). trans-2-(1-methoxy-1-(2-phenyl-1-phenylmethoxycarbonylamino)ethyl)-phosphinyl-2-methylpropenylcyclopentane
c) To a solution of the compound of Example 11 (a), (1.92 g, 5.50 mmol) in dry CH2CI2 (15 ml) under Ar was added SOCI2 (0.40 ml, 5.5 mmol). After 2.5 hr the solvent was removed under vacuum. Residual HCl was removed by addition and re-evaporation of dry CH2CI2 (10 ml) followed by dry THF
(10 ml). The remaining gummy phosphonyl chloride was diluted with dry THF to a volume of 11.0 ml; an aliquot of the solution (8.6 ml; 4.3 mmol) was added with stirring to a -78° solution of Grignard reagent (8.6 mmol) as prepared in step (a) above. The homogenous mixture was allowed to stir 1 hr. at -78°C, then 1 hr. at -20°C. Aqueous 10% HCl (50 ml) was added, followed by water (200 ml). The mixture was extracted three times with ether. The combined ether extracts were rinsed with 5% NaHCO3, dried over MgSO4 and concentrated to an oil (2.1 g). Flask chromatography (CHCI3) provided the titled compound as a gum (864 mg, 1.90 mmol; 44% yield) and as a mixture of four diastereoisomers.
TLC: (25:1 CHC13:CH3OH) Rf=0.4.
GC (Column: CHROMPACK 51 mm x 0.22 mm i.d.; liquid phase CP sil 5 CB. Oven: 240°C) : RT (rel. area) 4.04 (1.0), 4.17 (1.3), 4.42 (1.2), 4.58 (1.9). NMR (CDCI3) : δ7.35-7.03 (10H, m), 5.56-5.10 (1H, m; NH), 5.05-4.87 (3H, m), 4.33 (1H, m), 3.76-3.60 (3H, m), 3.29-2.69 (3H, m), 2.08-1.56 (12H, m), 1.29 (1H, m).
MS (DCI/NH3) : m/z 456 (M + H)+, 378, 365, 348, 322, 213, 203, 120, 108, 91. trans-2-((1-methoxy-1-(2-phenyl-1-phenylmethoxycarbonylamino)ethyl)
phosphinyl)cyclopentanecarboxylic acid
d) Using the ozonolysis procedure of Example 3(f), the above compound of Example 11(c) (680 mg, 1.49 mmol) provided the titled compound as a crude gum. Flash
chromatography (25:1 CHCl3:CH3OH followed by 25:1:1
CHCl3:CH3OH: acetic acid) provided the pure product (365 mg, 0.820 mmol) in 55% yield as a crispy foam.
NMR (CDCI3) : δ 7.32-7.12 (10H, m), 5.00-4.91 (2H, m), 4.45
(1H, m), 3.78-3.64 (3H, m), 3.35-2.68 (4H, m), 2.08-1.60 (7H, m). Performing the same sequence except substituting 4-bromo-1-butene for 2-(2-methyl propenyl) lithiocyclopentane, yields the corresponding 2-((1-methoxy-1-(2-phenyl-1- phenylmethoxycarboxylamino)ethylphosphinyl)propanoic acid. Example 12
Preparation of (5S)-4-oxo-5-(t-butoxycarbonylamino)-6-phenyl-hexanoic acid (6S)-7-phenyl-6-(t-butoxycarbonylamino)hept-1-en-5-one
a) To a stirring suspension of magnesium powder (1.82 g, 75 mmol) in dry diethyl ether (10 ml) under argon were added several drops of 4-bromo-1-butene. Once spontaneous reflux had begun, 4-bromo-1-butene (6.75 g, 50 mmol) was added dropwise at a rate that maintained gentle reflux. The mixture was stirred for an additional 30 minutes with heating to reflux. After cooling, the solution of Grignard reagent was added to a stirring solution of (Boc)-L-phenylalanine-N- methoxy-N-methylamide (1.0 g, 3.2 mmol) in dry diethyl ether (10 ml) at 0°. After 1.5 hours the reaction mixture was diluted with 10% HCl and extracted 3x with diethyl ether.
The organic layer was washed successively with 1M HCl, saturated aqueous sodium bicarbonate, saturated aqueous sodium chloride, dried (MgSO4) and evaporated under reduced pressure to yield the titled compound (780 mg, 81.8% yield) as white crystals.
NMR (CDC13) : δ7.20(5H,m); 5.73 (1H,m); 5.1(1H,d);
5.05 (2H,m); 4.55 (1H,-quartet); 3.05 (2H,m);
2.48 (2H, quartet); 2.30(2H,m); 1.40(9H,s).
MS (DP/NH3) : m/z (M+H)+ 304; 248, 204, 120.
(5-S)-4-oxo-5-(t-butoxycarbonylamino)-6-phenyl-hexanoic acid b) Ozone was introduced into a solution of the compound of Example 12(a) (400 mg, 1.32 mmol) in 4 : 1 CH2Cl2:MeOH (5 ml) at -78°C until a blue color persisted. The solution was purged with argon for several minutes, then dimethyl sulfide (2 ml) was added. The mixture was warmed to room temperature for 2 hrs., then concentrated under reduced pressure to an oil. The oily residue was dissolved in acetone and cooled with stirring to 0°C. Jones reagent (1.32 mmol, 2M soln.) was added dropwise. After 5 minutes isopropanol was added. The mixture was diluted with H2O and extracted 3x with dichloromethane. The organic layer was dried (MgSO4), filtered and concentrated to an oil. Flash chromatography over silica gel (60: 40 hexane: ethyl acetate, followed by 65:35:5 hexane: ethyl acetate: acetic acid) provided the titled compound as an oil (175 mg, 41% yield
NMR (CDCI3) : δ7.24(5H,m); 5.1(1H,d);
4.55, (1H, quartet); 3.05(2H,m); 2.68(4H,m); 1.38(9H,s).
MS (FAB+) : m/z 322; (FAB-) : m/z 320.
Using the same sequence, except substituting Bocphenylglycine for Boc-(O-benzyl)tyrosine yields 4-oxo-5- (tert-butyloxycarbonyl-amino)-5-phenylpentanoic acid. Example 13
Preparation of (5S)-4-oxo-5-(tert-butoxγcarbonylamino)-6-(4-benzyloxyphenyl)-hexanoic acid
Boc-(O-benzyl)tyrosine-N-methoxy-N-methyl amide
a) To a solution of Boc- (O-benzyl) tyrosine (7.42 g; 30.0 mmol) in dry CH2CI2 (20 ml) were added triethylamine
(3.0 ml; 21.5 mmol) and benzotriazol-1-yloxytris(dimethylamino) phosphonium hexaf luorophosphate
(6.96 g; 20.0 mmol). After 10 minutes, triethylamine (3.0 ml; 21.5 mmol) and O,N dimethylhydroxylamine (2.15 g; 22.0 mmol). After 16 hr., the solution was diluted with ethyl acetate and washed successively with 5% HCl, saturated aqueous sodium bicarbonate, and saturated aqueous sodium chloride. The organic solution was dried (MgSO4), filtered, and concentrated to a foam. Flash chromatography over silica gel (50: 50 hexane/ethyl acetate) provided the titled
compound (5.87 g, 71% yield) as a white powder.
NMR (CDCI3) : δ7.40 (5H, m); 7.02, (4H), dd;
5.12 (1H, d); 5.05 (2H, s); 4.90 (1H, broad);
3.62 (3H, s); 3.15 (3H, s); 2.92 (2H, m);
1.38 (9H, s).
MS: m/z (M+H)+ 415; 359, 341, 315
(6S)-7-(4-benzyloxyphenyl)-6-(tert-butoxycarbonylamino)hept- 1-ene-5-one
b) To a suspension of magnesium powder (6.68 g, 0.275 mol) in anhydrous diethyl ether (100 ml), under an argon atmosphere was added several drops of 4-bromo-1-butene. Once spontaneous reflux was initiated, 4-bromo-1-butene (24.72 g, 0.183 mol) was added at a rate as to maintain a gentle reflux. Upon completion of the addition, the mixture was refluxed an additional 30 min. A solution of t-butyloxycarbonyltyrosine-(O-benzyl)-methoxymethyl amide
(18.95 g, 0.046 mol) in anhydrous THF was prepared and slowly added to the previously prepared Grignard reagent at 0°C. After 90 min, the reaction was complete as indicated by TLC and was quenched with 10% aqueous HCl. The reaction mixture was extracted with ether three times, and the combined organic extracts were washed successively with 1 M HCl, saturated aqueous NaHCO3, and saturated aqueous NaCl. The solution was dried (MgSO4), filtered, and evaporated under reduced pressure to give a white solid. Purification by column chromatography on silica gel eluting with 17% ethyl acetate/ hexanes provided the titled compound as a white solid (18.1 g, 96%).
NMR (CDC13) : δ7.42 (5H, m); 6.96 (4H, dd);
5.72 (1H, m); 5.10 (1H, br d)); 5.06 (2H, s);4.95 (2H, m); 4.48 (1H, q); 2.95 (2H, m); 2.5-2.0 (4H, m); 1.38 (9H, s). MS: m/z (M+H)+ 410, 371, 354, 310 (5S)-4-oxo-5-(tert-butoxycarbonylamino)-6-(4-benzyloxyphenyl)-hexanoic acid
c) To a solution of the compound of Example 13(b) (8.0 g, 19.6 mmol) in 4 : 1 CHCI3 : MeOH at -78°C was introduced ozone until a blue color persisted. The solution was then purged with argon for several min, followed by the addition of dimethyl sulfide (6 ml). The resulting mixture was stirred for 2 h at room temperature and then evaporated. The oily residue was dissolved in acetone (175 ml) and cooled to 0°C. Jones reagent (12 ml of a 2 M solution) was added dropwise, and the mixture was stirred for 10 min before quenching with isopropanol. The solution was poured into H2O and extracted with CH2CI2 three times. The combined organic extracts were dried (MgSO4), filtered and evaporated under reduced pressure. The oily residue was purified by column chromatography using silica gel, eluting first with 2:3 ethyl acetate: hexanes, followed by 5: 35: 60 acetic acid: ethyl acetate: hexanes to give the title compound as a tan solid (3.39 g, 40% yield).
NMR (CDCI3) : δ7.40 (5H, m); 7.0 (4H, dd);
NMR (CD3OD) : δ 5.05 (1H, obsc); 5.03 (2H, s);
4.52 (1H, quartet); 3.2- 2.5 (7H, m); 1.40 (9H, s). Example 14
Preparation of (3R,4S)-4-(N-benzyloxycarbonyl)amino-2,2-difluoro-3-hydroxy-5-phenylpentanoic acid
Ethyl (3R,4S)-4-(N-benzyloxycarbonyl)amino-2,2-difluoro-3-hydroxy-5-phenylpentanoate
a) A solution of N-Cbz-L-phenylalanol (0.77g, 2.75 mmol) in 10 ml of dry CH2CI2 was added to a solution of the Dess-Martin periodinane (1.28g, 3.02 mmol) in 15 ml of dry CH2CI2 in a slow steady stream. After stirring for 30 min.,
100 ml of a solution of 1 part 10% aqueous sodium thiosulfate and 1 part saturated aqueous NaHCO3 was introduced and the mixture was stirred vigorously for 30 min. The mixture was extracted three times with CH2CI2 and the combined organic extracts were dried over MgSO4, filtered, and concentrated in vacuo to give N-Cbz-L-phenylalanal as a yellow solid. A suspension of zinc (0.54g, 8.24 mmol) and CuBr (60 mg, 0.22 mmol) in 15 ml of dry THF was treated with diethylaluminum chloride (6.04 ml, 6.04 mmol, 1M in hexanes) and cooled to 20°C. To this suspension was added a solution of the crude N-Cbz-L-phenylalanal and ethyl bromodifluoroacetate in 25 ml of dry THF in a dropwise manner over 20 min. The reaction mixture was stirred for 45 min. then was quenched by addition of 5% aqueous HCl and allowed to warm to room temperature. The mixture was extracted three times with Et2O and the combined organic extracts were dried over MgSO4, filtered, and concentrated. Flash chromatography over silica gel (1.5:1 Et2O:hexanes) yielded 0.78g (70%) of a 3:2 mixture of diastereomers. The diastereomers were separated by repeated flash chromatography (1:1 hexanes :Et2O) to provide 468 mg
(42%) of the titled product as a white solid.
NMR (CDCI3) : δ7.27 (10H, m) ; 5.02 (3H, m); 4.31 (2H, q; J=7.5
Hz); 4.23 (1H, m); 4.09 (1H, m); 3.86 (1H, br d; J=6.2 Hz); 3.01 (2H, m); 1.31 (1H, t, J=7.5 Hz) (3R,4S)-4-(N-benzyloxycarbonyl)amino-2,2-difluoro-3-hydroxy-5-phenylpentanoic acid
b) The ester of Example 14(a) (1.0g, 2.45 mmol) was dissolved in 40 ml of 3:2 MeOH:THF. This solution was added to K2CO3 (2.7 g, 19.6 mmol) in water (25 ml) and the mixture was stirred vigorously for 3 hr. The aqueous solution was washed with Et2θ (discarded), acidified with HCl and
extracted once with Et2O and twice with CH2CI2. The combined organic extracts were dried over MgSO4 and filtered.
Evaporation of the solvent in vacuo furnished the titled acid
(0.93g, 90%) as a white solid.
NMR (CDCI3) : δ7.21 (10H, m); 4.91 (3H, m); 4.22 (3H, m); 2.97
(2H, m)
MS: m/z 380
Example 15
Preparation of 2-(acetyl seryl glutaminyl asparaginyl) amino-3-phenyl-propyl-prolylvalylvalinamide
The compound of Example 2(d) (0.35 g, 1.0 mmol) was coupled to Val-Val-BHA (1.0 mmol) using DCC (0.21 g, 1.0 mmol) and HOBT (0.15 g, 1 mmol) in 50% CH2Cl2/DMF overnight.
Quantitative ninhydrin test indicated 83% coupling. The peptide resin was acetylated with Ac2O (1 mL in 30 mL CH2C12) until the ninhydrin test was negative. The peptide was then completed and acetylated, according to the procedure of Example 1, using half of the resin. The peptide-resin
intermediate was cleaved with 10 mL anhydrous HF with 1 mL anisole for 1 h at 0°C. The peptide was extracted from the resin with glacial HOAc. Lyophilization afforded 150 mg crude peptide (37%). The peptide was purified by counter current distribution (n-butanol : acetic acid: water; 4:1:5) yielding 60 mg. The peptide was further purified by
preparative HPLC, k' 4.00 (Hamilton PRP-1 305 X 7 mm semipreparative HPLC column, water-acetonitrile- 0.1% TFA, 95:5 to 78:22 in 13 min, 78:22 to 60:40 in 6.5 min) giving 17.9 mg.
TLC: Rf 0.34 (B:A:W 4 : 1 :1), 0.68 (B:E:A:W 1:1:1:1). HPLC: (Hamilton PRP-1 250 X 4.1 mm analytical HPLC column, water-acetonitrile- 0.1% TFA, 95:5 to 60:40 over 15 min.) k' 2.73.
FAB-MS: m/z 817 (M+H)+.
Amino acid analysis: Ser 0.57, Gln 1.00, Asn 1.00, Val 2.00.
Performing the same sequence, except substituting 1.1 molar equivalents of butyryl chloride for acetic anhydride, yields 2-(butyryl-serylglutaminylasparaginyl)-amino-3-phenyl-propyl-prolylvalyl valinamide.
Example 16
Preparation of 2-(seryl glutaminylasparaginyl)amino-3-phenylpropyl-prolylvalyl valinamide
The compound of Example 2(d) (0.87 g, 2.5 mmol) was coupled to Val-Val-BHA (1.2 mmol) with DCC (0.52 g, 2.5 mmol) and HOBt (0.38 g, 2.5 mmol) in 30 mL of 50% CH2Cl2/DMF overnight. Ninhydrin test showed complete coupling. The peptide was completed using 0.6 g (0.4 mmol) of the resin. The peptide was cleaved from the resin using 15 mL HF with 1.5 mL anisole at 0°C for 1 h. The peptide resin mixture was washed with ether (3X) followed by HOAc (4X). Lyophilization of the HOAc gave 192.5 mg crude peptide (62%). A 100 mg portion of the crude peptide was purified by gel filtration through Sephadex® G-15 using 1% HOAc. This afforded 33.3 mg of peptide, which was further purified by preparative HPLC (Hamilton PRP-1 305 X 7 mm semi-preparative HPLC column, water-acetonitrile- .1% TFA, 85:15 to 60:40 in 15 min) to give 8.10 mg.
Rf 0.93 (B:A:W 4:1:1), 0.97 (B :E :A: W 1 : 1 : 1 : 1).
HPLC: (Hamilton PRP-1 250 X 4.1 mm analytical HPLC column, water-acetonitrile- .1% TFA, 95:5 to 60:40 over 15 min.) k' 2.87
FAB-MS m/z 775 (M+H)+ Example 17
Preparation of 4-(acetyl-serylglutaminylasparaginyl)amino-3(RS)-hydroxy-1-oxo-5-phenylpentyl-prolylvalyl valinamide
The resin supported intermediate Ac-Ser (Bzl) -Gln-Asn- [3(RS)-AHPPA]-Pro-Val-Val-BHA was prepared on a 1 mm scale in the usual manner according to Example 1. Boc-AHPPA used was racemic at the 3 position. The peptide was cleaved from the resin and the benzyl group was removed from the serine hydroxyl by treatment at 0° with 10 ml of anhydrous HF and 1 ml of anisole for 60 min. The HF was removed in vacuo at 0°. The residue was triturated with diethyl ether, the peptide was extracted with acetic acid (3 x 20 ml) and lyophilized to yield 302 mg. Purification was accomplished by counter current distribution (n-Butanol:Acetic Acid:Water, 4:1:5; 200 transfers). The major fractions were pooled, concentrated, diluted with acetic acid and lyophilized to yield 103 mg of the titled compound.
TLC: (B:E:A:W, 1:1:1:1) Rf=.51;
FAB-MS: m/z 875 (M+H)+;
Amino Acid Analysis: Asp=1.00, Ser=.14, Glu=.94, Pro=1.09, Val=2.24; Peptide Content (based on Asp)=80.8%.
Example 18
Preparation of 4-(acetyl-serylglutaminylasparaginyl)amino- 3(RS)-hydroxy-1-oxo-5-phenylpentyl-valyl valinamide
The resin supported intermediate Ac-Ser (Bz)-Gln-Asn- [3(RS)-AHPPA]-Val-Val-NH2 was prepared in the usual manner on a .5 mm scale. The Boc-AHPPA used was racemic in the 3 position. The peptide was cleaved from the resin with removal of the benzyl protecting group by treatment with anhydrous HF (10 ml) in the presence of anisole (1 ml) at 0° for 60 min. After removal of the HF at 0° under vacuum, the resin was triturated with diethyl ether and air-dried. The peptide was extracted from the resin with acetic acid (4 x 20 ml) and lyophilized to yield 110 mg. The peptide was purified using counter current distribution (B:A:W, 4:1:5; 200 transfers). The major fractions were pooled,
concentrated, diluted with acetic acid and lyophilized to yield 21 mg of the titled compound.
TLC: (B:E:A:W, 1:1:1:1) Rf=.53
HPLC: (4.5 mm X 25 cm Altex Ultrasphere 5m ODS,
acetonitrile-water-.1% TFA, gradient of 10-50% acetonitrile over 20 min.), k' = 4.47, 4.37
FAB-MS: m/z 778 (M+H)+;
Amino Acid Analysis: Asp=1.00, Ser=.71, Glu=1.00, Val=2.09; Peptide Content (based on Asp) =72.75%.
Example 19
Preparation of 4- (serylglutaminylasparaginyl)amino-3(R)-hydroxy-1-oxo-5-phenylpentyl-valyl valinamide
The resin supported intermediate Boc-Ser (Bzl)-Gln-Asn- [3(R)-AHPPA]-Val-Val-BHA was prepared in the usual manner on a 1 mm scale. Omitting the acetylation step, the peptide was cleaved from the resin with removal of the benzyl protecting group by treatment with HF (10 ml) and anisole (1 ml) at 0° for 60 min. The HF was removed under vacuum at 0°. The residue was triturated with diethyl ether and the peptide was extracted from the residue with acetic acid (4 x 10 ml). The acetic acid extract was lyophilized to yield 85 mg. 40 mg of the crude peptide was purified by preparative HPLC
(Ultrasphere ODS, 15% acetonitrile/H2O-.1% TFA). The fractions containing the desired product were combined, concentrated in vacuo, diluted with acetic acid and
lyophilized to yield 20 mg of the titled peptide.
HPLC: (4.6 mm X 25 cm Altex Ultrasphere ODS, 15%
acetonitrile-water-.1% TFA) k'=6.33.
FAB MS: m/z 736 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser .71, Glu .99, Val 1.96 Example 20
Preparation of 4-(serylglutaminylasparaginyl)amino-3(S)-hydroxy-1-oxo-5-phenylpentyl-valyl valinamide
The resin supported peptide intermediate Boc-Ser (Bz)-Gln-Asn-[3(S)-AHPPA]-Val-Val-NH2 was prepared in the usual manner on a 1 mm scale. The peptide was cleaved from the resin, deblocked and purified in the same manner as in
Example 19 to yield 12 mg of the titled compound.
HPLC (4.6 mm X 25 cm Altex Ultrasphere ODS, 15% acetonitrilewater-.1% TFA): k'=6.33
FAB MS: m/z 736 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser .71, Glu .99, Val 1.96 Example 21
Preparation of (1R,2R)-2-(((2S)-2-(tert-butyloxycarbonyl-serylalanylalanyl)amino-1-oxo-3-phenyl)propyl)-cyclopentylcarbonyl-valyl valine methyl ester
(1R,2R)-2-(((2S)-2-tert-butyloxycarbonylamino-1-oxo-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
(a) To a solution of the compound of Example 3(f) (10.5 mg, 29.0 m mol) in THF (0.4 ml) under argon at -40°C were added N-methylmorpholine (6 ml, 55 mmol) and isobutyryl chloroformate (3.8 ml, 29.1 mmol). After 20 min. more N-methylmorpholine (6 ml) was added, followed by a solution of valyl valine methyl ester hydrochloride (16 mg, 60 mmol) in THF (0.5 ml). The mixture was stirred at -40°C for 30 min., then at 20°C for 17 hr. The mixture was diluted with ethyl acetate, washed with 5% HCl, dried over MgSO4 and
concentrated. Flash chromatography (50:1 CHCl3:CH3OH) provided the titled compound as a white solid (13.4 mg, 23 mmol; 81% yield).
TLC: (50:1 CHCl3:CH3OH) Rf=0.28.
NMR (CDCI3 ) : δ 7 . 26 (3H, m; aromatic) , 7 . 10 (2H, m, aromatic) ,
6 . 50 ( 1H, d; J=8 . 7 Hz ; NH) , 6. 35 (1H, d; J=8 . 6 Hz ; NH) , 5 . 11 (1H, d; J=7.9 Hz; BocNH), 4.70 (1H, apparent quartet), 4.52 (1H, dd; J=8.7, 4.9 Hz), 4.26 (1H, dd; J=8.6, 7.1 Hz), 3.73 (3H, s), 3.51 (1H, apparent quartet), 3.16 (1H, dd; J=14.1,
5.5 Hz; benzylic), 3.07 (1H, apparent quartet), 2.86 (1H, dd; J=14.1 6.7 Hz; benzylic), 2.25-1.60 (8H, m), 1.38 (9H, s),
0.941-0.874 (12H, overlapping doublets).
MS (FAB + VE) : m/z 574 (M + H)+, 518, 474, 443, 387, 343,
244, 229. (1R,2R)-2-(((2S)-2-amino-1-oxo-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester, trifluoroacetic acid salt
(b) The compound of Example 21(a) (13 mg, 23 mmol, was dissolved in trifluoroacetic acid (0.5 ml). After 2 hr. the solution was concentrated under vacuum, and the residue was combined with methylene chloride and reconcentrated to provide the titled compound (13 mg) as a white solid.
(1R,2R)-2- ((2S)-2-(tert-butyloxycarbonyl-(O-phenylmethyl)serylalanyl-alanyl)amino-1-oxo-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
(c) To a solution of Boc-Ser (Bzl)-Ala-Ala (15.1 mg, 34.5 mmol) in THF at -40°C under argon, N-methyl morpholine (7.7 ml) and isobutyl chloroformate (4.5 ml, 35 mmol) were added. After stirring 20 min., additional N-methylmorphonine (7.7 ml) was added, followed by a solution of the tripeptide of Example 21(b) (13 mg) in THF. The mixture was warmed to 20°C and stirred overnight. The reaction mixture was diluted with CH2CI2 and washed with 5% HCl, 5% NaHCO3 and water. Evaporation of the solvent afforded a crude product which was purified by flash chromatography (gradient elution, 50:1 to 25:1 CHCl3:CH3OH) to give the titled product (17.9 mg, 20 mmol) as a white solid.
TLC: (95:5 CHC13:CH3OH) Rf=0.35.
NMR (1:1 CD3OD :CDCl3) : δ 7.35 - 7.20 (5H, m), 4.80 (1H, dd;
J=8.7, 4.8 Hz), 4.54 (2H, s; PhCH2O), 4.42-4.16 (5H, m), 3.73 (3H, s), 3.78-3.62 (2H, m; BnOCH2), 3.40 (1H, m), 3.20 (1H, dd; J=14.4, 4.7 Hz; benzylic), 3.09 (1H, m), 2.92 (1H, dd; J = 14.4, 8.7 Hz; benzylic), 2.25-1.95 (4H, m), 1.85-1.65 (4H, m), 1.47 (9H, s), 1.35 (3H, d; J=7.2 Hz), 1.23 (3H, d;
J=7.2Hz), 0.956-0.922 (12H, overlapping doublets).
MS (FAB + VE) : m/z 893 (M + H)+, 793, 762, 706, 662, 645, 634, 514, 474, 420, 364.
(1R,2R)-2-(((2S)-2-(tert-butyloxycarbonyl-serylalanylalanyl)amino-1-oxo-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
(d) A solution of the hexapeptide of Example 21(c) (8.1 mg, 9.1 mmol) in methanol (4 ml) was stirred with 10% Pd/C (7 mg) under an H2 atmosphere for 15 hr. Filtration and
evaporation provided the titled compound (7.2 mg, 9 mmol) as a white solid.
TLC (95:5 CHCI3 :CH3OH) : Rf=0.15.
NMR (1:1 CD3OD:CDC13) : δ7.21(5H, m), 4.80 (1H, m), 4.36-4.12 (5H, m), 3.81 (1H, dd; J=10.9, 5.3 Hz; CH2OH), 3.72 (3H, s), 3.67 (1H, dd; J=10.9, 5.8 Hz; CH2OH), 3.41 (1H, m), 3.20 (1H, dd; J=14.3, 4.6 Hz; benzylic), 3.07 (1H, m), 2.88 (1H, dd; J=14.3, 9.0 Hz; benzylic), 2.22-1.96 (4H, m), 1.81-1.67 (4H, m), 1.47 (9H, s), 1.38 (3H, d; J=7.3 Hz), 1.27 (3H, d; J=7.3 Hz), 0.960-0.932 (12 H, overlapping doublets).
MS (FAB + VE) : m/z 803 (M + H)+, 787, 703, 672, 616, 572, 544, 473, 330, 315, 298, 274, 244, 203.
MS (FAB - VE) : m/z 802 698, 307, 273, 241, 201, 185, 153.
Example 22
Preparation of (1R,2R)-2-(((2S)-2-(serylalanylalanyl)amino-1- oxo-3-phenyl)propyl)cyclopentylcarbonyl-valvl valine methyl ester, hydrochloride
The compound of Example 21(d) (5 mg, 6.2 mmol) was dissolved in trifluoroacetic acid (.25 ml). After 90 min., the solution was concentrated under vacuum, the residue was dissolved in methanol (.5 ml) and concentrated HCl (about .025 ml) was added. The solution was concentrated, the resulting gum was triturated with ether and dried under vacuum to afford the titled compound (4.5 mg.) as a white solid.
NMR (CD3OD) : δ7.20 (5H, m), 4.72 (1H, dd; J=8.5, 5.0 Hz),
4.38 (1H, m), 4.31 (2H, m), 4.19 (1H, d), 3.92 (3H, m), 3.70 (3H, s), 3.48 (1H, m), 3.19 (1H, dd; J=14.3, 5.0 Hz;
benzylic), 3.08 (1H, m), 2.83 (1H, dd; J=14.3, 8.5 Hz;
benzylic), 2.21-1.98 (4H, m), 1.84-1.65 (4H, m), 1.35 (3H, d; J=7.2 Hz), 1.29 (3H, d; J=7.1 Hz), 0.958-0.921 (12H, overlapping doublets).
MS (FAB + VE) : m/z 703 (M + H)+.
Example 23
Preparation of (1S,2S)-2-(((1S,2S)-2-(tert-butyloxycarbonyl-serylalanylalanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
(1S,2S)-2-(((1RS,2S)-2-tert-butyloxycarbonylamino-1-hydroxy-3-phenyl)propyl)cyclopentanecarbonyl-L-valyl-L-valine methyl ester
a) The product of Example 8 (35.5 mg, 97.8 mmol) and HOBT (26 mg, 196 mmol) were dissolved in dioxane(0.5 ml) and DMF (0.1 ml), and DCC (20.2 mg, 98.1 mmol) was added. After 20 min. stirring, N-methyl
morpholine (32 ml, 290 mmol) and valyl valine methyl ester hydrochloride (52 mg, 195 mmol) were added. After 3 days, the mixture was diluted with ethyl acetate, filtered and
extracted with dilute HCl. The organic layer was
concentrated. Flash chromatography (50:1 CHCl3:CH3OH) of the crude product provided isomer A (26 mg, 45.9 mmol;
47% yield) which eluted first, and isomer B (25 mg, 43.1 mmol; 44% yield). isomer A:
(1S,2S)-2-(((1R,2S)-2-(tert-butyloxycarbonyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentanecarbonyl-valyl valine methyl ester
TLC: (25:1 CHCl3:CH3OH) Rf=0.55. NMR (CDCI3) : δ7.28 (5H, m), 6.73 (1H, d; J=8.7 Hz;
NH), 6.42 (1H, d; J=8.6 Hz; NH), 5.16(1H, d; J=9.5 Hz; BocNH), 4.58 (1H, dd; J=8.8, 5.2 Hz), 4.32 (1H, dd; J=8.6, 6.0 Hz), 3.91 (1H, apparent quartet), 3.76(3H, s), 3.25 (1H, apparent doublet; J=10.2 Hz), 2.95-2.83 (2H; benzylic), 2.52 (1H, apparent quartet), 2.30-2.10 (3H, m), 2.00-1.55 (6H, m),
1.39(9H, s), 0.990-0.907 (12H, apparent quartet).
MS(FAB + VE) : m/z 576(M + H)+, 476, 389, 345, 317, 246, 225. isomer B :
(1S, 2S) -2- ( ( (1S, 2S) -2- (tert-butyloxycarbonyl) amino-1-hydroxy- 3-phenyl) propyl) cyclopentanecarbonyl-valyl valine methyl ester
TLC: (25:1 CHCl3:CH3OH) Rf=0.45.
NMR (CDCI3) : δ 7.24-7.15 (5H, m), 6.77 (1H, d; J=8.3 Hz), 6.56 (1H, d; J=8.2 Hz), 4.80 (1H, d; J=8.4 Hz), 4.47 (1H, dd;
J=8.4, 4.9 Hz), 4.36(1H, apparent triplet), 3.80-3.60 (5H, m), 3.08 (1H, dd), 2.69(2H, m; benzylic), 2.53 (1H, m), 2.252.05 (2H, m), 2.00-1.60 (6H, m), 1.32 (9H, s), 0.979-0.855 (12H, overlapping doublets).
MS(FAB + VE) : m/z 576(M + H)+, 476, 389, 246, 231, 152, 132.
(1S,2S)-2-(((1S,2S)-2-amino-1-hydrpxy-3-phenyl)propyl)- cyclopentanecarbonyl-valyl valine methyl ester, hydrochloride b) Isomer B of Example 23(a) (25 mg, 43 mmol) was dissolved in trifluoracetic acid (0.25 ml). After 1 hr., the solution was concentrated by rotary evaporation. The residue was dissolved in CH3OH, treated with cone. HCl (.05 ml) and re-concentrated. Trituration with Et2O and drying under vacuum provided the titled compound as a white powder (22 mg, 43 mmol).
(1S,2S)-2-(((1R,2S)-2-amino-1-hydroxy-3-phenyl)- propyl)cyclopentanecarbonyl-valyl valine methyl ester hydrochloride
c) Isomer A of Example 23(a) (26 mg, 45 mmol) was treated with trifluoroacetic acid and HCl according to the procedure of Example 23 (b) to provide the titled compound ( 19 . 9 mg, 39 mmol) .
(1S,2S)-2-( (1S,2S)-2-(tert-butyloxycarbonyl-L-(O-phenylmethyl)serylalanylalanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester d) To a solution of Boc-Ser (Bzl)-Ala-Ala (19.4 mg, 44.4 mmol) in THF (0.5 ml) under Argon at -40°C were added N-methyl morpholine (8.8 ml) and isobutyl chloroformate (5.8 ml, 44.4 mmol). After stirring 20 min., additional N-methyl morpholine (8.8 ml) was added followed by a solution of the compound of Example 23(b) (22 mg, 43 mmol) in THF (1.0 ml),
The mixture was warmed to 20°C and stirred overnight. The reaction mixture was diluted with CH2CI2 and washed with 5% HCl, dried (MgSO4) and concentrated. Flash chromatography of the residue provided the titled compound as a white solid (25 mg, 28 mmol; 65% yield).
NMR (CDCI3) : δ7.40-7.05 (11H, m), 7.00-6.80 (4H, m; NH), 5.53
(1H, d; BocNH), 4.52 (2H, s), 4.47-4.30 (4H, m), 4.19-4.06 (2H, m), 3.97 (1H, broad), 3.80-3.62 (2H, m), 3.69 (3H, s), 3.07 (1H, dd), 2.83 (1H, dd), 2.66 (1H, m), 2.52 (1H, m),
2.34 (1H, broad), 2.23-2.03 (2H, m), 2.00-1.84 (2H, m), 1.801.60 (4H, m), 1.46 (9H, s), 1.32 (3H, d; J=7.0 Hz), 1.15 (3H, d; J=7.1 Hz), 0.939 (6H; two overlapping doublets), 0.871 (6H, two overlapping doublets).
MS (FAB + VE) : m/z 895 (M + H)+, 795 (M-Boc + H)+, 764, 708, 664, 618, 565, 547, 476, 416, 388.
(1S,2S)-2-(((1R,2S)-2-(tert-butyloxycarbonyl-L-(O-phenylmethyl)serylalanylalanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester e) By a procedure substantially similar to Example
23(d), using the tripeptide prepared in Example 25(c) (19.9 mg, 39 mmol), Boc-Ser (Bzl)-Ala-Ala (17.5 mg, 40 mmol), isobutyryl chloroformate (5.2 ml, 40 mmol) and N-methylmorpholine (2x8.8 ml), the titled compound was obtained as a white solid (23.2 mg, 26 mmol; 67% yield).
NMR (CDCI3) : δ7.38-7.17 (10H, m), 7.10 (2H, m; NH), 6.96 (1H, d; J=8.3 Hz; NH), 6.87 (1H, d; J=9.1 Hz; NH), 6.63 (1HH d; J=8.4 Hz; NH), 5.50 (1H, d; J=6.4 Hz; BocNH), 4.56 (2H, s; benzylic), 4.53-4.36 (4H, m), 4.39 (2H, m), 4.15 (1H,
apparent quartet), 3.84 (1H, dd; J=9.4, 4.6 Hz), 3.74 (3H, s), 3.66 (1H, dd; J=9.4, 5.8 Hz), 3.33 (1H, apparent
triplet), 2.94-2.91 (2H, m; benzylic), 2.57 (1H, apparent quartet), 2.26-2.08 (4H, m), 1.95-1.75 (3H, m), 1.67-1.50 (2H, m), 1.45 (9H, s), 1.37 (3H, d; J=7.1 Hz), 1.30 (3H, d; J=7.1 Hz), 0.950-0.892 (12H, overlapping doublets). (1S,2S)-2-(((IS.2S)--2-(tert-butyloxycarbonyl-L-serylalanylalanyl)-amino-1-hydroxy-3-phenyl)propyl)-cyclopentylcarbonyl-valyl valine methyl ester
f) A solution of the compound of Example 23 (d) (25 mg, 28 mmol) in methanol (1 ml) was stirred with 10% Pd/C (12 mg) under an H2 atmosphere for 15 hrs. Filtration and
evaporation of the solvent provided the titled compound (20.7 mg, 25.7 mmol; 92% yield) as a white solid.
TLC: (95:5 CHC13:CH3OH) Rf=0.39.
NMR (CDCI3) : δ7.71 (1H, broad; NH), 7.58 (1H, broad d; NH), 7.16 (5H, m), 6.97 (2H, m; NH), 6.12 (1H, broad; NH), 4.75
(1H, broad; BocNH), 4.42 (1H, dd), 4.40-4.04 (5H, m), 3.89
(1H, broad), 3.70 (3H, s), 3.64 (2H, m), 3.03 (1H, dd), 2.82¬
2.44 (4H, m), 2.23-1.87 (4H, m), 1.80-1.60 (4H, m), 1.45 (9H, s), 1.35 (3H, d; J=6.8 Hz), 1.09 (3H, d; J=6.9 Hz), 0.963 (6H; two doublets), 0.853 (6H, two doublets).
MS (FAB + VE) : m/z 805 (M + H)+, 789, 705, 674, 618, 574,
476, 416, 388, 300.
MS (FAB-VE) : m/z 803 (M-H)-. Example 24
Preparation of (1S,2S)-2-(((1S,2S)-2-(L-seryl-L-alanyl-L- alanyl)-amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl- valyl valine methyl ester, trifluoroacetic acid salt
The product of Example 23(f) (1.3 mg, 1.6 mmol), was dissolved in trifluoroacetic acid. After 90 min. the solution was concentrated to dryness under vacuum. The residue was triturated with ether and the ether was removed under vacuum to yield the titled hexapeptide as a white solid.
Example 25
Preparation of (1S,2S)-2-(((1R,2S)-2-(tert-butyloxycarbonyl-serylalanylalanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-L-valyl-L-valine methyl ester
Using the procedure of Example 23(f), the hexapeptide of Example 23(e) (23 mg, 26 mmol) was debenzylated to provide the titled compound as a white solid (18.9 mg, 23.5 mmol; 90% yield).
TLC: (95:5 CHC13:CH3OH) Rf=0.45.
NMR (CDC13) : δ7.47 (1H, d; J=7.3 Hz; NH), 7.34 (1H, d; J=6.8
Hz; NH), 7.29-7.16 (5H, m), 7.09 (1H, d; J=8.9 Hz, NH), 6.79
(1H, d; J=8.5 Hz; NH), 5.79 (1H, d; J=6.5 Hz; NH), 4.76 (1H, broad), 4.45-4.20 (5H, m), 4.11 (1H, apparent quartet), 3.94
(1H, dd; J=10.9, 4.3 Hz), 3.74 (3H, s), 3.66 (1H, dd), 3.31 (1H, broad doublet), 2.91 (2H, apparent doublet), 2.58 (1H, apparent quartet), 2.44 (2H, broad), 2.28-2.08 (3H, m), 1.951.71 (3H, m), 1.59 (2H, m), 1.45 (9H, s), 1.41 (3H, d; J=7.1 Hz), 1.30 (3H, d; J=7.1 Hz), 0.951-0.906 (12H, m).
MS (FAB + VE) : m/z 805 (M + H)+, 787, 731, 705, 674, 618, 547, 519, 476.
MS (FAB-VE) : m/z 803, 711, 699.
Example 26 Preparation of (1S,2S)-2-(((1R,2S)-2- (serylalanylalanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester. trifluoroacetic acid salt
The compound of Example 25 (1.2 mg, 1.5 mmol) was dissolved in trifluoroacetic acid. After 90 min. the solution was concentrated to dryness under vacuum. The residue was triturated with ether to yield a white solid. Example 27
Preparation of (1R,2R)-2-(((1S,2S)-2-(tert-butyloxy-carbonyl-serylalanvlalanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
(1R,2R)-2-(((1RS,2S)-1-hydroxy-2-tert-butyloxγcarbonylamino-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine
a) To a solution of the epimers of Example 5 (36 mg, 0.10 mmol) in dioxane (0.4 ml) were added N-hydroxy
benzotriazole (27 mg, 0.20 mmol) and DCC (22 mg, 0.11 mmol). After 20 min. stirring, N-methyl morpholine (27 ml, 0.25 mmol) was added, followed by valyl valine methyl ester hydrochloride (53 mg, 0.20 mmol). The mixture was stirred 5 days, then was filtered and concentrated. Flash
chromatography (25:1 CHCI3/CH3OH)
provided the titled epimeric compounds in 89% yield as a white foam (51 mg, 0.089 mmol).
TLC (20:1 CHC13:CH3OH) : Rf=0.37.
NMR (CDCI3) : δ 7.35-7.15 (5H, m), 7.05-6.75 (2H, m; NH), 5.13 (1H, m; BocNH), 4.50 (1H, m), 4.30 (1H, m), 3.85-3.60 (5H, m), 2.95-2.58(3H, m), 2.43-1.55 (8H, m), 1.45-1.25 (9H, two
singlets; Boc), 1.05-0.90 (12H, m).
MS(FAB+) : m/z 576 (M+H)+, 476 (M-OCOC (CH3) 3)+.
(1R,2R)-2-(((1RS,2S)-1-hydroxy-2-amino-3-phenyl)propyl)- cyclopentylcarbonyl-valyl valine methyl ester, hydrochloride b) The peptides of Example 27(a) (48mg, 83 mmol) were dissolved in trifluoroacetic acid (0.5 ml). After 1 hr. the solution was concentrated by rotary evaporation, and the residue was dissolved in CH3OH, treated with concentrated HCl
(0.1 ml) and reconcentrated. Trituration with ether and drying under vacuum provided the epimeric titled compounds as a white powder (42 mg, 82 mmol). (1R,2R)-2-(((1RS,2S)-2-(tert-butyloxycarbonyl-(O-phenylmethyl)-serylalanylalanyl)amino-1-hydroxv-3-phenyl)propyl)cyclopentyl-carbonyl-valyl valine methyl ester c) To a solution of Boc-Ser (Bzl)-Ala-Ala (35 mg; 0.080 mmol) in THF (0.4 ml) under argon at -40°C were added N-methyl morpholine (11 ml, 0.10 mmol) and isobutyryl
chloroformate (10.4 ml, 0.080 mmol). After 20 minutes stirring, N-methylmorpholine (11 ml) was added, followed by a solution of the compounds of Example 27(b) (42 mg, 0.082 mmol) in THF (1 ml). The mixture was stirred with warming to 20°C overnight, then was dissolved in CH2CI2 and washed with 5% HCl, 5% NaHCO3 and water. Evaporation of solvent provided 61 mg of a crude product. A 50 mg portion of the crude product was purified by flash chromatography (gradient elution, 50:1 to 25:1 CHCl3:CH3OH) to elute pure isomer A (16 mg), followed by a mixed fraction (11 mg), and finally pure isomer B (13 mg). isomer B:
(1R,2R)-2-(((1S.2S)-2-(tert-butyloxycarbonyl-L- (O-phenylmethyl)serylalanylalanyl)amino-1-hydroxy- 3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
TLC: (25:1 CHC13:CH3OH) Rf=0.40.
NMR (CDCI3) : δ 7.40-6.95 (15H, m; aryl + NH), 5.58 (1H,d;
BocNH), 4.53 (2H,s; benzylic), 4.51(1H,dd), 4.37(2H,m), 4.264.20 (3H, m), 3.75 (2H, m), 3.71 (3H, s), 3.54 (1H, broad), 2.96-2.90 (2H; benzylic), 2.69(1H, m), 2.38 (1H, m), 2.15 (2H, m; CH(CH3)2), 1.90-1.60 (6H, m), 1.46(9H, s; Boc), 1.37 (3H,d; J=7.2 Hz; CH3), 1.20 (3H, d; J=7.2 Hz; CH3), 0.937 - 0.980 (12H, overlapping doublets; CH3). isomer A
(1R,2R)-2-(((1R,2S)-2-(tert-butyloxycarbonyl-L-(O-phenylmethyl)serylalanylalanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester TLC: (25:1 CHCl3:CH3OH) Rf=0.45
NMR (CDCI3) : δ7.79 (14H, d; NH), 7.40-7.10 (11H, m; aryl + NH), 6.70 (2H; NH), 5.59 (1H,d; J=3.3 Hz;NH), 4.93 (1H, d; J=3.2 Hz), 4.54 (2H, s; benzylic), 4.47 (1H, dd; J = 8.5, 5.0 Hz), 4.30-4.20 (4H, m), 4.14 (1H, m), 3.78 (1H, m), 3.71 (3H, s), 3.67 (1H, m), 2.90 (1H, dd; benzylic), 2.77 (2H, m), 2.35-2.10 (4H, m), 1.95-1.55 (6H, m), 1.49 (9H, s; Boc), 1.40 (3H, d; J=7.3 Hz; CH3), 1.12 (3H, d; J=7.3 Hz; CH3), 0.99 (6H, two doublets; CH3), 0.91 (6H, two doublets; CH3).
(1R,2R)-2-(((1S,2S)-2-(tert-butyloxycarbonylserylalanyl-alanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
d) A solution of isomer B of Example 27 (c) (13 mg, 15 mmol) in methanol (5 ml) was stirred with 10% Pd/C (10 mg) under an H2 atmosphere for 15 hr. Filtration and evaporation provided the titled peptide (12 mg, 15 mmol) as a white solid.
TLC: (95:5 CHC13:CH3OH) Rf=0.21.
NMR (CD3OD) : δ7.21 (5H, m), 4.35 (1H, m), 4.30-4.13 (4H, m),
4.08 (1H, broad), 3.85 (1H, dd; J=10.8, 5.4 Hz) CH2OH) , 3.73
(1H, m), 3.72 (3H, s), 3.58 (1H, apparent t; J=4.3 Hz), 2.92 (1H, dd; J=13.7, 6.2 Hz; benzylic), 2.75 (1H, dd; benzylic),
2.71 (1H, m), 2.37 (1H, broad m), 2.19-2.02 (2H, m;
CH(CH3)2), 1.85-1.60 (6H, m), 1.48 (9H, s; Boc), 1.41 (3H, d;
J=7.3 Hz; CH3), 1.21 (3H, d; J=7.3; CH3), 0.934-0.928 (12H; overlapping doublets; CH3).
MS (FAB + VE) : m/z 805 (M + H)+, 674, 618, 574, 476, 309,
274, 246, 228, 203.
Example 28 Preparation of (1R,2R)-2-(((1S,2S)-2-(serylalanylalanyl)- amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester, hydrochloride
The product of Example 27(d) (12 mg, 15 mmol) was dissolved in trifluoroacetic acid (0.5 ml). After 90 min the solution was concentrated under vacuum; the residue was dissolved in methanol (1 ml) and cone. HCl (ca .05 ml) was added. The solution was concentrated, the resulting gum was triturated with ether and dried under vacuum to afford the titled compound (11 mg) as a white powder.
NMR (CD3OD) : δ7.23 (5H, m), 4.50-4.25 (3H, m),
4.16 (1H, m), 4.05-3.90 (3H, m), 3.70 (3H, s),
3.51 (1H, dd), 3.00-2.70 (2H, m), 2.56 (1H, m),
2.32 (1H, m), 2.20-1.95 (2H, m), 1.80-1.58 (6H, m),
1.40 (3H, d; J=7.1 Hz), 1.27 (3H, d; J=7.2 Hz),
0.959-0.931 (12H, overlapping doublets).
MS (FAB + VE) : m/z 705(M+H)+, 574, 476. Example 29
Preparation of (1R,2R)-2-(((1R,2S)-2-(tert-butyloxycarbonyl-serylalanylalanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
Isomer A of Example 27(c) (15.5 mg, 17.3 mmol) was stirred with 10% Pd/C (10 mg) in methanol (5 ml) under an H2 atmosphere for 15 hr. Filtration and evaporation provided the titled peptide (13.8 mg, 17.2 mmol).
TLC: (95:5 CHC13:CH3OH) Rf=0.27.
NMR (CD3OD) : δ7.22 (5H, m), 4.40 - 4.10 (6H, m), 3.86 (1H, dd; J=11.0, 5.5 Hz; CE2OH), 3.78 (1H, dd; J=11.0, 6.0;
CH2OH), 3.72 (3H, s), 3.58(1H, dd; J=10.0, 1.8), 2.98 (1H, dd;
J=14.1, 3.4 Hz; benzylic), 2.81-2.71 (2H, m), 2.34 (1H, m), 2.24-1.60 (8H, m), 1.50 (9H, s), 1.40 (3H, d; J=7.3 Hz; CH3), 1.11 (3H, d; J=7.4 Hz; CH3), 1.02-0.940 (12H, four doublets; CH(CH3)2).
MS (FAB + VE) : m/z 805 (M + H) +, 674, 618, 574, 519, 475,
308, 264. Example 30
Preparation of (1R,2R)-2-(((1R,2S)-2-(serylalanyl-L-alanyl)amino-hydroxy-3-phenyl)propyl)cyclopentyl-carbonyl-valyl valine methyl ester, hydrochloride
Using the procedure of Example 28, the hexapeptide of Example 29 (13.8 mg, 17.2 mmol) was treated with
trifluoroacetic acid and HCl to provide the titled compound (13 mg). NMR (CD3OD) : δ7.20 (5H, m), 4.39-4.17 (4H, m), 4.07-3.92 (4H, m), 3.70 (3H, s), 3.52 (1H, dd; J=9.5, 2.9 Hz), 2.98 (1H, dd; J=14.2, 3.4 Hz; benzylic), 2.82-2.68 (2H, m), 2.38 (1H, m), 2.21-1.55 (8H, m), 1.35 (3H, d; J=7.2 Hz), 1.20 (3H, d; J = 7.1 Hz), 1.01-0.889 (12H, four doublets) .
MS (FAB + VE) : m/z 705 (M + H)+, 575, 476.
Example 31 Preparation of (1R,2R)-2-(((1RS,2S)-2-(acetyl-serylalanylalanyl)amino-1-hydroxy-3-phenyl)propyl)-cyclopentylcarbonyl-valyl valine methyl ester
(1R,2R)-2-(((1RS,2S)-2-(acetyl-(O-phenylmethyl)serylalanyl alanyl)amino-1-hydroxy-3-phenyl)propyl)cyclopentylcarbonvy-valyl valine methyl ester
a) A 1:1 mixture of the epimers of the compound in Example 27(c) (10.8 mg, 12.2 mmol) was dissolved in
trifluoroacetic acid (0.5 ml). After 75 min. the solution was concentrated under vacuum. The residue was dissolved in CH2Cl2 and extracted with 5% NaHCO3. The CH2CI2 layer was dried over MgSO4 and concentrated to a white solid (8.8 mg, TLC: (25:1 CHCl3:CH3OH) Rf=0.13. The solid was stirred as a suspension in 1:1 CH2CI2 : dioxane (2 ml) and acetic
anhydride (1.1 ml, 12 mmol). After 30 min. the solvent was removed by rotary evaporation. The residue was purified by flash chromatography (9:1 CHCl3:CH3OH) to provide the titled epimeric mixture as a white solid (9.2 mg, 11.0 mmol).
TLC: (25:1 CHCI3 : CH3OH) Rf=0.25, 0.18.
NMR (CD3OD) : δ 7.38-7.11 (10H, m), 4.57 (2H, s), 4.53-3.97
(6H, m), 3.78 (2H, apparent triplet), 3.70 (3H, s), 3.68 (1H, m), 3.53 (1H, m), 3.00-2.59 (2H, m), 2.35 (1H, m), 2.18-1.98 (5H, m), 1.95-1.55 (6H, m), 1.37 (3H; overlapping doublets), 1.17-1.07 (3H, two doublets), 0.94 (12H, overlapping
doublets). (1R,2R)-2-(((1RS,2S)-2-(acetyl-serylalanylalanyl)amino- 1-hydroxy-3-phenyl)propyl)cyclopentylcarbonyl-valyl valine methyl ester
b) A solution of the epimers of Example 31(a) (9.2 mg, 11.0 mmol) in acetic acid (1 ml), was stirred with 10% Pd on carbon (6.0 mg) under hydrogen (1 atm.) for 18 hr. The solution was filtered and concentrated under vacuum to provide the titled epimeric mixture as a white solid (8.2 mg, 11.0 mmol).
TLC: (9:1 CHC13 : CH3OH) Rf=0.35, 0.27.
NMR (CD3OD) : δ7.21 (5H, m), 4.42-4.09 (6H, m), 3.89-3.60 (2H, m), 3.70 (3H, s), 3.04 (1H, m), 2.99-2.59 (2H, m), 2.34 (1H, m), 2.18-1.99 (5H, m), 1.92-1.55 (6H, m), 1.38 (3H,
overlapping doublets), 1.20-1.08 (3H, two doublets), 0.93 (12H, overlapping doublets).
MS (FAB + VE) : m/z 747 (M + H)+, 616, 517, 476, 317, 272, 246, 228, 201, 183.
Example 32
Preparation of trans-2-((1-methoxy-1-(2-phenyl-1-(tert-butyloxycarbonyl-serylalanylalanyl)amino)ethyl)phosphinyl)-cyclopentylcarbonyl-valyl valine methyl ester trans-2-((1-methoxy-1-(2-phenyl-1-phenylmethoxycarbonylamino)ethyl)-phosphinyl)cyclopentylcarbonyl-valyl valine methyl ester
a) Isobutyl chloroformate (13 ml, 0.10 mmol) was added to a stirred solution of the compound of 11(d) (45 mg, 0.10 mmol) and N-methyl morpholine (17 ml, 0.15 mmol) in THF at 40°C. After 30 min. N-methyl morpholine (17 ml, 0.15 mmol) was added, followed by solid valyl valine methyl ester hydrochloride (40 mg, 0.15 mmol). The mixture was allowed to warm to 20°C with stirring. After 14 hr. the mixture was diluted with 5% HCl and extracted with CH2C12. The CH2C12 extract was concentrated and purified by flash chromatography (25:1 CHCl3:CH3OH) to provide the titled compound as a white solid (65 mg, 98.9 mmol) in 99% yiell. TLC: (9:1 CHCI3 : CH3OH) Rf=0.6.
NMR (CDCI3) : δ 7.33-7.10 (10H, m), 5.08-4.77 (2H, m), 4.70¬
4.24 (3H, m), 3.82-3.66 (6H, m), 3.41-2.63 (3H, m), 2.24-1.51 (8H, m), 1.03-0.89 (13H, m). trans-2-((1-methoxy-1-(1-amino-2-phenyl)ethyl)-phosphinyl)cyclopentylcarbonyl-valyl valine methyl ester
b) A solution of the compound of Example 32 (a) (30 mg, 46 mmol) in methanol (1-.5 ml) was stirred with 10% Pd/C (30 mg) under hydrogen (1 atm) for 9 hr. The mixture was
filtered and concentrated under vacuum to provide the titled compound as a glass (20 mg, 38 mmol; 84% yield).
NMR (CDCI3) : δ7.38-7.18 (5H, m), 4.51 (1H, m), 4.30 (1H, m),
3.90-3.68 (6H, m), 3.44-3.03 (2H, m), 2.93-2.48 (1H, m), 2.25-1.67 (8H, m), 1.27 (1H, m), 1.01-0.85 (13H, m). trans-2-((1-methoxy-1-(2-phenyl-1-(tert-butyloxycarbonyl-(O- phenylmethyl)serylalanylalanyl)amino)ethyl)phosphinyl)cyclope ntyl-carbonyl-valyl valine methyl ester
c) By a procedure substantially similar to Example
27(c), using the compound of Example 32(b) (20 mg, 38 mmol), Boc-Ser (Bzl)-Ala-Ala (18.4 mg, 42.0 mmol), N-methylmorpholine (7.0 ml, 63 mmol) and isobutyryl chloroformate (5.5 ml, 42 mmol), and subsequent flash chromatography (50:1
CHCI3 :CH3OH), the titled compound was obtained as a glass
(23.5 mg, 24.9 mmol; 65% yield).
TLC: (9:1 CHC13:CH3OH) Rf=0.5.
NMR (CDCI3) : δ 7.39-7.13 (10H, m), 4.80-4.20 (8H, m), 3.903.60 (8H, m), 3.45-2.70 (3H, m), 2.22-1.64 (8H, m), 1.50-1.25 (12H, m), 1.10 (3H, m), 1.04-0.85 (13H, m). trans-2-((1-methoxy-1-(2-phenyl-1-(tert-butyloxycarbonyl- serylalanylalanyl) amino) ethyl) phosphinyl) cyclopentylcarbonyl- valyl valine methyl ester
d) Using the procedure of Example 27 (d), the above compound of Example 32(c) (23 mg, 24 mmol) was hydrogenolyzed to provide the titled compound (19.1 mg, 22
mmol; 93% yield) as a white solid. NMR (CD3OD) : δ7.32-7.16 (5H), 4.75-4.10 (6H), 3.87-3.66 (8H), 3.32-2.72 (3H), 2.20-1.62 (8H), 1.50-1.28 (12H), 1.13 (3H), 1.05-0.85 (13H).
MS (FAB + VE) : 853 (M + H)+, 753.
Example 33
Preparation of trans-2-((1-hydroxy-1-(2-phenyl-1- (serylalanylalanyl)amino)ethyl)phosphinyl)cyclopentylcarbonyl -valyl valine methyl ester hydrobromide
Trimethylsilyl bromide (4.0 ml, 30 mmol) was added to a solution of the compound of Example 32(d) (9.6 mg, 11.3 mmol) in dry CH2Cl2 (1 ml). After 4.5 hr 1:1 water:acetic acid
(0.5 ml) was added. The mixture was concentrated and dried to a solid under vacuum. The residue was dissolved in methanol (1 ml) and treated with 30% HBr in acetic acid (50 ml), then reconcentrated and dried under vacuum to provide the titled compound (9 mg) as a light yellow powder.
NMR (CD3OD) : δ 7.30-7.15 (5H, m), 4.55-3.92 (5H, m), 3.83-3.66 (5H, m), 3.30-2.08 (4H, m), 2.20-1.64 (8H, m), 1.47-1.25 (4H, m), 1.12 (3H, m), 1.05-0.90 (12H, m).
MS (FAB + VE) : m/z 739, (M-HBr + H)+, 260, 232, 159.
Example 34
Preparation of (5S,4RS)-5-(tert-butyloxycarbonyl-serylalanylalanyl)-amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester (5S)-5-(t-butyloxycarbonylamino)-1,4-dioxo-6-phenylhexyl-valyl valine methyl ester
a) To a solution of the compound of 12(b) (160 mg, .495 mmol) in THF (5 ml) at -40°C under argon was added N-methyl morpholine (66 mg, .66 mmol), followed by isobutyl
chloroformate (68 mg, .495 mmol). The reaction mixture was stirred for 15 minutes, then N-methyl morpholine (66 mg, .66 mmol) was added, followed by a solution of valyl valine methyl ester hydrochloride (120 mg, .45 mmol) in THF (6 ml) in a dropwise manner. The mixture was stirred at -40°C for 30 min, then at 20°C for 17 hours. The reaction mixture was then diluted with 1:1 ethyl acetate :dichloromethane (100 ml) and washed successively with 5% HCl, 5% sodium bicarbonate, and saturated aqueous sodium chloride. The organic extracts were dried (MgSO4), filtered, and evaporated under reduced pressure to an oil. Flash chromatography over silica
gel (25:1 chloroform:methanol) provided the titled compound (160 mg; 70% yield) as a white foam.
NMR (CDCI3) : δ7.25(5H,m), 6.34 (1H,d), 6.15 (1H, d), 5.24 (1H,d),
4.58(2H,m), 4.31 (1H,dd), 3.78(3H,s), 3.19(1H,m), 2.95(1H,m), 2.87 (2H,m), 2.52 (2H,t), 2.21 (2H,pentet), 1.43 (9H, s),
0.98(12H,m).
MS (FAB+) : m/z 534;
MS (FAB-) : m/z 532
(5S,4RS)-5-(tert-butyloxycarbonyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester)
b) To a solution of the compound of Example 34(a) (160 mg, 3.0 mmol) in methanol at 0°C was added sodium borohydride
(5.7 mg, 1.5 x 10-4 mole) in portions. After 20 min. the mixture was diluted with 5% HCl and extracted (3x) with dichloromethane. The organic extracts were dried with MgSO4, filtered, and evaporated to white flakes. Flash
chromatography over silica gel (40:1 chloroform:methanol) yielded the titled compound as white flakes (112 mg, 70%). NMR (CDCl3/MeOD) : δ7.15(5H,m); 4.38(1H,dd); 4.10(1H,m);
3.63(3H,s); 3.0 to 1.5(8H,m); 1.28(9H,s); 0.88(12H,m). (5S,4RS)-5-(tert-butyloxycarbonyl-(O- phenylmethyl)serylalanyl-alanyl)amino-4-hydroxy-1-oxo-6- phenylhexyl-valyl valine methyl ester
c) The peptide of Example 34(b) (98 mg, .183 mmol) was dissolved in neat trifluoroacetic acid (3 ml) and stirred at room temperature for two hours. The solution was then concentrated under reduced pressure, dissolved in methanol, treated with concentrated HCl (3 drops), and evaporated under reduced pressure to give 86 mg of the tripeptide amine hydrochloride as white flakes.
To a solution of Boc-Ser (OBz)-Ala-Ala (87.4 mg, .20 mmol) in THF (5 ml) at -40°C under argon, N-methyl morpholine (25 ml, 0.27 mmol) was added, followed by isobutyl
chloroformate (27 mg, 0.20 mmol). The mixture was stirred for 15 minutes, then N-methylmorpholine (25 ml, 0.27 mmol) was added, followed by the previously prepared 5-amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine hydrochloride (86 mg, 0.18 mmol) in THF (1 ml) dropwise. The mixture was stirred at -40°C fof 30 minutes, then at 20°C for 17 hours. The reaction mixture was diluted with 1 : 1 ethyl
acetate : dichloromethane (100 ml) and washed successively with 5% HCl, 5% aqueous sodium bicarbonate, saturated aqueous sodium chloride, and evaporated to a white solid. The solid was purified by flash chromatography over silica gel (20:1 chloroform:methanol) to yield the titled hexapeptide as white crystals (98 mg; 63% yield).
NMR (CDCI3/CD3OD) : δ7.1 (5H, m), 6.95 (5H, m), 3.48 (3H, s),
1.29 (9H, s), 1.05 (6H, m), 4.2-1.5 (m), 0.70 (12H, m).
MS (FAB+) : m/z 855;
MS (FAB-) : m/z 853
(5S,4RS)-5-((tert-butoxycarbonyl-serylalanylalanyl)amino)-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester
d) To a solution of the compound of Example 34(c) (31 mg, 36.2 mmol) in 9:1 methanol : acetic acid, 10% Pd/C (35 mg) was added. The mixture was stirred under H2 (1 atm) for 6 hours. The reaction mixture was filtered through a pad of Celite® and the Celite® was rinsed successively with acetic acid, methanol, and ethyl acetate. The combined solution was evaporated under reduced pressure to yield the titled
compound as white crystals (21 mg; 75% yield).
NMR (CDCI3/CD3OD) : δ7.14 (5H, m), 4.33 (1H,m), 4.08 (4H, m),
3.60 (3H, s), 2.95 (1H, dd), 2.70 (1H, m), 2.35 (1H, m), 2.06 (2H, m), 1.72 (1H, m), 1.40 (9H, s), 1.22 (6H, m); 0.85 (12H, m).
MS (FAB+) : m/z 765;
MS (FAB-) : m/z 764. Example 35
Preparation of (4RS,5S)-5-(tert-butyloxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester
(5S)-5-(tert-butyloxycarbonylamino)-1,4-dioxo-6-(4-benzyloxyphenyl)hexyl-valyl valine methyl ester
a) To a solution of the compound of Example 13(c) (810 mg, 1.9 mmol) in THF (20 ml) at -40°C under an argon
atmosphere was added N-methyl morpholine (0.27 ml, 2.5 mmol), followed by isobutyl chloroformate (0.246 ml, 1.9 mmol). The reaction mixture was stirred for 15 min, and additional
N-methyl morpholine (0.27 ml, 2.5 mmol) was added followed by valyl valine methyl ester hydrochloride salt (459 mg, 1.7 mmol). The resulting mixture was stirred at -40°C for 30 min, then allowed to warm to room temperature and stirred for 17 h. The reaction mixture was diluted with 1: 1 ethyl acetate: CH2CI2 and washed successively with 5% HCl, 5% aqueous NaHCO3, and saturated aqueous NaCl. The solution was dried (MgSO4), filtered and evaporated under reduced
pressure. The solid residue was purified by column
chromatography using silica gel, eluting with 40:1 CHCI3 :
MeOH to give the titled compound (838 mg, 76%).
NMR (CDCl3);δ7.4 (5H, m), 7.02 (4H, dd), 6.42 (1H, br d),
6.18 (1H, br d), 5.19 (1H, br d), 5.0 (2H, s), 4.51 (2H, m), 4.25 (1H, m), 3.70 (3H, s), 3.04 (1H, m), 2.82 (3H, m), 2.48 (2H, m), 2.15 (2H, m), 1.39 (9H, s), 0.91 (12H, m). (4RS,5S)-5-(tert-butyloxycarbonyl)amino-4-hydroxy-1-oxo-6-(4- benzyloxyphenyl)hexyl-valyl valine methyl ester
b) To a solution of the compound of Example 35(a) (144 mg, .225 mmole) in methanol at 0°C, sodium borohydride (4.28 mg, .113 mmole) was added in portions. After 20 min. the mixture was diluted with 5% HCl and extracted (3x) with dichloromethane. The organic extracts were dried (MgSO4), filtered, and evaporated to a white solid. The crude product was purified by flash chromatography over silica gel (20:1 chloroform:methanol) to yield the tripeptide as white crystals (118 mg; 82% yield).
NMR (CDCl3):δ7.4 (5H, m), 7.02 (4H, dd), 6.40 (2H, m), 5.03
(2H, s), 4.54 (2H, m), 4.30 (1H, m), 3.70 (3H, s), 3.61 (2H, m), 3.0 to 1.6 (11H, m), 1.38 (9H, s), 0.91 (12H, m).
(4RS, 5S)-5-(tert-butyloxycarbonyl-(O-phenylmethyl)-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-(4-benzyloxyphenyl)hexyl-valyl valine methyl ester
c) The tripeptide of Example 35(b) (115 mg, .179 mmol) is treated with trifluoroacetic acid and HCl according to the procedure of Example 34 (c). The resulting hydrochloride salt was coupled to Boc-Ser (Bzl)-Ala-Ala (83 mg, .19 mmol) using N-methyl morpholine (50 mg, .51 mmol), and
isobutylchloroformate (26 mg, .19 mmol). The titled
hexapeptide was obtained as white crystals (40 mg; 25% yield) .
NMR (CDCI3/CD3OD) : δ7.35 (10H, m), 6.91 (4H, dd), 4.95 (2H, d), 4.48 (2H, d), 4.37 (1H, d), 4.07 (4H, m), 3.62 (4H, s), 3.60 (1H, obsc m), 2.5 to 1.5 (3H, m), 1.38 (9H, s), 1.2 (6H, m), 0.80 (12H, m) .
(4RS,5S)-5-(tert-butoxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxy-phenyl)hexyl-valyl valine methyl ester
d) The compound of Example 35(c) (39 mg, 40.6 mmol) was deprotected by the hydrogenolysis procedure of Example 34 (d).
The titled compound was obtained as white crystals (2.3 mg;
73% yield).
NMR (CDCI3/CD3OD) : δ 6.79 (4H, m), 4.35 (1H, q),
4.2 to 3.8 (5H, m), 3.67 (3H, s), 3.0 to 2.5 (2H, m),
2.5 to 1.5 (4H, m), 1.41 (9H, s), 1.20 (6H, m),
0.89 (12H, m). Example 36
Preparation of (3R,4S)-4-(tert-butyloxycarbonyl- serylalanylalanyl)-amino-2,2-difluoro-3-hydroxy-1-oxo-5- phenylpentyl-valyl valine methyl ester
(3R,4S)-4-(benzyloxycarbonyl)amino-2.2-difluoro-3-hydroxy-5-phenylpentanoyl-valyl valine methyl ester
a) Triethylamine (0.66 ml, 4.83 mmol) was added to a solution of the compound of Example 14(b) (0.82 g, 2.20 mmol), benzotriazol-1-yloxy tris (dimethylaminophosphonium hexafluorophosphate (1.07 g, 2.41 mmol) and valyl valine methyl ester hydrochloride (0.64g, 2.41 mmol) in 75 ml of dry acetonitrile. After 4 hr. of stirring, additional neat triethylamine (0.66 ml, 4.83 mmol) was introduced and the reaction mixture was stirred overnight. The solution was diluted with ethyl acetate and washed successively with 2N HCl, 5% NaHCO3, and H2O. After drying over MgSO4 and
filtering, the solution was concentrated in vacuo. Flash chromatography with 40:1 CHCI3 :methanol as the eluent
afforded the titled tripeptide as a white flakey solid (466 mg; 36% yield).
NMR (CDCI3) : δ7.34 (10H, m), 6.93 (1H, br, J=7.1 Hz), 6.75
(1H, br d, J=8.9 Hz), 5.03 (2H, s), 4.87 (1H, m), 4.60 (1H, m), 4.38 (3H, m), 3.63 (3H, s), 3.07 (2H, m), 2.32 (1H, m), 2.14 (1H, m), 1.93 (1H, m), 0.98 (12H, m)
MS: m/z 592
(3R,4S)-4-amino-2,2-difluoro-3-hydroxy-1-oxo-5-phenylpentyl- valyl-valine methyl ester, hydrochloride
b) A solution of the tripeptide of Example 36(a) (466 mg, 0.79 mmol) in glacial acetic acid (40 ml) containing 10% Pd/C (450 mg) was saturated with H2 gas and stirred overnight under an atmosphere of H2. After filtering through a pad of Celite®, the solution was diluted with methanol and treated with concentrated HCl (100 ul, 1.0 mmol). Concentration of the solution in vacuo yielded the crude tripeptide hydrochloride as a fluffy white crystalline solid (390 mg, 100%).
(3R,4S)-4-(tert-butyloxycarbonyl-(O-benzyl)serylalanyl-alanyl)amino-2,2-difluoro-3-hydroxy-1-oxo-5--phenylpentyl-valyl valine methyl ester
c) To a solution of Boc-Ser (Bzl)-Ala-Ala (380 mg, 0.87 mmol) and N-methyl morpholine (108 ul, 0.99 mmol) in dry THF
(6 ml) at -40°C was added isobutyl chloroformate (112 ml, 0.87 mmol) in a dropwise manner. After stirring for 30 min., N-methyl morpholine (112 ml, 0.87 mmol) was added followed by addition of the compound of Example 36(b) as a solid. The reaction mixture was stirred overnight with gradual warming to room temperature. The solution was diluted with CH2CI2 and washed successively with 10% HCl, 5% NaHCO3 and H2O. The organic portion was dried over MgSO4, filtered and
concentrated in vacuo. Flash chromatography with 30:1
CHCI3 : methanol as the eluent provided the titled hexapeptide as a light yellow solid (636 mg, 83%).
NMR (DMSO-d6) : δ8.31 (1H, brd; J=7.1 Hz), 8.12 (1H, brd;
J=9.5 Hz), 7.98 (1H, brd; J=6.5 Hz), 7.78 (2H, m), 7.31 (5H, m), 7.18 (5H, m), 6.99 (1H, brd; J=7.1 Hz), 6.28 (1H, m), 4.48 (2H, s), 4.22 (4H, m), 3.62 (3H, s), 3.57 (1H, m), 2.98 (1H, m), 2.71 (1H, m), 2.17 (2H, m), 1.41 (9H, s), 1.15 (3H, d; J=6.5 Hz), 1.03 (3H, d; J=7.1 Hz), 0.92 (12H, m).
MS (FAB +) : m/Z=877 (M+H+)
(3R,4S)-4-(tert-butyloxycarbonyl-serylalanylalanyl)amino-2,2-difluoro-3-hydroxy-1-oxo-5-phenylpentyl-valyl-L-valine methyl ester
d) The protected hexapeptide of Example 36(c) (13 mg, 15 mmol) was dissolved in 5:1 acetic acid:methanol (6 ml). To this solution, 10% Pd/C (15 mg) was added and the mixture was saturated with H2 gas. After stirring overnight under an atmosphere of H2, the solution was filtered through a pad of
Celite® and concentrated in vacuo to provide the titled product as a white crystalline solid (11.5 mg, 99%).
NMR (CDCI3/CD3OD) : δ7.24 (5H, m), 4.18 (6H, m), 3.77 (1H, m), 3.65 (3H, s), 3.52 (1H, m), 3.09 (1H, m), 2.87 (1H, m), 2.03 (3H, m), 1.39 (9H, s), 1.31 (3H, d, J=5.94 Hz), 1.06 (3H, d, J=6.6 Hz), 0.90 (12H, m)
MS: m/z 787
Example 37
Preparation of (3R,4S)-4-(serylalanylalanyl)amino-2,2-difluoro-3-hydroxy-1-oxo-5-phenylpentyl-valyl valine methyl ester, trifluoroacetic acid salt
Two drops of TFA were added to the N-protected
hexapeptide of Example 36(d) (1.1 mg, 1.4 mmol). After 2 hr., a slow stream of Argon was passed over the mixture to evaporate the excess TFA. Three drops of diethyl ether were added and evaporated in the same manner three times. The residue was dried in vacuo.
Example 38 Preparation of 4-(tert-butyloxycarbonyl- serylalanylalanyl)amino-2,2-difluoro-1,3-dioxo-5-phenylpentyl-valyl valine methyl ester
4-(tert-butyloxycarbonyl-(O-benzyl)serylalanylalanyl)amino- 2,2-difluoro-1,3-dioxo-5-phenylpentyl-valyl valine methyl ester
a) To a solution of α,α-difluoro alcohol of Example 37
(102 mg, 0.12 mmol) and Dess-Martin periodinane (247 mg, 0.58 mmol) in 2 ml of dry DMF was introduced neat TFA (45 ul, 0.58 mmol) in a dropwise manner. After stirring for 16 h., the solution was diluted with Et2O and poured over a mixture of saturated aqueous NaHCl3 (20 ml) and 10% aqueous sodium thiosulfate (7 ml). This mixture was stirred vigorously for 1 hr and extracted with ethyl acetate. The combined extracts were dried over MgSO4, filtered, and concentrated in vacuo.
Flash chromotography using a gradient elution of 0-30% methanol in chloroform yielded the titled α,α-difluoro ketone as a white solid (70 mg, 69% yield). NMR (CDCI3/CD3OD) : δ7.27 (10H, m), 4.50 (2H, s), 4.34 (6H, m), 3.71 (3H, s), 3.66 (2H, m), 3.25 (1H, m), 2.99 (1H, m), 2.24 (2H, m), 1.42 (9H, s), 1.34 (3H, m), 1.08 (3H, m), 0.92 (12H, m).
MS (FAB +) : m/z 875 (M+H+) .
4-(tert-butyloxycarbonyl-serylalanylalanyl)amino-2.2-difluoro-1,3-dioxo-5-phenylpentyl-valyl valine methyl ester b) A solution of the protected hexapeptide of Example 38(a) (15 mg, 17 μm01 ) in glacial acetic acid (4 ml) containing 10% Pd/C (15 mg) was saturated with H2 gas and stirred overnight under an atmosphere of H2 gas. The mixture was filtered through a pad of Celite® and concentrated in vacuo. Flash chromatography using a gradient elution of 050% methanol in chloroform provided the titled debenzylated product as a white crystalline solid (9 mg, 67%).
NMR (DMSO-d6) : δ 9.01 (1H, m), 8.36 (2H, m), 7.95 (2H, m),
7.17 (5H, m), 6.68 (1H, m), 4.85 (1H, m), 4.18 (4H, m), 3.91 (1H, m), 3.58 (3H, s), 3.45 (2H, m), 3.08 (2H, m), 2.66 (1H, m), 2.00 (2H, m), 1.45 (9H, s), 1.11 (6H, m), 0.88 (12H, m). MS (FAB +) : m/z 785 (M+H+).
Example 39 Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
The protected heptapeptide resin Boc-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared in the usual manner according to Example 1. After removal of the N-terminal Boc group with 50% TFA in CH2CI2 and neutralizing the resulting TFA salt with 7% DIEA in CH2CI2, the resin-bound peptide was acetylated with acetic anhydride (2 ml) in CH2CI2 (30 ml) for 30 minutes.
The peptide was cleaved from the resin with removal of the side chain protecting groups by treatment with anhydrous liquid HF (10 ml) in the presence of anisole (1 ml) at 0°C for 50 minutes. After removal of the HF under vacuum, the resin was washed with ethyl ether and air-dried. The resin was then extracted with 2 x 30 ml 1% HOAC/H2O followed by 2 x 30 ml 10% HOAC/H2O. The combined extracts were lyophilized to yield 318 mg crude peptide.
An aliquot of 130 mg crude peptide was purified by gel filtration on a 2.6 x 70 cm column of G-15 Sephadex® using 1% HOAc as eluant. The appropriate fractions were pooled and lyophilized to yield 120 mg of the titled compound.
TLC: (n-BuOH/HOAc/H2O 4:1:1) Rf=0.34; (n- BuOH/EtOAc/HOAc/H2O 1:1:1:1) Rf=0.66; HPLC k'=3.0 (Hamilton PRP-1, CH3CN/H2O/0.1% TFA, 10% to 40% CH3CN, 15 minutes, linear gradient, 1.5 ml/min.);
FAB-MS: m/z 847.6 (M+H+).
Substituting Boc-Thr(Bzl) for Boc-Ser (Bzl) in the above method yields Ac-Thr-Gln-Asn-Tyr-Pro-Val-Val-NH2.
Example 40
Preparation of Ac-Ser-Ala-Ala-Tyr-Pro-Val-Val-NH2
The protected heptapeptide resin Boc-Ser (Bzl)-Ala-Ala-Tyr (BrZ)-Pro-Val-Val-BHA was prepared in the usual manner. After removal of the N-terminal Boc group with 50% TFA in CH2CI2 and neutralizing the resulting TFA salt with 7% DIEA in CH2CI2, the resin-bound peptide was acetylated with acetic anhydride (2 ml) in CH2CI2 (30 ml) for 30 minutes.
The peptide was cleaved from the resin with removal of the side chain protecting groups by treatment with anhydrous liquid HF (10 ml) in the presence of anisole (1 ml) at 0°C for 50 minutes. After removal of the HF under vacuum, the resin was washed with ethyl ether and air-dried. The resin was then extracted with 2 x 30 ml 1% HOAC/H2O followed by 2 x 30 ml 10% HOAc/H2O. The combined extracts were lyophilized to yield 599 mg crude peptide.
The crude peptide was purified by countercurrent distribution using the system n-BuOH/HOAc/H2O 4:1:5. The appropriate fractions were pooled, evaporated to dryness and the residue lyophilized from 1% HOAc to yield 435 mg
partially purified peptide. An aliquot of 100 mg partially purified peptide was further purified by gel filtration on a 2.6 x 70 cm G-15 Sephadex® column using 1% HOAc as eluant. The appropriate fractions were pooled and lyophilized to yield 95 mg of the purified title compound.
TLC: (n-BuOH/HOAc/H2O 4:1:1) Rf=0.72; HPLC k'=2.8 (Hamilton PRP-1, CH3CN/H2O/0.1% TFA, 5% to 40% CH3CN, 15 minutes, linear gradient, 1.5 ml/min.);
FAB-MS: m/z 747 (M+H+).
Example 41 Preparation of Ac-Ser-Gln-Asn-Tyr-D-Pro-Val-Val-NH2
One mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-D-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml glacial HOAc. The HOAc extracts were combined and lyophilized to yield 406 mg crude peptide.
The crude peptide was purified by countercurrent distribution in nBuOH-HOAc-H2O (4:1:5). The appropriate fractions were located by tic, pooled, evaporated to dryness and the residue lyophilized from 1% HOAc, yielding 260 mg purified peptide .
TLC: (n-BuOH-HOAc-H2O 4:1:1), Rf=0.15; (n-BuOH-HOAc-H2O 1:1:1), Rf=0.54; (n-BuOH-EtOAc-HOAc-H2O 1:1:1:1), Rf=0.72 FAB-MS: m/z 847 (M+H)+
Amino Acid Analysis (hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Asp, 1.00; Ser, 0.75; Glu, 0.99; Pro, 0.99; Val, 0.96; Tyr, 1.10 Example 42
Preparation of Dns-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Dns-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from the resin y treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 30 ml 10% HOAc followed by 2 x 30 ml 1% HOAc. The HOAc extracts were combined and lyophilized to yield 290 mg crude peptide.
The crude peptide (73 mg) was purified by gel filtration on Sephadex® G-Ϊ5 using 10% HOAc as eluant. The appropriate fractions were lyophilized, yielding 56 mg purified peptide. TLC: (n-BuOH-HOAc-H2O 4:1:1), Rf=0.15
HPLC (Hamilton PRP-1, CH3CN / H2O / 0.1% TFA, gradient of 5-40% CH3CN, 15 min), k' 3.32.
FAB-MS: m/z 1038 (M+H)+
Amino Acid Analysis (hydrolysis in 6N HCl at 110° for 24 hr): Asp, 1.00; Ser, 0.17; Glu, 1,00; Pro, 1.00; Val, 1.38; Tyr, 1.78
Example 43
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-Arg-NH2
One mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Arg (Tos)-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml glacial HOAc. The HOAc extracts were combined and lyophilized to yield 639 mg crude peptide.
The crude peptide was purified by countercurrent distribution in nBuOH-HOAc-H2O (4:1:5). The appropriate fractions were located by tlc, pooled, evaporated to dryness and the residue lyophilized from 1% HOAc, yielding 518 mg partially purified peptide. A 100 mg aliquot of the
partially purified peptide was further purified by gel filtration on G-15 with 1% HOAc as eluant. The appropriate fractions were pooled and lyophilized, yielding 61.5 mg purified peptide.
TLC: (n-BuOH-pyridine-HOAc-H2O 15:10:3:12), Rf=0.43;
(nBuOH-EtOAc-HOAc-H2O 1:1:1:1), Rf=0.34;
HPLC (Hamilton PRP-1, CH3CN / H2O / 0.1% TFA, gradient of 5- 40% CH3CN, 15 min), k' 1.94.
FAB-MS: m/z 904 (M+H)+
Amino Acid Analysis (hydrolysis in 6N HCl at 110° for 18 hr): Asp, 1 . 00 ; Ser, 0 . 98 ; Glu, 1 . 00 ; Pro, 0 . 88 ; Val , 0 . 5 6 ; Tyr, 0 . 86 ; Arg, 0 . 67
Example 44
Preparation of Ac-Ser-Gln-Ala-Tyr-Pro-Val-Val-NH2
One-half mole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Ala-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 220 mg, 55% yield. 100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 85 mg.
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k'=2.61
TLC: (B:A:W 1:1:1), Rf=0.67.
FAB-MS: m/z 804 (M+H)+
Amino Acid Analysis: (HCl: TFA 2:1, 0.005% w/v phenol, 160°C, 1 hr.), Ser 0.89, Glu 1.00, Pro 1.04, Ala 1.00, Val 1.75, Tyr 0.89. Peptide Content is 98.94%.
Example 45
Preparation of Ac-Ser-Ser-Asn-Tyr-Pro-Val-Val-NH2
One-half mole of the protected peptide resin Ac-Ser) (Bzl)-Ser (Bzl)-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from the resin by
treatment with 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 283 mg, 70% yield.100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 78 mg.
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k'=2.58
TLC: rf-0.70, B:A:W 1:1:1 FAB-MS : m/z 806 (M+H) +
Amino Acid Analysis: (HCl: TFA 2:1, 0.005% w/v phenol, 160°C, 1 hr.), Asp 1.00, Ser 1.59, Pro 0.90, Val 1..91, Tyr 0.91.
Peptide Content was 80.6%.
Example 46
Preparation of Ac-Ser-Arg-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Arg-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 348.5mg, 80% yield. 100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 87 mg.
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k'=2.64
TLC: (B:A:W 1:1:1), Rf=0.60
FAB-MS: m/z 875 (M+H)+
Amino Acid Analysis: HCl/TFA/Phenol, Asp 1.00, Ser 0.80, Pro
0.83, Val 1.85, Tyr 0.94, Arg 0.97. Peptide Content was
101.3%.
Example 47
Preparation of Ac-Ser-Lys-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac- Ser (Bzl)-Lys-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 343.79mg, 81% yield.
100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 87 mg.
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k ' =2 . 47
TLC : (B : A : W 1 : 1 : 1 ) , Rf=0 . 60
FAB-MS : m/z 847 (M+H) +
Amino Acid Analysis: (HCl: TFA 2:1, 0.005% w/v phenol, 160°C, 1 hr.). Asp 1.00, Ser 0.81, Pro 0.95, Val 1.87, Tyr 1.00, Lys 0.84. Peptide Content was 92.3%.
Example 48 Preparation of Ac-Ser-Glu-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Glu (OBzl)-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 286.22mg, 67% yield.
100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 77 mg.
TLC: (B:A:W 1:1:1), Rf=0.38
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15 min, k'=2.72
FAB-MS: m/z 848 (M+H)+
Amino Acid Analysis: HCl/TFA/Phenol, Asp 1.06, Ser 0.84, Glu 1.00, Pro 0.88, Ala 1.00, Val 1.85, Tyr 1.00. Peptide
Content was 94.3%.
Example 49
Preparation of Ac-Ser-Ala-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Ala-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 330 mg, 84% yield.
100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 86 mg.
TLC: (B:A:W 1:1:1), Rf=0.70 Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k'=2.62
FAB-MS: m/z 790 (M+H)+
Amino Acid Analysis: HCl/TFA/Phenol, Asp 1.00, Ser 0.81, Pro 0.94, Ala 1.00, Val 1.87, Tyr 0.76. Peptide Content was 72.77%.
Example 50 Preparation of Ac-Ser-Gln-Ser-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Ser (Bzl)-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 285 mg, 70% yield. 100 mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 87 mg.
TLC: (B:A:W 1:1:1), Rf=0.68
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k'=2.51
FAB-MS: m/z 820 (M+H)+
Amino Acid Analysis: HCl/TFA/Phenol, Ser 1.60, Glu 1.00, Pro 0.91, Val 1.83, Tyr 0.94. Peptide Content was 84%.
Example 51
Preparation of Ac-Ser-Gln-Arg-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac- Ser (Bzl)-Gln-Arg-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 380.54 mg, 86% yield. 100 mg of crude peptide was purified by gel filtration on Sephadex® G- 15 using 1% HOAc as eluant, yielding 89 mg.
TLC: (B:A:W 1:1:1), Rf=0.66
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k ' =2 . 58
FAB-MS : m/z 889 (M+H) +
Amino Acid Analysis: HCl/TFA/Phenol, Ser 0.80, Glu 1.00, Pro 1.00, Val 1.88, Arg 1.01, Tyr 0.81. Peptide Content was 85.33%.
Example 52
Preparation of Ac-Ser-Gln-Lys-Tγr-Pro-Val-Val-NH2
One-half mmole' of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Lys (Clz)-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 332 mg, 77.32% yield. 100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 85 mg.
TLC: (B:A:W 1:1:1), Rf=0.69
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k'=2.48
FAB-MS: m/z 861 (M+H)+
Amino Acid Analysis: HCl/TFA/Phenol, Ser 0.79, Glu 1.00, Pro
0.94, Val 1.85, Tyr 0.96, Lys 0.90. Peptide Content is
71.26%.
Example 53
Preparation of Ac-Ser-Gln-Asp-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gin-Asp (OBzl)-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from 10ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 340 mg, 80% yield. 100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 84 mg.
TLC: (B:A:W 1:1:1), Rf=0.73
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k ' =2 . 63
FAB-MS : m/z 848 (M+H) +
Amino Acid Analysis: HCl/TFA/Phenol, Asp 1.02, Ser 0.79, Glu 1.00, Pro 0.97, Val 1.86, Tyr 0.82. Peptide Content is
79.13%.
Example 54
Preparation of Ac-Asp-Gln-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole' of the protected peptidyl resin Ac-Asp (OBzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved and deprotected using 10 mL of anhydrous HF with 10% anisole at 0°C for 1 h. The HF was removed in vacuo at 0°C and the resin was washed with diethyl ether. The peptide was extracted with glacial acetic acid and lyophilized to yield 288 mg (65.9%). The peptide was purified by countercurrent distribution in 1-butanol-acetic acid-water (4:1:5 v/v/v). Tubes were checked by thin layer chromatography (TLC) and the appropriate fractions were pooled, evaporated and lyophilized from 0.2 N HOAC to yield 234 mg (81.2%).
TLC: (B:E:A:W 1:1:1:1) Rf=0.77; (B:P:A:W 15:10:3:12) Rf=0.56.
FAB MS: m/z 875 (M+H)+
HPLC: 4.5 mm X 25 cm Altex Ultrasphere 5 m ODS, UV detection at 220 nm, water-acetonitrile- 0.1% TFA gradient of 5 to 40% acetonitrile over 15 min., k' = 3.71
Isocratic HPLC: 85:15 water-acetonitrile- 0.1% TFA, k'=4.77 Amino Acid Analysis: (hydrolysis at 160°C for 1 h. in
HCl/TFA 2:1 containing 0.005% w/v phenol) Asp 2.05, Glu 1.00, Pro 1.03, Val 1.94, Tyr 0.84
Example 55
Preparation of Ac-His-Gln-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac- His (Tos)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved and deprotected using 10 mL of anhydrous HF with 10% anisole at 0°C for 1 h. The HF was removed in vacuo at 0°C and the resin was washed with diethyl ether. The peptide was extracted with glacial acetic acid and lyophilized to yield 311 mg (69.4%). The peptide was partially purified by countercurrent distribution in 1-butanol-acetic acid-water (4:1:5 v/v/v). Tubes were checked by thin layer chromatography (TLC) and the appropriate fractions were pooled, evaporated and lyophilized from 0.2 N HOAC to yield 200 mg (65.3%). Final purification was obtained by subjecting 87 mg to gel filtration on Sephadex® G-15 using 0.2 N HOAC as the eluent to yield 48 mg (55.2%). TLC: (B:P:A:W 15:10:3:12) Rf=0.51; (B:A:W 1:1:1) Rf=0.71.
HPLC: 4.5 mm X 25 cm Altex Ultrasphere 5 m ODS, UV detection at 220 nm, water-acetonitrile- 0.1% TFA gradient of 5 to 40% acetonitrile over 15 min., k'=4.94
Isocratic HPLC: 85:15 water-acetonitrile- 0.1% TFA, k'=3.76 FAB MS: m/z 897 (M+H)+
Amino Acid Analysis: (hydrolysis at 160°C for 1 h. in
HCl/TFA 2:1 containing 0.005% w/v phenol) Asp 1.03, Glu 1.00, Pro 1.13, Val 2.00, Tyr 1.97, His 1.28.
Example 56
Preparation of Ser-Gln-Asn-Tvr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Boc-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved and deprotected using 10 mL of anhydrous HF with 10% anisole at 0°C for 1 h. The HF was removed in vacuo at 0°C and the resin was washed with diethyl ether. The peptide was extracted with glacial acetic acid and lyophilized to yield 225 mg (55.9%). The peptide was purified by countercurrent distribution in 1-butanol-acetic acid-water (4:1:5 v/v/v). Tubes were checked by thin layer chromatography (TLC) and the appropriate fractions were pooled, evaporated and lyophilized from 0.2 N HOAC to yield 188 mg (83.5%).
TLC: (B:E:A:W 1:1:1:1) Rf=0.68; (B :P :A:W 15 : 10 : 3 : 12) Rf=0.54.
HPLC: 4.5 mm X 25 cm Altex Ultrasphere 5 m ODS, UV detection at 220 nm, water-acetonitrile- 0.1% TFA gradient of 5 to 40% acetonitrile over 15 min., k'=4.89
Isocratic HPLC: 85:15 water-acetonitrile- 0.1% TFA, k'=2.78 FAB MS: m/z 805.6 (M+H)+
Amino Acid Analysis: (hydrolysis at 160°C for 1 h. in
HCl/TFA 2:1 containing 0.005% w/v phenol) Asp 1.03, Ser 0.78, Glu 1.00, Pro 0.88, Val 1.93, Tyr 0.66.
Substituting 3-benzyloxy-propanoic acid for Boc-Ser (Bzl) in the above sequence yields 3-hydroxypropionyl-glutaminylasparaginyltyrosylprolylvalyl valinamide, which is a des-amino peptide.
Substituting Boc-D-Ser (Bzl) for Boc-Ser (Bzl) in the above sequence of reactions yields D-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2.
Example 57
Preparation of Ac-Ser-Gln-Gly-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac- Ser (Bzl)-Gln-Gly-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved and deprotected using 10 mL of anhydrous HF with 10% anisole at 0°C for 1 h. The HF was removed in vacuo at 0°C and the resin was washed with diethyl ether. The peptide was extracted with glacial acetic acid and lyophilized to yield 200 mg (50.6%). The peptide was purified by countercurrent distribution in 1-butanol-acetic acid-water (4:1:5 v/v/v). Tubes were checked by thin layer chromatography (TLC) and the appropriate fractions were pooled, evaporated and lyophilized from 0.2 N HOAC to yield 145 mg (72.5%).
TLC: (B:E:A:W 1:1:1:1) Rf=0.63; (B:A:W 4:1:1) Rf=0.40.
HPLC: 4.5 mm X 25 cm Altex Ultrasphere 5 m ODS, UV detection at 220 nm, water-acetonitrile- 0.1% TFA gradient of 5 to 40% acetonitrile over 15 min., k'=4.56
Isocratic HPLC: 85:15 water-acetonitrile- 0.1% TFA, k'=3.46
FAB MS: m/z 790 (M+H)+
Amino Acid Analysis: (hydrolysis at 160°C for 1 h. in HCl/TFA 2:1 containing 0.005% w/v phenol) Ser 0.71, Glu 0.97, Gly 1.00, Pro 1.02, Val 1.70, Tyr 0.76.
Example 58
Preparation of Ala-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Boc-Ala-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved and deprotected using 10 mL of anhydrous HF with 10% anisole at 0°C for 1 h. The HF was removed in vacuo at 0°C and the resin was washed with diethyl ether. The peptide was extracted with glacial acetic acid and lyophilized to yield 245 mg (56.0%). The peptide was purified by countercurrent distribution in 1-butanol-acetic acid-water (4:1:5 v/v/v). Tubes were checked by thin layer chromatography (TLC) and the appropriate fractions were pooled, evaporated and lyophilized from 0.2 N HOAC to yield 185 mg (75.5%).
TLC: (B:E:A:W 1:1:1:1) Rf=0.64; (B:P :A:W 15 : 10 :3 : 12) Rf=0.60. HPLC: 4.5 mm X 25 cm Altex Ultrasphere 5 m ODS, UV detection at 220 nm, water-acetonitrile- 0.1% TFA gradient of 5 to 40% acetonitrile over 15 min., k'=3.86
Isocratic HPLC: 85:15 water-acetonitrile- 0.1% TFA, k'=2.71 FAB MS: m/z 876 (M+H)+
Amino Acid Analysis: (hydrolysis at 160°C for 1 h. in
HCl/TFA 2:1 containing 0.005% w/v phenol) Asp 1.00, Ser 0.69, Glu 0.98, Pro 0.95, Ala 0.99, Val 1.91, Tyr 0.94.
Example 59
Preparation of Ac-Ser-Gln-Asn-(4'NO2)Phe-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Asu- (4'NO2) Phe-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from 15ml HF/lml anisole 1 hr at 0°C. The peptidyl resin was washed with ether and the peptide was extracted with glacial acetic acid. The extract was lyophilized to afford 701.8mg, 80% yield.
100mg of crude peptide was purified by gel filtration on Sephadex® G-15 using 1% HOAc as eluant, yielding 68 mg. A 35mg aliquot was further purified by preparative HPLC (PRP-1 semi prep, 18% 0.1% TFA(CH3CN), 6ml/min) yielding 22 mg.
TLC: (B:A:W 1:1:1), Rf=0.54
Gradient HPLC: 5% to 40%, 0.1% TFA(CH3CN), linear, 15min, k'=3.18
FAB-MS: m/z 876 (M+H)+
Amino Acid Analysis: (hydrolysis at 160°C for 1 h. in
HCl/TFA 2:1 containing 0.005% w/v phenol) Asp 1.01, Ser 0.81, Glu 1.00, Pro 0.90,-Val 2.00, nitroPhe 0.91. Peptide Content is 103.67%.
Example 60 Preparation of Dns-Arg-Ala-Ser-Gln-Asn-Tyr-Pro-Val-Val-OH
One-half mmole of the protected peptidyl resin Boc- Arg (Tos)-Ala-Ser (Bzl) -Gln-Asn-Tyr (BrZ)-Pro-Val-Val- Merrifield resin was prepared as above. After removal of the
Boc group with 50% TFA/CH2CI2 and neutralizing
with 7% DIEA/CH2CI2, the peptide was dansylated by the addition of 3 equiv. dansyl chloride in DMF and reacting for one hour. The dansyl peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min.
After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml glacial
HOAc. The HOAc extracts were combined and lyophilized to yield 321 mg crude peptide.
An aliquot of 100 mg of the crude peptide was purified by gel filtration on a 2.6 x 70 cm column of Sephadex® G-15 using 1% HOAc as eluant. The appropriate fractions were pooled and lyophilized, yielding 74.6 mg of the titled peptide .
TLC: (B:A:W 1:1:1) Rf=0.84
HPLC: (Hamilton PRP-1, CH3CN / H2O / 0.1% TFA, gradient of 5-40% CH3CN, 15 min), k'=3.61.
FAB-MS: m/z 1266 (M+H)+
Amino Acid Analysis: (hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Asp, 1.00; Ser, 0.31; Glu, 0.91; Pro, 0.99; Ala, 0.96; Val, 1.96; Tyr, 1.19; Arg, 0.85.
Example 61
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-Gln-Asn-NH2
One mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-Gln-Asn-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml glacial HOAc. The HOAc extracts were combined and lyophilized to yield 862.3 mg crude peptide.
The crude peptide was purified by countercurrent distribution in nBuOH-HOAc-H2O (4:1:5). The appropriate fractions were located by tlc, pooled, evaporated to dryness and the residue lyophilized from 1% HOAc, yielding 712.9 mg of the titled peptide.
TLC: (B:A:W 1:1:1) Rf=0.61
HPLC: (Hamilton PRP-1, CH3CN / H2O / 0.1% TFA, gradient of
5-40% CH3CN, 15 min), k'=2.17.
FAB-MS: m/z 1089 (M+H)+
Amino Acid Analysis: (hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Asp, 1.81; Ser, 0.97;
Glu, 2.00; Pro, 0.88; Val, 1.23; Tyr, 1.81.
Example 62 Preparation of Ac-Ala-Thr-Leu-Asn-Phe-Pro-Ile-Ser-Pro-Ile¬Glu-NH2
One mmole of the protected peptidyl resin Ac-Ala-Thr (Bzl)-Leu-Asn-Phe-Pro-Ile-Ser (Bzl)-Pro-Ile-Glu (OBzl)-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml 1% HOAc and 3 x 30 ml 50% HOAc. The HOAc extracts were combined, diluted with water and lyophilized to yield 862.3 mg crude peptide.
The crude peptide was purified by countercurrent distribution in nBuOH-HOAc-H2O (4:1:5). The appropriate fractions were located by tlc, pooled, evaporated to dryness and the residue lyophilized from 1% HOAc. The peptide was further purified by gel filtration on a 2.6 x
70 cm Sephadex® G-15 column using 1% HOAc as eluant. The appropriate fractions were collected and lyophilized. An aliquot of 100 mg of the peptide was further purified by preparative hplc on a Hamilton PRP-1 column using CH3CN / H2O / 0.1% TFA, gradient of 20-40% CH3CN, 15 min. The
appropriate fractions were pooled, evaporated to dryness and lyophilized from glacial HOAc, yielding 22.6 mg of the titled peptide.
HPLC: (Hamilton PRP-1, CH3CN / H2O / 0.1% TFA, gradient of 5-40% CH3CN, 15 min), k'=2.94.
FAB-MS: m/z 1241 (M+H)+ Example 63
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-NH2
One mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min . After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml 1% HOAc and 3 x 30 ml 10% HOAc. The HOAc extracts were combined and lyophilized to yield 144.7 mg crude peptide.
The crude peptide was purified by countercurrent distribution in nBuOH-HOAc-H2O (4:1:5). The appropriate fractions were located by tlc, pooled, evaporated to dryness and the residue lyophilized from 1% HOAc, yielding 150 mg peptide. The peptide was further purified by gel filtration on a 2.6 x 70 cm Sephadex® G-15 column using 1% HOAc as eluant. The appropriate fractions were pooled and
lyophilized to yield 101.3 mg of the titled peptide. TLC : (B : A : W 4 : 1 : 1 ) Rf= 0 . 65
HPLC: (Hamilton PRP-1, CH3CN / H2O / 0.1% TFA, gradient of 5-40% CH3CN, 15 min), k'=2.08.
FAB-MS: m/z 748 (M+H)+
Amino Acid Analysis: (hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Asp, 1.00; Ser, 0.55; Glu, 0.98; Pro, 1.19; Val, 0.95; Tyr, 0.99.
Example 64
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-Arg-NH2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-Arg (Tos)-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml glacial HOAc. The HOAc extracts were combined and lyophilized to yield 329 mg crude peptide.
The crude peptide was purified by countercurrent distribution in nBuOH-HOAc-H2O (4:1:5). The appropriate fractions were located by tlc, pooled, evaporated to dryness and the residue lyophilized from 1% HOAc, yielding 79 mg of the titled peptide.
TLC: (B:E:A:W 1:1:1:1) Rf=0.46
HPLC: (Altex Ultrasphere C18, CH3CN / H2O / 0.1% TFA, gradient of 5-40% CH3CN, 15 min), k'=3.71.
FAB-MS: m/z 1003 (M+H)+
Amino Acid Analysis: (hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Asp, 1.00; Ser, 0.73;
Glu, 0.98; Pro, 0.98; Val, 1.84; Tyr, 1.08; Arg, 0.99.
Example 65 Preparation of Ac-Ala-Gln-Asn-Tyr-Pro-Val-Val- 2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-Arg (Tos)-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min.
After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml glacial HOAc. The HOAc extracts were combined and lyophilized to yield 275 mg crude peptide.
The crude peptide was purified by countercurrent
distribution in nBuOH-HOAc-H2O (4:1:5). The appropriate fractions were located by tlc, pooled, evaporated to dryness and the residue lyophilized from 1% HOAc, yielding 235 mg of the titled peptide.
TLC: (B:E:A:W 1:1:1:1) Rf=0.69
HPLC: (Altex Ultrasphere C18, CH3CN / H2O / 0.1% TFA, gradient of 5-40% CH3CN, 15 min), k'=4.48.
FAB-MS: m/z 831 (M+H)+
Amino Acid Analysis: (hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Asp, 1.00; Ala, 0.99;
Glu, 0.98; Pro, 0.95; Val, 1.97; Tyr, 1.85.
Example 66
Preparation of Ala-Ala-Gln-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Boc-Ala- Ala-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above.
The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the
HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml glacial HOAc. The HOAc extracts were combined and lyophilized to yield 265 mg crude peptide.
An aliquot of 75 mg crude peptide was purified by gel filtration on a 2.6 x 70 cm Sephadex® G-15 column using 1%
HOAc as eluant. The appropriate fractions were pooled and lyophilized, yielding 50 mg of the titled peptide.
TLC: (B:A:W 1:1:1) Rf=0.54
HPLC: (Altex Ultrasphere C18, CH3CN / H2O / 0.1% TFA, gradient of 5-40% CH3CN.. 15 min), k'=4.67.
FAB-MS: m/z 947 (M+H)+
Amino Acid Analysis: (hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Asp, 1.00; Ser, 0.61; Ala, 1.52; Glu, 0.99; Pro, 0.86; Val, 1.90; Tyr, 0.98.
Example 67 Preparation of Ac-Cys-Gln-Asn-Tyr-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac-Cys (Mbz)-Gln-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 3 x 30 ml glacial HOAc. The HOAc extracts were combined and lyophilized to yield 292 mg crude peptide.
The crude peptide was purified by countercurrent
distribution in nBuOH-HOAc-H2O (4:1:5). The appropriate fractions were located by tic, pooled, evaporated to dryness and the residue lyophilized from 1% HOAc, yielding 188 mg of the titled peptide.
TLC: (B:E:A:W 1:1:1:1) Rf=0.67
HPLC: (Altex Ultrasphere C18, CH3CN / H2O / 0.1% TFA, gradient of 5-40% CH3CN, 15 min), k'=3.7.
FAB-MS: m/z 863 (M+H)+
Amino Acid Analysis: (oxidation with performic acid at 0°C for 4 hr followed by hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Cys-SO3H, 0.98; Asp,
1.03; Glu, 1.00; Pro, 1.13; Val, 1.94; Tyr, 1.78.
Example 68 Preparation of Ac-Ser-Gln-Asn-Tyr-Δ3-Pro-Val-Val-NH2
One-half mmole of the protected peptidyl resin Ac-Ser (Bzl)-Gln-Asn-Tyr (BrZ)-Δ3-Pro-Val-Val-BHA was prepared as above. The peptide was cleaved from the resin by treatment with 10 ml HF / 1 ml anisole at 0° for 50 min. After removal of the HF under vacuum, the resin was washed with ether, air dried and extracted with 4 x 20 ml glacial HOAc. The HOAc extracts were combined and lyophilized to yield 250 mg crude peptide. An aliquot of 100 mg crude peptide was purified gel filtration on a 2.6 x 70 cm Sephadex® G-10 column using 0.2 N HOAc as eluant. The appropriate fractions were pooled and lyophilized, yielding 41 mg of the titled peptide.
HPLC: (Altex Ultrasphere C18, CH3CN / H2O / 0.1% TFA, gradient of 10-40% CH3CN, 30min), k'=3.00.
FAB-MS: m/z 803 (M+H)+
Amino Acid Analysis: (hydrolysis in HCl/TFA 2:1 containing .005% w/v phenol at 160° for one hr) : Asp, 1.00; Ser, 0.66; Glu, 0.95; Val, 1.88; Tyr, 0.95.
Example 69
Preparation of Ac-Ser-Gly-Asn-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Boc-Ser (Bzl)-Gly-Asn-Tyr (BrZ)-Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lypohilized to yield 167 mg crude product. The crude peptide was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 138 mg purified product.
HPLC: k' = 4.17 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1%
TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 776 (M+H)+
Amino Acid Analysis: Asp 1.00, Gly 1.03, Pro 0.90, Val 1.88, Tyr 0.80, Ser 0.68.
Example 70
Preparation of 2-asparaginylamino-3-phenyl-propvl-prolylvalyl valinamide
The protected peptidyl resin Boc-Asn- (2-amino-3- phenylpropyl-prolyl)-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale using the compound of Example 2(d) and the procedure of Example 15. The peptide was deprotected and removed from the resin by treatment with anhydrous HF (10 ml) in the presence of anisole (1 ml) at 0 ºC for one hour. After removal of the HF under vacuum, the resin was washed with ethyl ether, air-dried and then extracted with 2 x 30 ml glacial HOAc. The HOAc extracts were combined and
lyophilized to give 139.6 mg crude peptide. The peptide was purified by gel filtration on G-15 Sephadex® using 1% HOAc as eluant. The appropriate fractions were combined to yield 81.1 mg purified peptide, single peak by hplc.
HPLC: (Hamilton PRP-1, 5-40% CH3CN / 0.1 % TFA, 15 min.) k'=2.47
FAB-MS: m/z 560.5 (M+H)+. Example 71
Preparation of (4S,5S) 5-amino-4-hydroxy-1-oxo-6-(4- hydroxyphenyl)hexyl-valyl valine methyl ester, hydrochloride (4S,5S) 5-(tert-butyloxycarbonyl)amino-4-hydroxy-1-oxo-6-(4-benzyloxyphenylhexyl-valyl valine methyl ester
a) To a solution of the compound of Example 35(a) (1.08 g, 1.70 mmol) in MeOH at 0°C was added sodium borohydride (32 mg, 0.85 mmol) in portions. After 30 min, the reaction was complete as indicated by TLC, was diluted with 5% aqueous HCl and extracted with CH2C12 three times. The combined organic extracts were dried (MgSO4), filtered and evaporated under reduced pressure to give a mixture of isomers as a white solid (1.05g, 97%). The isomers were eluted through a 1" x 25 cm HPLC silica column with 40:1 CH2C12 : MeOH at a rate of 20 ml/ min. The desired (4S) isomer which eluted first at 14.5 min, was collected and evaporated to give the titled compound as a white solid (295 mg, 34%).
NMR (CDCI3) : δ 7.43 (5H, m), 7.02 (4H, dd), 6.40 (1H, d), 6.32 (1H, d), 5.04 (2H, s), 4.50 (2H, m), 4.26 (2H, m), 3.70 (3H, s), 2.71 (2H, m), 2.43 (2H, m), 2.11 (2H, m), 1.39 (9H, s), 0.91 (12H, m).
MS (FAB): m/z 642.4 (M+H)+. (4S,5S) 5-amino-4-hydroxy-1-oxo-6-(4-benzyloxyphenyl)hexyl-valyl valine methyl ester, hydrochloride
b) The compound of Example 71(a) (295 mg, 0.46 mmol) was dissolved in neat trifluoroacetic acid (1 ml) and stirred for 3 min. The solution was evaporated under reduced
pressure, dissolved in MeOH, treated with cone. HCl (3 drops) and evaporated under reduced pressure to give the titled compound as a white solid. Example 72
Preparation of (4S,5S) 5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester, acetic acid salt
(4S,5S)-5-(carbobenzyloxyalanylalanyl)amino-6-(4-benzyloxy)phenyl-4-hydroxy-(1-oxo)hexyl-valyl valine methyl ester
a) A solution of carbobenzyloxyalanyl alanine (56 mg, 0.19 mmol) in THF was cooled to -40°C under an argon
atmosphere . To this solution was added N-methyl morpholine (28 ml, 0.251 mmol), followed by isobutyl chloroformate (25 ml, 0.19 mmol). The reaction mixture was stirred for 15 min, and additional N-methyl morpholine (28 ml, 0.251 mmol) was added, followed by the compound of Example 71(b) (100 mg,
0.173 mmol). The resulting mixture was stirred for 30 min at -40°C, warmed to room temperature and stirred for 16 h. The mixture was diluted with 1:1 ethyl acetate: CH2C12 and washed successively with 5% aqueous HCl, 5% aqueous NaHCO3 and saturated NaCl. The solution was dried (MgSO4), filtered and evaporated under reduced pressure. The solid residue was eluted through a 1" x 25 cm HPLC silica gel column with 95: 5: 0.5 CHCI3 : MeOH: H2O to give the titled compound as a white solid (96 mg, 77%).
NMR (CD3OD/CDCI3) : δ 7.15 (10H, m), 6.80 (4H, dd), 4.90 (2H, s), 4.81 (2H, s), 3.90 (2H, q), 3.75 (1H, m), 3.51 (3H, s), 3.36 (1H, m), 2.59 (2H, m), 2.11 (2H, m), 1.88 (3H, m), 1.48 (2H, m), 1.10 (8H, m), 0.76 (12H, d). MS (FAB) : m/z 818 . 3 (M+H) + .
(4S,5S) 5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester, acetic acid salt
b) To a solution of the compound of Example 72(a) (90 mg, 0.11 mmol) in acetic acid was added 10% palladium on activated carbon (90 mg). Hydrogen gas was bubbled via balloon through the solution for 60 min, then the stirring mixture was maintained under a hydrogen atmosphere for 14 h. The suspension was filtered through a pad of Celite® and evaporated under reduced pressure to give the titled compound as a white solid (74 mg, 98%).
NMR (CD3OD/CDCI3) : δ 7.06 (1H, d), 6.78 (4H, dd), 4.29 (1H, d), 4.16 (1H, m), 4.03 (1H, d), 3.60 (3H, s), 2.62 (2H, m), 1.85 (7H, br m), 1.57 (2H, m), 1.16 (6H, m), 0.80 (12H, d). MS (FAB): m/z 594.4 (M+H)+.
Example 73
Preparation of (4S,5S)-5-alanylamino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)-hexyl-valyl valine methyl ester, acetic acid salt (4S,5S) 5-(carbobenzyloxyalanyl)amino-4-hydroxy-1-oxo-6-(4-benzyloxyphenyl)hexyl-valyl valine methyl ester
a) Using the procedure of Example 72 (b), substituting carbobenzyloxyalanine (34 mg, 0.15 mmol) for
carbobenzyloxyalanyl alanine, and using N-methyl morpholine (44 ml, 0.40 mmol; added in two equal portions), isobutyl chloroformate (20 ml, 0.15 mmol), and the compound of Example 71(b) (79 mg, 0.137 mmol), the titled compound was prepared. The crude product was purified by column chromatography using silica gel, eluting with 5: 95 MeOH: CHCI3 to give the titled compound as a white solid (60 mg, 82%).
NMR (CD3OD/CDCI3) : δ 7.13 (10H, m), 6.81 (4H, dd), 4.92 (2H, s), 4.70 (2H, s), 4.21 (1H, m), 3.96 (2H, d), 3.76 (1H, m), 3.55 (3H, s), 3.34 (1H, m), 2.61 (2H, m), 2.12 (2H, m), 1.89 (3H, m) , 1 . 48 (2H, m) , 1 . 04 ( 4H, d) , 0 . 71 (12H, d) .
MS (FAB) : m/z 747 .3 (M+H) + .
(4S,5S)-5-alanylamino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)-hexyl-valyl valine methyl ester, acetic acid salt
b) The titled compound was made by a procedure
identical to that of 72 (b), substituting the compound of Example 73(a) (60 mg) for the compound of Example 72(a) to give the titled compound as a white solid (52 mg, 100%).
NMR (CD3OD/CDCI3) : δ 8.19 (1H, d), 7.95 (1H, d), 7.70 (1H, d), 6.78 (4H, dd), 4.15 (2H, m), 3.95 (1H, m), 3.73 (1H, q), 3.58 (3H, s), 3.43 (1H, m), 2.66 (2H, m), 2.21 (2H, t), 1.90 (3H, m), 1.53 (2H, q), 1.36 (3H, d), 1.17 (2H, br), 0.93 (2H, m), 0.78 (12H, d).
MS (FAB): m/z 523.2 (M+H)+.
Example 74
Preparation of (4S,5S) 5-(tert-butyloxycarbonylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester
The titled compound was prepared by a prodedure
identical to that of Example 72 (a), substituting
t-butyloxycarbonylalanine (52 mg, 0.275 mmol) for
carbobenzyloxyalanyl alanine, and using the compound of
Example 71(b) (144 mg, 0.25 mmol), N-methyl morpholine (79 ml, 0.724 mmol; in two portions) and isobutylchloroformate (36 ml, 0.275 mmol). The crude product was purified by eluting through a silica gel column with 1: 25 MeOH: CH2C12 to a white solid (55 mg, 55%). A portion of this product (12.5 mg, 0.0172 mmol) was stirred in acetic acid with 10% palladium on activated carbon (10 mg). Hydrogen gas was bubbled through the solution via balloon for 60 min, then the mixture was maintained under a positive hydrogen pressure for 14 h. The suspension was filtered through a pad of Celite® and evaporated under reduced pressure to give the titled compound as a white solid (7.5 mg, 70%).
NMR (CD3OD/CDCI3) : δ 6.72 (4H, dd), 4.23 (1H, d), 3.65-3.92 (3H, m), 3.54 (3H, s), 3.38 (2H, m), 2.60 (2H, m), 1.62-2.20 (5H, m), 1.49 (3H, m), 1.26 (9H, s), 1.04 (5H, m), 0.77 (12H, d).
MS (FAB): m/z 623.3 (M+H)+.
Example 75
Preparation of (4S,5S) 5-((β-alanyl)alanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester, hydrochloride
(4S,5S) 5-((carbobenzyloxy-β-alanyl)alanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester
a) To a solution of carbobenzyloxy-β-alanine (23 mg, 0.105 mmol), and hydroxybenzotriazole (26 mg, 0.19 mmol) in
DMF (0.8 ml) was added dicyclohexylcarbodiimide (22 mg, 0.105 mmol), and the mixture was stirred at room temperature for 20 min. To this solution was added N-methylmorpholine (32 ml, 0.29 mmol) and the compound of Example 73(b) (50 mg, 0.0956 mmol). The solution was allowed to stir at room temperature for 6 days and was then diluted with CHCI3 and washed
successively with 10% HCl, 5% aqueous NaHCO3 and H2O. The organic layer was dried (MgSO4 ), filtered, and evaporated under reduced pressure to a white solid (44 mg). The product was eluted through a 1" x 25 cm HPLC silica column with 6: 96 MeOH: CHCI3 to give the titled compound as a white solid (12 mg, 20%).
NMR (CD3OD/CDCI3) : δ 7.51 (1H, d), 7.30 (1H, d), 7.18 (5H, br s), 6.94 (1H, d), 6.69 (4H, dd), 4.90 (2H, s), 4.19 (1H, m), 3.82 (1H, m), 3.56 (3H, s), 3.42 (1H, m), 3.18 (3H, m), 2.59 (2H, m), 2.15 (4H, m), 1.90 (2H, m), 1.49 (2H, m), 1.08 (3H, d), 0.80 (12H, d).
MS (FAB): m/z 728.3 (M+H)+. (4S,5S) 5-((β-alanyl)alanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester hydrochloride b) To a solution of the compound of Example 75(a)
(11 mg, 0.015 mmol) in MeOH was added 10% palladium on activated carbon (5 mg). Hydrogen gas was bubbled through the solution via balloon for 1 h, and then the stirring mixture was maintained under a hydrogen (1 atm) for 14 h.
The suspension was filtered through a pad of Celite® and several drops of cone. HCl were added. The solution was evaporated under reduced pressure to give the titled compound as a white solid (10 mg, 95%).
NMR (CD3OD/CDCI3) : δ 7.60 (1H, d), 6.59 (4H, dd), 4.06 (1H, t), 3.89 (2H, m), 3.66 (1H, m), 3.44 (3H, s), 3.27 (1H, m), 2.72 (2H, m), 2.41 15H, m), 1.98 (2H, t), 1.79 (3H, m), 1.32 (2H, m), 1.07 (1H, m), 0.94 (3H, d), 0.67 (12H, d).
Example 76 Preparation of (4S,5S) 5-amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester, hydrochloride (4S,5S)-5-(tert-butyloxycarbonyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester
a) To a solution of the compound of Example 34(a) (4.59 g, 8.61 mmol) in MeOH (150mL) at 0°C was added sodium
borohydride (0.33 g, 8.7 mmol). The resulting mixture was allowed to warm to room temperature and stirred for 30 min. The mixture was poured into 5% HCl (500 ml) and extracted with CH2Cl2 (3 x 100 ml). The combined organic extracts were dried (MgSO4), filtered and evaporated under reduced pressure to afford a mixture of stereoisomers. The residue was dissolved in 2% MeOH/CHCl3 (70 ml), filtered and purified in batches by HPLC using a 2" x 25 cm silica column and eluting with 2% MeOH/CHCl3. The desired (4S) isomer eluted first, was collected and evaporated under reduced pressure to afford the titled compound (1.23 g, 27% yield).
NMR (CDCI3) : δ 7.27 (5H, m), 6.94 (1H, d), 6.76 (1H, d), 5.10
(1H, d), 4.51 (1H, dd), 4.36 (1H, br t), 3.74 (3H, s), 3.703.50 (3H, m), 2.89 (2H, d), 2.40 (2H, m), 2.24-2.00 (2H, m), 1.95-1.65 (2H, m), 1.38 (9H, s), 0.91 (12H, m).
MS (FAB): m/z 536.2 (M+H)+. (4S,5S) 5-amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester, hydrochloride
b) The peptide of Example 76(a) (1.0 g, 1.87 mmol) was treated with trifluoroacetic acid (5 ml), and the resulting mixture was stirred for 10 min. Methanol was added (25 ml) followed by cone. HCl (0.20 ml). The solvent was evaporated under reduced pressure; Et2O was added to the residue and reevaporated, to produce the titled compound as a white powder which was used without further purification.
NMR (CD3OD) : δ 7.30 -(5H, m), 4.26 (2H, m), 3.69 (3H, s), 3.60
(1H, m), 3.34 (1H, m), 3.07 (1H, dd), 2.88 (1H, dd), 2.40 (2H, m), 2.08 (2H, m), 1.80 (2H, m), 0.94 (12H, m).
MS (FAB): m/z 436.2 (M+H)+. Example 77
Preparation of (4S,5S) 5-(alanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine, methyl ester acetic acid salt (4S,5S) 5-(carbobenzyloxyalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester
a) To a solution of carbobenzyloxyalanine (413 mg, 1.85 mmol) in anhydrous THF (5 ml) at -40°C under an argon
atmosphere was added N-methyl morpholine (0.24 ml, 2.2 mmol) followed by isobutyl chloroformate (0.240 ml, 1.85 mmol).
After stirring 20 min, additional N-methyl morpholine (0.24 ml, 2.2 mmol) was added followed by a solution of the
compound of Example 76(b) (0.83 g, 1.76 mmol) in THF (10 ml). The resulting mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was dissolved in EtOAc and washed successively with 10% HCl, 5% aqueous NaHCO3 and H2O, then dried (MgSO4). Filtration and removal of the solvent in vacuo gave a white solid which was purified by flash chromatography eluting with a solvent gradient from 4% to 10% MeOH/CHCl3 (0.975 g, 86% yield).
NMR (CD3OD) : 6 7.34 (5H, m), 7.23 (5H, m), 5.09 (2H, s), 4.32 (1H, d), 4.19 (1H, d), 4.09 (2H, m), 3.71 (3H, s), 3.60 (1H, m), 2.85 (2H, m), 2.30 (2H, m), 2.10 (2H, m), 1.70 (2H, m), 1 .23 (3H, d) , 0 . 94 ( 12H, m) .
MS (FAB) : m/z 641 .3 (M+H) + .
(4S,5S) 5-(alanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine, methyl ester acetic acid salt
b) To a solution of the compound of Example 77(a) (969 mg, 1.51 mmol) in 1 : 1 MeOH: HOAc (15 ml) was added 10% palladium on activated carbon (100 mg). Hydrogen gas was introduced into the mixture, which was then maintained under a hydrogen atmosphere for 18 h. The reaction mixture was filtered through a pad of Celite® and evaporated under reduced pressure to afford the titled compound as a white solid (0.84 g, 98% yield).
NMR (CD3OD) : δ 7.25 (5H, m), 4.32 (1H, d), 4.21 (1H, d), 4.10 (1H, br t), 3.77 (1H, apparent q), 3.71 (3H, s), 3.60 (1H, br t), 2.96 (1H, dd), 2.83 (1H, dd), 2.35 (2H, t) , 2.08 (2H, m), 1.96 (3H, s), 1.70 (2H, m), 1.44 (3H, d), 0.95 (12H, d).
MS (FAB): m/z 507.2 (M+H)+. Example 78
Preparation of (4S,5S) 5-(alanylalanyl)amino-4-hydroxy-1-oxo- 6-phenylhexyl-valyl valine methyl ester (4S,5S) 5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-1-oxo- 6-phenylhexyl-valyl valine methyl ester
a) To a solution of carbobenzyloxyalanine (337 mg, 1.51 mmol) and N-methyl morpholine (0.198 ml, 1.80 mmol) in anhydrous THF (10 ml) at -40°C under an argon atmosphere was added isobutyl chloroformate (0.196 ml, 1.51 mmol) over a 10 min period. After stirring an additional 20 min, more N- methyl morpholine (0.198 ml, 1.80 mmol) was added followed by a solution of the compound of 77(b) (0.84 g, 1.48 mmol) in THF (20 ml). Dimethylformamide (10 ml) was added, and the cold temperature bath was removed briefly to facilitate stirring. The reaction mixture was recooled to -40°C, allowed to gradually warm to room temperature and stirred overnight. The reaction mixture was dissolved in 10% MeOH/CHCl3 (500 ml) and washed successively with H2O (200 ml), 10% HCl (200 ml) and H2O (200 ml). The organic extract was evaporated under reduced pressure, and the residue was dissolved in 80:20:2 CHCI3: MeOH: H2O (22 ml). The solution was purified in three portions by flash chromatography eluting with 90:10:1 CHCI3 : MeOH: H2O to provide the crude product as an off-white solid (950 mg). This material was dissolved in 5% MeOH/CHCI3 (75 ml), filtered and further purified in portions of 8 ml each by HPLC using a 1" x 25 cm silica column eluting with 5% MeOH/CHCI3 to afford the titled compound as a white solid (721 mg, 68% yield).
NMR (CD3OD/CDCI3) : δ 7.35 (5H, m), 7.22 (5H, m), 5.12 (2H, d), 4.36 (1H, d), 4.29 (1H, q), 4.16 (2H, m), 4.05 (1H, m), 3.73 (3H, s), 3.57 (1H, m), 2.92 (1H, dd), 2.81 (1H, dd), 2.32 (2H, m), 2.09 (2H, m), 1.72 (2H, m), 1.36 (3H, d), 1.27 (3H, d), 0.94 (12H, 2 overlapping d's).
MS (FAB): m/z 712.4 (M+H)+.
(4S,5S) 5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester
b) To a solution of the compound of Example 78(a) (715 mg, 1.01 mmol) in MeOH (45 ml) was added 10% palladium on activated carbon (100 mg). Hydrogen gas was introduced into the reaction mixture which was then maintained under a hydrogen atmosphere for 48 h. The mixture was filtered, and the solvent was removed in vacuo to afford the titled
compound as a white solid (599 mg, 100% yield).
NMR (CD3OD) : δ 7.24 (5H, m), 4.32 (2H, m), 4.21 (1H, d), 4.03
(1H, br t), 3.94 (1H, q), 3.71 (3H, s), 3.59 (1H, br t), 2.86 (2H, 2 overlapping dd's), 2.31 (2H, t), 2.07 (2H, m), 1.68
(2H, m), 1.52 (3H, d), 1.32 (3H, d), 0.94 (12H, overlapping d's).
MS (FAB): m/z 578.3 (M+H)+. Example 79
Preparation of (4S,5S) 5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-cγclohexyl-hexyl-valyl valine methyl ester To a solution of the compound of Example 78(b) (5.4 mg, 9.4 mmol) in MeOH (5 ml) was added PtO2 (10 mg), and the resulting mixture was shaken on a Parr hydrogenator at 60 psig H2 for 2 d. The mixture was filtered, and the solvent was removed in vacuo to afford the titled compound as a white solid (3.4 mg, 62% yield).
NMR (CD3OD) : δ 4.42-4.15 (3H, m), 3.97 (2H, m), 3.71 (3H, s),
3.52 (1H, m), 2.35 (2H, t), 2.10 (2H, m), 1.85 (1H, br d), 1.80-1.15 (21H, m), 1.65 (12H, m).
MS (FAB): m/z 584. A" (M+H)+.
Example 80
Preparation of (4S,5S) 5-(serylalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester, acetic acid salt
(4S,5S) 5-(carbobenzyloxy-(O-phenylmethyl)serylalanylalanyl) amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester a) To a solution of carbobenzyloxy-(O-benzyl)serine (311 mg, 0.945 mmol) and N-methyl morpholine (130 ml, 1.20 mmol) in THF (20 ml) at -40°C was added isobutyl
chloroformate (123 ml, 0.945 mmol) over a 10 min period.
After stirring an additional 30 min, the compound of Example 78(b) (520 mg, 0.900 mmol) was added in 20% DMF/THF (25 ml). The resulting mixture was allowed to slowly warm to room temperature and stirred for 20 h. The mixture was diluted with CHCI3 (150 ml) and washed with H2O (2x). The organic extract was evaporated under reduced pressure. The solid residue (870 mg) was purified by flash chromatography eluting with 10% MeOH/CHCI3 to afford material which was still slightly impure (640 mg). The product was dissolved in 4% MeOH/CHCI3 (20 ml), filtered and further purified by HPLC in 6 portions using a 1" x 25 cm silica column eluting with 4% MeOH/CH2Cl2 to afford the titled compound as a white solid
(414 mg, 52% yield).
NMR (CD3OD/CDCl3) : δ 7.10 (10H, m), 7.01 (5H, m), 4.94 (2H, s), 4.35 (2H, s), 4.25-3.80 (6H, m), 3.55 (2H, m), 3.52 (3H, s), 3.38 (1H, m), 2.73 (1H, dd), 2.63 (1H, dd), 2.10 (2H, m), 1.90 (2H, m), 1.57 (2H, m), 1.17 (3H, d), 0.93 (3H, d), 0.73 (12H, overlapping d's).
MS (FAB): m/z 889.4 (M+H)+.
(4S,5S) 5-[(O-phenylmethyl)serylalanylalanyl]amino-1-oxo-6-phepylhexyl-valyl valine methyl ester, acetic acid salt
b) To a mixture of the compound of Example 80(a) (409 mg, 0.461 mmol) in 2:1 -MeOH: HOAc (15 ml) was added 10% palladium on activated carbon (80 mg). Hydrogen gas was introduced into the reaction mixture which was then
maintained under a hydrogen atmosphere for 16 h. The mixture was filtered through Celite® and evaporated under reduced pressure to afford the titled compound as a white solid (353 mg, 94% yield).
NMR (CDCI3) : δ 7.31 (5H, m), 7.24 (5H, m), 4.58 (2H, s),
4.42-4.18 (4H, m), 4.05 (1H, m), 3.94 (1H, m), 3.85-3.70 (2H, m), 3.70 (3H, s), 3.58 (1H, m), 2.91 (1H, dd), 2.81 (1H, dd), 2.30 (2H, m), 2.12 (2H, m), 1.98 (3H, s), 1.72 (2H, m), 1.37 (3H, d), 1.22 (3H, d), 0.94 (12H, m).
MS (FAB): m/z 755.3 (M+H)+.
(4S,5S) 5-(serylalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester, acetic acid salt
c) To a solution of the compound of Example 80(c) (353 mg, 0.46 mmol) in MeOH (20 ml) was added 10% palladium on activated carbon (85 mg). Hydrogen gas was introduced into the mixture which was then maintained under a hydrogen atmosphere for 2 days. Acetic acid (5 ml) was added followed by additional 10% Pd/C (150 mg). After stirring an
additional 4 days under a hydrogen atmosphere, the reaction mixture was filtered through Celite®, and the solvent was evaporated under reduced pressure to afford the titled compound (273 mg, 88% yield).
NMR (CD3OD) : δ 7.23 (5H, m), 4.43-4.18 (4H, m) 4.05 (1H, br t), 3.85 (2H, m), 3.70 (3H, s), 3.59 (2H, m), 2.92 (1H, dd), 2.80 (1H, dd), 2.30 (2H, m), 2.07 (2H, m), 1.96 (3H, s), 1.71 (2H, m), 1.40 (3H, d), 1.25 (3H, d), 0.94 (12H, m). MS (FAB): m/z 665.3 (M+H)+.
Example 81 Preparation of (4S,5S) 5-T(D-seryl)alanylalanyl]amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester
(4S,5S) 5-((carbobenzyloxy-D-seryl)alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester
a) To a solution of carbobenzyloxy-D-serine (8.4 mg, 35 mmol) and hydroxybenzotriazole (9.5 mg, 70 mmol) in DMF (8 drops) was added dicyclohexylcarbodiimide (7.2 mg, 35 mmol), and the resulting mixture was stirred for 20 min. The compound of Example 78(b) (20 mg, 35 mmol) was added followed by additional DMF (7 drops), and the mixture was stirred for 2 days. The mixture was diluted with 10% MeOH/CHCI3 and washed successively with 10% HCl, 5% aqueous NaHCO3 and H2O. The solvent was removed in vacuo, and the residue was
purified by flash chromatography eluting with 10% MeOH/CHCI3 to afford the titled compound (4.2 mg, 14% yield).
NMR (CDCI3/CD3OD) : δ 7.26 (5H, s), 7.17 (5H, m), 5.11 (1H, d), 4.96 (1H, d), 4.35-4.10 (5H, m), 3.96 (1H, m), 3.83 (1H, dd), 3.72 (1H, dd), 3.64 (3H, s), 3.47 (1H, m), 2.87 (1H, dd), 2.72 (1H, dd), 2.34-1.95 (4H, m), 1.70 (2H, m), 1.34 (3H, d), 1.24 (3H, d), 0.87 (12H, d).
MS (FAB): m/z 799.5 (M+H)+.
(4S,5S) 5-((D-seryl)alanylalanyl)amino-4-hydroxy-1-oxo-6- phenylhexyl-valyl valine methyl ester
b) To a solution of the compound of Example 81(a) (3.9 mg, 4.9 mmol) in MeOH (2 ml) was added 10% palladium on activated carbon (2 mg). Hydrogen gas was introduced into the reaction mixture which was then maintained under a hydrogen atmosphere for 2 d. The mixture was filtered through Celite® and evaporated under reduced pressure to afford the titled compound as a white solid (3.4 mg, 98% yield).
NMR (CD3OD) : δ 7.22 (5H, m), 4.25 (4H, m), 4.05 (1H, m), 3.82 (2H, m), 3.69 (3H, s), 3.55 (1H, m), 2.90 (1H, dd), 2.78 (1H, dd), 2.29 (2H, br t), 2.05 (2H, m), 1.69 (2H, m), 1.37 (3H, d), 1.25 (3H, d), 0.92 (12H, overlapping d's).
MS (FAB): m/z 665.4 (M+H)+.
Example 82
Preparation of (4RS,5S) 5-amino-6-(4-benzyloxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine benzyl ester, hydrochloride
(5S) 6-(4-benzyloxy)phenyl-5-(t-butyloxycarbonyl)amino-(1.4-dioxo) hexyl-valyl valine benzyl ester
a) To a solution of the compound of Example 13(c) (43 mg, 0.10 mmol) in THF at -40°C under an argon atmosphere was added N-methyl morpholine (16 ml, 0.14 mmol) followed by isobutyl chloroformate (13 ml, 0.10 mmol). After stirring 15 min, additional N-methyl morpholine (16 ml, 0.14 mmol) was added followed by valyl valine benzyl ester hydrochloride (51 mg, 0.15 mmol). The resulting mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with 5% HCl and extracted with CHCI3 (3x). The combined organic extracts were evaporated, and the residue was purified by flash chromatography eluting with 1: 25 MeOH: CHCI3 to afford the titled compound as a white solid (62 mg, 100% yield).
NMR (CDCI3) : δ 7.34 (10H, m), 7.07 (2H, d), 6.89 (2H, d),
6.52 (1H, d), 6.31 (1H, d), 5.2 (1H, m), 5.16 (2H, dd), 5.02 (2H, s), 4.59 (1H, dd), 4.49 (1H, dd), 4.30 (1H, dd), 3.08 (1H, dd), 2.84 (3H, m), 2.46 (2H, m), 2.13 (2H, m), 1.86 (1H, br s), 1.39 (9H, s), 0.91 (12H, m).
(4RS,5S) 6-(4-benzyloxy)phenyl-5-(t-butyloxycarbonyl)amino-4-hydroxy-1-oxo-hexyl-valyl valine benzyl ester
b) To a solution of the compound of Example 82(a) (61 mg, 0.10 mmol) in 5 : 1 MeOH: CH2Cl2 (6 ml) was added sodium borohydride (5 mg, 0.13 mmol) and the resulting mixture was stirred for 20 min. The reaction mixture was diluted with 5% aqueous HCl and extracted several times with CH2CI2. The combined organic extracts were dried (MgSO4), filtered, and evaporated under reduced pressure to give the titled compound as a white solid (61 mg, 100% yield).
NMR (CDCI3/CD3OD) : δ 7.35 (10H, m), 7.12 (2H, d), 6.90 (2H, d), 5.17 (2H, dd), 5.02 (2H, s), 4.47 (1H, m), 4.17 (1H, apparent t), 3.68 (1H, m), 3.53 (1H, m), 2.96-2.55 (2H, m), 2.36 (2H, m), 2.19 (1H, m), 2.10-1.81 (2H, m), 1.70 (1H, m), 1.35 (9H, 2 singlets), 0.91 (12H, m).
MS (FAB) : m/z 718.5 (-M+H)+ .
(4RS,5S) 5-amino-6-(4-benzyloxy)phenyl-4-hydroxy-1-oxo-hexyl-valvl valine benzyl ester, hydrochloride
c) To a mixture of the compound of Example 82 (b) (60 mg, 97 mmol) in CH2CI2 (2 ml) there was added trifluoroacetic acid (0.5 ml), and the resulting solution was stirred for 2 h. Methanol was added followed by cone. HCl (2 drops), and the solution was evaporated under reduced pressure. The residue was triturated with Et2O, giving the titled compound as a white solid (56 mg, 100% yield).
NMR (CD3OD) : δ 7.36 (10H, m), 7.20 (2H, d), 6.97 (2H, d),
5.15 (2H, m), 5.07 (2H, s), 4.34 (1H, m), 4.21 (1H, m), 3.843.53 (1H, m), 3.44-3.20 (1H, m), 2.97 (1H, m), 2.80 (1H, m), 2.44 (2H, m), 2.15 (1H, m), 2.02 (1H, m), 1.94-1.62 (2H, m), 0.94 (12H, m).
(4RS,5S) 5-amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine benzyl ester, hydrochloride
c) The compound of Example 82(c) (50 mg) is dissolved in acetic acid and stirred with 10% palladium on activated carbon (50 mg). Hydrogen gas is bubbled through the solution for 2 h. and the reaction is stirred for 20 h. under a hydrogen atmosphere. The suspension is filtered through a pad of Celite® and evaporated under reduced pressure to yiel the titled compound. Example 83
Preparation of ( 4RS , 5S ) 5- ( serylalanylalanyl ) amino-6- ( 4 -hydroxy) phenyl-4-hydroxy-1-oxo-hexyl-valyl val ine ,
hydrochloride
(4RS,5S) 5-[(t-butyloxycarbonyl-(O-phenylmethyl)serylalanyl- alanyl)-amino]-6-(4-benzyloxy)phenyl-4-hydroxy-1-oxohexyl-valyl valine benzyl ester
a) To a solution of t-butyloxycarbonyl-(O-benzyl) serylalanyl alanine (46.8 mg, 107 mmol) in THF (1 ml) at -40°C under an argon atmosphere was added N-methyl morpholine (16.5 ml, 150 mmol) followed by isobutyl
chloroformate (13.8 ml, 107 mmol). After stirring 15 min, additional N-methyl morpholine (16.5 ml, 150 mmol) was added followed by a solution of the compound of Example 82(c) (56 mg, 97 mmol) in THF (0.75 ml). The resulting mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with 5% HCl and extracted with CH2CI2 several times. The combined organic extracts were evaporated under reduced pressure, and the solid residue was purified by flash chromatography eluting with 1: 9 MeOH: CHCI3 to give the titled compound (79.5 mg, 87% yield).
NMR (CDCI3/CD3OD) : δ 7.32 (15H, m), 7.14 (2H, m), 6.84 (2H, m), 5.16 (2H, dd), 5.00 (2H, d), 4.56-4.40 (2H, 2d), 4.21¬
3.53 (9H, m), 3.10-2.65 (2H, m), 2.48-2.28 (2H, m), 2.25-2.0 (2H, m), 1.96-1.68 (2H, m), 1.50 (9H), 1.39 (3H, overlapping d's), 1.17 (3H, 2d's), 0.96 (12H, m).
MS (FAB): m/z 1037.4 (M+H)+.
(4RS,5S) 5-(t-butyloxycarbonylserylalanylalanyl)amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine
b) To a solution of the compound of Example 83(a) (79 mg, 76 mmol) prepared above in 3:1 MeOH: HOAc (5 ml) was added 10% palladium on activated carbon (45 mg). Hydrogen was introduced into the mixture which was then maintained under 1 atm H2 for 24 h. The reaction mixture was filtered through a pad of Celite®, and the solvent was removed under reduced pressure. The residue was purified by flash
chromatography eluting with a gradient from 90: 10: 1: 1 to 80: 20: 2: 1 CHCI3 : MeOH: H2O: HCO2H to afford the titled compound as a white solid (37.5 mg, 64% yield).
NMR (CD3OD) : δ 7.03 (2H, m), 6.66 (2H, m), 4.4-4.05 (5H, m),
4.03-3.50 (4H, m), 3.06-2.54 (2H, m), 2.38 (2H, m), 2.14 (2H, m), 1.96-1.62 (2H, m), 1.48 (9H), 1.38 (3H, m), 1.22 (3H, 2d's), 0.96 (12H, d).
MS (FAB): m/z 767.3 (M+H)+.
(4RS,5S) 5-(serylalanylalanyl)amino-6-(4-hydroxy)phenvl-4-hydroxy-1-oxo-hexyl-valyl valine. hydrochloride
c) The compound of Example 83(b) (5.9 mg, 7.7 mmol) was treated with trifluoroacetic acid (0.25 ml), and the
resulting solution was stirred for 90 min. Methanol was added followed by cone. HCl (1 drop), and the mixture was evaporated under reduced pressure. The residue was
triturated with Et2O to afford the titled compound as a white powder.
NMR (CD3OD) : δ 7.03 (2H, m), 6.68 (2H, m), 4.42-4.17 (5H, m),
3.92 (4H, m), 3.04-2.54 (2H, m), 2.33 (2H, m), 2.22-1.97 (2H, m), 1.95-1.55 (2H, m), 1.35 (3H, overlapping d' s), 1.26 (3H, overlapping d's), 0.98 (12H, m).
MS (FAB): m/z 667.4 (M+H)+.
Example 84
Preparation of (4RS,5S) 5-(t- butyloxycarbonylserylalanylalanyl)amino-4-hydroxy-6-(4- hydroxy)phenyl-1-oxo-hexyl-valyl amide
(5S) 6-(4-benzyloxy)phenyl-5-(t-butyloxycarbonyl)amino-1,4- dioxo-hexyl-valyl amide
a) To a solution of the compound of Example 13(c) (25 mg, 58.5 μmol) in THF at -40°C under an argon atomosphere was added N-methyl morpholine (9.9 μl, 90 μmol) followed by isobutyl chloroformate (7.6 ml, 58.5 mmol). After stirring for 15 min, valinamide (14 mg, 120 mmol) was added, and the resulting mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture was diluted with 5% HCl and extracted with CHCI3 three times. The solvent was removed in vacuo. and the residue was purified by flash chromatography eluting with 1: 9 MeOH: CHCI3 to afford the titled compound as a yellow solid (23.5 mg, 75% yield).
NMR (CD3OD/CDCI3) : δ 7.36 (5H, m), 7.12 (2H, d), 6.91 (2H, d), 5.05 (2H, s), 4.33 (1H, m), 4.22 (1H, m), 3.07 (1H, dd), 2.83 (3H, m), 2.52 (2H, t), 2.13 (1H, septet), 1.39 (9H, s), 0.97 (6H, overlapping d's).
(4RS,5S) 6-(4-benzyloxy)phenyl-5-(t-butyloxycarbonyl)amino-4hydroxy-1-oxo-hexyl-valyl amide
b) To a solution of the compound of Example 84(a) (23 mg, 44 mmol) prepared above in 1 : 4 CH2CI2 : MeOH (2.5 ml) was added NaBH4 (3 mg, 80 mmol). After stirring 15 min, the mixture was diluted with 5% HCl and extracted with CH2CI2 several times. The combined organic extracts were washed with H2O and dried (MgSO4). Filtration and removal of the solvent in vacuo provided the titled compound as a white solid (23 mg, 100% yield) .
NMR (CD3OD/CDCI3) : δ 7.36 (5H, m), 7.13 (2H, d), 6.90 (2H, d), 5.04 (2H, s), 4.20 (1H, apparent t), 3.67 (1H, m), 3.53 (1H, m), 3.02-2.30 (4H, m), 2.10 (1H, m), 2.02-1.61 (2H, m), 1.35 (9H, 2 singlets), 0.97 (6H, overlapping d's).
MS (FAB): m/z 528.3 (M+H)+.
(4RS,5S)-6-(4-benzyloxy)phenyl-5-amino-4-hydroxy-1-oxo-hexyl-valyl amide, hydrochloride
c) The compound of Example 84 (b) (22 mg, 42 mmol) was dissolved in neat trifluoroacetic acid (0.1 ml). After 1 h, methanol was added followed by cone. HCl (2 drops). Removal of the solvent in vacuo gave the titled compound as a
hygroscopic solid (22 mg).
NMR (CD3OD) : δ 7.35 (5H, m), 7.20 (2H, 2 doublets), 6.98
(2H, 2 doublets), 5.07 (2H, s), 4.21 (1H, m), 3.83-3.53 (1H, m), 3.47-3.21 (1H, m), 2.98 (1H, m), 2.81 (1H, m), 2.43 (2H, m), 2.09 (1H, m), 1.98-1.62 (2H, m), 0.98 (6H, m). (4RS,5S) 5-(t-butyloxycarbonyl-(O-phenylmethyl)serylalanyl-alanyl)amino-6-(4-benzyloxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl amide
d) To a solution of t-butyloxycarbonyl-(O-phenylmethyl) serylalanyl alanine (20 mg, 46 mmol) in THF (1 ml) at -40°C under an argon atmosphere was added N-methyl morpholine (8.2 ml, 75 mmol) followed by isobutyl
chloroformate (6.0 ml, 46 mmol). The resulting mixture was stirred for 15 min,-and additional N-methyl morpholine (8.2 ml, 75 mmol) was added followed by a solution of the compound of Example 84(c) (22 mg) in THF (0.8 ml). The resulting mixture was allowed to warm to room temperature and stirred overnight. The reaction mixture which solidified overnight was dissolved in 1 : 1 CHCI3 : MeOH and washed with 5% HCl. The organic extract was evaporated under reduced pressure. The residue (51 mg) was dissolved in 9:1:0.5 CHCI3 : MeOH: acetic acid (2 ml), appIled to a 6" x 15 mm flash silica column and eluted with 9:1 CHCI3 : MeOH to afford a yellow solid (19.5 mg). Analytical HPLC (silica; 9:1 CH2CI2 : MeOH mobile phase; detector 275 nm) indicated a 2: 1 ratio of 4-hydroxy
diastereomers. Further purification was effected by flash chromatography on silica using 80: 20: 2 CHCI3 : MeOH: H2O, to yield the titled compound (13.8 mg, 39% yield) as a white solid.
NMR (CD3OD/CDCl3/DMSO-d6) : δ 7.32 (10H, m), 7.12 (2H, m),
6.82 (2H, m), 5.00 (2H, s), 4.19 (5H, m), 4.00 (1H, m), 3.68 (4H, m), 3.10-2.60 (2H, m), 2.42 (2H, m), 2.13 (1H, m), 1.991.63 (2H, m), 1.50 (9H, s), 1.37 (3H, overlapping d' s), 1.12 (3H, d), 0.95 (6H, m).
MS (FAB): m/z 847.5 (M+H)+.
(4RS,5S) 5-(t-butyloxycarbonylserylalanylalanyl)amino-4- hydroxy-6-(4-hydroxy)phenyl-1-oxo-hexyl-valyl amide
e) To a solution of the compound of Example 84(d) (13.8 mg, 16.3 mmol) prepared above in MeOH (5 ml) was added 10% palladium on activated carbon (7 mg). Hydrogen gas was bubbled into the resulting mixture which was then maintained at 1 atm H2 for 24 h. Filtration and evaporation of the solvent under reduced pressure provided the titled compound as a white solid (10.7 mg, 99% yield).
NMR (CD3OD) : δ 7.05 (2H, 2 doublets), 6.64 (2H, 2 doublets), 4.18 (5H, m), 3.95 (1H, m), 3.88-3.67 (3H, m), 3.60 (1H, m), 3.09-2.53 (2H, m), 2.37 (2H, m), 2.11 (1H, m), 2.00-1.65 (2H, m), 1.47 (9H, 2s), 1.38 (3H, overlapping d's), 1.21 (3H, 2 doublets), 0.95 (6H, m).
MS (FAB): m/z 667.2 (M+H)+.
Example 85
Preparation of (1R,2R)-2-(((1S,2S)-1-hydroxy-2-amino-3-cyclohexyl) propyl)cyclopentanecarbonyl-valyl valine methyl ester, hydrochloride (1R,2R)-2-(((1S,2S)-1-hydroxy-2-t-butyloxycarbonylamino-3-phenyl)propyl)-cyclopentanecarbonyl-valyl valine methyl ester a) Using the procedure of Example 27 (a), the compound of Example 6(b) (54 mg, 150 μmol) was reacted with N-hydroxy benzotriazole (40 mg, 300 μmol), DCC (33 mg, 170 μmol), N-methyl morpholine (40 μl, 380 μmol) and valyl valine methyl ester hydrochloride (80 mg, 300 μmol) to afford the titled compound.
(1R,2R) 2-(((1S,2S)-1-hydroxy-2-t-butyloxycarbonylamino-3-cyclohexyl)propyl)-cyclopentanecarbonyl-valyl valine methyl ester
b) A solution of the compound of Example 85(a) (10 mg, 17.4 mmol) in MeOH (3 ml) was shaken with PtO2 (10 mg) on a Parr hydrogenator at 60 psig H2. After 26 h, the mixture was filtered through a pad of Celite® and evaporated under reduced pressure. The residue was purified by flash
chromatography eluting with 25:1 CHCI3 : MeOH to afford the titled compound (9 mg, 89% yield).
NMR (CDCI3) : δ 6.58 (1H, d), 6.44 (1H, d), 4.68 (1H, d), 4.51
(1H, dd), 4.23 (1H, br t), 3.74 (3H, s), 3.60 (1H, m), 3.47 ( 1H, m) , 2 . 68 (1H, br t ) , 2 .39-2 . 02 (4H, m) , 2 .0-1. 5 (12H, m) , 1 . 45 ( 9H, s ) , 1 . 40-1 . 08 ( 6H, m) , 0 . 94 (12H, m) .
(1R,2R)-2-(((1S,2S)-1-hydroxy-2-amino-3-cyclohexyl)propyl)-cyclopentanecarbonyl-valyl valine methyl ester, hydrochloride c) The compound of Example 85(b) (9 mg, 15.5 mmol) was dissolved in neat trifluoroacetic acid and stirred for several min. The solution was evaporated under reduced pressure, the residue dissolved in MeOH, and treated with cone. HCl. Removal of the solvent in vacuo gave the titled compound.
Example 86 Preparation of (1R,2R) 2-(((1S.2S)-1-hydroxy-2- (serylalanylalanyl)amino-3-cyclohexyl)propyl)
cyclopentanecarbonyl-valyl valine methyl ester, hydrochloride
(1R,2R) 2-(((1S,2S)-]-hydroxy-2-(t-butyloxycarbonyl-(O-phenylmethyl)serylalanylalanyl)amino-3-cyclohexyl)propyl) cyclopentanecarbonyl-valyl valine methyl ester
a) To a solution of t-butyloxycarbonyl-(O-benzyl)serylalanyl alanine (6.6 mg, 15 mmol) in THF (0.5 ml) at -40°C under an argon atmosphere was added N-methyl morpholine (2.2 ml, 20 mmol) followed by isobutyl
chloroformate (2.0 ml, 15 mmol). The resulting mixture was stirred for 15 min, and additional N-methyl morpholine (2.2 ml, 20 mmol) was added followed by a solution of the compound of Example 85(c) (15 mmol) in THF (0.5 ml). The resulting mixture was allowed to warm to room temperature and stirred overnight. The mixture was partitioned between EtOAc and dilute HCl. The organic extract was washed with aqueous NaHCO3, saturated aqueous NaCl and dried (MgSO4). Filtration and removal of the solvent in vacuo gave a white solid (12 mg). The product was purified by flash chromatography eluting with 25:1 CHCI3 : MeOH to afford the titled compound as a colorless glass (6.2 mg, 46% yield).
NMR (CDCI3) : δ 7.35 (5H, m), 7.0-6.6 (5H, m), 5.49 (1H, br d), 4.54 (2H, s), 4.52-4.08 (5H, m), 3.99 (IH, br), 3.78 (2H, m), 3.72 (3H, s), 3.42 (IH, br t), 2.71 (IH, m), 2.20 (4H, m), 1.95-1.55 (12H, m), 1.46 (9H, s), 1.40 (6H, d), 1.35-1.06
(6H, m), 0.94 (12H, m) .
(1R,2R) 2-(((1S,2S)-1-hydroxy-2-(t-butyloxycarbonylserylalanyl-alanyl)amino-3-cyclohexyl])propyl)cyclopentanecarbonyl-valyl valine methyl ester
b) To a solution of 86(a) (6.2 mg, 6.9 mmol) in MeOH (1 ml) was added 10% palladium on activated carbon (5mg).
Hydrogen gas was introduced into the reaction mixture which was then maintained under 1 atm H2 for 6 h. The mixture was filtered through a pad of Celite®, and the solvent was removed in vacuo to afford the titled compound as a colorless glass (6 mg).
NMR (CDCI3/CD3OD) : δ 4.43 (1H, d), 4.38-4.05 (4H, m), 3.85
(2H, m), 3.73 (3H, s), 3.62 (1H, m), 3.45 (1H, m), 2.68 (1H, m), 2.30-2.05 (4H, m), 1.9-1.55 (12H, m), 1.46 (9H, s), 1.40 (6H, overlapping d's), 1.35-1.10 (6H, m), 0.94 (12H, m).
MS (FAB): m/z 811.5 (M+H)+.
(1R,2R) 2-(((1S,2S)-1-hydroxyl-2-(serylalanylalanyl)amino-3-cyclohexyl)propyl)cyclopentanecarbonyl-valyl valine methyl ester, hydrochloride
c) The compound of Example 86(b) (6 mg, 7 mmol) was dissolved in a few drops of trifluoroacetic acid. After stirring at room temperature for 40 min, the solution was diluted with MeOH and one drop of cone. HCl/dioxane was added. The resulting mixture was evaporated under reduced pressure to afford the titled compound.
NMR (CD3OD) : δ 4.50-4.15 (4H, m), 3.93 (4H, m), 3.71 (3H, s),
3.45 (1H, t), 2.65 (1H, m), 2.29 (1H, m), 2.2-2.0 (3H, m), 1.93-1.53 (12H, m), 1.5-1.1 (6H, m), 1.41 (3H, d), 1.35 (3H, d), 0.96 (12H, m).
MS (FAB): m/z 711.5 (M+H)+. Example 87
(4S,5S)-5-(methoxycarbonyl-alanylalanyl)amino-6-phenyl-4-hydroxy-(1-oxo)hexyl-valyl valine
(5S)-5-(tert-butyloxycarbonyl)amino-6-phenyl-(1.4-dioxo)hexyl-valyl valine benzyl ester
a) To a solution of (5S)-5-(tert-butyloxycarbonyl)amino-4-oxo-6-phenylhexanoic acid (160 mg, 0.500 mmol) and N-methyl morpholine (66 μl, 0.60 mmol) in THF (4 ml) at -40°C was added isobutyl chloroformate (65 μl, 0.50 mmol) over a 5 min period. After stirring an additional 15 min, more N-methylmorpholine (66 μl) was added, followed by valyl valine benzyl ester hydrochloride (205 mg, 0.60 mmol) in DMF (1.5 ml). The resulting mixture was allowed to slowly warm to room temperature and stirred for 15 h. The mixture was diluted with CHCI3 and washed with 10% HCl then H2O. The organic extract was evaporated under reduced pressure and the residue was purified by flash chromatography (25:1
CHCI3:MeOH) to provide the titled compound as a white solid (253 mg, 85% yield).
(4S,5S)-5-(tert-butyloxycarbonyl)amino-4-hydroxy-6-phenyl-(1-oxo)hexyl-valyl valine benzyl ester
b) The product of Example 87(a) (253 mg, 0.415 mmol) was dissolved in 5 ml MeOH, and NaBH4 (17 mg, 0.45 mmol) was added. After 20 min stirring, the mixture was diluted with 5% HCl and extracted with CH2CI2. The solvent was removed and the residue was purified by HPLC on silica eluting with 2% MeOH in CH2CI2 to provide the titled compound (75.6 mg), which eluted first, followed by the corresponding (4R) diastereomer (135 mg).
(4S,5S)-5-amino-4-hydroxy-6-phenyl-(1-oxo)hexyl-valyl valine benzyl ester hydrochloride
c) The product of Example 87 (b) (75 mg) was dissolved in TFA (0.5 ml). After 5 min MeOH (2 ml) was added followed by conc. HCl (50 μl). The solution was concentrated to a gum, triturated with ether and dried to yield a white powder (70 mg).
(4S,5S)-5-(methoxycarbonyl-alanylalanyl)amino-4-hydroxy-6-phenyl-(1-oxo)hexyl-valyl valine benzyl ester
d) To a solution of methoxycarbonylalanylalanine (29.7 mg, 0.136 mmol) and N-methyl morpholine (17 μl, 0.15 mmol) in THF (2 ml) at -40°C was added isobutyl chloroformate (17.6 μl, 0.136 mmol) over a 5 min period. After stirring an additional 15 min, itfore N-methylmorpholine (17 μl) was added, followed by a solution of (4S,5S)-5-amino-4-hydroxy-6-phenyl- (1-oxo)hexyl-valyl valine benzyl ester hydrochloride (68 mg, 0.124 mmol) in 2:1 THF:DMF (1.5 ml). The resulting mixture was allowed to slowly warm to room temperature and stirred for 15 h. The mixture was diluted with 9:1 CHCI3:MeOH and washed with 10% HCl then H2O. The organic extract was evaporated under reduced pressure to provide the titled compound as a white solid (95 mg).
TLC (9:1 CHCI3:MeOH): Rf = 0.5.
NMR (CD3OD/ CDCI3) : δ 7.4-7.25 (10H, m), 5.17 (2H, dd), 4.45
(1H, obsc), 4.30 (1H, m), 4.18-4.00 (3H, m), 3.69 (3H, s), 3.56 (1H, m), 2.88 (2H, ddd), 2.32 (2H, m), 2.19 (1H, m), 2.03 (1H, m), 1.72 (2H, m), 1.34 (3H, d), 1.28 (3H, d), 0.91 (12H, overlapping d's).
MS (FAB): m/z 712.4 (M+H)+. (4S,5S)-5-(methoxycarbonyl-alanylalanyl)amino-6-phenyl-4-hydroxy-(1-oxo)hexyl-valyl valine
e) To a mixture of the product of Example 87 (d) (85 mg, 0.12 mmol) in MeOH (5 ml) was added 10% palladium on
activated carbon (13 mg). Hydrogen gas was introduced into the reaction mixture which was then maintained under a hydrogen atmosphere for 3.5 h. The mixture was filtered through Celite® and evaporated under reduced pressure to afford the titled compound as a white solid (70.5 mg, 95% yield).
NMR (CD3OD) : δ 7.23 (5H, m), 4.37-4.00 (5H, m), 3.66 (3H, s),
3.58 (1H, m), 2.88 (2H, ddd), 2.32 (2H, m), 2.18 (1H, m), 2.06 (1H, m), 1.73 (2H, m), 1.32 (3H, d), 1.26 (3H, d), 0.95 (12H, m).
MS (FAB): m/z 622.3 (M+H)+. Example 88
Preparation of (4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-(1-oxo)hexyl-valyl valinol
To a solution of (4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-(1-oxo)hexyl-valyl valine methyl ester (4.8 mg) in 9 : 1 CHCI3:MeOH (1 ml) was added excess LiBH4 (ca. 5 mg). After 10 min the solution was diluted with 5% HCl, and extracted with 9:1 CHCI3:MeOH. The organic layer was washed with water and concentrated. The residue was purified by flash chromatography 9:1 CHCI3:MeOH) to provide the titled compound (1.9 mg) as a white solid.
NMR: (CD3OD/CDCI3) : δ 7.2-7.0 (10H, m), 4.93 (2H, d), 4.1
(1H, obsc), 4.00-3.80 (3H, m), 3.50-3.35 (4H, m), 2.68 (2H, ddd), 2.13 (2H, m), 1.92 (1H, m), 1.69 (1H, m), 1.54 (2H, m), 1.16 (3H, d), 1.08 (3H, d), 0.75 (12H, m).
MS (FAB): m/z 684.3 (M+H)+.
Example 89 Preparation of (4S,5S)-5-(4S,5S) 5- (carbobenzyloxyalanylalanyl)-amino-4-hydroxy-6-phenyl-(1- oxo)hexyl-valine isobutylamide
(5S)-5-(tert-butyloxycarbonyl)amino-4-oxo-6-phenylhexanoic acid benzyl ester
a) To a solution of (5S)-5-(tert- butyloxycarbonyl)amino-4-oxo-6-phenylhexanoic acid (1 mmol) in dry acetonitrile (10 ml) was added DBU (1 mmol) followed by benzyl bromide (1.5 mmol) with stirring. After 2 h the mixture was diluted with 5% HCl and extracted with CH2CI2. The organic layer was concentrated, and the residue was purified by flash chromatography (CHCI3) to provide the ester (370 mg). NMR (CDCI3) : δ 7.4-7.0 (10H, m), 5.10 (2H, s), 5.03 (1H, d), 4.51 (1H, q), 3.18-2.83 (2H, m), 2.73 (2H, m), 2.60 (2H, m), 1.39 (9H, s).
MS (FAB): m/z 412 (M+H)+.
(4S,5S)-5-(tert-butyloxycarbonyl)amino-4-(tert-butyldimethylsiloxy)-6-phenylhexanoic acid benzyl ester.
b) The product of Example 89(a) is reduced with NaBH4 in MeOH by the procedure of Example 87(b) (96 - 98% yield). The resulting crude diastereomeric mixture of alcohols is dissolved in DMF at a concentration of ca . 2M, and imidazole (2.4 equiv.) and tert-butyldimethylsilyl chloride (1.2 equiv.) are added. The mixture is stirred for 2 days, then diluted with water and extracted with ethyl acetate. The organic layer is dried (MgSO4) and concentrated. The residue is purified by flash chromatography (5:1 hexanes : EtOAc) followed by HPLC (15:1 hexanes :EtOAc) to provide the titled compound (25 % yield), which elutes first, followed by the corresponding (4R)-siloxy benzyl ester (70 % yield).
(4S)-isomer:
NMR (CDCI3) : δ 7.4-7.12 (10H, m), 5.08 (2H, s), 4.67 (1H, d), 3.85 (1H, q), 3.68 (1H, m), 2.72 (2H, m), 2.36 (2H, m), 1.78 (2H, m), 1.41 (9H, s), 0.88 (9H, s), 0.10 (6H, d).
MS (FAB): m/z 529 (M+H)+.
(4S,5S)-5-(tert-butyloxycarbonyl)amino-4-(tert-butyldimethylsiloxy)-6-phenylhexanoic acid
c) Hydrogenolysis of the product of Example 89(c) by the procedure of Example 87(e) provided the titled compound (99 % yield) as a crispy foam.
NMR (CDCI3) : δ 7.35-7.10 (5H, m), 4.69 (2H, br d), 3.88 (1H, q), 3.70 (1H, m), 2.72 (2H, m), 2.31 (2H, m), 1.78 (2H, m),
1.30 (9H, s), 0.89 (9H, s), 0.10 (6H, d).
MS (FAB): m/z 438.2 (M+H)+. (4S,5S)-5-(carbobenzyloxyalanylalanyl)amino-4-(tert-butyldimethylsiloxy)-6-phenyl-(1-oxo)hexyl-valine
isobutylamide
d) The product of Example 89(c) was coupled with valine isobutylamide hydrochloride by the procedure of Example 87 (a) to provide crude (4S,5S)-5-(tert-butyloxycarbonyl)amino-4- (tert-butyldimethylsiloxy)-6-phenylhexanoyl-valine
isobutylamide (80 % yield), which was converted directly to the corresponding hydrochloride by the procedure of Example 87 (c). The crude hydrochloride was in turn coupled to carbobenzyloxyalanine by the procedure of 1-step-1 followed by flash chromatography (20:1 CHCI3:MeOH) to yield the titled compound (60 % yield) as a white solid.
NMR (CDCI3) : δ 7.45-7.10 (10H, m), 6.38 (1H, m), 5.08 (2H, m), 4.21 (2H, m), 3.70 (1H, m), 2.73 (2H, m), 2.33 (1H, m), 2.12 (2H, m), 1.25 (4H, m), 0.91 (22H, m), 0.10 (6H, d).
MS (FAB): m/z 697.3 (M+H)+.
(4S,5S)-5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-6-Phenyl-(1-oxo)hexyl-valine isobutylamide
e) To the product of Example 89(d) in THF was added tetrabutylammonium bromide (5 equiv.). After stirring for 14 h, the mixture was diluted with water and extracted with dichloromethane. Removal of solvent afforded the titled compound as a white solid.
NMR (CDC13/CD3OD) : δ 7.28-7.05 (10H, m), 4.96 (2H, s), 4.02¬
3.76 (4H, m), 3.47 (1H, m), 2.9 -2.60 (4H, m), 2.13 (2H, m), 1.82 (1H, q), 1.55 (3H, m), 1.09 (4H, d), 0.70 (12H, d).
MS (FAB): m/z 583.3 (M+H)+.
Example 90
Preparation of (4RS, 5S)-5-((tert-butyloxycarbonyl)- isoleucyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl- aspartic acid methyl ester (5S)-5-(tert-butyloxycarbonyl)amino-7-methyl-4-oxo-octanoic acid
a) The titled compound was prepared by the procedures of examples 12(a,b), except using Boc-leucine N-methoxy-N-methyl amide in place of Boc-phenylalanine N-methoxy-N-methyl amide .
NMR (CDCI3) : δ 5.0 (1H, d), 4.35 (1H, m), 3.5 (1H, s), 2.8
(2H, m), 2.6 (3H, t), 1.5 (9H, s), 0.90 (8H, d). (5S)-5-(tert-butyloxycarbonyl)amino-7-methyl-(1,4)-dioxo-octyl-leucyl-(O-benzyl)aspartic acid methyl ester
b) The titled compound was prepared by the coupling procedure of Example 34 (a), using the product of Example 90(a) and leucyl-(O-benzyl)aspartic acid methyl ester
hydrochloride.
(4RS,5S)-5-(tert-butyloxycarbonyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl-(O-benzyl)aspartic acid methyl ester
c) The product of Example 90 (b) was reduced with excess NaBH3CN in acetic acid (2 days) to provide the titled compound as a 1:1 mixture of 4R and 4S diastereomers after aqueous workup and flash chromatography.
NMR (CDCI3) : δ 7.35 (5H, s), 7.05 (1H, d), 6.15 (1H, m),
5.15 (2H, s), 4.85 (2H, m), 4.55 (1H, d), 4.4 (1H, m), 3.65 (3H, s), 2.9 (2H, m), 2.4 (2H, t), 1.5 (9H, s), 0.90 (12H, m).
MS (FAB): 622.3 (M+H)+.
(4RS,5S)-5-((tert-butyloxycarbonyl)isoleucyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl-(O-benzyl)aspartic acid methyl ester
d) The titled compound was prepared from the product of Example 90(c) by the procedures of examples 76(b) and 77(a), except substituting Boc-isoleucine in place of Cbz-alanine. NMR (CDCI3) : δ 7.4 (5H, s), 7.0 (1H, d), 6.3 (0.5H, d), 6.2
(0.5H, d), 5.15 (2H, s), 5.05 (2H, m), 4.9 (1H, m), 4.5 (1H, m), 3.7 (3H, d), 3.0 (2H, m), 2.45 (3H, m), 1.5 (15H, s), 1.3 (15H, s), 0.90 (19H, m). MS (FAB) : 735 . 5 (M+H) + .
(4RS,5S)-5-((tert-Butyloxycarbonyl)isoleucyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl-aspartic acid methyl ester
e) The titled compound was prepared from the product of Example 90(d) by the procedure of example 77(b).
NMR: δ 4.55 (1H, t), 4.35 (1H, m), 3.8 (2H, m), 3.65 (3H, s),
3.45 (1H, m), 2.7 (1H, m), 2.5 (1H, m), 2.3 (2H, m), 1.4 (9H, s), 1.2 (6H, s), 0.90 (15H, m).
MS (FAB): 667.4 (M+Na)+; 643.5 (M-H)-.
Example 91
Preparation of (4R,5S) and (4S,5R)-carbobenzyloxy-alanyl-(3-hydroxy-5-amino-6-phenyl)hexanoyl-valyl-(4-aminomethyl)pyridine
Boc-valyl-(4-aminomethyl)pyridine
a) Boc-L-valine (5.0 g, 23 mmol) was dissolved in 100 ml CH2CI2 along with 4-amino-methylpyridine (2.5 g, 23 mmol).
Dicyclohexylcarbodiimide (4.75 g, 23 mmol) was added and the reaction allowed to stir overnight. The reaction mixture was filtered, washed with 1 N NaHCO3 (3 x 50 ml), water (1 x 50 ml) and dried over Na2SO4. The solvent was removed under reduced pressure and the residue was triturated with hexane, filtered and crystallized. The partially purified product was purified by passing it over a bed of silica gel in ethyl acetate. Evaporation of the solvent gave 3.64 g product as a white solid.
NMR (CDCI3) : δ 0.83 (d), 0.90 ( 6H, d), 1.30 (9H, s), 3.8-4.0
(1H, dd) 4.38 (2H, d), 5.2 (1H, d), 7.1 (d), 8.5 (4H, d).
(5S)-carbobenzyloxy-alanyl-(4-oxo-5-amino-6-phenyl)hexanoyl- valyl-(4-aminomethyl)pyridine
b) Boc-L-valyl-(4-aminomethyl)pyridine (2.0 g) was treated with 4 N HCl/dioxane at room temperature for 30 min,
evaporated to dryness and the residue dissolved in water, filtered and lyophilized to yield L-valyl-(4- aminomethyl) pyridine dihydrochloride salt.
L-valyl-(4-aminomethyl)pyridine dihydrochloride salt (0.16 g, 0.5 mmol) and Boc-4-oxo-5(S)-amino-6-phenylhexanoic acid were dissolved in 10 ml DMF. To this was added benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (0.332 g, 0.75 mmol), 1-hydroxybenzotriazole (.101 g, 0.75 mmol) and diisopropylethylamine (.097 g, 0.75 mmol) and the reaction mixture was stirred overnight at room temperature. Additional benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate (0.332 g, 0.75 mmol), 1-hydroxybenzotriazole (.101 g, 0.75 mmol) and
diisopropylethylamine (.097 g, 0.75 mmol) was added and the reaction allowed to proceed an additional 24 hr. at room temperature. After evaporation of solvent, the reaction mixture was dissolved in ethyl acetate, washed with 10%
K2CO3, saturated NaHSO4 and water, dried over Na2SO4 and concentrated to an oil. Purification on silica gel using 5% methanol/methylene chloride gave 99 mg (4S) Boc-(3-oxo-4-amino-5-phenyl)hexanoyl-valyl-(4-aminomethyl)pyridine.
The 5(S) Boc-(4-oxo-5-amino-6-phenyl)hexanoyl-valyl-(4-aminomethyl)pyridine from above was treated with 4 N
HCl/dioxane at room temperature for 30 min, evaporated to dryness and the residue dissolved in water, filtered and lyophilized to yield 70 mg (5S) 3-oxo-5-amino-6-phenyl)hexanoyl-valyl-(4-aminomethyl)pyridine dihydrochloride salt.
(5S) 3-oxo-5-amino-6-phenyl)hexanoyl-valyl-(4-aminomethyl)pyridine dihydrochloride salt (67 mg, 0.15 mmol) was dissolved in DMF along with carbobenzyloxy-L-alanine (51 mg, 0.23 mmol), benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluoro-phosphate (102 mg, 0.23 mmol), 1-hydroxybenzotriazole (31 mg, 0.23 mmol) and diisopropylethylamine (30 mg, 0.23 mmol) and the reaction was stirred at room temperature overnight. The reaction mixture was evaporated, dissolved in acetonitrile and purified by preparative hplc on Beckman Ultrasphere® ODS using a gradient of 10% acetonitrile-water-0.1% TFA to 50% acetonitrile-water0.1% TFA over 30 min. at 4 ml/min. The appropriate fractions were pooled, evaporated to dryness and lyophilized from 1% acetic acid to yield 29 mg of the desired product .
FAB-MS m/z 616.2 (M+H)+, 614.2 (M-H)-. (3R, 4S) and (3S, 4R)-carbobenzyloxy-alanyl-(3-hydroxy-4-amino-5-phenyl)hexanoyl-valyl-(4-aminomethyl)pyridine
c) (4S) carbobenzyloxy-alanyl-(3-oxo-4-amino-5-phenyl)hexanoyl-valyl-(4-aminomethyl)-pyridine (14) (20 mg, .033 mmol) was dissolved in 5 ml methanol and sodium
borohydride (1.4 mg,-.036 mmol) was added. After 30 min at room temperature, and additional 1 mg sodium borohydride was added and the reaction allowed to proceed an additional 30 min at room temperature. The solvent was removed by
evaporation and the residue dissolved in acetic acid and lyophilized. The diastereomeric mixture of alcohols was separated by prep hplc on Beckman Ultrasphere® ODS using 28.5% acetonitrile-71.5% water-0.1% TFA. The appropriate fractions were pooled, evaporated to dryness and lyophilized from 1% acetic acid to yield 7 mg isomer A and 6 mg isomer B. Isomer A:
FAB-MS m/z 618.5 (M+H)+, 616.4 (M-H)-.
HPLC: k' = 9.6 (Beckman Ultrasphere® ODS using a gradient of 10% acetonitrile-water-0.1% TFA to 50% acetonitrile-water0.1% TFA over 30 min.).
Isomer B:
FAB-MS m/z 618.5 (M+H)+, 616.4 (M-H)-.
HPLC: k' = 9.9 (Beckman Ultrasphere® ODS using a gradient of 10% acetonitrile-water-0.1% TFA to 50% acetonitrile-water0.1% TFA over 30 min.).
Example 92
Preparation of (3S)-Boc-valyl-4-methyl-3-aminopentan-2-one Boc-L-valine N,O-dimethylamide
a) Dimethylhydroxylamine hydrochloride (3.91 g, 40 mmol) was dissolved in 25 ml CH2CI2 and cooled to 0 ºC.
Triethylamine (4.14 g, 40 mmol) was added to give a thick suspension which was allowed to warm to room temperature.
Boc-L-valine (8.68 g, 40 mmol) was dissolved in 50 ml THF and 180 ml CH2CI2 and cooled to -20 ºC. N-Methylpiperidine (4.88 ml, 40 mmol) was added followed by ethyl chloroformate (4.34 g, 40 mmol). After 5 minutes, the dimethylhydroxylamine solution was added and the reaction was allowed to warm to room temperature. After 3 hours, the reaction mixture was washed with 1 N HCl (2 x 100 ml), 1 N NaOH (2 x 100 ml), dried over Na2SO4 and evaporated to a colorless oil which was used without further purification.
3(S)-4-methyl-3-t-butyloxycarbonylaminopentan-2-one
b) Boc-L-valine N,O-dimethylamide (2.6 g, 10 mmol) was dissolved in 30 ml diethyl ether and added dropwise to 17 ml of a 3 M solution of methylmagnesium bromide in diethyl ether (51 mmol). The reaction mixture was stirred for 3 hours at room temperature and then poured into ice-water, acidified to pH 2 with 1 N HCl and extracted with ethyl acetate (3 x 50 ml). The extracts were dried over Na2SO4 and concentrated to a colorless oil which was purified by silica gel
chromatography using 2% methanol/CH2Cl2 to give 1.74 g of the desired product.
NMR (CDCI3) : δ 0.82 (3H, d), 1.05 (3H, d), 1.45 (9H, s), 2.2
(3H, s) 4.3 (1H, m), 5.25 (1H, br.d).
(3S)-Boc-valyl-4-methyl-3-aminopentan-2-one
c) 4-Methyl-3(S)-t-butyloxycarbonylaminopentan-2-one is stirred with 4N HCl/dioxane at room temperature for 30 minutes, concentrated under high vacuum and then evaporated from CH2CI2 several times to remove residual HCl. The resulting hydrochloride salt is dissolved in CH2CI2 and neutralized with one equivalent of triethylamine. Boc-L-valine (one equiv.) and dicyclohexylcarbodiimide (one equiv.) are then added and the reaction is stirred at room
temperature overnight. The reaction mixture is filtered, washed with 1 N Na2CO3, dried over Na2SO4 and concentrated to yield the crude dipeptide, which is then purified by silica gel chromatography. (4S,5S)-benzyloxycarbonylalanyl-alanyl-(6-phenyl-5-amino-4-hydroxy-hexanoyl)-valyl-(4-methyl-3(S)-aminopentan-2-one)
d) The compound of Example 92 (c) is treated with 4N
HCl/dioxane at room temperature for 30 min, concentrated under high vacuum and evaporated from CH2CI2 several times to remove residual HCl to yield (3S) valyl-4-methyl-3-aminopentan—2-one, hydrochloride. Substituting this compound for valine isobutylamide in the procedure of Example 89 provides the titled compound.
Example 93
Preparation of-(5S) Boc-5-amino-6-phenyl-trans-hex-3-enoic acid monomethyl trans-3-hexenoic acid
a) Diazald® (21.4 g, 100 mmol) was dissolved in ether and added dropwise to a solution of KOH (5 g), water (8 ml) and ether (25 ml) at 65 ºC. The resulting diazomethane was distilled directly into a solution of β-trans-hydromuconic acid (10 g, 69 mmol). The solution was evaporated and the residue purified by flash chromatography on silica gel using 2% acetic acid/chloroform to give 1.24 g of the desired product.
NMR (CDCI3) : δ 10.85 (1H, s), 5.75 (2H, m), 3.68 (3H, s),
3.23 (4H, m).
(4S)-methyl 6-(2-oxo-4-(phenylmethyl)-3-oxazolidinyl)-trans- hex-3-enoate
b) Monomethyl trans-3-hexenoic acid (1.24 g, 7.8 mol) was dissolved in 50 ml THF along with triethylamine (1.42 ml, 10.2 mmol) and cooled to -78 ºC. Pivaloyl chloride (1.06 ml, 8.6 mmol) was added, the reaction stirred for 15 min at -78 ºC and then allowed to warm to 0 ºC for 45 min.
(S)-Benzyloxazolidinone (2.5 g, 14.1 mmol) was dissolved in 30 ml THF and cooled to -78 ºC under argon. Butyllithium (5.6 ml of 2.5 M in hexanes) was added slowly and the mixture stirred 5 min. The mixed anhydride from above was cooled to -78 ºC and the lithiated oxazolidinone was added via cannula. Reaction was stirred at -78 ºC for 15 min and then allowed to warm to room temperature over 1.5 hr. The reaction was quenched with 100 ml 1M NaHSO4 and the THF removed under reduced pressure. The aqueous residue was extracted with CH2CI2 and the combined extracts were washed with 0.25 M NaHSO4, dried over MgSO4 and evaporated to dryness. The crude product was purified by flash chromatography on silica gel in 30% ethyl acetate/hexane to give 1.40 g of the desired product.
NMR (CDCI3) : δ 7.3 (5H, m), 5.8 (2H, m), 4.7 (1H, m), 4.2
(2H, d), 3.62 (3H, s), 3.1 (6H, m).
FAB-MS, m/z 318 (M+H)+.
( 4S,5S)-methyl 6-(2-oxo-4-(phenylmethyl)-3-oxazolidinyl)-5- (phenylmethyl)-trans-hex-3-enoate
c) The oxazolidinone from Example 93(b) (3.9 mmol) was dissolved in 50 ml THF and cooled to -78 ºC. Potassium hexamethyldisilazide (7.8 ml of 0.5 M in THF, 3.9 mmol) was added and the mixture stirred at -78 ºC for 15 min. Benzyl bromide (0.93 ml, 7.8 mmol) was added and the mixture was allowed to warm to room temperature and stir overnight. The reaction mixture was concentrated and the residue purified by gravity chromatography on silica gel using 20% ethyl
acetate/hexane to yield 0.38 g of the desired product (and
0.09 g of the 5 (R) isomer).
NMR (CDCI3) : δ 7.27 (10H, m), 7.0 (2H, m), 5.73 (2H, m), 4.75
(3H, m) 4.05 (2H, m), 3.60 (3H, s), 3.0 (7H, m).
FAB-MS: m/z 408 (M+H)+.
(5S)-monomethyl 5-(phenylmethyl)-trans-hex-3-enoate
d) The alkylated oxazolidinone of Example 93(c) (0.38 g, 0.93 mmol) was dissolved in 13.9 ml THF and 4.6 ml water and cooled to 0ºC. Hydrogen peroxide (0.63 ml of 30% solution) was added followed by lithium hydroxide (78.1 mg, 2 equiv.) After stirring at 0 ºC for 30 min., the reaction was quenched by the addition of 4.5 ml 1.5 M Na2SO3. The THF was removed under reduced pressure and the pH of the aqueous solution was adjusted to 10 with NaHCO3 and washed with ethyl acetate and ether. The pH was then lowered to 1 with 1 M HCl and
extracted with ethyl acetate. The extracts were combined, dried over Na2SO4 and evaporated to give the crude product. Purification by flash chromatography on silica gel using 2% acetic acid: chloroform gave 50 mg of the desired product.
NMR (CDCI3) : δ 9.43 (1H, s), 7.25 (5H, m), 5.64 (2H, m), 3.65
(3H, s), 3.05 (5H, m).
(5S)-monomethyl 5-(phenylmethyl)-trans-hex-3-enamide
e) The carboxylic acid of Example 93(d) (50 mg, 0.2 mmol) was dissolved in 3 ml toluene and cooled to -5 ºC.
Triethylamine (28 ml, 0.2 mmol) was added followed by ethyl chloroformate (16 ml, 0.2 mmol). After stirring one hr at -5 ºC, ammonia was bubbled into the solution which was then allowed to warm to room temperature and stir for 2 days. The solution was evaporated and the residue dissolved in ethyl acetate, washed with 0.5 M NaHCO3 and dried over MgSO4.
Evaporation of the solvent gave 50 mg of the desired product. NMR (CDCI3) : δ 7.25 (5H, m), 5.84 (2H, m), 3.68 (3H, s), 3.0
(5H, m).
(5S)-methyl 5-amino-6-phenyl-trans-hex-3-enoate
f) The carboxamide of Example 93(e) is dissolved in acetonitrile-water (4:1) and I,I-bis(trifluoro-acetoxy)iodosobenzene (1.5 equiv.) is added and the reaction is stirred at room temperature until complete. The reaction mixture is acidified to pH 2 with 1 N HCl and washed with ether. The pH of the aqueous solution is then adjusted to 10 with IN NaOH and the product is extracted with ethyl acetate. The extracts are dried over Na2SO4 and evaporated to give the desired product. (5S)-methyl 5-t-butyloxycarbonylamino-6-phenyl-trans-hex-3- enoate
g) The compound of Example 93 (f) is dissolved in DMF along with triethylamine (3 equiv.). Di-t-butyldicarbonate (3 equiv.) is added and the reaction allowed to proceed at room temperature overnight. The solvent is removed under reduced pressure and the product is purified by flash chromatography on silica gel.
(5S)-Boc-5-amino-6-phenyl-trans-hex-3-enoic acid
h) The compound of Example 93 (g) is dissolved in 1 : 1 dioxane:l N NaOH (1 equiv. NaOH) and stirred at room
temperature until the reaction is complete. The solution is acidified with 1 N HCl and extracted with ethyl acetate to yield the desired product.
Example 94 Preparation of (5S)-alanyl-alanyl-(5-amino-6-phenyl-trans-hex-3-enoyl)-valyl-valinamide
The protected peptidyl resin (5S) Boc-Ala-Ala-(5-amino-6-phenyl-trans-hex-3-enoyl)-Val-Val-BHA is prepared according to the usual method of Example 1. The peptidyl resin is cleaved and deprotected by treatment with 10 ml anhydrous liquid HF/1 ml anisole at 0 ºC for 1 hour. After removal of the HF under vacuum, the resin is washed with diethyl ether, air dried and extracted with 2 x 50 ml glacial acetic acid, which is lyophilized to yield the crude peptide. The crude product is purified by gel filtration on Sephadex® G-15 using 10% aqueous acetic acid as eluant.
Example 95 Preparation of Asn-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Boc-Asn-Tyr(BrZ)-Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and
lyophilized to yield 145 mg crude product. The crude peptide (100 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 84.4 mg purified product.
HPLC: k' = 2.95 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, Ϊ5 min.).
MS (FAB): m/z 590 (M+H)+
Example 96
Preparation of Ala-Asn-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Boc-Ala-Asn-Tyr(BrZ)-Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 136.6 mg crude product. The crude peptide was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 116.7 mg of purified product. HPLC: k' - 2.47 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.).
MS (FAB): m/z 661 (M+H)+
Example 97
Preparation of Ser-Gln-Asn-Tyr-Pro-Val-Val
The protected peptidyl resin BocSer(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-Val-Val-Merrifield resin was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 248.8 mg crude product. The crude peptide (90 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 58.8 mg purified product.
HPLC: k' = 2.86 (Hamilton PRP-1®, 10% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.). MS (FAB): m/z 806 (M+H)+
Example 98
Preparation of Ser-Gln-Asn-Cha-Pro-Val-Val-NH2
The protected peptidyl resin Boc-Ser(Bzl)-Gln-Asn-Cha- Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the
HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 316 mg crude product. The crude peptide (100 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 88.1 mg purified product.
HPLC: k' = 3.31 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 795 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser 0.72, Glu 1.02, Pro 0.97,
Val 2.01.
Example 99
Preparation of Ac-Ser-Gln-Asn-Cha-Pro-Val-Val-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Asn-Cha-Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 280 mg crude product. The crude peptide (100 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 74.1 mg
purified product.
HPLC: k' = 3.27 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB) : m/z 837 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser 0.75, Glu 0.99, Pro 0.96, Val 1.90.
Example 100
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-Val-BHA was prepared in the usual manner on a
1.0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 145 mg of crude product. The crude peptide (130 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 101 mg of purified product.
MS (FAB) : m/z 748.7 (M+H)+
HPLC: k' = 2.08 (Hamilton PRP-1®, 5% CH3CN/0.1% TFA to 40% CH3CN/0.1% TFA, 15 min.).
Amino Acid Analysis: Asp 1.00, Ser 0.55, Glu 0.98, Pro 1.19, Val 0.95, Tyr 0.99.
Example 101
Preparation of Ac-Asp-Gln-Asn-Tyr-Pro-Val-Arg-NH2
The protected peptidyl resin Ac-Asp(OBzl)-Gln-Asn- Tyr(BrZ)-Pro-Val-Arg(Tos)-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 404 mg crude product. The crude peptide (100 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 84.2 mg partially purified product. The partially purified peptide was further purified by preparative hplc (Hamilton PRP-1®, 11% CH3CN/ 0.1% TFA) to yield 78.8 mg purified product.
HPLC: k' = 2.04 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB) : m/z 932 (M+H)+
Amino Acid Analysis: Asp 1.88, Glu 0.90, Pro 0.76, Val 1.00, Tyr 0.33, Arg 1.01.
Example 102
Preparation of Asp-Gln-Asn-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Boc-Asp(OBzl)-Gln-Asn-Tyr(BrZ)-Pro-Val-Val-BHA was prepared in the usual manner on a 1.0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 671 mg crude product. The crude peptide (100 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 74.5 mg purified product.
HPLC: k' = 2.44 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0 . 1% TFA, 15 min . )
MS (FAB) : m/z 833 (M+H) +
Amino Acid Analysis: Asp 2.00, Glu 0.98, Pro 0.96, Val 2.04, Tyr 0.34.
Example 103
Preparation of Ac-Ala-Ala-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Ac-Ala-Ala-Ser(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield the crude
product. Example 104
Preparation of Ac-Ala-Gln-Gly-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Ac-Ala-Gln-Gly-Tyr(BrZ)- Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the
HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 275 mg crude product. The crude peptide was purified by countercurrent distribution using the system n-BuOH-HOAc-H2O 4:1:5, yielding 235 mg purified product.
HPLC: k' = 4.48 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1%
TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB) : m/z 831 (M+H)+
Amino Acid Analysis: Asp 1.02, Glu 1.00, Pro 0.97, Val 1.23,
Tyr 0.87, Ala 1.04.
Example 105
Preparation of D-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Boc-D-Ser(Bzl)-Gln-Asn- Tyr(BrZ)-Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 271 mg crude product. The crude peptide (98 mg) was dissolved in 10% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 73 mg purified product.
HPLC: k' = 4.45 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 805 (M+H)+
Amino Acid Analysis: Asp 1.00, Glu 0.99, Pro 1.11, Val 1.89, Tyr 0.57, Ser 0.68.
Example 106
Preparation of Ac-D-Ser-Gly-Asn-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Ac-D-Ser(Bzl)-Gly-Asn-Tyr(BrZ)-Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 248 mg crude product. The crude peptide (93 mg) was dissolved in 10% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 75 mg purified product.
HPLC: k1 = 4.16 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 847 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser 0.67, Glu 0.99, Pro 0.93, Val 2.00, Tyr 0.30.
Example 107
Preparation of Ser-Gln-Asn-Tyr-Pro-Ala-Val-NH2
The protected peptidyl resin Boc-Ser(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-Ala-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 202 mg crude product. The crude peptide (102 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 74 mg purified product.
HPLC: k' = 3.96 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 777 (M+H)+
Amino Acid Analysis: Asp 1.05, Ser 0.91, Glu 1.00, Ala 1.02, Pro 0.86, Val 1.09, Tyr 0.61.
Example 108 Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Gly-Val-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-Gly-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 153 mg crude product. The crude peptide (100 mg) was dissolved in 10% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 76 mg purified product.
HPLC: k' = 3.87 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB) : m/z 805 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser 0.84, Glu 0.95, Gly 1.00, Pro 0.97, Val 1.06, Tyr 0.77.
Example 109 Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-Arg-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Asn- Tyr(BrZ)-Pro-Val-Val-Arg(Tos)-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 329 mg of crude product. The crude peptide was purified by countercurrent distribution in the system n-BuOH-HOAc-H2O 4:1:5. The appropriate fractions were pooled and lyophilized to yield 172 mg of purified product.
MS (FAB): m/z 1003 (M+H)+
HPLC: k' = 3.71 (Beckman Ultrasphere® Ci8, 5% CH3CN/0.1% TFA to 40% CH3CN/0.1% TFA, 15 min.).
Amino Acid Analysis: Asp 1.00, Ser 0.73, Glu 0.98, Pro 0.98, Val 1.84, Tyr 1.01, Arg 0.99. Example 110
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Glu-Val-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-Glu(OBzl)-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 184 mg crude product. The crude peptide (92 mg) was dissolved in 10% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 64 mg purified product.
HPLC: k' = 3.83 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 877 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser 0.77, Glu 2.03, Pro 0.87, Val 1.08, Tyr 1.01. Example 111
Preparation of Ser-Gln-Asn-Tyr-Pro-Glu-Val-NH2
The protected peptidyl resin Boc-Ser(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-Glu(OBzl)-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 216 mg crude product. The crude peptide (91 mg) was dissolved in 10% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 67 mg purified product.
HPLC: k' = 3.35 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB) : m/z 835 (M+H)+
Amino Acid Analysis: Asp 0.97, Ser 0.90, Glu 2.03, Pro 1.00, Val 0.84.
Example 112
Preparation of Ac-Ser-Gln-Gly-Tyr-Pro-Lys-Val-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Gly- Tyr(BrZ)-Pro-Lys (CI2Z)-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 280 mg crude product. The crude peptide was purified by countercurrent distribution using the system n-BuOH-HOAc-H2O 4:1:5, yielding 242 mg purified product.
HPLC: k' = 4.41 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 876 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser 0.68, Glu 1.01, Pro 0.82, Val 1.14, Tyr 1.06, Lys 1.00.
Example 113
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Asn- Tyr(BrZ)-Pro-BHA was prepared in the usual manner on a 1 . 0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 400 mg crude product. The crude peptide (100 mg) was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 92.8 mg of purified product.
MS (FAB): m/z 649 (M+H)+
HPLC: k' = 1.57 (Hamilton PRP-1®, 5% CH3CN/0.1% TFA to 40% CH3CN/0.1% TFA, 15 min.).
Amino Acid Analysis. Asp 1.00, Ser 0.92, Glu 1.03, Pro 0.87, Tyr 0.95.
Example 114
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-Val-Gln-Asn-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-Val-Val-Gln-Asn-BHA was prepared in the usual manner on a 1.0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 862 mg of crude product. The crude peptide was purified by
countercurrent distribution in the system n-BuOH-HOAc-H2O 4:1:5. The appropriate fractions were pooled and lyophilized to yield 713 mg of purified product.
MS (FAB): m/z 1089 (M+H)+
HPLC: k' = 2.17 (Hamilton PRP-1®, 5% CH3CN/0.1% TFA to 40% CH3CN/0.1% TFA, 15 min.).
Amino Acid Analysis: Asp 1.81, Ser 0.97, Glu 2.00, Pro 0.88, Val 1.81, Tyr 1.23.
Example 115
Preparation of Ac-Ser-Gln-Asn-Phe-Pro-Val-Val-NH2
The protected peptidyl resin Ac-Ser(Bzl)-Gln-Asn-Phe-Pro-Val-Val-BHA was prepared in the usual manner on a 1.0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 573 mg of crude product . The crude peptide (30 mg) was by preparative hplc (Hamilton PRP1®, 17% CH3CN/0.1 % TFA) to give 24.5 mg of purified product. MS (FAB): m/z 831 (M+H)+
HPLC: k' = 3.02 (Hamilton PRP-1®, 5% CH3CN/0.1% TFA to 40% CH3CN/0.1% TFA, 15 min.).
Amino Acid Analysis: Asp 1.06, Ser 0.86, Glu 1.00, Pro 1.02, Val 1.95, Phe 1.00.
Example 124
Preparation of Boc-L-valine isopropylamide
Boc-L-Valine (0.5 g, 2.3 mmol) was dissolved in 25 ml
DMF along with isopropylamine (0.39 ml, 4.6 mmol),
benzotriazol-1-yloxytris(dimethylamino)-phosphonium
hexafluorophosphate (2.03 g, 4.6 mmol), 1-hydroxybenzotriazole (0.62 g, 4.6 mmol) and
diisopropylethylamine (1.2 ml, 6.9 mmol). The reaction was stirred at room temperature for 2 hr. then evaporated to dryness. The residue was dissolved in ethyl acetate and washed with 1 N NaHSO4, 1 N NaHCO3 and water and then dried over Na2SO4. THe solvent was removed under reduced pressure to give 0.53 g crude product. The product was purified by flash chromatography on silica gel using 25% MeOH/CHCI3 to yield 358 mg purified product.
MS (DCI), m/z 259 (M+H)+
NMR (CDCI3) : δ 0.90 ppm, d, 0.98 ppm d, 6H; 1.16 ppm, d, 6H; 1.35 ppm, s, 9H; 4.1 ppm, dd, 1H; 5.25 ppm, d, 1H; 6.14 ppm, d, 1H.
Example 117 Preparation of Ac-Tyr-Pro-Val-Val-NH2
The protected peptidyl resin Ac-Tyr (BrZ)-Pro-Val-Val-BHA was prepared in the usual manner on a 0.5 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and
lyophilized to yield 98.7 mg crude product. The crude peptide was dissolved in 1% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 78.5 mg purified product. HPLC: k' = 2.96 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.).
MS (FAB): m/z 518 (M+H)+
Example 118
Preparation of Ac-Arg-Ala-Ser-Gln-Asn-Tyr-Pro-NH2
The protected peptidyl resin Ac-Arg(Tos)-Ala-Ser(Bzl)-Gln-Asn-Tyr(BrZ)-Pro-BHA was prepared in the usual manner on a 1.0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 621 mg crude product. The crude peptide was purified by countercurrent distribution in the system n-BuOH-EtOAc-HOAc-H2O 2:2:1:5. The appropriate fractions were pooled and lyophilized to yield 549 mg partially purified product. This partially purified peptide (100 mg) was dissolved in 10% HOAc and purified on a 2.6 x 70 cm Sephadex® G-15 column. The appropriate fractions were pooled and lyophilized to yield 94 mg of purified product.
MS (FAB): m/z 876 (M+H)+
HPLC: k' = 2.78 (Beckman Ultrasphere® C18, 5% CH3CN/0.1% TFA to 40% CH3CN/0.1% TFA, 15 min.).
Amino Acid Analysis: Asp 1.00, Ser 1.03, Glu 1.01, Pro 0.91, Ala 1.02, Arg 0.99, Tyr 0.94. Example 119
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro
The protected peptidyl resin Ac-Ser(Bzl)-Gln-AsnTyr(BrZ)-Pro-Merrifield resin was prepared in the usual manner on a 1.0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 458.5 mg crude product, which was used without further
characterization.
Example 120
Preparation of Ac-Ser-Gln-Asn-Tyr-Pro-Val-HNiPr
Boc-Val isopropylamide 1034 (24.4 mg, 154 mmol) was deprotected by treatment with 50% TFA/CH2CI2 for 20 min at room temperature. The reaction mixture was evaporated to dryness and the residue evaporated from CH2CI2 six times, treated with 7% diisopropyl-amine/CH2Cl2 and evaporated three times and then evaporated from CH2CI2 four times. The residue was dissolved in 25 ml DMF along with the peptide 1035 (50 mg, 77 mmol), benzotriazol-1- yloxytris(dimethylamino)phosphonium hexafluorophosphate (68 mg, 154 mmol), 1-hydroxybenzotriazole (20.8 mg, 154 mmol) and diisopropylethylamine (40.2 ml, 231 mmol) and the reaction was allowed to proceed overnight at room temperature. The reaction mixture was evaporated to dryness and the residue dissolved in MeOH and purified by preparative hplc (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.) to give 41 mg purified peptide.
HPLC: k' = 4.97 (Beckman Ultrasphere® ODS, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 790.5 (M+H)+
Amino Acid Analysis: Asp 1.00, Ser 0.72, Glu 1.02, Pro 1.13, Val 0.65, Tyr 0.83. Example 121
Preparation of Ac-Arg-Lys-Ile-Leu-Phe-Leu-Asp-Gly-NH2
The protected peptidyl resin Boc-Arg(Tos)-Lys(Cl2Bzl)- Ile-Leu-Phe-Leu-Asp(OBzl)-Gly-BHA was prepared in the usual manner on a 1.0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 520 mg crude product. The crude peptide was purified by countercurrent distribution in the system n-BuOH-HOAc-H2O 4:1:5. The appropriate fractions were pooled and lyophilized to yield 440 mg partially purified product. The partially purified peptide (50 mg) was further purified by preparative hplc (Hamilton PRP-1®, 23% CH3CN/ 0.1% TFA) to yield 37.5 mg purified peptide.
HPLC: k' = 3.81 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 1002 (M+H)+
Amino Acid Analysis: Asp 1.00, Gly 1.05, Ile 0.91, Leu 2.08, Lys 0.94, Arg 1.07, Phe 1.29.
Example 122
Preparation of Ac-Arg-Lys-Ile-Leu-(4'NO2)Phe-Leu-Asp-Gly-NH2 The protected peptidyl resin Ac-Arg(Tos)-Lys(CI2Z)-Ile-Leu-(4'NO2)Phe-Leu-Asp(OBzl)-Gly-BHA was prepared in the usual manner on a 1.0 mmol scale. The peptide was cleaved from the resin with anhydrous liquid HF at 0 ºC for 1 hr. After removal of the HF, the resin was washed with ether, air-dried and extracted with 3 x 30 ml 10% HOAc. The HOAc extracts were diluted with water and lyophilized to yield 980 mg crude product. The crude peptide was purified by
countercurrent distribution using the system n-BuOH-HOAc-H2O 4:1:5, yielding 853 mg partially purified product. The partially purified peptide (50 mg) was further purified by preparative hplc (Hamilton PRP-1®, 23% CH3CN/ 0.1% TFA) to give 43.4 mg purified peptide.
HPLC: k' = 3.87 (Hamilton PRP-1®, 5% CH3CN/ 0.1% TFA to 40% CH3CN/ 0.1% TFA, 15 min.)
MS (FAB): m/z 1047.7 (M+H)+
Amino Acid Analysis: Asp 1.00, Gly 1.04, Ile 0.89, Leu 2.00, Arg 0.91, (4'N02)Phe 0.97, Lys 0.91.
Example 123 Preparation of (4S,5S)-4-(tert-butyldimethylsiloxy)-5-(tert-butyloxycarbonyl)-amino-6-phenylhexanoic acid
(S)-tert-butyloxycarbonylphenylalanine N-methoxy-N-methyl amide.
a) The titled compound was prepared by following the procedure of Pro. Syn., 67, 69 (1988), except using Boc-(L)-Phe in place of Boc-(L)-Leu.
[a] 365 = + 34° (c 1, ethanol). (6S)-5-oxo-6-(tert-butyloxycarbonyl)amino-7-phenylhept-1-ene b) A flame-dried, 2-liter 3-neck flask fitted with mechanical stirrer, thermometer, condenser, Ar bubbler, and addition funnel containing neat 4-bromo-1-butene (90.2 ml, 0.889 mol), was charged with Mg powder (32 g, 1.3 mol), and dry ether (600 ml). A 2 ml portion of the bromobutene was added, and the stirring mixture was warmed to 30°C with a water bath until the reaction initiated (ca. 5 min). The remainder of the bromobutene was then added over 1.5 hr, at a rate such that a gentle reflux was maintained. The mixture was heated to reflux for an additional 30 min, then was cooled to 5°C. A solution of the compound of Example 123(a) (54.0 g, 0.175 mol) in ether (130 ml) was added in portions over 15 min, with the reaction temperature maintained below 12°C. After 1 hr vigorous stirring at 5°C, the mixture was poured cautiously into 500 ml cold (5-10°C) 3N HCl. The layers were separated and the aqueous layer was extracted with two 200 ml portions of ether. The combined organic layers were washed with 5% NaHCO3 and brine, then were dried over MgSO4, filtered and concentrated by rotary evaporation to afford the crude product (49.4 g, 0.163 mol, 93% yield) as a white solid, sufficiently pure for use in the next
reaction. A portion of the product was purified by flash chromatography (silica, 10% ethyl acetate in hexanes) for analysis.
mp: 74-75°C.
[a]D = -36.8° (c 1, ethanol). (5S)-4-oxo-5-(tert-bu_tyloxycarbonyl)amino-6-phenylhexanoic acid
c) The compound of Example 123(b) (45.0 g, 0.148 mol) was rapidly stirred with benzene (550 ml), water (550 ml) and acetic acid (115 ml) at 3°C. Tetrabutylammonium bromide (490 mg) was added, followed by KMnO4 (83 g). The stirring mixture was allowed to warm to room temperature. After 2.5 hr more KMnO4 (14 g) was added. After an additional 30 min, the reaction mixture was cooled to 5°C and 500 ml saturated aqueous KHSO4 was added. The mixture was stirred 30 min, then filtered. The layers were separated, the aqueous layer was extracted with four 200 ml portions of ethyl acetate. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated to an oil. The oil was crystallized from 350 ml of 6:1 hexane: ethyl acetate to provide the titled compound (33.3 g, 70% yield) as a white solid.
[a.D = -36.1°.
(5S)-4-oxo-5-(tert-butyloxycarbonyl)amino-6-phenylhexanoic acid, benzvl ester.
d) To a stirred solution of the compound of Example 123(c) (33.2 g) in acetonitrile (500 ml) at 4°C was added diazabicycloundecane (15.7 g), followed by benzyl bromide (26.0 g). The mixture was stirred with warming to room temperature for 3 hr, then was concentrated to 70 ml by rotary evaporation. The mixture was diluted with CH2CI2, washed with 1 N HCl, 5% NaHCO3, and brine, dried over MgSO4 and concentrated to a yellow solid. The solid was triturated with 3:1 ether: hexane to provide the titled compound (33.0 g, 78% yield).
mp: 86-87.5°C.
[a.D = -27.8º (4S,5S)-4-(tert-butyldimethylsiloxy)-5-(tert-butyloxycarbonyl)amino-6-phenylhexanoic acid benzyl ester.
e) A solution of the compound of Example 123 (d)
(28.0 g) in methanol (840 ml) was cooled to 5°C, and NaBH4 (1.30 g) was added in one portion with stirring. After 30 min acetic acid (10 ml) was added and the mixture was
concentrated by rotary evaporation, then diluted with CH2CI2 and washed with water. The organic layer was dried (Na2SO4) and concentrated to provide the crude diastereomeric alcohols as a white solid (27.7 g, 99% yield). The crude alcohols were dissolved in DMF (140 ml) along with imidazole (17.7 g) and tert-butyldimethylsilyl chloride (20.7 g). The mixture was allowed to stand at room temperature for 3 days, then was diluted with 500 ml cold IN HCl and extracted with six 100 ml portions of CH2CI2. The combined organic extracts were washed with 3x100 ml water, dried (Na2SO4) and concentrated under vacuum with warming to 40°C to provide an oil (42 g). The two isomers were separated by preparative HPLC in four equal portions on 2.5 Kg (3 in x 1 m) Vydac HS silica using 90:10 hexane ethyl acetate at 200 ml/min to provide 9.0 g of the titled compound as an oil.
HPLC: RT 9.18 min (4S isomer), 12.2 min (4R isomer) (YMC silica A-003, 4.6 mm x 25 cm, UV detection at 254 nm, 91:9 hexane:ethyl acetate, 1.0 ml/min), (4R) : (4S) = 3:1.
[a.D = -14.4º
(4S,5S)-4-(tert-butyldimethylsiloxy)-5-(tert- butyloxycarbonyl)-amino-6-phenylhexanoic acid
f) The compound of Example 123(e) (7.7 g) was dissolved in ethyl acetate (150 ml) with 5% Pd on carbon (0.75 g) and shaken under 25 psi H2 for 4 hr. The mixture was filtered through Celite® and concentrated under vacuum with warming to provide the titled compound as a colorless glass (6.3 g, 98 % yield).
[a]D = -24.7º
Example 124
Preparation of (5S)-benzyloxycarbonylalanyl-alanyl-(5-amino-6-phenyl-trans-hex-3-enoyl)-valyl-valinamide
The compound of Example 94 is dissolved in DMF to which is added 2 equiv. of triethylamine and 1.5 equiv. N- (benzyloxycarbonyloxy) succinimide. The extent of reaction is monitored by hplc and the product is purified directly from the reaction mixture by preparative hplc using an
acetonitrile-water-0.1% trifluoroacetic acid system on a Hamilton PRP-1® polystyrene column.
Example 125
Preparation of (5S)-benzyloxycarbonylalanyl-alanvl-(5-amino-6-phenyl-cis-3.4-dihydroxy-hexanoyl)-valyl-valinamide
The compound of Example 124 is dissolved in THF along with N-methylmorpholine N-oxide (3 equiv.) Osmium tetroxide (0.04 equiv. of a 2.5% solution in t-butanol) is added and the reaction allowed to proceed at room temperature. When the reaction is complete, the reaction mixture is partitioned between ethyl acetate and brine, the brine back-washed with ethyl acetate and the combined ethyl acetate layers are washed with 10% Na2SO3, 1 N NaHSO4, dried over Na2SO4 and evaporated to give the crude product as a mixture of
diastereomeric cis alcohols. The products are purified by preparative hplc using an acetonitrile-water-0.1%
trifluoroacetic acid system on a Hamilton PRP-1® polystyrene column. Example 126
Preparation of (4S,5S)-alanylalanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-valine
The protected peptidyl resin (4S,5S) Boc-Ala-Ala-(6-phenyl-5-amino-4-t-butyldimethyl-silyloxyhexanoyl)-Val-Val- Merrifield resin is prepared on the according to the usual method. The peptidyl resin is cleaved and deprotected by treatment with 10 ml anhydrous liquid HF/1 ml anisole at 0 ºC for 1 hour. After removal of the HF under vacuum, the resin is washed with diethyl ether, air dried and extracted with 2 x 50 ml glacial acetic acid, which is lyophilized to yield the crude peptide. The crude product is purified by gel filtration on Sephadex® G-15 using 10% aqueous acetic acid as eluant.
Example 127
(4S,5S)-benzvloxycarbonylalanyl-alanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-valine
The compound of Example 126 is dissolved in DMF to which is added 2 equiv. of triethylamine and 1.5 equiv. N- (benzyloxycarbonyloxy) succinimide. The extent of reaction is monitored by hplc and the product is purified directly from the reaction mixture by preparative hplc using an
acetonitrile-water-0.1% trifluoroacetic acid system on a Hamilton PRP-1® polystyrene column.
Example 128 Preparation of (4S,5S)-benzyloxycarbonylalanyl-alanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-valyl-(5- aminopentyl)amide mono-Boc-1,5-diaminopentane
a) A solution of 1,5-diaminopentane (14.0 ml, 120 mmol) in 70 ml CH2CI2 was treated with di-t-butyldicarbonate (7.24 g, 33.2 mmol) at 0 ºC and was then stirred overnight at room temperature. The reaction mixture was diluted with 75 ml CHCI3, washed with 5% aqueous sodium carbonate, dried over MgSO4 and evaporated. The residue was dissolved in a minimum volume of 1 N HCl (10 ml) and washed with diethyl ether. The aqueous layer was then basified to pH 10 with 2 N NaOH and extracted with ethyl acetate. The extracts were combined, dried over MgSO4 and evaporated to give 1.6 g of the desired product.
NMR (CDCI3) : δ 1.43 (17 H, br.s), 2.53-2.83 (2 H, m), 2.90¬
3.10 (2H, m), 4.80-5.10 (1 H, br.s).
MS (CD: m/z 237 (M+.Cl)-.
(4S,5S)-benzyloxycarbonylalanyl-alanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-valyl-(5-aminopentyl) amide
b) The compound of Example 126 is dissolved in DMF with mono-Boc-1, 5-diamino-pentane (3 equiv.), 1-hydroxybenzotriazole (1.5 equiv.) and diisopropylcarbodiimide (1.5 equiv.) and the reaction is stirred at room temperature and monitored by hplc. When the reaction is complete, the reaction mixture is evaporated to dryness and the residue treated with trifluoroacetic acid at 0 ºC for 30 minutes. The trifluoroacetic acid is removed under reduced pressure and the residue is dissolved in methanol and purified by reverse phase hplc using an acetonitrile-water-0.1%
trifluoroacetic acid system on a Hamilton PRP-1® polystyrene column.
Example 129
Preparation of (4S,5S)-benzyloxycarbonylalanyl-alanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-valyl-(5-guanidinopentyl)amide
The compound of Example 128 is dissolved in water and the pH adjusted to 10 with 3 N NaOH. After cooling to 0 ºC, an aqueous solution of O-methylisourea sulfate adjusted to pH 10 with 3 N NaOH is added. The reaction is monitored by hplc and the pH continually adjusted to 10 with the addition of 3 N NaOH. After completion of the reaction, the pH is lowered to 4.5 by the addition of 1% acetic acid and the product is purified by reverse phase hplc using an acetonitrile-water0.1% trifluoroacetic acid system on a Hamilton PRP-1®
polystyrene column. Example 130
Preparation of (4S,5S)-alanyl-alanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-valinamide
The protected peptidyl resin (4S,5S) Boc-Ala-Ala-(6-phenyl-5-amino-4-t-butyldimethyl-silyloxyhexanoyl)-Val-Val-BHA is prepared according to the usual method of Example 1. The peptidyl resin is cleaved and deprotected by treatment with 10 ml anhydrous liquid HF/1 ml anisole at 0 ºC for 1 hour. After removal of the HF under vacuum, the resin is washed with diethyl ether, air dried and extracted with 2 x 50 ml glacial acetic acid, which is lyophilized to yield the crude peptide. The crude product is purified by gel filtration on Sephadex® G-15 using 10% aqueous acetic acid as eluant. Example 131
Preparation of (4S,5S)-alanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-valinamide
The protected peptidyl resin (4S,5S) Boc-Ala-(6-phenyl-5- amino-4-t-butyldimethyl-silyloxyhexanoyl)-Val-Val-BHA is prepared according to the usual method. The peptidyl resin is cleaved and deprotected by treatment with 10 ml anhydrous liquid HF/1 ml anisole at 0 ºC for 1 hour. After removal of the HF under vacuum, the resin is washed with diethyl ether, air dried and extracted with 2 x 50 ml glacial acetic acid, which is lyophilized to yield the crude peptide. The crude product is purified by gel filtration on Sephadex® G-15 using 10% aqueous acetic acid as eluant. Example 132
Preparation of (4S,5S)-benzyloxycarbonylalanyl-alanyl-(6-phenyl-5(S)-amino-4(S)-hydroxyhexanoyl)-valyl-valinamide
The compound of Example 130 is dissolved in DMF to which is added 1 equiv. of triethylamine and 1.5 equiv. N- (benzyloxycarbonyloxy) succinimide. The extent of reaction is monitored by hplc and the product is purified directly from the reaction mixture by preparative hplc using an
acetonitrile-water-0.1% trifluoroacetic acid system on a Hamilton PRP-1® polystyrene column.
Example 133 Preparation of (4S,5S)-alanylalanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valine
The protected peptidyl resin (4S,5S) Boc-Ala-Ala-(6-phenyl-5-amino-4-t-butyldimethyl-silyloxyhexanoyl)-Val-Merrifield resin is prepared according to the usual method. The
peptidyl resin is cleaved and deprotected by treatment with 10 ml anhydrous liquid HF/1 ml anisole at 0 ºC for 1 hour. After removal of the HF under vacuum, the resin is washed with diethyl ether, air dried and extracted with 2 x 50 ml glacial acetic acid, which is lyophilized to yield the crude peptide. The crude product is purified by gel filtration on Sephadex® G-15 using 10% aqueous acetic acid as eluant.
Example 134 Preparation of (4S,5S)-benzyloxycarbonylalanylalanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valine
The compound of Example 133 is dissolved in DMF to which is added 2 equiv. of triethylamine and 1.5 equiv. N-(benzyloxycarbonyloxy) succinimide. The extent of reaction is monitored by hplc and the product is purified directly from the reaction mixture by preparative hplc using an
acetonitrile-water-0.1% trifluoroacetic acid system on a Hamilton PRP-1® polystyrene column. Example 135
Preparation of (4S,5S)-benzyloxycarbonylalanylalanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-(1-aminomethyl-2-methyl)propylamide carbobenzyloxy-L-valinol
a) L-valinol is dissolved in water containing 1 equiv. of NaOH and cooled to 5 ºC in an ice bath. Benzyl chloroformate
(1.1 equiv) and 4 N NaOH (1.2 equiv.) are added alternately in several portions. When the reaction is complete, the reaction mixture is extracted with ethyl acetate and the extracts are combined, dried over Na2SO4, and concentrated. The crude product is purified by flash chromatography on silica gel.
1-phthaloylamino-2-carbobenzyloxyamino-3-methylbutane
b) Carbobenzyloxy-L—valinol is dissolved in THF along with triphenylphosphine (1.1 equiv.) and phthalimide (1.1 equiv.) and cooled to -5 ºC in a salt-ice bath. Diisopropyl-azidodicarboxylate (1.1 equiv.) is added and the reaction stirred for 1 hr. at -5 ºC and allowed to warm to room temperature. After stirring overnight at room temperature, the reaction mixture is evaporated and the residue is
purified by flash chromatography to yield the deisred
compound.
1-t-butyloxycarbonylamino-2-carbobenzyloxyamino-3- methylbutane
c) 1-Phthaloylamino-2-carbobenzyloxyamino-3-methylbutane is dissolved in ethanol and treated at room temperature with hydrazine hydrate (2 equiv.). When the reaction is complete by tlc, the reaction mixture is eavporated and the residue dissolved in DMF. Di-t-butyldicarbonate (3 equiv.) and triethylamine (3 equiv.) are added and the reaction is stirred at room temperature overnight. The reaction mixture is eavporated and the residue is purified by flash chromatography on silica gel to yield the desired compound.
(4S,5S)-benzyloxycarbonylalanyl-alanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-(1-aminomethyl-2-methyl)propylamide d) 1-t-Butyloxycarbonylamino-2-carbobenzyloxyamino-3-methylbutane is dissolved in methanol and hydrogenated over 10% palladium on carbon at 40 psig for 1 hr. The reaction mixture is filtered through a pad of celite, evaporated to dryness to give 1-t-butyloxycarbonyl-2-amino-3-methylbutane.
(4S,5S)-benzyloxycarbonylalanyl-alanyl-(6-phenyl-5-amino-4-hydroxyhexanoyl)-valyl-(1-aminomethyl-2-methyl)propylamide e) The compound of Example 134 is dissolved in DMF along with 1-t-butyloxycarbonyl-2-amino-3-methylbutane (3 equiv.), 1-hydroxybenzotriazole (1.5 equiv.) and diisopropyl-carbodiimide (1.5 equiv.) and the reaction is stirred at room temperature and monitored by hplc. When the reaction is complete, the reaction mixture is evaporated to dryness and the residue treated with trifluoroacetic acid at 0 ºC for 30 minutes. The trifluoroacetic acid is removed under reduced pressure and the residue is dissolved in methanol and purified by reverse phase hplc using an acetonitrile-water-0.1% trifluoroacetic acid system on a Hamilton PRP-1® polystyrene column.
Example 136
Preparation of (2R,5S)-2-(phenylmethyl)-5-t-butyloxycarbonylamino-6-phenylhex-3-enoic acid
2(S)-t-butyloxycarbonylamino-3-phenylpropanol
a) Boc-L-Phenylalanine is dissolved in THF containing triethylamine (1 equiv.) cooled to -5 ºC. Ethyl
chloroformate (21 equiv.) in THF is added dropwise over 15 min. and the reaction is stirred 30 min at -5 ºC. The reaction mixture is filtered and added dropwise over 30 min. to a solution of sodium borohydride (2.5 equiv.) in water at 0 ºC. The reaction is allowed to warm to room temperature and is stirred 2 hr. The reaction mixture is acidified with
1 N HCl, the aqueous layer separated and washed with ether. The ether and THF layers are combined, washed with 10% NaOH, water, dried over Na2SO4 and concentrated to yield the titled compound.
(2S)-1-(methylsulfonyl)oxy-2-t-butyloxycarbonylamino-3-phenylpropane
b) The compound of Example 136(a) is dissolved in CH2CI2 containing triethylamine (1.5 equiv.) and cooled to -10 ºC. To this is added methanesulfonyl chloride (1.1 equiv.) over 10 min. After stirring for 10 min and -10 ºC, the reaction mixture is extracted with ice water, cold 10% HCl, saturated NaHCO3, and brine. The organic layer was dried over Na2SO4 and concentrated to give the titled compound.
(2S)-1-phenylthio-2-t-butyloxycarbonylamino-3-phenylpropane c) Thiophenol (4 equiv.) is dissolved in a mixture of THF and methanol. Sodium methoxide (4 equiv.) is added and the reaction is stirred at room temperature for 15 min. The compound of Example 136(b) (1 equiv.) is added and the temperature raised to 50 ºC for 2.5 hr. The reaction mixture is diluted with 10% NaOH, extracted with CH2CI2, and
evaporated to give the titled compound.
(2S)-1-(benzenesulfonyl)-2-t-butyloxycarbonylamino-3-phenylpropane
d) The compound of Example 136(c) is dissolved in CH2CI2, cooled to 0ºC and m-chloroperbenzoic acid (3.5 equiv.) is added. The reaction is allowed to warm to room temperature and stir for 1 hr. The reaction mixture is partitioned between CH2CI2 and saturated NaHSO4, and the organic layer washed with 1 N NaHCO3, dried over Na2SO4 and evaporated to give the titled compound. (4R)-(2-oxo-4-(Phenylmethyl)-3-oxazolidinyl)-5-methylpent-3-enoate
e) The titled compound is prepared according to the procedure of Example 93 (b), substituting 4-methylpent-3-enoic acid for monomethyl trans-hex-3-enoic acid, and (R)-benzyloxazolidinone for (S)-benzyloxazolidinone.
(2R,4R)-(2-oxo-4-(phenylmethyl)-3-oxazolidinyl)-2- (phenylmethyl)-5-methylpent-3-enoate
f) Using the compound of Example 136(e), the titled compound is prepared according to the procedure of Example 93(c).
(2R) 2-(phenylmethyl)-5-methylpent-3-en-1-ol
g) The compound of Example 136(f) in THF is cooled to -78 ºC and treated with LiAlH4 (1 equiv.). After stirring 30 min. at -78 ºC, the reaction is allowed to warm to 0 ºC over 1 hr. After 30 min. at 0 ºC, the reaction mixture is then cooled again to -78 ºC and 1 ml ethyl acetate is added. The reaction is quenched with saturated aqueous ammonium chloride at -78 ºC, allowed to warm to room temperature and diluted with water. The reaction mixture is extracted with ether and the extracts are dried over Na2SO4 and evaporated to yield the titled compound, which is purified by flash
chromatography on silica gel.
(2R)-1-(tetrahydropyranyl)oxy-2-(phenylmethyl)-5-methyl-3-pentene
h) The compound of Example 136(g) is dissolved in CH2CI2 and dihydropyran (1.5 equiv.) is added along with pyridinium p-toluenesulfonate (0.1 equiv.) and stirred at room
temperature for 4 hrs. The solution is diluted with ether, washed with brine, dried over Na2SO4 and evaporated to yield the titled compound.
(2S)-2-(phenylmethyl)-3-tetrahydropyranyloxypropionaldehyde i) The compound of Example 136(h) is dissolved in CH2CI2, cooled to -78 ºC and treated with ozone until a blue oolor persists. The reaction is quenched with dimethylsulfide, allowed to warm to room temperature and concentrated by evaporation to yield titled compound, which is used without further purification.
(2R,5S)-1-(tetrahydropyranyl)oxo-2-(phenylmethyl)-5-t-butyloxycarbonylamino-6-phenylhex-3-ene
j) A solution of the sulfone of Example 136(d) in THF is cooled to -78ºC and is treated with methyl-lithium (2 equiv. of 1.6 M solution in ether) over 5 min. and is stirred at -78 ºC for 20 min. In a separate flask, the aldehyde of Example 136 (i) (2.75 equiv) in THF is cooled to -78 ºC and treated with diisobutylaluminum methoxide (2.25 equiv.) in THF
(prepared by the addition of an equimolar amount of methanol to 1 M diiosbutylaluminum hydride in THF). The aldehyde solution is transferred to the sulfone dianion via cannula and stirred at -78 ºC for 30 min. The reaction is quenched by the addition of saturated aqueous ammonium chloride and the product extracted with ether, dried over MgSO4 and concentrated under reduced pressure.
The crude β-hydroxysulfone is dissolved in methanol and cooled to 0 ºC. Disodium hydrogen phosphate (4 equiv.) is added followed by 5% sodium amalgum (12 equiv.). After stirring 4 hr. at 0 ºC, the reaction is diluted with water and extracted with CH2CI2, dried over MgSO4, and
concentrated. The crude product is purified by flash
chromatography on silica gel to afford the titled compound.
(2R,5S)-2-(phenylmethyl)-5-t-butyloxycarbonylamino-6- phenylhex-3-enoic acid
k) The compound of Example 136 (j) is dissolved in acetone, cooled to 0 ºC and treated dropwise with Jones reagent (3 equiv.). After stirring for 3 hr., the reaction mixture is diluted with water and extracted with ether. The ethereal extracts are washed with 5% NaOH and the aqueous washings are combined, acidified to pH 2 with 10% HCl and extracted with ether. The ether extracts are dried over Na2SO4 and
evaporated to give the titled compound. Example 137
Preparation of-(2R,5S) alanylalanyl-(2-(phenylmethyl)-5-amino-6-phenyl-trans-hex-3-enoyl)-valyl-valinamide
The protected peptidyl resin (2R,5S) Boc-Ala-Ala-(2- (phenylmethyl)-5-amino-6-phenyl-trans-hex-3-enoyl)-Val-Val-BHA is prepared on the according to the usual method of
Example 1. The peptidyl resin is cleaved and deprotected by treatment with 10 ml anhydrous liquid HF/1 ml anisole at 0 ºC for 1 hour. After removal of the HF under vacuum, the resin is washed with diethyl ether, air dried and extracted with 2 x 50 ml glacial acetic acid, which is lyophilized to yield the crude peptide. The crude product is purified by gel filtration on Sephadex® G-15 using 10% aqueous acetic acid as eluant to yield the titled compound.
Example 138 Preparation of (2R,5S)-benzyloxycarbonylalanylalanyl-(2-(phenylmethyl)-5-amino-6-phenyl-trans-hex-3-enoyl)-valyl-valinamide
The compound of Example 137 is dissolved in DMF to which is added 2 equiv. of triethylamine and 1.5 equiv. N-(benzyloxycarbonyloxy) succinimide. The extent of reaction is monitored by hplc and the product is purified directly from the reaction mixture by preparative hplc using an
acetonitrile-water-0.1% trifluoroacetic acid system on a Hamilton PRP-1® polystyrene column.
Example 139
Preparation of (6S)-6-(tert-butyloxycarbonyl)amino-7-phenyl-5-oxo-heptanoic acid
Using the procedure of Example 12, except substituting 5-bromo-1-pentene for 4-bromo-1-butene, the titled compound is prepared.
Using the detailed procedures described herein in Examples 19, 34, 76, 77, 78, 88, and 135, the following specific compounds are prepared:
a) (5S,6S)-6-(carbobenzyloxy-alanylalanyl)amino-7-phenyl-5-hydroxy-(1-oxo)heptyl-valyl valine methyl ester;
b) (5S,6S)-6-(carbobenzyloxy-alanyl)amino-7-phenyl-5-hydroxy-(1-oxo)heptyl-valyl valine methyl ester;
c) (5S,6S)-6-(carbobenzyloxy-alanylalanyl)amino-7-phenyl-5-hydroxy-(1-oxo)heptyl-valyl valinamide;
d) (5S,6S)-6-(carbobenzyloxy-alanyl)amino-7-phenyl-5- hydroxy-(1-oxo)heptyl-valyl valinamide;
e) (5S,6S)-6-(carbobenzyloxy-alanylalanyl)amino-7-phenyl-5-hydroxy-(1-oxo)heptyl-valyl valinol;
f) (5S,6S)-6-(carbobenzyloxy-alanyl)amino-7-phenyl-5-hydroxy-(1-oxo)heptyl-valyl valinol;
g) (5S,6S)-6-(carbobenzyloxy-alanylalanyl)amino-7-phenyl-5-hydroxy-(1-oxo)heptyl-valyl valin-((S)-1-amino-3-methylbutyl-2-)amide; and
h) (5S,6S)-6-(carbobenzyloxy-alanyl)amino-7-phenyl-5-hydroxy-(1-oxo)heptyl-valyl valin-((S)-1-amino-3-methylbutyl-2-)amide.
Example 140
Using the procedure of Example 151 to prepare (2R,5S)-2- methyl-5-(tert-butyloxycarbonyl)amino-6-phenyl-4-oxo-hexanoic acid and employing the detailed procedures described herein in Examples 19, 34, 76, 77, 78, 88 and 135, the following specific compounds are prepared:
a) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6- phenyl-4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valine methyl ester;
b) (2R,4S,5S)-5 (carbobenzyloxy-alanylalanyl)amino-6- phenyl-4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valinamide;
c) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl- 4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valinamide;
d) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6- phenyl-4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valinol;
e) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl- 4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valinol;
f) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valin-((S)-1-amino-3-methylbutyl-2-)amide;
g) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valin-((S)-1-amino-3-methylbutyl-2-)amide;
h) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valine; and
i) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-2-methyl-(1-oxo)hexyl-valyl valine.
Example 141 Preparation of (2R,5S)-2-benzyl-5-(tert-butyloxycarbonyl)amino-6-phenyl-4-oxo-hexanoic acid
Using the procedure of Example 151, except using 3-bromo-2-phenylmethyl-1-benzyloxypropane for 3-bromo-2-methyl-1-benzyloxypropane, the titled compound is prepared.
Using (2R,5S)-2-benzyl-5-(tert-butyloxycarbonyl)amino-6-phenyl-4-oxo-hexanoic acid and employing the detailed
procedures described herein in Examples 19, 34, 76, 77, 78, 88 and 135, the following specific compounds are prepared: a) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valine methyl ester;
b) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valine methyl ester; c) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valinamide;
d) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valinamide;
e) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valinol;
f) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valinol;
g) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valin-((S)-1- amino-3-methylbutyl-2-) amide;
h) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valin-((S)-1-amino-3-methylbutyl-2-)amide;
i) (2R,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valine; and
j) (2R,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-2-benzyl-(1-oxo)hexyl-valyl valine. Example 142
Preparation of (3RS,5S)-3-isobutyl-5-(tert-butyloxycarbonyl)amino-6-phenyl-4-oxo-hexanoic acid 4-hydroxy-6-methyl-hept-1-ene
a) To a solution of isobutyraldehyde (1.0 g, 11.6 mmol) in anhydrous THF (30 ml) at 0°C, allylmagnesium bromide (12.2 mmol) is added. After addition the reaction is allowed to warm to room temperature and stirred for an additional 2 h. The reaction is quenched by pouring into a stirred mixture of 5% HCl and diethyl ether. The organic layer is separated, washed with water and brine and dried over MgSO4. Filtration and evaporation of the solvent yields the titled compound. 4-bromo-6-methyl-hept-1-ene
b) The compound of Example 142(a) (0.8 g, .625 mmol) is dissolved in CH2CI2 (25 ml) and treated with mesyl chloride (0.72 g, .625 mmol) and triethylamine (0.63 g, .625 mmol) in methylene chloride. After stirring 3 h at room temperature, the reaction is poured into cold 5% HCl and diethyl ether. Standard extractive workup affords the crude mesylate. The crude mesylate is treated with an excess of LiBr (3 equiv.) in dry DMF at 120°C for 6 h. The reaction is cooled and the reaction mixture is diluted with water. Standard extractive workup with pentane yields the titled compound, which is purified by distillation. (3RS,5S)-3-isobutyl-5-(tert-butyloxycarbonyl)amino-6-phenyl-4-oxo-hexanoic acid
c) Using the procedure of Example 12, except
substituting 4-bromo-6-methyl-hept-1-ene for 4-bromo-1-butene, yields the titled compound.
Using the detailed procedures described herein in
Examples 19, 34, 76, 77 and 78, the following specific compounds are prepared:
al) (3SR,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-3-isobutyl-(1-oxo)hexyl-valyl valine methyl ester;
bl) (3SR,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-3-isobutyl-(1-oxo)hexyl-valyl valine methyl ester;
cl) (3SR,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-3-isobutyl-(1-oxo)hexyl-valyl valinamide; and
dl) (3SR,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-3-isobutyl-(1-oxo)hexyl-valyl valinamide.
Example 143
Preparation of (3RS,5S)-3-methyl-5-(tert-Butyloxycarbonyl)amino-6-phenyl-4-oxo-hexanoic acid
Using the procedure of Example 142, except substituting acetaldehyde for isobutyraldehyde, the titled compound is prepared.
Using the detailed procedures described herein in
Examples 19, 34, 76, 77, and 78, the following specific compounds are prepared:
a) (3SR,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-3-methyl-(1-oxo)hexyl-valyl valine methyl ester;
b) (3SR,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-3-methyl-(1-oxo)hexyl-valyl valine methyl ester; c) (3SR,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-3-methyl-(1-oxo)hexyl-valyl valinamide; and d) (3SR,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-3-methyl-(1-oxo)hexyl-valyl valinamide.
Example 144
Preparation of (3RS,5S)-3-benzyl-5-(tert-butyloxycarbonyl)amino-6-phenyl-4-oxo-hexanoic acid
Using the procedure of Example 142, except substituting phenylacetaldehyde for isobutyraldehyde, the titled compound is prepared.
Using the detailed procedures described herein in
Examples 19, 34, 76, 77 and 78, the following specific compounds are prepared:
a) (3SR,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-3-benzyl-(1-oxo)hexyl-valyl valine methyl ester;
b) (3SR,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-3-benzyl-(1-oxo)hexyl-valyl valine methyl ester; c) (3SR,4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-3-benzyl-(1-oxo)hexyl-valyl valinamide; and d) (3SR,4S,5S)-5-(carbobenzyloxy-alanyl)amino-6-phenyl-4-hydroxy-3-benzyl-(1-oxo)hexyl-valyl valinamide.
Example 145
Preparation of (5S)-5-(tert-Butyloxycarbonyl)amino-5-phenyl- 4-oxo-pentanoic acid
Using procedure of Example 12, except substituting Bocphenylglycine for Boc-phenylalanine, the titled compound is prepared.
Using the detailed procedures described herein in
Examples 34, 76, 77 and 78, the following specific compounds are prepared:
a) (5S,4S)-5-(carbobenzyloxy-alanylalanyl)amino-5- phenyl-4-hydroxy-(1-oxo)pentyl-valyl valine methyl ester; and b) (5S,4S)-5-(carbobenzyloxy-alanyl)amino-5-phenyl-4- hydroxy-(1-oxo)pentyl-valyl valine meehyl ester. Example 146
Preparation of (5S)-5-(tert-Butyloxycarbonyl)amino-7-phenyl-4-oxo-heptanoic acid
Using the procedure of Example 12, except substituting Boc-homophenylalanine in place of Boc-phenylalanine, the titled compound is prepared.
Using the detailed procedures described herein in
Examples 34, 76, 77 and 78 the following specific compounds are prepared:
a) (4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-7-phenyl-4-hydroxy-(1-oxo)heptyl-valyl valine methyl ester; and b) (4S,5S)-5-(carbobenzyloxy-alanyl)amino-7-phenyl-4hydroxy-(1-oxo)heptyl-valyl valine methyl ester.
Example 147
Preparation of (5S)-5(carbobenzyloxyalanyl)amino-4-hydroxy-1-oxo-6-phenyl-hexyl-valine, isobutyl amide (5S)-5-(tert-butyloxy)amino-1,4-dioxo-6-phenylhexyl-valine, isobutylamide
a) A solution of the compound of Example 12(b) (1.0 mmol) and NMM (1.2 mmol) in THF (5 ml.) at -40° is treated in dropwise fashion with isobutyrylchloroformate ( 1 . 0 mmol ) . After 15 min . , a solution of L-valine isobutylamide (1.2 mmol) in DMF (2 ml.) is added. The mixture is stirred with warming to room temperature overnight, then is poured into 4% aq. HCl and extracted with CHCI3. The organic layer is washed with 5% NaHCO3, then H2O, and concentrated to yield the titled compound.
(5S)-5-(tert-butyloxycarbonyl)-4-hydroxy-1-oxo-6-phenyl-hexyl-valine. isobutyl amide
b)The product of Example 147(a) is reduced with NaBH4 (1. equiv) in methanol. Dilute HCl is added and the product is isolated by extraction with CHCI3. Preparative HPLC in silica using a CH2CI2/CH3OH system yields the titled
compound, along with its hydroxy epimer. (5S)-5-amino-4-hydroxy-1-oxo-6-phenyl-hexyl-valine, isobutyl amide
c) The product of Example 147(b) is dissolved in a minimal volume of neat TFA. After 5 minutes, methanol is added, followed by 1 equivalent of cone. HCl. The solvents are removed in vacuo to yield the titled compound.
(5S)-5-(carbobenzyloxyalanyl)amino-4-hvdroxy-1-oxo-6-phenyl-hexyl-valine isobutyl amide
d) A solution of Cbz-alanine (0.50 mmol) and NMM
(0.60 mmol) in THF (5 ml.) at -40° is treated dropwise with isobutyrylchloroformate (0.50 mmol). After 15 minutes, more NMM (0.60 mmol) is added, followed by a solution of the product of Example 147(c) (0.60 mmol) in DMF (2 ml.). The mixture is allowed to warm to room temperature with stirring overnight. 5% HCl is added and the product is isolated by extraction with CHCI3. Example 148
Preparation of (5S)-5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-1-oxo-6-phenyl-hexyl valine, isobutylamide
The titled compound is prepared as described in Example 147(d), except Cbz-alanylalanine (0.50 mmol) is used in place of Cbz-alanine.
Example 149 Preparation of 5-(myristyl)amino-4-hydroxy-1-oxo-6-phenyl- hexyl valine, isobutyl amide
To a solution of the product of Example 147(c) (0.10 mmol) in pyridine (2 ml.) is added myristic anhydride (0.12 mmol). After 12 hours the solution is diluted with 10% HCl and extracted with ethyl acetate. The organic Layer is washed with 5% NaHCO3 and H2O, then concentrated to afford the titled compound. Example 150
Preparation of 5-(stearyl)amino-4-hydroxy-1-oxo-6-phenyl-hexyl valine, isobutyl amide
The titled compound is prepared as in Example 149 except substituting stearic anhydride for myristic anhydride.
Example 151 Preparation of 5-(carbobenzyloxyalanyl)amino-4-hydroxy-2-methyl-1-oxo-6-phenyl-hexylvalyl valine, methyl ester
5-(tert-butyloxycarbonyl)amino-4-oxo-2-methyl-6-phenyl-1-benzyloxy hexane
a) The titled compound is prepared as in the procedure of Example 12(a), except instead of 4-bromo-1-butene, the 3-bromo-2-methyl-1-benzyloxy-propane (J. Med. Chem. 30, 374, (1987)) is used. 5-(tert-butyloxycarbonyl)amino-4-oxo-2-methyl-1-hydroxy-6-phenyl hexane
b) The titled compound is prepared by hydrogenolysis of the product of Example 151 (a) using the procedure of Example 86(b).
5-(tert-butyloxycarbonyl)amino-4-oxo-2-methyl-6-phenyl-hexanoic acid
c) To a mixture of the product of Example 151 (b) and 5:1:1 benzene/H2O/AcOH is added (n-Bu) 4NBr (0.01 eq.). KMnO4 (3.5 eq.) is added and the mixture is stirred for 2 hours, then sat. aqueous sodium bisulfite is added. After several minutes, the mixture is acidified to pH 1-2 with sat. aqueous KHSO4, then is extracted with EtOAc. The organic layer is concentrated and the residue is purified by silica
chromatography (ethyl acetate/hexane/HOAc) to yield the titled compound. 5-(carbobenzyloxy alanyl)amino-4-hydroxy-1-oxo-6-phenyl-hexylvalyl valine, methyl ester
d) The compound of Example 151 (c) is coupled to valyl valine methyl ester using the method of Example 35 (a) except substituting the compound of Example 151(c) for 5-(tert- butyloxycarbonyl)amino-4-oxo-6-(4-benzyloxy-phenyl)hexanoic acid. The ketone is reduced with NaBH4 using the procedure of Example 84 (b). The amino group is deprotected by the method of Example 35(c) and coupled to Cbz-alanine by the method of Example 72'(a) to yield the titled compound.
Example 152
Preparation of 7-methyl-5-(carbobenzyloxyalanyl)amino-3,4-dihydroxy-2-phenylmethyl-1-oxo-octyl valine, isobutylamide
7-methyl-4.5-0,(tert-butyloxycarbonyl)N-isopropylidine-3-hydroxy-2-phenylmethyl-octanoic acid, benzyl ester
a) A solution of 2,2-dimethyl-3-(tert-butyloxy
carbonyl)-4-isopropyl-5-formy1-1,3 oxazolidine (1.0 mmol) (J. Med. Chem. 30. 976 (1987)) in THF (2 ml) is added to a -78° solution of 1.1 mmol lithio-benzyl-3-phenylpropionate
(prepared from lithium diisopropyl amide (1.1 mmol) and benzyl-3-phenylpropionate (1.1 mmol)). The mixture is stirred at -78° for 1 hour, then allowed to warm to room temperature and is diluted with pH 7 phosphate buffer. The mixture is extracted with chloroform, the organic layer is concentrated, and the residue is purified by flash
chromatography to yield the titled compound as a mixture of isomers.
7-methyl-5-(tert-butyloxycarbonyl)amino-3,4-dioxy- isopropylidine-2-phenylmethyl-octanoic acid, benzyl ester
b) A solution of the product of Example 152(a) (0.5 mmol) in CH2C12 (10 ml) is stirred with camphor-sulfonic acid (0.1 mmol) overnight. Excess solid NaHCO3 is added with acetone (10 ml), the mixtue is stirred vigorously for 1 hour, and filtered through Celite. Concentration and flash chromatography provides the titled compound.
7-methyl-5(tert-butyloxycarbonyl)amino-3,4-dioxy-isopropylidene-2-phenylmethyl-octanoic acid
c) A solution of the product of Example 152(b) (0.2 mmol) in methanol (5 ml) is stirred with 10% Pd on activated carbon (20 mg) for 8 hours under 1 atm. H2. The mixture is filtered through Celite and concentrated to yield the titled compound.
7-methyl-5(tert-butyloxyamino)-3.4-dioxy-isopropylidine-2-phenylmethyl-1-oxo-octyl valine, isobutyl amide
d) The titled compound is prepared by the procedure of Example 87 (a) except substituting the product of Example 152(c) for 5-(tert-butyloxycarbonyl)amino-4-oxo-6-phenyl hexanoic acid, and eliminating the wash with 5% HCl in the workup.
7-methyl-5-amino-3,4-dihydroxy-2-phenylmethyl-1-oxo-octyl valine, isobutyl amide, hydrochloride
e) The titled compound is prepared from the product of Example 152 (d) by the procedure of Example 147 (c).
7-methyl-5-(carbobenzyloxyalanyl)amino-3,4-dihydroxy-2-Phenylmethyl-1-oxo-octyl valine. isobutyl amide
f) The titled compound is prepared by the procedure of Example 147 (d), except substituting the product of Example 152(e). Example 153
Preparation of (4S,5S)-5-(alanylalanyl)amino-4-hvdroxy-1-oxo-6-(4-hydroxyphenyl)-hexyl-valyl valinol (4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-benzyloxyphenyl)-hexyl-valyl valine
a) The compound of Example 72(a) (1 mmol) is dissolved in methanol (10 ml) and potassium hydroxide (1.5 mm) in H2O (2 ml) is added dropwise. The reaction is monitored by thin layer chromatography until hydrolysis of the ester is
complete. The reaction is neutralized with 5% HCl, the methanol is evaporated under reduced pressure and the residue is dissolved in CHCI3. The organic extract is washed with 5% HCl and water and dried over MgSO4. Filtration and
evaporation of the solvent provides the titled compound.
(4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-benzyloxyphenyl)-hexyl-valyl valinol
b) A solution of the compound of Example 153(a) (.5 mmol) is dissolved in CH2CI2 (5 ml) under an Ar atmosphere and cooled to 0°C. Borane methyl sulfide (.55 mmol) is added dropwise. The reaction is stirred .5 hr. at 5°C and 2 hr. at room temperature. Methanol (3 ml) is added, followed by acetic acid (2 ml) and the solution is stirred at room temperature for an additional 2 hr. The solvents are
evaporated under reduced pressure, the residue is dissolved in CHCI3, and washed successively with 5% HCl, H2O and 5% NaHCO3. The organic extract is dried over MgSO4, filtered and the solvent is evaporated to yield the titled compound. (4S,5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)-hexyl-valyl valinol
c) To a solution of the compound of Example 153(b) (.2 mmol) in acetic acid, 10% palladium (150 mg) on activated carbon is added. Hydrogen is bubbled through the mixture for 60 min. and the reaction is stirred under a hydrogen
atmosphere for 20 hr. The suspension is filtered through Celite® and the solvent is evaporated under reduced pressure to yield the titled compound.
Example 154 Preparation of 4-methyl-3-[5- (alanylalanyl) amino-4-hydroxy-1- oxo-6- (4-hydroxyphenyl) -hexyl-valyl] amino-pentan-2-one 4-methyl-3-[_ 5-(carbobenzyloxy-alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-benzyloxyphenyl)-hexyl-valyl] amino-pentan-2-one
a) The compound of Example 153(a) (.2 mmol) is
dissolved in methylene chloride (4 ml) at 0°C and oxalyl chloride (.25 mmol) is added followed by 1 drop DMF. After stirring for .5 hr. at 0°C and .5 hr. at room temperature, the methylene chloride solution is added dropwise to a solution of an excess of diazomethane (>4 mmol) in a mixture of Et2O and THF. After stirring at 10°C for 1 hr., acetic acid is added until nitrogen evolution ceases. The solvents are evaporated, the residue is dissolved in CHCI3 , washed with water and dried over MgSO4. Filtration and evaporation of the solvent yields the titled compound. 4-methyl-3-[5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)-hexyl-valyl]amino-pentan-2-one
b) To a solution of the compound of Example 154(a) (.1 mmol) in acetic acid, 10% palladium (80 mg) on activated carbon is added. Hydrogen is bubbled through the mixture for 60 min. and the reaction is stirred under a hydrogen
atmosphere for 20 hr. The suspension is filtered through Celite® and the solvent is evaporated under reduced pressure to yield the titled compound. Example 155
Preparation of Ac-Arg-Ala-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2
Using the procedure of Example 1, except substituting Boc-Phe for Boc-Tyr (BrZ), the titled compound was prepared.
Example 156
Using the method of Example 58, except substituting Boc-His(Tos), Boc-Val, Boc-Ile, Boc-Lys(Clz), Boc-Ser(Bzl), Boc-D-Arg(Tos) or Boc-Met for Boc-Ala, yields the following peptides :
His-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2;
Val-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2; Ile-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2;
Lys-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2;
D-Arg-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2;
Ser-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2; and
Met-Ser-Gln-Asn-Tyr-Pro-Val-Val-NH2.
Example 157
Using the method of Example 39, except beginning the sequence with Boc-Ala-BHA, Boc-Gly-BHA, Boc-Ile-BHA, Boc-Leu-BHA or Boc-Met-BHA, yields the following peptides.
Ac-Ser-Gln-Asn-Tyr-Pro-Val-Ala-NH2;
Ac-Ser-Gln-Asn-Tyr-Pro-Val-Gly-NH2;
Ac-Ser-Gln-Asn-Tyr-Pro-Val- Ile-NH2;
Ac-Ser-Gln-Asn-Tyr-Pro-Val-Leu-NH2; and
Ac-Ser-Gln-Asn-Tyr-Pro-Val-Met-NH2.
Example 158 Using the method of Example 39, except substituting
Boc-Ala, Boc-Gly, Boc-Ile, Boc-Arg(Tos), Boc-Leu or Boc-Met for Boc-Val in the second residue of the peptide, yields the following peptides.
Ac-Ser-Gln-Asn-Tyr-Pro-Ala-Val-NH2;
Ac-Ser-Gln-Asn-Tyr-Pro-Gly-Val-NH2;
Ac-Ser-Gln-Asn-Tyr-Pro-Ile-Val-NH2;
Ac-Ser-Gln-Asn-Tyr-Pro-Arg-Val-NH2.
Ac-Ser-Gln-Asn-Tyr-Pro-Leu-Val-NH2; and
Ac-Ser-Gln-Asn-Tyr-Pro-Met-Val-NH2
Example 159
Using the method of Example 40, except substituting Boc-His(Tos), Boc-Val, Boc-Ile, Boc-Leu, Boc-Thr(Bzl) or Boc- Gln for Boc-Ala in the fifth residue of the peptide, yields the following peptides.
Ac-Ser-Ala-His-Tyr-Pro-Val-Val-NH2; Ac-Ser-Ala-Val-Tyr-Pro-Val-Val-NH2;
Ac-Ser-Ala-Leu-Tyr-Pro-Val-Val-NH2;
Ac-Ser-Ala-Thr-Tyr-Pro-Val-Val-NH2; and
Ac-Ser-Ala-Gln-Tyr-Pro-Val-Val-NH2.
Example 160
Preparation of (5S,4RS)-5-(tert-butoxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine
The compound of Example 34(d) (50 mg, 6.5 X 10-5 mole) is dissolved in methanol (5 ml) and water (1 ml) containing potassium carbonate (27 mg, 19.5 X 10-5 mole) is added dropwise. After stirring for 6 hr. at room temperature, the reaction mixture is diluted with ethyl acetate and water.
The pH is adjusted to 3.0 with dil. HCl and the aqueous layer is separated. The organic layer is washed with water (IX) and dried over MgSO4. Filtration and evaporation of the ethyl acetate yields the titled compound.
Exampie 161
Preparation of (5S,4RS)-5-_(tert-butoxycarbonyl-serylalanyl-alanyl)-amino]-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine-diethylamide
The compound of Example 160 (60 mg, 7.8 X 10-5 mole) is dissolved in anhydrous THF (4 ml) at -40°C under an argon atmosphere and N-methyl morpholine (10.2 mg, 1.01 X 10-4 mole) is added, followed by isobutyrlchloroformate (11 mg,
7.8 X 10-5 mole). After stirring for 15 min., diethyl amine (11 mg, 1.56 X 10-4 mole) is added. After stirring for an additional 30 min. at -40°C the reaction mixture is stirred at room temperature. The reaction is
diluted with ethyl acetate and washed successively with 5%
HCl, 5% sodium bicarbonate and brine. The organic extract is dried over MgSO4, filtered and evaporated in vacuo to yield the titled compound. Using the same procedure, except substituting n-butylamine for the diethylamine, yields (5S,4RS)-5-[(tert-butoxycarbonyl-serylalanylalanyl)amino]-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine-butylamide
Example 162
Preparation of (5S,4RS)-5-[(tert-butoxycarbonyl-serylalanyl-alanyl)amino[-4-hydroxy-1-oxo-6-phenylhexyl valine-isobutylamide
(5S,4RS)-5-[(tert-butoxycarbonyl-serylalanylalanyl)amino[-4-hydroxy-1-oxo-6-phenylhexyl valine methyl ester
a.) Using the procedure of Example 34, except
substituting valine methyl ester for valyl valine methyl ester, the titled compound is produced.
(5S,4RS)-5-[(tert-butoxycarbonyl-serylalanylalanyl)amino[-4-hydroxy-1-oxo-6-phenylhexyl valine
b.) Using the procedure of Example 160, except
substituting the peptide of Example 162 (a), the titled carboxylic acid is produced. (5S,4RS)-5-[(tert-butoxycarbonyl-serylalanylalanyl)amino[-4- hydroxy-1-oxo-6-phenylhexyl valine-isobutylamide
c.) Using the peptide of Example 162(b) and the procedure of Example 161, except substituting isobutylamine for diethylamine, the titled compound is produced.
Example 163
Liposomal Dosage Unit Composition
Phosphatidylcholine (1.4 g) and phosphatidylglycerol (.6g) are dissolved in 300 ml of a 20% methanol in chloroform solvent and evaporated to dryness. A solution of the peptide (30 mg in 200 ml of phosphate buffered saline) is added to the dry phospholipid film which is allowed to equilibrate at room temperature for 1-2 hr. The liposome dispersion formed is then vortexed to insure uniform mixing. The resulting suspension is extruded through a 0.2μ polycarbonate filter five times to produce a uniform size distribution. If necessary the suspension can be dialysed or ultracentrifuged to remove non-encapsulated peptide.
Example 164 Liposomal Dosage Unit Composition
In a beaker, cholesterol (49 mg) and oleic acid (.358 g) are warmed to 65°C for 20-30 min. Maintaining the
temperature, phospholipids (1 g) are added slowly, ensuring complete wetting by the oleic acid. A solution of arginine (.22 g in 3.37 g water) at 40°C is added in small aliquots and thoroughly mixed into the slurry. Mixing is maintained at 40°C. After equilibration for one week, the peptide (150 mg) is mixed thoroughly into the gel. The pH is adjusted to 7.0 with acetic acid if necessary. Phosphate buffered saline (pH 7.4) is added in small aliquots with vortexing to achieve a concentration of 200 mg of liposomal gel per ml. Liposomes form spontaneously. This procedure produces 5 g of liposomal suspension. A standard dosage unit is 1 g of liposomal suspension.
Example 165
Parenteral Dosage Unit Composition
A preparation which contains 25 mg of a peptide of this invention is prepared as follows:
25 mg of the peptide is dissolved in 15 ml of distilled water. The solution is filtered under sterile conditions in to a 25 ml multi-dose ampoule and lyophilized. The powder is reconstituted by addition of 20 ml of 5% dextrose in
water (D5W) for intravenous or intramuscular injection. The dosage is thereby determined by the injection volume. This solution is also suitable for use in other methods for administration, such as addition to a bottle or bag for IV drip infusion.
Example 166
Oral Dosage Unit Composition
A capsule for oral administration is prepared by mixing and milling 35 mg of the peptide with 75 mg of lactose and 5 mg of magnesium stearate. The resulting powder is screened and filled into a hard gelatin capsule.
The above description fully discloses how to make and use this invention. This invention, however, is not limited to the precise embodiments described herein, but encompasses all modifications within the scope of the claims which follow.

Claims

What is claimed is:
1. A peptide of the formula: A-B-(Q)a-(C)b-(D)c-M-(W)d-(X)e-Y-Z
(I)
wherein:
A is BocNH, CbzNH, H, R'R"N, R"CONR' or DnsNH, or if a, b and c are 0 and Y is a covalent bond, then A is H, Boc, Cbz, R" or R"CO;
B is one or more D or L amino acids, β-Ala or is a covalent bond;
C and D are the same or different and are Glx, Asx, Ala, β-Ala, Arg, Gly, Ile, Leu, Lys, Ser, Thr, Val, Met or His;
Q is a D or L amino acid and is Ser, Thr, Asp, His, Cys, Arg or Ala;
W is Pro or Δ3-dehydro-Pro;
X is Ala, Gly, Ile, Leu, Val, Met, Lys, Glx or Asx;
Y is one or more D or L amino acids, or is a covalent bond;
Z is CO2R"", CONR'R"", COR', CH2OH, CH2NR'R"" or H, or if d and e are O and Y is a covalent bond, Z is OR"" or
NR'R""; a, b, c, d and e are each independently 0 or 1, provided that c and e are not simultaneously 0;
M is Cha, Phe(4'Ra) or -NHCHR1R2-; wherein: R1 is independently C1-5Alk, (CH2 ) nSC1-5Alk,
(CH2) nOC1-5Alk, (CH2) nC3-7cycloalkyl or (CH2 ) mC6H4-Ra;
Ra is halogen, OR ' , NO2, NH2 or H;
R2 is (CH2)n-, CHR3(CH2)mCO-, CO(CH2)mCO-,
CHR3CHR3' (CH2)mCO-, CHR3CHR3'CHR1 (CH2)mCO-,
CHR3CHR1CHR' (CH2)mCO-, CHR3CHR'CHR1 (CH2) mCO-,
COCR1CHR' (CH2)mCO-, COCF2CR'R" (CH2) mCO-, COCF2 (CH2) mCO-, CH=CR'CHR"(CH2)mCO-, COCH=CR' (CH2) mCO-,
CH2S(O)pCHR' (CH2)mCO-, CH2NR'CHR" (CH2)mCO-,
P=O(OR') (CH2)mCO-,
Figure imgf000198_0001
R3 and R3' are each independently OH, H or NH2;
R4 is OH, H, NH2 or =0; m is independently 0, 1, 2 or 3; n is independently 1 or 2; p is 0, 1 or 2;
R' is H or C1-5Alk;
R" is H or C1-18Alk; R"" is H, C1-5Alk, C3-6cycloalkyl, (CH2)nC6H5,
(CH2)nC5H4N, (CH2)nOH, (CH2)nNH2, or (CH2)nNHC(NH)NH2; and pharmaceutically acceptable salts thereof.
2. A peptide according to claim 1 in which B is one or two D or L amino acids chosen from the group consisting of Ala, Gly, Val, Ile, Leu, Met, His, Lys, Arg, Glx, Asx, Cys, Ser and Thr, or is a covalent bond.
3. A peptide according to claim 1 in which Y is one to three D or L amino acids chosen from the group consisting of Ala, Gly, Ile, Leu, Met, Val, Arg, Lys, Thr, Ser, Cys, Glx and Asx, or is a covaleat bond.
4. A peptide according to claim 3 in which B is one or two D or L amino acids chosen from the group consisting of Ala, β-Ala, Gly, Val, Ile, Leu, Met, His, Lys, Arg, Glx, Asx, Cys, Ser and Thr, or is a covalent bond, and Q is a D or L amino acid chosen from the group consisting of Ser, Thr, Asp and His.
5. A peptide according to claim 4 in which D is chosen from the group consisting of Glx, Asx, Ser, Ala, β-Ala, Ile, Leu,
Val and Met.
6. A peptide according to claim 5 in which Y is one amino acid chosen from the group consisting of Ala, Gly, Ile, Met, Asx, Arg and Val, or is a covalent bond.
7. A peptide according to claim 6 in which M is -NHCHR1R2-.
8. A peptide according to claim 7 in which d is 0.
9. A peptide according to claim 8 in which R1 is CH2C6H4-Ra, CH2C6H11 or C1-5Alk.
10. A peptide according to claim 9 in which R2 is
CHR3CHR3' (CH2)mCO-, CHR3CHR3' CHR1CO-, CHR3CHR1CHR'CO-,
CHR3(CH2)mCO-, CO(CH2)mCO-, COCR1CHR' (CH2)mCO-,
CHR3CF2(CH2)mCO-, -COCF2 (CH2)mCO-, P=O (OR') (CH2) mCO-,
Figure imgf000200_0001
11. A peptide according to claim 10 in which B is a covalent bond.
12. A peptide according to claim 11 in which C and D are chosen from the group consisting of Gln, Asn and Ala.
13. A peptide according to claim 12 in which Q is a D or L amino acid chosen from the group consisting of Ser and Thr.
14. A peptide according to claim 13 in which X and Y are Val.
15. A peptide according to claim 14 in which C is Gin and D is Asn.
16. A peptide according to claim 14 in which C and D are Ala.
17. A peptide according to claim 5 in which M is (4'Ra)Phe.
18. A peptide according to claim 17 in which at least one of X and Y is Val.
19. A peptide according to claim 18 which is:
acetyl-serylglutaminylasparaginyltyrosylprolylvalyl valinamide;
acetyl-serylalanylalanyltyrosylprolylvalyl valinamide; or acetyl-arginylalanylserylglutaminylasparaginyltyrosyl- prolylvalyl valinamide.
20. A peptide according to claim 11 in which R1 is
-CH2C6H5-Ra
21. A peptide according to claim 20 which is:
5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy- (1-oxo)hexyl-valyl valinol;
carbobenzyloxy-alanyl-(3-hydroxy-5-amino-6-phenyl)hexanoyl-valyl-(4-aminomethyl)pyridine;
5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-6-phenyl- (1-oxo)hexyl-valine isobutylamide;
2-(acetyl-serylglutaminylasparaginyl)amino-3-phenylpropyl-prolylvalyl valinamide;
2-(serylglutaminylasparaginyl)amino-3-phenylpropyl-prolylvalyl valinamide;
4-(acetyl-serylglutaminylasparaginyl)amino-3-hydroxy-1-oxo-5-phenylpentylprolylvalyl valinamide;
4-(acetyl-serylglutaminylasparaginyl)amino-3-hydroxy-1-oxo-5-phenylpentylvalyl valinamide; or
4-(seryl glutaminylasparaginyl)amino-3(S)-hydroxy-1-oxo-5-phenylpentylvalyl valinamide;
and pharmaceutically acceptable salts thereof.
22.A peptide according to claim 20 which is:
2-((2-(tert-butoxycarbonyl-serylalanylalanyl)amino-1-oxo-3-phenylpropyl)cyclopentylcarbonylvalyl valine methyl ester;
2-(2-(serylalanylalanyl)amino-1-oxo-3-phenylpropyl)cyclopentylcarbonylvalylvaline methyl ester;
2-(2-(tert-butoxycarbonyl-serylalanylalanyl)amino-1-hydroxy-3-phenylpropyl)cyclopentylcarbonylvalyl valine methyl ester;
2-(-1-hydroxy-3-phenyl-2-(serylalanylalanyl)amino-propyl)cyclopentylcarbonylvalylvaline methyl ester;
2-((1-methoxy-1-(2-phenyl-1-(tert-butyloxycarbonyl-serylalanylalanyl)amino)ethyl)phosphinyl)cyclopentyl-carbonyl-valylvaline methyl ester;
2-((1-hydroxy-1-(2-phenyl-1-(serylalanylalanyl)amino) ethyl)phosphinyl)cyclopentylcarbonyl-valyl valine methyl ester;
5-(tert-butoxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl esttr; 5-(tert-butoxycarbonyl-serylalanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxy-phenyl)hexyl-valyl valine methyl ester;
4-(tert-butoxycarbonyl-serylalanylalanyl)amino-2,2-difluoro-3-hydroxy-1-oxo-5-phenylpentyl-valyl valine methyl ester;
4-(serylalanylalanyl)amino-2,2-difluoro-3-hydroxy-1-oxo-5-phenylpentyl-valyl valine methyl ester;
4-(serylalanylalanyl)amino-2,2-difluoro-1,3-dioxo-5-phenylpentyl-valyl valine methyl ester;
5-(t-butyloxycarbonylserylalanylalanyl)amino-4-hydroxy-6-(4-hydroxy)phenyl-1-oxo-hexyl-valyl amide
5-((carbobenzyloxy-D-seryl)alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester;
5-((D-seryl)alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester;
5-(t-butyloxycarbonylserylalanylalanyl)amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine;
5-(serylalanylalanyl)amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine; or
2-((1-hydroxy-2-(serylalanylalanyl)amino-3-cyclohexyl)propyl)cyclopentanecarbonyl-valyl valine methyl ester; or the carboxamide thereof;
and pharmaceutically acceptable salts thereof.
23. The peptide according to claim 22 which is
(1R,2R)-2-((1S,2S)-(-1-hydroxy-3-phenyl-2-(serylalanyl-alanyl)aminopropyl)cyclopentylcarbonylvalyl valine methyl ester, and pharmaceutically acceptable salts thereof.
24. A peptide according to claim 11 in which a is 0.
25. A peptide according to claim 24 in which R2 is
-CHOHCH2CH2CO-.
26. A peptide according to claim 24 in which b is 0.
27. A peptide according to claim 24 in which Y is a covalent bond.
28. A peptide according to claim 25 in which D is Ala and X is Val.
29. A peptide according to claim 26 in which c is 0.
30. A peptide according to claim 26 which is:
(4RS,5S)-5-((tert-butyloxycarbonyl)isoleucyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl-aspartic acid methyl ester;
(4RS,5S)-5-((tert-butyloxycarbonyl)isoleucyl)amino-7-methyl-4-hydroxy-1-oxo-octyl-leucyl-(O-benzyl)aspartic acid methyl ester;
(4S,5S)-5-(carbobenzyloxyalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester;
(4S,5S)-5-(alanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester;
(4S,5S)-5-(tert-butyloxycarbonylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester; or (4S,5S)-5-alanylamino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)-hexyl-valyl valine methyl ester; or the carboxamides thereof;
and pharmaceutically acceptable salts thereof.
31. A peptide according to claim 27 in which e is 0.
32. A peptide according to claim 28 which is:
(4S,5S)-5-(methoxycarbonyl-alanylalanyl)amino-6-phenyl-4-hydroxy-1-oxo-hexyl-valyl valine;
(4S,5S)-5-(carbobenzyloxy-alanylalanyl)amino-6-phenyl-4-hydroxy-1-oxo-hexyl-valyl valine;
(4S,5S)-5-(alanylalanyl)amino-6-phenyl-4-hydroxy-1-oxo-hexyl-valyl valine;
(4S,5S) 5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester;
(4S,5S)-5-[(carbobenzyloxy-β-alanyl)alanyl]amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester; (4S,5S)-5-[(β-alanyl)alanyl]amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)hexyl-valyl valine methyl ester;
(4S,5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-cyclohexyl-hexyl-valyl valine methyl ester;
(4S,5S)-5-(carbobenzyloxyalanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester; or
(4S,5S)-5-(alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester; or the carboxamides thereof;
and pharmaceutically acceptable salts thereof.
33. A peptide according to claim 29 which is:
(4RS,5S)-5-amino-6-(4-hydroxy)phenyl-4-hydroxy-1-oxo-hexyl-valyl valine benzyl ester;
(1R,2R)-2-(((1S,2S)-1-hydroxy-2-amino-3-cyclohexyl)-propyl)cyclopentanecarbonyl-valyl valine methyl ester;
(4S,5S)-5-amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester; or
(4S,5S)-5-(tert-butyloxycarbonyl)amino-4-hydroxy-1-oxo- 6-phenylhexyl-valyl valine methyl ester; or the carboxamides thereof;
and pharmaceutically acceptable salts thereof.
34. A peptide according to claim 30 which is (4S,5S)-5- (alanyl)amino-4-hydroxy-1-oxo-6-(4-hydroxyphenyl)-hexyl-valyl valine methyl ester and pharmaceutically acceptable salts thereof.
35 A peptide according to claim 30 which is (4S,5S)-5- (carbobenzyloxyalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl- valyl valine methyl ester.
36 A peptide according to claim 32 which is (4S,5S)-5- (carbobenzyloxyalanylalanyl)amino-4-hydroxy-1-oxo-6- phenylhexyl-valyl valine methyl ester.
37 A peptide according to claim 32 which is (4S,5S)-5- (alanylalanyl)amino-4-hydroxy-1-oxo-6-phenylhexyl-valyl valine methyl ester and pharmaceutically acceptable salts thereof.
38. A pharmaceutical composition which comprises a peptide according to claim 9 and a pharmaceutically acceptable carrier.
39. A pharmaceutical composition which comprises a peptide according to claim 9 and a liposomal carrier.
40. A pharmaceutical composition which comprises a peptide according to claim 9, azidothymidine and a pharmaceutically acceptable carrier.
41. A pharmaceutical composition which comprises a peptide according to claim 20 and a pharmaceutically acceptable carrier.
42. A pharmaceutical composition which comprises a peptide according to claim 22 and a pharmaceutically acceptable carrier.
43. A pharmaceutical composition which comprises a peptide according to claim 28 and a pharmaceutically acceptable carrier.
44. A pharmaceutical composition which comprises a peptide according to claim 32 and a pharmaceutically acceptable carrier.
44. A method of inhibiting viral disease in a mammal which comprises internally administering an effective amount of a peptide according to claim 9.
45. A method of inhibiting retroviral disease in a mammal which comprises administering an effective amount of a peptide according to claim 9.
46. A method of inhibiting retroviral disease in a mammal which comprises internally administering an effective amount of a peptide according to claim 9 and azidothymidine.
47. A method of treating disease states associated with HIV infection which comprises administering an effective amount of a peptide according to claim 9.
48. A method of treating disease states associated with HIV infection which comprises administering an effective amount of a peptide according to claim 9 and azidothymidine.
49. A method for assaying retroviral protease activity which comprises incubation of a peptide according to claim 17 with a retroviral protease and analysis of the hydrolysis
products.
50. A method for assaying retroviral protease activity which comprises incubation of a peptide according to claim 19 with a retroviral protease and analysis of the hydrolysis
products.
51. A compound of the formula:
Figure imgf000206_0001
wherein:
R1 is independently C1-5Alk, -(CH2)nSC1-5Alk,
-(CH2)nOC1-5Alk, -(CH2)nC3-7cycloalkyl or -(CH2)mC6H4-Ra;
Ra is halogen, NO2, OH, OC1-5Alk, NH2, or H;
R2 is (CH2)n-X, (CH2)nCO-X, CHR3CHR1CHR'(CH2)mCO-X, CHR3CF2(CH2)mCO-X, COCF2CR'R"(CH2)mCO-X, CHR3 (CH2)mCO-X, CO(CH2)mCO-X, COCR1CHR' (CH2)mCO-X,
Figure imgf000207_0001
R3 is H, NH2 or- OH;
R4 is H, NH2, OH, or =0;
R5 is H;
R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk;
R' and R" are H or C1-5Alk; m is independently 0, 1, 2 or 3; and n is independently 1 or 2; provided that R2 is not CHR3CH2CO-X, COCH2CO-X, COCF2CO-X or CHR3CF2CO-X when R1 is phenylmethylene, isobutyl or cyclohexylmethylene, and R2 is not CH(OH) CH2CH2CO-X or
COCH2CH2CO-X, when R1 is isobutyl.
52. A compound according to claim 51 which is:
wherein:
Figure imgf000207_0002
R1 is C1-5Alk, -(CH2)nSC1-5Alk, - (CH2)nOC1-5Alk,
-(CH2)nC3-7cycloalkyl or -(CH2)mC6H4-Ra;
Ra is halogen, NO2, OH, OC1-5Alk, NH2 or H; m is 0, 1, 2 or 3; n is 1 or 2; R4 is H, NH2, OH, or =0;
R5 is H;
R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; and
R' and R" are H or C1-5Alk.
53. A compound according to claim 52 which is :
Figure imgf000208_0001
wherein :
Ra is halogen, NO2, OH, OC1-5Alk, NH2 or H;
R4 is H, NH2, OH, or =0; R5 is H;
R6 is CH3CO, C1-5Alk, Dns Cbz or Boc, or taken together R5 and R5 are phthalimido; X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; and R' and R" are H or C1-5Alk.
54. A compound according to claim 51 which is:
Figure imgf000209_0001
wherein : R1 is C1-5Alk, - (CH2)nSC1-5Alk, - (CH2)nOC1-5Alk,
-(CH2)nC3-7cycloalkyl or - (CH2)mC6H4-Ra;
Ra is halogen, NO2, OH, OC1-5Alk, NH2 or H; m is 0, 1, 2 or 3; n is 1 or 2;
R5 is H;
R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; and
R' and R" are H or C1-5Alk.
55. A compound according to claim 54 which is:
Figure imgf000209_0002
wherein : Ra is halogen, NO2, OH, OCi-sAlk, NH2 or H;
R5 is H; R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together
R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; and R' and R" are H or C1-5Alk.
56. A compound according to claim 51 which is:
wherein:
Figure imgf000210_0001
R1 is C1-5Alk, -(CH2)nSC1-5Alk, -(CH2)nOC1-5Alk,
-(CH2)nC3-7cycloalkyl or -(CH2)mC6H4-Ra; R1' is C1-5Alk, - (CH2)nSC1-5Alk, -(CH2)nOC1-5Alk,
-(CH2)nC3-7Cycloalkyl or -(CH2)mC6H4-Ra; m is 0, 1, 2 or 3; n is 1 or 2;
Ra is halogen, NO2, OH, OC1-5Alk, NH2 or H;
R4 is OH, NH2, H or =0;
R5 is H;
R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; and R' and R" are H or C1-5Alk; provided that R1 is not isobutyl.
57. A compound according to claim 56 which is:
Figure imgf000211_0001
wherein: R4 is OH, NH2, H or =0:
Ra is halogen, NO2, OH, OC1-5Alk, NH2 or H; R5 is H;
R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; and
R' and R" are H or C1-5Alk.
58. A compound according to claim 57 in which R4 is OH or =0 and Ra is H or OH.
59. A compound according to claim 51 which is:
wherein :
Figure imgf000211_0002
R1 is C1-5Alk, -(CH2)nSC1-5Alk, -(CH2)nOC1-5Alk,
-(CH2)nC3-7cycloalkyl or - (CH2)mC6H4-Ra; Ra is halogen, NO2, OH, OC1-5Alk, NH2 or H; m is 0, 1, 2 or 3; n is 1 or 2;
R5 is H; R6 is CH3CO, C1 -5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; and R' and R" are H or C1-5Alk.
60. A compound according to claim 59 which is:
wherein :
Figure imgf000212_0001
Ra is halogen, NO2, OH, OC1-5Alk, NH2 or H;
R5 is H;
R6 is CH3CO, C1-5Alk, Dns, Cbz or Boc, or taken together R5 and R6 are phthalimido;
X is H, halogen, OH, OC1-5Alk, NHR'R" or OCOC1-5Alk; and
R' and R" are H or C1-5Alk.
61. A method for producing protease inhibiting activity in a peptide which is a substrate for a protease, which comprises incorporating the compound of claim 51 into the peptide in the place of one or two of the amino acids which undergo proteolytic cleavage by the protease.
PCT/US1989/002972 1988-07-08 1989-07-07 Retroviral protease binding peptides WO1990000399A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FI910084A FI910084A0 (en) 1988-07-08 1991-01-07 RETROVIRALA PROTEASER BINDANDE PEPTIDER.
DK002691A DK2691A (en) 1988-07-08 1991-01-07 PEPTIDES THAT BIND THE RETROVIRAL PROTEASE
NO91910053A NO910053L (en) 1988-07-08 1991-01-07 RETROVIRUS PROTEASE BINDING PEPTIDES.
NO920319A NO920319D0 (en) 1988-07-08 1992-01-23 RETROVIRUS PROTEASE BINDING PEPTIDES
NO920318A NO920318D0 (en) 1988-07-08 1992-01-23 RETROVIRUS PROTEASE BINDING PEPTIDES

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21617888A 1988-07-08 1988-07-08
US216,178 1988-07-08
US32193789A 1989-03-10 1989-03-10
US37432689A 1989-06-29 1989-06-29
US374,326 1989-06-29
US321,937 1994-10-12

Publications (1)

Publication Number Publication Date
WO1990000399A1 true WO1990000399A1 (en) 1990-01-25

Family

ID=27396241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1989/002972 WO1990000399A1 (en) 1988-07-08 1989-07-07 Retroviral protease binding peptides

Country Status (6)

Country Link
JP (1) JPH03505875A (en)
AU (1) AU3964489A (en)
DK (1) DK2691A (en)
FI (1) FI910084A0 (en)
HU (1) HUT58764A (en)
WO (1) WO1990000399A1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
EP0610744A1 (en) * 1993-02-09 1994-08-17 Bayer Corporation Sulfonamide aminomethylene derivatives as immunosuppressants
EP0610745A2 (en) * 1993-02-09 1994-08-17 Bayer Corporation Novel aminomethylene derivatives as immunosuppressants
WO1995001958A1 (en) * 1993-07-08 1995-01-19 Merrell Pharmaceuticals Inc. Difluoro statone analogs
FR2714621A1 (en) * 1994-01-06 1995-07-07 Centre Nat Rech Scient Process for the preparation of liposomes without the use of an organic solvent
US5516786A (en) * 1989-05-13 1996-05-14 Bayer Aktiengesellschaft Fungicidal substituted amino acid amides
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5580984A (en) * 1989-05-23 1996-12-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US5716973A (en) * 1991-01-02 1998-02-10 Merrell Pharmaceuticals Inc. Anti-viral compounds
US5831094A (en) * 1993-09-09 1998-11-03 Merrell Pharamceuticals Inc. Difluoro statone antiviral analogs
US5969132A (en) * 1994-02-04 1999-10-19 Merrell Pharmaceuticals Inc. Macrocyclic difluorostatone derivatives useful as antiviral agents
US6114380A (en) * 1995-12-18 2000-09-05 Merrell Pharmaceuticals Inc. Difluoro statone analogs
EP1138673A2 (en) * 1994-03-25 2001-10-04 Vertex Pharmaceuticals Incorporated Novel carbamates and ureas as modifiers of multi-drug resistance
US20110039786A1 (en) * 2008-04-30 2011-02-17 Kyoto University Metastin derivative and use thereof
CN105294535A (en) * 2015-11-13 2016-02-03 弓保成 Pharmaceutical composition used for treating pelvic inflammation
JP2016523238A (en) * 2013-06-12 2016-08-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Hydroxyethylene derivatives for the treatment of arthropathy

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3833764A1 (en) * 1988-10-05 1990-04-12 Merck Patent Gmbh MEDICINAL PRODUCTS FOR THE TREATMENT OF RETROVIRUS DISEASES
CA2036413C (en) * 1990-02-23 2000-12-12 Paul Cates Anderson Hiv protease inhibitors
CA2036398C (en) * 1990-02-23 2000-06-13 Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee Hiv protease inhibiting agents
CA2036397C (en) * 1990-02-23 2000-12-12 Paul Cates Anderson Hiv protease inhibitors containing derived amino acid units

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016148A (en) * 1975-01-27 1977-04-05 Hoffmann-La Roche Inc. Peptide derivatives of phosphonic and phosphinic acids and intermediates therefor
US4128542A (en) * 1976-07-13 1978-12-05 Hoffmann-La Roche Inc. Peptide derivatives
US4143134A (en) * 1976-07-21 1979-03-06 Hoffmann-La Roche Inc. Halo-phosphonopeptides
US4250085A (en) * 1977-12-23 1981-02-10 Hoffmann-La Roche Inc. Acyl derivatives
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4816561A (en) * 1983-05-09 1989-03-28 Todaro George J Biologically active polypeptides
US4816441A (en) * 1985-11-15 1989-03-28 Novo Industri A/S Peptides and compositions
US4818748A (en) * 1986-03-12 1989-04-04 Bayer Aktiengesellschaft Renin inhibitors and aminoacid and aminoaldehyde derivatives

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016148A (en) * 1975-01-27 1977-04-05 Hoffmann-La Roche Inc. Peptide derivatives of phosphonic and phosphinic acids and intermediates therefor
US4128542A (en) * 1976-07-13 1978-12-05 Hoffmann-La Roche Inc. Peptide derivatives
US4143134A (en) * 1976-07-21 1979-03-06 Hoffmann-La Roche Inc. Halo-phosphonopeptides
US4250085A (en) * 1977-12-23 1981-02-10 Hoffmann-La Roche Inc. Acyl derivatives
US4816561A (en) * 1983-05-09 1989-03-28 Todaro George J Biologically active polypeptides
US4798787A (en) * 1984-09-19 1989-01-17 Cetus Corporation Peptide antibodies and their use in detecting oncogene products
US4629783A (en) * 1985-04-29 1986-12-16 Genetic Systems Corporation Synthetic antigen for the detection of AIDS-related disease
US4816441A (en) * 1985-11-15 1989-03-28 Novo Industri A/S Peptides and compositions
US4818748A (en) * 1986-03-12 1989-04-04 Bayer Aktiengesellschaft Renin inhibitors and aminoacid and aminoaldehyde derivatives

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516786A (en) * 1989-05-13 1996-05-14 Bayer Aktiengesellschaft Fungicidal substituted amino acid amides
US5580984A (en) * 1989-05-23 1996-12-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5670675A (en) * 1989-05-23 1997-09-23 Abbott Laboratories Retroviral protease inhibiting compounds
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US5545750A (en) * 1989-05-23 1996-08-13 Abbott Laboratories Retroviral protease inhibiting compounds
US5716973A (en) * 1991-01-02 1998-02-10 Merrell Pharmaceuticals Inc. Anti-viral compounds
US5804552A (en) * 1991-07-23 1998-09-08 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5776933A (en) * 1992-07-20 1998-07-07 E. R. Squibb & Sons, Inc. Method of inhibiting protease
US5760036A (en) * 1992-07-20 1998-06-02 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5633277A (en) * 1993-02-09 1997-05-27 Miles Inc. Sulfonamide aminomethylene derivatives as immunosuppressants
EP0610745A3 (en) * 1993-02-09 1994-09-28 Miles Inc Novel aminomethylene derivatives as immunosuppressants.
EP0610745A2 (en) * 1993-02-09 1994-08-17 Bayer Corporation Novel aminomethylene derivatives as immunosuppressants
EP0610744A1 (en) * 1993-02-09 1994-08-17 Bayer Corporation Sulfonamide aminomethylene derivatives as immunosuppressants
WO1995001958A1 (en) * 1993-07-08 1995-01-19 Merrell Pharmaceuticals Inc. Difluoro statone analogs
US5717093A (en) * 1993-07-08 1998-02-10 Merrell Pharmaceuticals Inc. Difluoro statone analogs
US5948778A (en) * 1993-09-09 1999-09-07 Merrel Pharmaceuticals Inc. Difluoro statone antiviral analogs
US5831094A (en) * 1993-09-09 1998-11-03 Merrell Pharamceuticals Inc. Difluoro statone antiviral analogs
WO1995018601A1 (en) * 1994-01-06 1995-07-13 Centre National De La Recherche Scientifique (C.N.R.S.) Method for preparing liposomes without using an organic solvent
FR2714621A1 (en) * 1994-01-06 1995-07-07 Centre Nat Rech Scient Process for the preparation of liposomes without the use of an organic solvent
US6103259A (en) * 1994-01-06 2000-08-15 Capsulis Process for the preparation of liposomes without the use of an organic solvent
US5969132A (en) * 1994-02-04 1999-10-19 Merrell Pharmaceuticals Inc. Macrocyclic difluorostatone derivatives useful as antiviral agents
EP1138673A3 (en) * 1994-03-25 2001-10-17 Vertex Pharmaceuticals Incorporated Novel carbamates and ureas as modifiers of multi-drug resistance
EP1138673A2 (en) * 1994-03-25 2001-10-04 Vertex Pharmaceuticals Incorporated Novel carbamates and ureas as modifiers of multi-drug resistance
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US6114380A (en) * 1995-12-18 2000-09-05 Merrell Pharmaceuticals Inc. Difluoro statone analogs
US20110039786A1 (en) * 2008-04-30 2011-02-17 Kyoto University Metastin derivative and use thereof
US8592379B2 (en) * 2008-04-30 2013-11-26 Kyoto University Metastin derivative and use thereof
JP2016523238A (en) * 2013-06-12 2016-08-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Hydroxyethylene derivatives for the treatment of arthropathy
CN105294535A (en) * 2015-11-13 2016-02-03 弓保成 Pharmaceutical composition used for treating pelvic inflammation

Also Published As

Publication number Publication date
HU894124D0 (en) 1991-09-30
JPH03505875A (en) 1991-12-19
DK2691A (en) 1991-03-06
FI910084A0 (en) 1991-01-07
AU3964489A (en) 1990-02-05
HUT58764A (en) 1992-03-30
DK2691D0 (en) 1991-01-07

Similar Documents

Publication Publication Date Title
EP0352000A2 (en) Retroviral protease binding peptides
WO1990000399A1 (en) Retroviral protease binding peptides
EP1268525B1 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
EP0490667B1 (en) HIV protease inhibitors
AU2009210423B2 (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
IE902815A1 (en) Renin inhibitors, processes for their preparation and their¹use in medicaments
CA2024661A1 (en) Peptidase and isomerase inhibitors
AU8233491A (en) Retroviral protease inhibitors
US5212157A (en) Enzyme inhibitors
US20240124522A1 (en) Masp inhibitory compounds and uses thereof
EP0538396A1 (en) Inhibitors of retroviral proteases
EP0948523B1 (en) Peptidomimetic inhibitors of the human cytomegalovirus protease
AU6633490A (en) Method for treating hiv and other retroviruses and compounds useful therefor
EP0538374A1 (en) Aspartic protease inhibitors
JP3947228B2 (en) Cyclic depsipeptide and pharmaceutical comprising the same
EP0594586A1 (en) Hiv protease inhibitors
EP0575500A1 (en) Hiv protease inhibitors
MXPA99005961A (en) Peptidomimetic inhibitors of the human cytomegalovirus protease
AU2003216064A1 (en) Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
JPH0789993A (en) Novel cyclic pentapeptide

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI HU JP KR NO

WWE Wipo information: entry into national phase

Ref document number: 910084

Country of ref document: FI